0000950170-22-001958.txt : 20220224 0000950170-22-001958.hdr.sgml : 20220224 20220224160604 ACCESSION NUMBER: 0000950170-22-001958 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 83 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220224 DATE AS OF CHANGE: 20220224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cyclerion Therapeutics, Inc. CENTRAL INDEX KEY: 0001755237 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831895370 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38787 FILM NUMBER: 22670886 BUSINESS ADDRESS: STREET 1: 301 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-621-7722 MAIL ADDRESS: STREET 1: 301 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 10-K 1 cycn-20211231.htm 10-K 10-K
http://fasb.org/us-gaap/2021-01-31#QualifiedPlanMember12-31FYfalsetrue0001755237true0001755237us-gaap:OfficeEquipmentMember2020-12-310001755237cycn:SecondAmendedHeadquartersLeaseMember2021-01-012021-12-3100017552372021-07-012022-12-310001755237cycn:SecondAmendedHeadquartersLeaseMember2020-09-142020-09-150001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-12-310001755237cycn:CurrentWorkforceReductionsMembercycn:November2020WorkforceReductionPlanMember2020-11-052020-11-050001755237us-gaap:PerformanceSharesMember2021-01-012021-12-310001755237cycn:SubleaseTerminationAgreementMember2020-09-150001755237us-gaap:RetainedEarningsMember2021-12-310001755237cycn:JefferiesLLCMembercycn:AtTheMarketOfferingMember2021-12-310001755237us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-12-3100017552372021-06-300001755237cycn:OtherRelatedPartyTransactionsMember2020-12-310001755237us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001755237cycn:LaboratoryEquipmentMember2021-01-012021-12-310001755237us-gaap:RetainedEarningsMember2021-01-012021-12-3100017552372019-10-180001755237cycn:TerminationAgreementMember2021-01-012021-12-310001755237us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001755237cycn:CurrentWorkforceReductionsMembercycn:November2020WorkforceReductionPlanMember2020-10-012020-12-310001755237cycn:CyclerionSecuritiesCorporationMember2019-11-150001755237cycn:HeadquartersLeaseMember2019-10-180001755237us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-3100017552372019-12-310001755237srt:MaximumMember2021-01-012021-12-310001755237us-gaap:DomesticCountryMember2020-12-310001755237us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001755237us-gaap:CommonStockMember2021-01-012021-12-310001755237us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2020-12-3100017552372021-12-310001755237cycn:WorkforceReductionPlan2020Member2021-12-310001755237cycn:JefferiesLLCMembercycn:AtTheMarketOfferingMember2020-09-032020-09-030001755237us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001755237cycn:SecondAmendedHeadquartersLeaseMember2020-01-012020-12-310001755237us-gaap:LeaseholdImprovementsMember2020-12-310001755237us-gaap:OfficeEquipmentMember2021-01-012021-12-310001755237us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001755237us-gaap:CommonStockMember2020-12-310001755237cycn:JefferiesLLCMembercycn:AtTheMarketOfferingMember2021-01-012021-12-310001755237cycn:WeworkMember2021-01-012021-12-310001755237cycn:AkebiaResearchLicenseAgreementMember2021-06-032021-06-030001755237us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001755237us-gaap:DomesticCountryMember2021-12-310001755237us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-12-310001755237us-gaap:RestrictedStockUnitsRSUMember2021-12-310001755237cycn:AmendedHeadquartersLeaseMember2020-01-012020-12-3100017552372021-09-300001755237us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001755237us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001755237cycn:SubleaseTerminationAgreementMember2020-12-310001755237srt:MaximumMemberus-gaap:PerformanceSharesMember2021-01-012021-12-310001755237us-gaap:CommonStockMember2019-12-310001755237us-gaap:FairValueMeasurementsRecurringMember2020-12-310001755237cycn:HeadquartersLeaseMember2019-10-172019-10-180001755237us-gaap:CommonStockMember2020-01-012020-12-310001755237us-gaap:AdditionalPaidInCapitalMember2020-12-310001755237us-gaap:AdditionalPaidInCapitalMember2019-12-310001755237us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001755237cycn:HeadquartersLeaseMember2021-04-300001755237us-gaap:StateAndLocalJurisdictionMember2020-12-310001755237cycn:AmendedHeadquartersLeaseMember2020-02-272020-02-280001755237srt:MinimumMember2021-01-012021-12-310001755237us-gaap:LeaseholdImprovementsMember2021-12-3100017552372020-01-012020-12-310001755237cycn:HeadquartersLeaseMember2019-04-012019-04-010001755237us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-01-012021-12-310001755237cycn:MarketBasedStockOptionMember2020-01-012020-12-310001755237cycn:SubleaseTerminationAgreementMember2021-01-012021-12-3100017552372020-12-310001755237cycn:CyclerionGmbhMember2019-05-030001755237us-gaap:RetainedEarningsMember2020-01-012020-12-310001755237cycn:PaycheckProtectionProgramMember2020-04-212020-04-2100017552372019-01-012019-03-310001755237us-gaap:CommonStockMember2021-12-3100017552372022-02-2200017552372019-04-012019-04-010001755237cycn:MarketBasedStockOptionMember2021-01-012021-12-310001755237us-gaap:DomesticCountryMember2021-01-012021-12-310001755237us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001755237us-gaap:RetainedEarningsMember2019-12-310001755237cycn:MarketBasedStockOptionMember2020-12-310001755237cycn:SecondAmendedHeadquartersLeaseMember2020-09-150001755237cycn:MarketBasedStockOptionMember2021-12-310001755237srt:MaximumMembercycn:JefferiesLLCMembercycn:AtTheMarketOfferingMember2020-09-032020-09-030001755237us-gaap:IPOMember2020-07-240001755237us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-3100017552372021-01-012021-12-310001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2020-01-012020-12-310001755237us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001755237cycn:SecondAmendedHeadquartersLeaseMember2020-12-310001755237us-gaap:OfficeEquipmentMember2021-12-310001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2019-12-310001755237cycn:AkbeiaSupplyAgreementMember2021-01-012021-12-310001755237cycn:TerminationAgreementMember2021-04-300001755237us-gaap:PrivatePlacementMember2021-06-032021-06-030001755237us-gaap:FurnitureAndFixturesMember2021-01-012021-12-310001755237us-gaap:RetainedEarningsMember2020-12-310001755237us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001755237us-gaap:PrivatePlacementMember2021-01-012021-12-310001755237us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001755237cycn:InterestAndOtherIncomeMember2020-01-012020-12-310001755237us-gaap:EmployeeStockOptionMember2020-12-310001755237cycn:SubleaseTerminationAgreementMember2021-12-310001755237us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001755237cycn:PaycheckProtectionProgramLoanMember2020-04-212020-04-210001755237us-gaap:PrivatePlacementMember2020-07-292020-07-290001755237cycn:SubleaseTerminationAgreementMember2021-04-300001755237us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001755237us-gaap:RestrictedStockUnitsRSUMember2020-12-310001755237cycn:OtherRelatedPartyTransactionsMember2020-01-012020-12-310001755237cycn:SubleaseTerminationAgreementMember2020-09-142020-09-150001755237srt:ScenarioForecastMembercycn:AkebiaResearchLicenseAgreementMember2021-10-012023-03-3100017552372021-07-012021-09-300001755237us-gaap:StateAndLocalJurisdictionMember2021-01-012021-12-310001755237cycn:AmendedHeadquartersLeaseMember2020-02-280001755237us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-12-310001755237us-gaap:EmployeeStockOptionMember2021-12-310001755237us-gaap:LicenseAndServiceMember2021-01-012021-12-310001755237us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001755237cycn:DevelopmentAgreementMembercycn:IronwoodPharmaceuticalsIncMember2020-01-012020-12-310001755237cycn:WorkforceReductionPlan2020Member2021-01-012021-12-310001755237srt:MinimumMemberus-gaap:PerformanceSharesMember2021-01-012021-12-310001755237cycn:PaycheckProtectionProgramLoanMember2021-01-012021-12-310001755237us-gaap:AdditionalPaidInCapitalMember2021-12-310001755237cycn:HeadquartersLeaseMember2021-01-012021-12-3100017552372020-09-150001755237cycn:WorkforceReductionPlan2020Member2020-12-310001755237us-gaap:FairValueMeasurementsRecurringMember2021-12-310001755237us-gaap:StateAndLocalJurisdictionMember2021-12-310001755237cycn:HeadquartersLeaseMember2019-04-01cycn:Employeescycn:Itemxbrli:pureutr:sqftcycn:TradingDayxbrli:sharesiso4217:USDxbrli:sharescycn:Employeeiso4217:USDcycn:Segment

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-K

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the transition period from

 

 

 

to

 

 

 

 

Commission file number: 001-38787

 

CYCLERION THERAPEUTICS, INC.

(Exact Name of registrant as specified in its charter)

 

Massachusetts

(State or other jurisdiction of

incorporation or organization)

83-1895370

(I.R.S. Employer

Identification No.)

245 First Street, 18th Floor, Cambridge, Massachusetts

(Address of principal executive offices)

02142

(Zip Code)

 

(857) 327-8778

Registrant’s Telephone Number, Including Area Code

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, no par value

 

CYCN

 

The Nasdaq Stock Market LLC

(Nasdaq Global Select Market)

 

Securities registered pursuant of Section 12(g) of the Act:

None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer

 

 

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☒

The aggregate market value of the common stock held by non-affiliates of the registrant, as of June 30, 2021, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $131.5 million, computed using the closing price on that day of $3.90.

As of February 22, 2022, there were 43,410,185 shares of common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive Proxy Statement, to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934, for its 2022 Annual Meeting of Stockholders are incorporated by reference in Part III of this Form 10-K.

 


 

TABLE OF CONTENTS

 

PART I

Item 1.

Business.

5

Item 1A.

Risk Factors.

19

Item 1B.

Unresolved Staff Comments.

48

Item 2.

Properties

48

Item 3.

Legal Proceedings

48

Item 4.

Mine Safety Disclosures.

48

 

PART II

 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

49

Item 6.

Selected Financial Data.

49

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

50

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk.

57

Item 8.

Financial Statements and Supplementary Data.

57

Item 9.

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

58

Item 9A.

Controls and Procedures.

58

Item 9B.

Other Information.

59

Item 9C.

Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.

59

 

PART III

 

Item 10.

Directors, Executive Officers and Corporate Governance.

60

Item 11.

Executive Compensation.

60

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

60

Item 13.

Certain Relationships and Related Transactions, and Director Independence.

60

Item 14.

Principal Accounting Fees and Services.

60

 

PART IV

 

Item 15.

Exhibits, Financial Statement Schedules.

61

Item 16.

Form 10-K Summary.

62

 

2


 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K, or this Annual Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item 1. “Business,” Part I, Item 1A. “Risk Factors,” and Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” but are also contained elsewhere in this Annual Report. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “seeks,” “intends,” “evaluates,” “pursues,” “anticipates,” “continues,” “designs,” “impacts,” “affects,” “forecasts,” “target,” “outlook,” “initiative,” “objective,” “designed,” “priorities,” “goal” or the negative of those words or other similar expressions may identify forward-looking statements that represent our current judgment about possible future events, but the absence of these words does not necessarily mean that a statement is not forward-looking.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions and the following:

the timing, investment and associated activities involved in developing, obtaining regulatory approval for, launching and commercializing our product candidates, including CY6463;
the coronavirus ("COVID-19") pandemic and related constraints on supply chains and human resource availability affecting our clinical trials and other operating activities;
our relationships with third parties, collaborators and our employees;
our ability to execute our strategic priorities;
our ability to finance our operations and business initiatives;
the success of collaboration or license agreements of our product candidates;
whether the praliciguat out-license will result in the creation of any therapies;
whether any development, regulatory, and commercialization milestones or royalty payments provided for in the agreement with Akebia (as defined below) will be achieved;
the impact on our business of workforce and expense reduction initiatives;
our plans with respect to the development, manufacture or sale of our product candidates and the associated timing thereof, including the design and results of pre-clinical and clinical studies;
the safety profile and related adverse events of our product candidates;
the efficacy and perceived therapeutic benefits of our product candidates, their potential indications and their market potential;
U.S. and non-U.S. regulatory requirements for our product candidates, including any post-approval development and regulatory requirements, and the ability of our product candidates to meet such requirements;
our ability to attract and retain employees needed to execute our business plans and strategies and our ability to manage the impact of any loss of key employees;
our ability to obtain and maintain intellectual property protection for our product candidates and the strength thereof;

3


 

our future financial performance, revenues, expense levels, payments, cash flows, profitability, tax obligations, capital raising and liquidity sources, real estate needs and concentration of voting control, as well as the timing and drivers thereof, and internal control over financial reporting;
our ability to compete with other companies that are or may be developing or selling products that are competitive with our product candidates;
the impact of government regulation in the life sciences industry, particularly with respect to healthcare reform; and
trends and challenges in the markets for our potential products.

You should refer to “Item 1A. Risk Factors” in this Annual Report on Form 10-K for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this Annual Report represent our views as of the date of this Annual Report. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date following the date of this Annual Report.

You should read this report and the documents that we reference in this report, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

Unless the context requires otherwise, references in this report to “Cyclerion,” the “Company,” “we,” “us,” and “our” refer to Cyclerion Therapeutics, Inc. and, where appropriate, our consolidated subsidiaries.

4


 

PART I

Item 1. Business

Overview

Cyclerion Therapeutics, Inc. (“Cyclerion”, the “Company” or “we”) is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Our lead asset, CY6463, is a pioneering, central nervous system ("CNS")-penetrant, soluble guanylate cyclase ("sGC") stimulator that is currently in clinical development for Alzheimer's disease with vascular pathology ("ADv"), Cognitive Impairment Associated with Schizophrenia ("CIAS"), and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes ("MELAS"). sGC stimulators are small molecules that act synergistically with nitric oxide ("NO") as positive allosteric modulators of sGC to boost production of cyclic guanosine monophosphate ("cGMP"). cGMP is a key second messenger that, when produced by sGC, regulates diverse and critical biological functions in the CNS including neuronal function, neuroinflammation, cellular bioenergetics, and vascular function.

Cyclerion became an independent public company on April 1, 2019 after Ironwood Pharmaceuticals, Inc., or Ironwood, completed a tax-free spin-off of its sGC business, which we refer to herein as the "Separation". We are led by an accomplished team, with a track record of discovering, developing and commercializing meaningful therapies for patients while creating value for stockholders and with a long history of experience in the NO-sGC-cGMP pathway and expertise in CNS.

CY6463 is the core of our CNS portfolio with ongoing clinical programs in ADv, CIAS, and MELAS. In addition, our next-generation CNS asset, CY3018, is intended to expand the potential of sGC simulation for the treatment of disorders of the CNS. Outside of our CNS portfolio, we have clinical, preclinical and discovery phase compounds which are outside of our strategic focus and are available for out-licensing. We have successfully out-licensed praliciguat to Akebia Therapeutics, Inc. ("Akebia") for subsequent development in kidney disease. The following table presents the status of CNS pipeline and development-phase non-CNS programs in our portfolio:

 

img149660584_0.jpg 

 

5


 

The status of our programs in the table above represents the ongoing phase of development and does not correspond to the completion of a particular phase. Drug development involves a high degree of risk and investment, and the status, timing and scope of our development programs are subject to change. Important factors that could adversely affect our drug development efforts are discussed in the “Risk Factors” section of this Annual Report on Form 10-K.

Research and Development programs

CNS programs

CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases. NO-sGC-cGMP is a fundamental signaling network that is widely used in the nervous system. CY6463 enhances the brain’s natural ability to produce cGMP, an important second messenger in the CNS, by stimulating sGC, a key node in the NO-sGC-cGMP pathway. This pathway is critical to basic CNS functions, and deficient NO-sGC-cGMP signaling is believed to play an important role in the pathogenesis of neurodegenerative diseases. Agents that stimulate sGC to produce cGMP may compensate for deficient NO signaling.

On January 13, 2020, we announced positive results from our Phase 1 first-in-human study that provided the foundation for continued development of CY6463. The results from this study indicate that CY6463 was well tolerated. Pharmacokinetic (PK) data, obtained from both blood and cerebral spinal fluid (CSF), support once-daily dosing with or without food and demonstrated CY6463 penetration of the blood-brain-barrier with CSF concentrations expected to be pharmacologically active.

On October 14, 2020, we announced positive topline results from our CY6463 Phase 1 translational pharmacology study in healthy elderly participants. Treatment with CY6463 for 15 days in this 24-subject study confirmed and extended results seen in the earlier first-in-human Phase 1 study: once-daily oral treatment demonstrated blood-brain-barrier penetration with expected CNS exposure and target engagement. Results also showed significant improvements in neurophysiological and objective performance measures as well as in inflammatory biomarkers associated with aging and neurodegenerative diseases. CY6463 was safe and generally well tolerated in the study. Significant effects on cerebral blood flow and markers of bioenergetics were not observed in this study of healthy elderly participants. We believe that these results, together with nonclinical data, support continued development of CY6463 as a potential new medicine for serious CNS diseases.

We have initiated exploratory clinical trials with CY6463 in ADv, CIAS and MELAS. The ADv study will be supported in part by a grant from the Alzheimer’s Association’s Part the Cloud-Gates Partnership Grant Program ("PTC Grant"), which provides Cyclerion with $2 million of funding over two years.

Our next generation CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with greater CSF-to-plasma exposure relative to CY6463. CY3018 is intended to expand the potential of sGC stimulation for the treatment of disorders of the CNS.

Non-CNS assets

We have other assets that are outside of our current strategic focus. These non-core assets are not being internally developed at this time. Praliciguat is an orally administered, once-daily systemic sGC stimulator. On June 3, 2021, we entered into a License Agreement with Akebia Therapeutics, Inc. ("Akebia") relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing praliciguat and other related products and forms thereof enumerated in such agreement.

Olinciguat is an orally administered, once-daily, vascular sGC stimulator that was evaluated in a Phase 2 study of participants with sickle cell disease. We released topline results from this study in October 2020. This asset is available for licensing to a third-party partner.

6


 

Our Strategy

Our mission is to develop treatments that treat cognitive impairment. Key elements of our strategy include:

delivering results from our ongoing exploratory, clinical studies in ADv, CIAS and MELAS that enable go/no-go decisions and inform the subsequent development strategy for CY6463;
identifying additional indications for clinical development where the scientific rationale is strong and the unmet need is high, creating a compelling opportunity;
advancing our differentiated next-generation, CNS-penetrant, sGC stimulator program;
maintaining our out-license of non-CNS praliciguat with Akebia;
considering an out-license of olinciguat, in order to advance global development;
actively seeking partnerships and additional assets when we believe doing so will offer the greatest risk-adjusted value for our shareholders and accelerate global patient access to our drugs;
leveraging our experienced team of individuals who have a passion for innovative drug development by applying leading edge analytics and data collection techniques to best segment patient populations and measure pharmacodynamic changes in patients with cognitive impairment; and
growing external CNS network of advisors and collaborators to augment our core team

Intellectual Property

We vigorously protect the intellectual property and proprietary technology that we believe is important to our business, including by pursuing and maintaining U.S. and foreign patents that cover our products and compositions, their methods of use and the processes for their preparation, as well as any other relevant inventions and improvements that are commercially important to the development of our business. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.

Our commercial success depends in part on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions, improvements and know-how related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of third parties.

We have twenty-one issued U.S. patents, thirty pending U.S. patents applications (of which eight are in the provisional stage), three pending Patent Cooperation Treaty, or PCT, application, and numerous foreign patents and pending patent applications. The PCT applications are filed under an international patent law treaty that provides a unified procedure for filing a single initial patent application to seek patent protection for an invention simultaneously in each of the 153 contracting states, followed by the process of entering national phase, which requires a separate application in each of the member states in which national patent protection is sought.

The technology underlying our sGC patents and pending patent applications has been developed by us and was not acquired from any in-licensing agreement. We own all of the issued patents and pending applications.

The intellectual property portfolios for our most advanced product candidates are summarized below.

7


 

CY6463 Patent Portfolio

Our patent portfolio includes two U.S. issued patents, four pending US applications, two PCT applications, and numerous foreign patents and pending patent applications.

The two issued U.S. patents, US 10,858,363 and US 10,472,363 are directed to CY6463 and related compounds, and their pharmaceutical compositions thereof and will expire in 2037. The terms of these U.S. patents may be eligible for patent term extension as described below. One of the pending US patent applications is directed to compounds related to CY6463 and, if issued, will expire in 2037 or later. Another one of the pending U.S. patent applications is directed to methods of treating mitochondrial diseases with sGC stimulators, including CY6463 and, if issued, will expire in 2039 or later. Two additional pending U.S. patent applications are directed to solid forms and processes for the large-scale synthesis of CY6463 and, if issued, will expire in 2039 or later.

One PCT pending application is directed to the treatment of cognition using CY6463 and if issued will expire in 2041. Another PCT pending application is directed to compounds related to CY6463 and if issued will expire in 2041.

Furthermore, we have one European issued patent expiring in 2037, which was validated in multiple countries, and two issued patents in other foreign jurisdictions, also expiring in 2037. All of these are directed to CY6463 and related compounds. Some of these patents may be eligible for patent term extension depending on the jurisdiction.

Praliciguat Patent Portfolio

Our praliciguat patent portfolio includes six U.S. issued patents, ten pending U.S. patent applications, one PCT application, and numerous patents and pending patent applications in foreign jurisdiction.

One of the U.S. patents, US 9,481,689, which will expire in 2034, is directed to praliciguat and pharmaceutical compositions thereof. The term of this U.S. patent may be eligible for patent term extension as described below. Two other U.S. patents, US 8,748,442 and US 9,139,564, expire in 2031, and provide generic coverage of praliciguat and intermediates used in the preparation of praliciguat, respectively. A fourth U.S. patent, US 10,183,021 will expire in 2034 and is directed to the treatment of resistant hypertension with praliciguat or combinations of praliciguat and known anti-hypertensives. The fifth U.S. patent, US 209,639,308 will expire in 2034 and is directed to the treatment of diabetic nephropathy with praliciguat or combinations of praliciguat with other agents. The sixth U.S. patent, US 10,927,136 covers phosphorus prodrugs of praliciguat and will expire in 2037. Two pending U.S. patent applications that, if issued, will expire in 2031 and 2034, respectively, or later, provide generic coverage for praliciguat.

We have a pending PCT and two U.S. applications directed to methods of treating diabetic nephropathy and other diseases with praliciguat, that if issued, will expire in 2037 or later. We have a pending U.S. application directed to a praliciguat formulation, that, if issued, will expire in 2036 or later. The remaining five pending U.S. applications are directed to prodrugs of praliciguat, deuterated forms of praliciguat and processes and synthetic intermediates for preparing praliciguat that, if issued, will expire in 2037 or later.

Furthermore, we have three granted European patents, one expiring in 2031, another one in 2032 and the third one in 2034, each of them validated in multiple countries; three granted Japanese patents, one expiring in 2031, another in 2034, and another in 2037; four granted Chinese patents, two expiring in 2031, one in 2032, and the third expiring in 2034; and twenty-one issued patents in other foreign jurisdictions, one expiring in 2032, twelve of them expiring in 2031, seven expiring in 2034, and one expiring in 2037. Some of these patents may be eligible for patent term extension depending on the jurisdiction. We also have numerous patent applications pending in foreign jurisdictions.

8


 

Olinciguat Patent Portfolio

Our olinciguat patent portfolio includes six U.S. issued patents, eight pending U.S. patent applications (including three provisional applications) and numerous patents and pending applications in foreign jurisdictions.

One of the U.S. patents, US 9,586,937, which will expire in 2034, is directed to olinciguat and pharmaceutical compositions thereof. The term of this U.S. patent may be eligible for patent term extension as described below. Two other U.S. patents, US 8,748,442 and US 9,139,564, expire in 2031, and provide generic coverage of olinciguat and intermediates used in the preparation of olinciguat, respectively. Another U.S. patent, US 10,517,874, which will expire in 2034 is directed to the treatment of SCD using olinciguat alone or in combinations with other therapeutic agents. The fifth U.S. issued patent, US 10,889,577, will expire in 2037 and is directed to polymorphs of olinciguat. The sixth issued patent, US 11,207,323, will expire in 2034 and provides coverage for stereoisomers of olinciguat. A pending U.S. patent application, if issued, will expire in 2031 or later, and provides generic coverage for olinciguat.

The remaining pending U.S. patent applications are directed to other methods of use of olinciguat, deuterated forms of olinciguat, polymorphs of olinciguat and processes and synthetic intermediates for preparing olinciguat and, if issued, will expire in 2037 or later.

Furthermore, we have three granted European patents, one expiring in 2031, another in 2032, and a third one in 2034, the first two validated in multiple countries; and the third one pending validation in numerous countries; three granted Japanese patents, one expiring in 2031 and two others in 2034; four granted Chinese patents, two expiring in 2031, another one in 2032, and a fourth one in 2034; and twenty issued patents in other foreign jurisdictions, twelve of them expiring in 2031, one expiring in 2032 and six expiring in 2034 and one expiring in 2037. We also have numerous pending patent applications in foreign jurisdictions. Some of these patents may be eligible for patent term extension or the foreign jurisdiction equivalent, depending on the jurisdiction.

Additional Intellectual Property

In addition to the patents and patent applications related to CY6463, praliciguat and olinciguat, we currently have seven issued U.S. patents; six patents granted in foreign jurisdictions, including European patents that have each been validated in several countries; and a number of pending U.S. (including provisional applications) and foreign pending patent applications directed to other sGC stimulator molecules and uses thereof.

Patent Term

The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application, assuming that all applicable maintenance or annuity fees are paid. In the United States, a patent's term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO, in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in that country, and the validity and enforceability of the patent.

In addition, the term of a U.S. patent that covers an FDA-approved drug may be eligible for patent term extension under the Drug Price Competition and Hatch-Waxman Act, to account for some of the time the drug is under development and regulatory review after the patent is granted. For a drug for which FDA approval is the first permitted marketing of the active ingredient, the Hatch-Waxman Act allows for extension of the term of one U.S. patent that includes at least one claim covering the composition of matter of an FDA-approved drug (drug substance or drug product), an FDA-approved method of treatment using the drug and/or a method of manufacturing the FDA-approved drug. The extended patent term cannot exceed the shorter of five years beyond the non-extended expiration of the patent or 14 years from the date of the FDA approval of the drug. Some foreign jurisdictions,

9


 

including Europe and Japan, have similar patent term extension provisions, which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency.

Trade Secrets and Proprietary Information

In addition to patents, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We typically rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We protect our proprietary information, including trade secrets and know-how, by establishing confidentiality agreements with our commercial partners, collaborators, scientific advisors, employees and consultants and invention assignment agreements with our employees, consultants, scientific advisors and contractors. These agreements generally provide that all confidential information developed or made known during the course of an individual or entities' relationship with us must be kept confidential during and after the relationship. These agreements also typically provide that all inventions resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. However, these agreements may be breached, and we may not have adequate remedies for any breach. We also take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary information by third parties. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.

Government Regulation

United States Regulation

The FDA regulates medical products, including prescription drugs under the Federal Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations. Products are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including imposition of a clinical hold, refusal by the FDA to approve applications, withdrawal of an approval, import/export delays, issuance of warning letters and other types of enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, debarment, or civil or criminal investigations and penalties brought by the FDA, the Department of Justice, State Attorneys General, or other governmental entities.

The process required by the FDA before a drug may be approved and marketed in the United States generally involves the following:

completion of extensive nonclinical laboratory and animal studies conducted in accordance with applicable regulations, including Good Laboratory Practices, or GLP, regulations and applicable requirements for the humane use of laboratory animals;
submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may commence;
approval by an independent IRB to proceed with initiating the clinical trial at each corresponding investigational site.
performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, GCPs and other clinical-trial related regulations to establish the safety and efficacy of the product for each proposed indication;
preparation and submission to the FDA of an NDA;

10


 

satisfactory completion of one or more FDA inspections such as pre-approval inspection(s) of the manufacturing facility or facilities at which the product, or components thereof, are made to assess compliance with current GMP;
payment of user fees for FDA review of the NDA; and
FDA acceptance, review and approval of the NDA, which may include an Advisory Committee review.

The development and approval process requires substantial time, effort and financial resources and the receipt and timing of any approval is uncertain.

Nonclinical and Clinical Trials in Support of an NDA

Before testing any drug product candidate in humans, the product candidate must undergo rigorous nonclinical testing. Nonclinical studies include laboratory evaluations of the product candidate, as well as in vitro and animal studies to assess the potential safety and efficacy of the product candidate. The conduct of nonclinical studies that determine the product safety information for administration to humans must comply with federal regulations and requirements, including GLP regulations. The sponsor must submit the results of the nonclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical study protocol, to the FDA as part of an IND, which must become effective before clinical trials in a given indication may be commenced. The IND will become effective automatically 30 days after receipt by the FDA, unless the FDA raises concerns or questions about the content of the IND or the conduct of the proposed trial(s) as outlined in the IND prior to that time. In such a case, the IND sponsor must resolve any outstanding concerns with the FDA before the clinical trial(s) can proceed.

Clinical trials involve the administration of the product candidate to human subjects under the supervision of qualified investigators in accordance with GCP requirements. Each clinical trial must be reviewed and approved by an IRB for the sites at which the trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB will consider, among other things, ethical factors, the safety of human subjects and the possible liability of the institution. The IRB also approves the informed consent form, including a privacy statement, that must be provided to each clinical trial participant or his or her legal representative, and must monitor the clinical trial until completed.

Clinical trials are typically conducted in three sequential phases prior to approval, which may overlap or be combined:

Phase 1. Phase 1 clinical trials generally involve a small number of healthy participants or disease-affected participants who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacokinetics, pharmacologic action, side effect tolerability and safety of the drug.
Phase 2. Phase 2 clinical trials usually involve studies in a limited population of participants with a disease or disorder to evaluate the efficacy of the product candidate for specific indications, determine dosage tolerance and optimal dosage, and identify possible adverse effects and safety risks.
Phase 3. Phase 3 clinical trials generally involve a larger number of participants at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use, to establish the overall benefit/risk profile of the product and to provide an adequate basis for product approval by the FDA.

11


 

Phase 4. Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be required to be conducted after approval to gain additional experience from the treatment of participants in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated approval regulations, or when otherwise requested by the FDA. Failure to conduct the Phase 4 clinical trials per the plan required by the FDA could result in enforcement action or withdrawal of approval.

Progress reports detailing new information and changes such as the results of clinical trials, new nonclinical studies, new product quality data, or changes to manufacturing controls must be submitted at least annually to the FDA and more frequently if serious adverse events occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time, or the FDA may impose other sanctions on various grounds, including a finding that the research participants are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the requirements of the IRB or if the drug has been associated with unexpected serious harm to participants. There are also requirements related to registration and reporting of certain clinical trials and completed clinical trial results to public registries.

Submission and Review of an NDA

Assuming successful completion of the required nonclinical and clinical testing, the results of nonclinical studies and clinical trials, together with detailed information on the product's manufacture, composition, quality controls and proposed labeling, among other things, are submitted to the FDA in the form of an NDA, requesting approval to market the product for one or more indications. The application must be accompanied by a significant user fee payment, which typically increases annually, although waivers may be granted in limited cases (e.g., for products that have received an Orphan Designation).

The FDA has substantial discretion in the approval process and may refuse to accept any application or decide that the data is insufficient for approval and may require additional nonclinical or clinical studies, or other information (e.g., product quality data or manufacturing controls) before it accepts the filing. If an NDA has been accepted for filing, which occurs 60 days after submission, the FDA sets a user fee goal date that informs the applicant of the specific date by which the FDA intends to complete its review. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original NDAs, the FDA has ten months from the filing date in which to complete its review of a standard application, and six months from the filing date for an application with priority review. The FDA does not always meet its PDUFA goal dates, and the review process may be significantly extended by FDA requests for additional information and clinical data or clarification.

The FDA reviews NDAs to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with current GMP to assure and preserve the product's identity, strength, quality and purity. Before approving an NDA, the FDA typically will inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing facilities comply with current GMP. Additionally, the FDA will frequently inspect one or more clinical trial sites for compliance with GCPs and integrity of the data supporting safety and efficacy.

During the approval process, the FDA will also prepare an integrated benefit-risk assessment and determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to ensure that the benefits of the drug outweigh the risks and to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS. A REMS that includes elements to assure safe use, or ETASU, can substantially increase the costs of commercializing a drug. The FDA could also require a special warning, known as a boxed warning, to be included in the product label in order to highlight a particular safety risk. Boxed warnings may limit the type of advertising for a drug. The FDA may also convene an advisory committee of external experts to provide input on certain review issues relating to risk, benefit and interpretation of clinical trial data.

On the basis of the FDA's evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, FDA will issue either an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug and is accompanied by specific prescribing

12


 

information for specific conditions of use. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the submission identified by the FDA and may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either amend the NDA with data to address the raised concerns, resubmit the NDA addressing all the deficiencies identified in the letter, engage in dispute resolution with the FDA about the identified deficiencies in the CRL, or withdraw the application. Even with submission of this additional information, the FDA may ultimately decide that the re-submitted application does not satisfy the regulatory criteria for approval.

Orphan Drug Designation

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition affecting fewer than 200,000 individuals in the United States, or in other limited cases. Orphan drug designation must be requested before submitting an NDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process, though companies developing orphan drugs may be eligible for certain incentives, including tax credits for qualified clinical testing.

Generally, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same active moiety for the same indication for seven years from the date of such approval, except in limited circumstances. Competitors, however, may receive approval of different active moieties for the same indication or obtain approval for the same active moiety for a different indication. If one of our products designated as an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity.

Expedited Review and Approval

The FDA has various programs that are intended to expedite development and approval of drugs intended for the treatment of serious or life-threatening diseases or conditions and that demonstrate the potential to address unmet medical needs.

An application may be eligible for a "fast track" designation for a product that is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. Fast track designation provides opportunities for more frequent interactions with the FDA review team and permits FDA to consider sections of the NDA on a rolling basis before the complete application is submitted.

In addition, a sponsor can request designation of a product candidate as a "breakthrough therapy." A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The FDA must take certain actions with respect to breakthrough therapies, such as holding timely meetings with and providing advice to the product sponsor.

An application may be eligible for "accelerated approval" where the product candidate is intended to treat a serious or life-threatening illness and provides meaningful therapeutic benefit over existing treatments; applications eligible for accelerated approval may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA requires a sponsor to conduct confirmatory studies to verify the predicted effect on IMM or another clinical endpoint, and the product may be subject to expedited withdrawal procedures.

13


 

Once an NDA is submitted for a product intended to treat a serious condition, the FDA may assign a priority review designation if the FDA determines that the product, if approved, would provide a significant improvement in safety or effectiveness. Under priority review, the FDA must review an application in six months, compared to ten months for a standard review. A product may be eligible for more than one expedited approval program. Even if a product qualifies for one or more of these programs, however, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, these expedited review pathways do not change the standards for approval and may not ultimately expedite the development or approval process.

Non-Patent Exclusivity

In addition to patent exclusivity, the holder of the NDA for the listed drug may be entitled to a period of non-patent exclusivity, during which the FDA cannot approve an ANDA for approval of a generic or 505(b)(2) application that relies on the listed drug as protected by regulatory exclusivity.

An NDA for a new chemical entity may receive five years of exclusivity, whereby the FDA will not accept for filing, with limited exceptions, a product seeking to rely upon the FDA's findings of safety or effectiveness for such new chemical entity. An ANDA containing a paragraph IV patent certification can be filed after four years. Alternatively, an NDA may obtain a three-year period of non-patent market exclusivity for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical studies (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant.

Pediatric Exclusivity

Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity for both drugs and biologics, and also unexpired Orange Book listed patents in the case of drugs. This six-month exclusivity may be granted if a sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA's request, the additional protection is granted.

Post-Approval Requirements

Following approval of a new product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims and some manufacturing and supplier changes, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for marketed products and the establishments where such products are manufactured, as well as new application fees for certain supplemental applications. The FDA may impose a number of post-approval requirements as a condition of approval of an NDA, such as Phase 4 clinical trials or a REMS.

In addition, entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and such state agencies for compliance with current GMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from current GMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain current GMP compliance.

14


 

Once an approval is granted, the FDA may issue enforcement letters or withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Corrective action could delay product distribution and require significant time and financial expenditures. Later discovery of previously unknown safety issues with a product, including adverse events of unanticipated severity or frequency, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include:

restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market or product recalls;
fines, warning letters or other enforcement-related letters of clinical holds on post-approval clinical trials;
refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals;
product seizure or detention, or refusal to permit the import or export of products;
injunctions or the imposition of civil or criminal penalties; and
consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs.

The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications, in accordance with the provisions of the approved label and FDA guidance. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including investigation by federal and state authorities. Additionally, all promotional material must be truthful and non-misleading, and present balanced information regarding the risks and benefits of the drug product.

Other Regulatory Requirements

Outside the U.S., our abilities to develop and market a product are contingent upon receiving approval and ultimately marketing authorization from the appropriate regulatory authorities. The requirements governing the conduct of clinical trials, marketing authorization, pricing and reimbursement vary widely from jurisdiction to jurisdiction. At present, foreign marketing authorizations are applied for at a national level, although within the E.U. registration procedures are available to companies wishing to market a product in more than one E.U. member state.

We are subject to U.S. federal and foreign anti-corruption laws. Those laws include the U.S. Foreign Corrupt Practices Act, or FCPA, which prohibits U.S. corporations and their representatives from offering, promising, authorizing, or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA encompasses certain healthcare professionals in many countries. We are also subject to similar laws of other countries that have enacted anti-corruption laws and regulations.

Pediatric Development

In the European Union, companies developing a new medicinal product must agree to a Pediatric Investigation Plan, or PIP, with the EMA and must conduct pediatric clinical trials in accordance with that PIP, unless a deferral or waiver applies, (e.g., because the relevant disease or condition occurs only in adults). The MAA for the product must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies or a deferral has been granted, in which case the pediatric clinical trials must be completed at a later date. Where the MAA includes the results of all pediatric studies conducted in accordance with the PIP and the results are reflected in the approved summary of product characteristics, the holder of a patent or supplementary protection certificate is entitled to receive a six-month extension of the protection under a supplementary protection certificate or, in the case of orphan medicinal products, the product is eligible for a two-year extension of the orphan

15


 

market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.

In the US, under Pediatric Research Equity Act (PREA), a pediatric development plan is required to accompany an NDA for all drugs, except those receiving non-oncology Orphan Drug Designation. This may include waiver or deferral of pediatric studies. The Best Pharmaceuticals for Children Act (BPCA) also allows for agreement with FDA on a pediatric written request that, if fulfilled, may extend data exclusivity for the molecule for an additional 6 months.

Competition

The biopharmaceutical industry is highly competitive within and across therapeutic categories and indications. There are many public and private biopharmaceutical companies, universities, government agencies and other research organizations actively engaged in the research and development of products that may be similar to our product candidates or address similar markets. In addition, the number of companies seeking to develop and commercialize products and therapies competing with our product candidates is likely to increase. However, we seek to build our portfolio with key differentiating attributes to provide a competitive advantage in the markets we target. The success of all of our product candidates, if approved, will likely depend upon their efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors.

Many of our competitors, including those mentioned below, may have greater financial resources and broader expertise in research and development, manufacturing, nonclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved medicines than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with Cyclerion in establishing clinical trial sites and participant registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.

Competition can be viewed as through at least two lenses: 1) companies that are developing products with a different mechanism of action but to address the same therapeutic need and 2) companies that are developing products that act through the same mechanism of action (i.e., sGC modulators).

Competition within target therapeutic areas.

MELAS. There are currently no approved treatments for MELAS or Mitochondrial Disease in the United States. We are aware of the following companies engaged in clinical development of products for the treatment of MELAS or Mitochondrial Disease, which include patients with MELAS:

PTC Therapeutics has a registrational Phase 2/3 study ongoing of vatiquinone, an antioxidant/NQO1 modulator, assessing the treatment of Mitochondrial Disease in participants with refractory epilepsy. Khondrion B.V has a Phase 2b study ongoing with sonlicromanol, a redox modulator, assessing the attention domain of cognitive function in MELAS-spectrum disorders. Abliva AB has a Phase 1a/b study ongoing of KL1333, an NAD+ modulator, in Primary Mitochondrial Disease. Abliva AB has announced plans to initiate a pivotal clinical Phase II/III study of KL1333 in MELAS-Maternally inherited diabetes and deafness (MIDD) and Kearns-Sayre syndrome (KSS)-Chronic progressive external ophthalmoplegia (CPEO) spectrum disorders during 2021. Reneo Pharma LTD ran a Phase 1 study of REN001, a PPARδ agonist, in patients with Primary Mitochondrial Myopathy and has a planned Phase 2/3 study of REN001 in Primary Mitochondrial Myopathy. Astellas Pharma Inc has a planned Phase2/3 study of ASP0367, a PPARδ modulator, in patients with Primary Mitochondrial Myopathy.

ADv. There are currently no approved products in the United States to treat ADv. There are six products approved in the United States to treat AD symptoms.

16


 

Aricept® (donepezil) is a cholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer’s type, including in patients with mild, moderate and severe AD. Razadyne® (galantamine) and Exelon® (rivastigmine) are cholinesterase inhibitors indicated for treatment of mild to moderate dementia of the Alzheimer’s type. Namenda® (memantine) is an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Namzaric® is a combination of donepezil and memantine indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. Biogen received FDA approval for aducanumab, an anti-amyloid beta (Aβ) mAb, for the treatment of AD.

We are not aware of any companies engaged in clinical development of products for the treatment of ADv. There are many companies developing treatments for AD, which could be our competitors. These include the following companies engaged in the late-stage clinical development of products for the treatment of AD:

There are multiple Aβ targeting agents in Phase 3 studies for the treatment of AD, including Eli Lilly’s solanezumab (anti-Aβ mAb), Eisai/Biogen’s BAN2401 (anti-Aβ mAb), Roche’s gantenerumab (anti-Aβ mAb), Alzheon’s ALZ-801 (Aβ aggregation inhibitor) and AZTherapies’ALZT-OP1 (Aβ aggregation inhibitor). Compounds in Phase 3 studies with other mechanisms of action include TauRx’s TRx0237/LMTX (Tau aggregation inhibitor), Shanghai Greenvalley Pharmaceutical Co., Ltd.’s GV-971 (oligomannate), AB Science’s masitinib (c-Kit, Lyn, Fyn and CSF1R kinase inhibitor), Cassava Science’s simufilam (restores filamin A conformation) and Novo Nordisk’s semaglutide (glucagon-like-peptide 1 receptor agonist). Compounds in Phase 2/3 studies include AgeneBio’s AGB-101 (SV2A inhibitor), Grifols IVIG (Immunoglobulin), Cortexyme’s atuzaginstat (bacterial protease inhibitor), Anavex’s ANAVEX 2-73 (Sigma-1, M2/M3 RA), and vTv Therapeutics’ azeliragon/TTP-488 (RAGE antagonist). There are many other companies engaged in earlier stage clinical development for products targeting AD.

CIAS. There are currently no approved products in the United States to treat CIAS. There are many companies developing treatments for CIAS. These include the following companies engaged in the late-stage clinical development of products for the treatment of CIAS.

Boehringer Ingelheim has three ongoing registrational Phase 3 studies of the glycine transporter type-1 inhibitor, BI 425809, assessing safety and efficacy for the treatment of CIAS. Biogen has an ongoing Phase 2 study of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor positive allosteric modulator, BIIB104, assessing safety and efficacy in participants with CIAS. Neurocrine Biosciences has an ongoing Phase 2 study of the d-amino acid oxidase inhibitor, luvadaxistat, in participants with CIAS. atai Life Sciences has announced plans for a Phase 2 study of the cholinergic, glutamatergic and gamma-aminobutyric acid- B receptor modulator, RL-007, for the treatment of CIAS.

Competition within the sGC mechanism.

There is one major competitor that is actively developing sGC modulators. We are not aware of any efforts to develop sGC modulators for treatment of CNS or mitochondrial diseases Bayer and Merck have an active collaboration on sGC stimulators, focused primarily on cardiovascular, pulmonary, and renal indications. They have two approved sGC stimulators, ADEMPAS® (riociguat), indicated for PAH and CTEPH, and VERQUVO® (vericiguat) for heart failure with reduced ejection fraction (HFrEF).

Manufacturing

We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We depend on third-party contract manufacturing organizations, or CMOs, for all our requirements of raw materials, drug substance and drug product for our ongoing clinical trials of CY6463 and our nonclinical research. We intend to continue to rely on CMOs for the supply of CY6463 for all stages of clinical development and commercialization, as well as for the supply of any other product candidates that we may identify. We require all our CMOs to conduct manufacturing activities in compliance with current GMP requirements.

17


 

We believe that CY6463 drug substance and drug product may be manufactured from readily available raw materials and the processes are amenable to large-scale production and do not require unusual equipment or handling. We believe adequate supply of CY6463 drug substance and drug product is readily available from our current CMOs to satisfy our immediate clinical and nonclinical demands. We obtain our supplies from these CMOs on a purchase order basis and do not have arrangements in place for long-term supply or redundant supply of CY6463; however, we are working with our CMOs to implement improvements to our drug substance and drug product manufacturing processes to further ensure product capacity adequate to meet further development demands. We are evaluating CMOs for drug substance and drug product that could meet potential commercial demands.

Human Capital Resources

We have built an exceptional and diverse team of individuals who have a passion for developing important new medicines that will have a profound impact on the lives of patients with serious CNS diseases. As a small, innovative company, our success depends on attracting, retaining and motivating highly skilled and experienced scientific, medical and other personnel. Our ability to recruit and retain such employees depends on a number of factors, including our distinct corporate culture, our collaborative work environment and offering opportunities for our employees to grow and develop in their careers. We provide robust compensation and benefits programs which include competitive salaries, potential annual discretionary bonuses, stock awards, a 401(k) plan with employer match, healthcare and insurance benefits, health savings and flexible spending accounts, unlimited vacation time, among others. Our employees are further guided by our code of conduct and our cultural values of seeking to serve patients, acting with integrity, empowering people and innovating for solutions.

We are committed to our employees’ health, safety and wellness. We provide our employees and their families with access to a variety of innovative, flexible and convenient health and wellness programs. In response to the COVID-19 pandemic, we implemented significant changes that were determined to be in the best interest of our employees and the communities in which we live and work, while continuing to ensure the safety of patients in our trials.

Employee Profile

As of December 31, 2021, we had thirty-two (32) employees, of which fifteen (15) employees hold M.D. or Ph.D. degrees. Approximately three (3) employees are in discovery research, thirteen (13) are in our drug development organization, six (6) are in our strategy and corporate development organizations and ten (10) are in general and administrative functions. None of our employees is subject to a collective bargaining agreement or represented by a trade or labor union. We consider our employee relations to be good.

During the years ended December 31, 2020 and 2019, we initiated certain reductions in our workforce. Refer to Note 13, Workforce Reduction, to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K for further details.

Corporate Information

We were incorporated in the Commonwealth of Massachusetts on September 6, 2018. Our principal executive offices are located at 245 First Street, Riverview II, 18th Floor, Cambridge, MA 02142. Our telephone number is (857) 327-8778. Our common stock is listed on the Nasdaq Global Market under the symbol “CYCN.”

Available Information

Our internet website address is www.cyclerion.com. In addition to the information contained in this Annual Report, information about us can be found on our website. Our website and information included in or linked to our website are not part of this Annual Report.

Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge through our website as soon as reasonably practicable after they are

18


 

electronically filed with or furnished to the Securities and Exchange Commission, or the SEC. The SEC maintains an internet site that contains reports, proxy and information statements and other information. The address of the SEC’s website is www.sec.gov.

Item 1A. Risk Factors.

The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Annual Report on Form 10-K and those we may make from time to time. You should carefully consider the risks described below, in addition to the other information contained in this Annual Report on Form 10-K and our other public filings. Our business, financial condition or results of operations could be harmed by any of these risks. The risks and uncertainties described below are not the only ones we face. Additional risks not presently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business operations. In this section, we first provide a summary of the more significant risks and uncertainties we face and then provide a full set of risk factors and discuss them in greater detail.

Risk Factors Summary

Risks Related to Our Financial Position and Capital Needs

We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale.
We have incurred significant losses and have never generated revenue from product sales; we anticipate that we will continue to incur significant losses for the foreseeable future and may never be profitable.
We will need to raise additional funding to advance our product candidates, which may not be available on acceptable terms, or at all, and may dilute existing shareholders or restrict our operations.

Risks Related to our Business and Industry

Our approach to the discovery and development of our product candidates may never lead to marketable products.
We may encounter substantial delays in our clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities in the development of our compounds.
The COVID-19 pandemic may continue to disrupt our business, including our clinical development activities.
We could encounter difficulties in enrolling participants in our clinical studies, which could delay or prevent progress of our product candidates.
The FDA regulatory approval process is lengthy, time-consuming and inherently unpredictable. We may be unable to obtain regulatory approval for our product candidates and unable to generate product revenue.
Our product candidates may cause side effects that may result in label restrictions.
We may have to change our nonclinical or clinical study protocols due to regulatory reasons or unanticipated events, which could result in increased costs to us and could delay our development timeline.

Risks Related to Our Reliance on Third Parties

Akebia may not be successful in developing any therapies through the praliciguat out-license with the Company.
We may enter into a collaboration or license arrangement in the future that ultimately is not successful.

19


 

We rely, and expect that we will continue to rely, on third parties to conduct nonclinical or clinical studies and to manufacture drug supplies for our product candidates. If these third parties do not execute successfully, our business could be substantially harmed.
We share confidential information with third-party vendors, including trade secrets and know-how, which increases the possibility that our confidential information will be misappropriated or disclosed.

Risks Related to Our Intellectual Property Rights

We may be unable to adequately protect our proprietary technologies or obtain and maintain issued patents that are sufficient to protect our product candidates.
We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts.
We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
We may not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.
We may not be able to obtain additional protection under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, and similar foreign legislation by extending the patent terms and obtaining data exclusivity for our product candidates.
We may be subject to damages resulting from claims that we or our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers.

Risks Related to the Future Commercialization of Our Product Candidates

If the market opportunities for our product candidates are smaller than we estimate, our revenue and ability to achieve profitability may be harmed.
Even if we obtain regulatory approval for our product candidates, they may not achieve broad market acceptance by patients, physicians and healthcare payors, which would limit our revenue.
We may fail to comply with healthcare and other regulations and could face substantial penalties.
Our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours.
The impact of healthcare reform and other governmental and private payor initiatives may harm our business.

Risks Related to Our Business Operations

Our prospects for success depend on our ability to retain our management team and to attract, retain and motivate qualified personnel.
We may need to expand our organization and we may experience difficulties in managing growth of our employee base.
We face potential product liability exposure, and, if claims are brought against us, we may incur substantial liability.
We could fail to maintain proper and effective internal controls and our ability to produce accurate and timely financial statements could be impaired.
Our internal computer systems, or those of our third-party CROs, CMOs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product candidates' development programs.

20


 

If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur.
We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act, or the FCPA, and other worldwide anti-bribery laws.

Risks Related to the Separation

Our rights under the intellectual property license agreement with Ironwood could be challenged.
We may be required to make payments to indemnify Ironwood for certain liabilities in connection with the Separation.

Risks Related to Ownership of Our Common Stock

We have limited trading history and a relatively low-volume trading market for our shares and our market price of our common stock may fluctuate widely.
Our common stock market price is particularly volatile, and we expect it to be more volatile than that of a seasoned issuer.
We may not attract securities or industry analysts to initiate or maintain coverage of our stock; analysts may publish negative reports or change their recommendations regarding our stock adversely and our stock price and trading volume could decline.
We have adopted anti-takeover provisions in our articles of organization and bylaws and are subject to provisions of Massachusetts law that may frustrate any attempt to remove or replace our current board of directors or to effect a change of control or other business combination involving our company.

Risks Related to Our Financial Position and Capital Needs

As we are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale, valuing our business and predicting our prospects is challenging.

We are a clinical-stage biopharmaceutical company that was incorporated in 2018. Our business was conducted within Ironwood prior to that time, and we had no history as an independent company prior to the completion of the Separation. We are developing a pipeline of sGC stimulators, but we have no products approved for commercial sale, and we have never generated revenue from product sales. Our operating activities to date have been limited primarily to organizing and staffing our company, business planning, raising capital, developing our technology, identifying potential product candidates, pursuing partnership opportunities and conducting early-stage clinical trials for our product candidates, including CY6463.

To date, we have not obtained marketing approval for any of our product candidates, engaged, on our own or through a third party, in commercial scale manufacturing, or conducted sales and marketing activities necessary for the successful commercialization of our product candidates. Our short operating history offers limited insight into our prospects for success or even viability. We expect our operating performance to fluctuate. We will encounter challenges frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields and we have not yet demonstrated an ability to successfully navigate such challenges. If we do not successfully address the challenges we face, our business, prospects, financial condition and results of operations will be materially harmed.

Our business has incurred significant losses and we anticipate that we will continue to incur significant losses for the foreseeable future. We have never generated revenue from product sales and may never be profitable.

Our business has incurred operating losses due to costs incurred in connection with our research and development activities and general and administrative expenses associated with our operations. Our net losses for the years ended December 31, 2021 and 2020 were $51.6 million and $77.8 million, respectively. We expect to

21


 

incur significant losses for several years, as we continue our research activities and conduct development of, and seek regulatory approvals for, our product candidates.

Our ability to generate revenue from our product candidates and achieve profitability depends on our ability, alone or with strategic partners, to complete the development of, and obtain the necessary regulatory and essential pricing and reimbursement approvals to commercialize, our product candidates. We do not know when, if ever, we will generate revenues from sales of our products.

Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency (EMA), or other regulatory agencies, domestic or foreign, to perform clinical and other studies in addition to those that we currently anticipate. Even if one or more of the product candidates that we develop is approved for commercial sale, we may never generate revenue in amounts sufficient to achieve and maintain profitability.

We will need to raise additional funding to advance our product candidates, which may not be available on acceptable terms, or at all. Failure to obtain capital when needed may force us to delay, limit or terminate our product development efforts or other operations. Raising additional capital may dilute our existing shareholders, restrict our operations or cause us to relinquish valuable rights.

As of December 31, 2021, we had unrestricted cash and cash equivalents of approximately $54.0 million. Our management believes that such cash and cash equivalents will be sufficient to fund our current priorities, including the ADv, CIAS, and MELAS studies. However, we will require significant additional funding to advance our product candidates, alone or with strategic partners, through clinical studies and to seek marketing approval, as well as to continue advancing our research and development efforts with our other product candidates. We may also need to raise additional funds sooner than currently anticipated if we choose to pursue additional indications or geographies for our product candidates, identify additional product candidates to advance through clinical development or otherwise expand more rapidly than we presently anticipate. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant expenses related to product sales, medical affairs, marketing, manufacturing and distribution.

We are seeking funds through collaborations, strategic alliances, or licensing arrangements with third parties, and such agreements may impact rights to our product candidates or technologies, future revenue streams, research programs or products candidates or to grant licenses on terms that may not be favorable to us. Such arrangements will limit our participation in the success of any of our product candidates that receive regulatory approval.

We may also seek to raise such capital through public or private equity, royalty financing or debt financing. Raising funds in the then-current economic environment may be challenging, and such financing may not be available in sufficient amounts or on acceptable terms, if at all. The terms of any financing may harm existing shareholders. The issuance of additional securities, whether equity or debt, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities may dilute the ownership of existing shareholders. Incurring debt would result in increased fixed payment obligations, and we may agree to restrictive covenants, such as limitations on our ability to incur additional debt or limitations on our ability to acquire, sell or license intellectual property rights that could impede our ability to conduct our business.

If we are unable to raise capital when needed or on reasonable terms, we may curtail, delay or discontinue our research or development programs, scale back or cease any commercialization efforts or wind down our business. In addition, such additional fundraising efforts may divert our management from their day-to-day activities, which may impede our ability to develop and commercialize our product candidates.

22


 

Risks Related to our Business and Industry

Our approach to the discovery and development of product candidates for the treatment of serious CNS diseases may never lead to marketable products.

We are focusing our research and development efforts on addressing serious CNS disorders. The development of CNS therapies presents unique challenges, including an imperfect understanding of the biology, the presence of the blood-brain barrier that can restrict the flow of drugs to the brain, a frequent lack of translatability of nonclinical study results in subsequent clinical trials and dose selection, and the product candidate having an effect that may be too small to be detected using the outcome measures selected in clinical trials or if the outcomes measured do not reach statistical significance. There are few effective therapeutic options available for patients with MELAS and ADv and other CNS disorders. Our future success is highly dependent on the successful development of our technology and our product candidates for treating CNS. The scientific evidence to support the feasibility of developing our product candidates is both preliminary and limited. If we do not successfully develop and commercialize product candidates, we will not become profitable and the value of our common stock may decline.

We are currently pursuing clinical development activities for CY6463, and next generation compound, CY3018. Research and development of biopharmaceutical products is inherently risky. We may encounter substantial delays in our clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities in the development of CY6463 and CY3018 to treat patients with serious diseases of the central nervous system.

Our business depends heavily on the successful development, clinical testing, regulatory approvals and commercialization of our lead product candidates. On October 14, 2020, we announced topline results from our Phase 1 translational pharmacology study of CY6463, the first sGC stimulator in clinical development for CNS disorders, which supported the ongoing development of CY6463 in serious CNS diseases. The Company also announced its focus on discovering, developing and commercializing innovative medicines for people with serious diseases of the CNS. Although we have several product candidates, CY6463 and CY3018 are the only product candidates we are now developing internally. CY6463, CY3018. and any of our other current or potential product candidates, will require regulatory approvals based on substantial additional development and testing prior to commercialization.

Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive nonclinical and clinical studies that our product candidates are both safe and effective for use in each target indication. Each product candidate must demonstrate an adequate benefit-risk profile for its intended use in its intended patient population. In some instances, significant variability in safety or efficacy appear in different clinical studies of the same product candidate due to numerous factors, including changes in study protocols, differences in the number and characteristics of the enrolled study participants, variations in the dosing regimen and other clinical study parameters or the dropout rate among study participants. Product candidates in later stages of clinical studies often fail to demonstrate adequate safety and efficacy despite promising nonclinical testing and early clinical studies. Companies in the biopharmaceutical industry often suffer significant setbacks in later-stage clinical studies; most product candidates that begin clinical studies are never approved for commercialization by regulatory authorities. Favorable results in earlier stage trials, such as the topline results from CY6463’s Phase 1 translational pharmacology study may not be replicated in later stage trials. If we fail to produce positive results in our clinical trials of CY6463, the development timeline, regulatory approval and commercialization prospects of CY6463 and, correspondingly, our business and financial prospects, would be materially adversely affected.

The COVID-19 pandemic continues to disrupt our business, including our clinical development activities.

Many nations, including the United States, continue to implement stay-at-home orders, travel restrictions, and other limiting measures to contain the coronavirus (COVID-19) pandemic that, along with other related mitigation measures, has limited and may continue to limit our ability to access patients and physicians at certain local clinical centers that are participating in our development activities. To a limited extent, the pandemic delayed and disrupted our recently completed studies.

23


 

We may continue to face limitations and difficulties enrolling patients in our planned and future clinical trials if the patient populations that are eligible for our clinical trials continue to be affected by the coronavirus and/or the COVID-19 vaccines. COVID-19 restrictions and/or COVID-19 vaccination efforts at trial sites could delay our clinical studies. In addition, if the patients enrolled in our clinical trials become infected with COVID-19, we may have more adverse events and deaths in our clinical trials as a result. Vulnerable patients, including patients with serious diseases of the CNS, such as the patients enrolling in our clinical trials, may be at a higher risk of contracting COVID-19 and may experience more severe symptoms from the disease, adversely affecting our chances for regulatory approval or requiring further clinical studies. The adverse effects that may occur from administration of COVID-19 vaccines to patients participating in our clinical trials may adversely affect our clinical trial outcomes or data analysis. Furthermore, the extent to which the pandemic, or future outbreaks of infectious disease, hinders access to facilities, procurement of resources, raw materials or components necessary for research studies or preclinical or clinical development is not fully predictable. Delays and disruptions from the pandemic, or future outbreaks of infectious disease, may increase our capital needs while potentially interfering with our access to capital.

If we encounter difficulties in enrolling participants in our clinical studies, we could be delayed or prevented from proceeding with clinical trials of our product candidates.

Identifying and qualifying participants to participate in clinical studies of our product candidates is critical to our success. The timing of our clinical studies depends in part on the speed at which we can recruit participants to participate in testing our product candidates. Estimates of the prevalence of our target indications vary considerably. Determining the incidence of these conditions, including in specific geographies or demographic groups, is challenging. The lower the actual prevalence of these conditions, the more challenges we will encounter enrolling participants in our clinical studies, which could delay development of our product candidates. Clinical trial enrollment may also encounter difficulties for a variety of other reasons. The number of participants eligible for a clinical trial may be substantially limited by stringent eligibility criteria in a study protocol, such as the inclusion of biomarker-driven identification or other highly specific criteria related to stage of disease progression or to specific patient reported outcome measures. The number of participants required to power the statistical analysis of the study's endpoints may be very large leading to an extended enrollment period. Issues such as the proximity of participants to a study site, the complexity of the study design, our ability to recruit investigators with appropriate skill and experience, competing clinical studies for similar therapies or targeting similar participants, perceptions of the benefit-risk profile of the product candidate relative to other available therapies or product candidates, and ability to obtain and maintain institutional review board, or IRB, or ethics committee, or EC, approvals and participant consents all could have a substantial impact on the timing of clinical trial enrollment. If we are unable to enroll sufficient participants in clinical studies in a timely way, obtaining study results will be delayed, which may harm our business, prospects, financial condition and results of operations.

The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.

We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical studies and depends upon numerous factors, including the type and complexity of the product candidates involved. Regulatory authorities have substantial discretion in the approval process and may refuse to accept an application for review or may decide that our data are insufficient for approval and require additional nonclinical, clinical, or other information (e.g., product quality data or manufacturing controls). We have not requested or obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.

24


 

Our ongoing clinical studies may not be completed on schedule, and our planned clinical studies may not begin on schedule, if at all. The completion or commencement of clinical studies can be delayed or prevented for a number of reasons, including, among others:

the FDA or other regulatory bodies may not authorize us or our investigators to commence planned clinical studies, or require that we suspend ongoing clinical studies through imposition of clinical holds;
negative results from our ongoing studies or other industry studies involving product candidates modulating the same or similar mechanism of action;
delays in reaching or failing to reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the terms of which can be subject to considerable negotiation and may vary significantly among different CROs and study sites;
inadequate quantity or quality of a product candidate or other materials necessary to conduct clinical studies, for example delays in the manufacturing of sufficient supply of finished drug product;
difficulties obtaining EC or IRB approval(s) to conduct a clinical study at a prospective site or sites;
challenges in recruiting and enrolling participants in clinical studies, the proximity of participants to study sites, eligibility criteria for the clinical study, the nature of the clinical study protocol, the availability of approved effective treatments for the relevant disease and competition from other clinical study programs for similar indications;
severe or unexpected drug-related side effects experienced by participants in a clinical study;
the presence of unanticipated metabolites in participants in a clinical study may require considerable nonclinical and clinical assessment;
we may decide, or regulatory authorities may require us, to conduct additional clinical studies or abandon product development programs;
delays in validating, or inability to validate, any endpoints utilized in a clinical study;
the FDA or other regulatory bodies may disagree with our clinical study design and our interpretation of data from clinical studies, or may change the requirements for approval even after it has reviewed and commented on the design for our clinical studies;
reports from nonclinical or clinical testing of other competing candidates that raise safety or efficacy concerns; and
difficulties retaining participants who have enrolled in a clinical study but may be prone to withdraw due to rigors of the clinical studies, lack of efficacy, side effects, personal issues, or loss of interest.

Clinical studies may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical study may be suspended or terminated by us, the FDA or other comparable authorities, the IRBs or ECs overseeing a clinical study, a data and safety monitoring board overseeing the clinical study, or other regulatory authorities due to a number of factors, including, among others:

failure to conduct the clinical study in accordance with regulatory requirements or our clinical protocols;
inspection of the clinical study operations or study sites by the FDA or other regulatory authorities that reveals deficiencies or violations that require us to undertake corrective action, including in response to the imposition of a clinical hold;
unforeseen safety issues, including any that could be identified in our ongoing studies, adverse side effects or lack of effectiveness;
changes in government regulations or administrative actions;
problems with clinical supply materials; and

25


 

lack of adequate funding to continue clinical studies.

Our product candidates may cause side effects that are presented in the product labeling approved by regulatory authorities. Some may result in label restrictions.

The most commonly reported adverse events in the repeat-dose clinical studies for CY6463 were headache and GI-related symptoms, most commonly dyspepsia. As with ADEMPAS® (riociguat), the only FDA-approved sGC stimulator to date, CY6463 may cause serious birth defects if taken while pregnant, and our clinical studies require stringent contraceptive safeguards to prevent pregnancy. These side effects and any other undesirable side effects observed with our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical studies and could result in restrictive label language or delay or denial of regulatory approval.

Changes in regulatory requirements, FDA guidance or unanticipated events during our nonclinical studies and clinical studies of our product candidates may occur, which may result in changes to nonclinical or clinical study protocols or additional nonclinical or clinical study requirements, which could result in increased costs to us and could delay our development timeline.

Changes in regulatory requirements, FDA guidance or unanticipated events during our nonclinical studies and clinical studies may force us to amend nonclinical studies and clinical study protocols or the FDA may impose additional nonclinical studies and clinical study requirements. Amendments or changes to our clinical study protocols would require resubmission to the FDA and IRBs for review and approval, which may increase the cost or delay the timing or successful completion of clinical studies. Similarly, amendments to our nonclinical studies may increase the cost or delay the timing or successful completion of those nonclinical studies. If we experience delays completing, or if we terminate, any of our nonclinical or clinical studies, or if we are required to conduct additional nonclinical or clinical studies, the commercial prospects for our product candidates may be harmed and our ability to generate product revenue will be delayed.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.

In order to market any product outside of the United States, we must establish and comply with the numerous and varying safety, efficacy and other regulatory requirements of other countries. Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA or other comparable foreign regulatory authority grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional nonclinical or clinical studies, as studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. The marketing approval processes in other countries may implicate all of the risks detailed above regarding FDA approval in the United States, as well as other risks. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our product candidates is also subject to approval.

Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. Failure to obtain marketing approval in other countries or any delay or other setback in obtaining such approval would impair our ability to market our product candidates in such countries. Any such impairment would reduce the size of our potential market, which could have a material adverse impact on our business, prospects, financial condition and results of operations.

26


 

Data/market exclusivity may be more limited than we expect based upon the competitive landscape and other factors outside of our control that may occur during development or after approval

There are many types of data/market exclusivity mechanisms that we may seek to secure for our product candidates. Many of these have risk of loss of exclusivity if the competitive landscape changes or regulations are revised. If we seek and are awarded orphan drug designation in the US and/or the EU based upon criteria in effect at the time, this designation may be rescinded if a similar drug or another therapy that confers a significant benefit over ours is subsequently approved. If our product candidates were to fail to obtain orphan drug status, or lose such status after it is obtained, or the marketing exclusivity that such status provides, our business, prospects, financial condition and results of operations could be materially harmed. There are other types of data/market exclusivity rights granted after approval that may not confer exclusivity anticipated if the competitive landscape changes and our business, prospects, financial condition and results of operations could be materially harmed.

Risks Related to Our Reliance on Third Parties

Akebia may not be successful in developing any therapies through the praliciguat out-license and we may not realize any eligible revenue from the out-license.

On June 3, 2021, we entered into a license agreement with Akebia relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the pharmaceutical compound praliciguat and other related products and forms thereof enumerated in such agreement. Under the agreement, Akebia will be responsible for all future research, development, regulatory, and commercialization activities for certain products. Cyclerion is eligible to receive up to $15 million in the first 18 months of the term. Further milestone cash payments by Akebia are scheduled in the Agreement based on the initiation of phase 3 clinical trials in the U.S. for such products for first and second indication, for FDA approvals, for approvals in certain other major markets, and for certain sales milestones. In addition to these cash milestone payments, Akebia will pay Cyclerion tiered royalty payments on net sales in certain major markets at percentages ranging from the mid-single digits to the high-teens, subject to certain reductions and offsets. The agreement may be terminated by either party in the event a material breach by the other party, by us in the event of certain patent disputes or the failure by Akebia to initiate phase 2 clinical trials within a set period of time, and by Akebia, subject to a notice period, at any time after one year from the effective date. There can be no assurances that the agreement will result in any therapies or that it will not be terminated prior to the realization by us of any remaining eligible revenues.

Any collaboration or license arrangements that we enter into in the future may not be successful, which could impede our ability to develop and commercialize our product candidates.

We intend to seek collaboration or license arrangements for the commercialization, and/or potentially for the development, of certain of our product candidates depending on the merits of retaining commercialization rights for ourselves as compared to entering into collaboration or license arrangements. We will face significant challenges in seeking appropriate partners. Moreover, collaboration and license arrangements are complex and time-consuming to negotiate, document, implement and maintain. We may not be successful in our efforts to establish and implement such arrangements. The terms of any collaborations, licenses or other arrangements that we may establish may not be favorable to us.

Any future collaboration or license arrangements that we enter into may not be successful. The success of such arrangements will depend heavily on the efforts and activities of our partners. Collaboration and license arrangements are subject to numerous risks, including that:

partners have significant discretion in determining the efforts and resources that they will apply to collaborations;
a partner with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;
partners may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation

27


 

that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;
collaboration and license arrangements may be terminated, and, if terminated, this may result in a need for additional capital to pursue further development or commercialization of the applicable current or future product candidates;
partners may own or co-own intellectual property covering products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property;
disputes may arise with respect to the ownership of any intellectual property developed pursuant to our collaboration or license arrangements; and
a partner’s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.

We rely, and expect that we will continue to rely, on third parties to conduct any nonclinical or clinical studies for our product candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.

We do not have the infrastructure or internal resources and capabilities to independently conduct nonclinical or clinical studies. We rely on contract laboratories, medical institutions, clinical investigators, and other third parties, such as CROs, to conduct nonclinical studies on our discovery compounds and product candidates and clinical studies on product candidates. We rely heavily on such parties for execution of nonclinical and clinical studies and can control only certain aspects of their activities. As a result, we have less direct control over the conduct, timing and completion of our nonclinical and clinical studies and the management of data developed through these studies than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may have staffing difficulties, fail to comply with contractual obligations, experience regulatory compliance issues, undergo changes in priorities, become financially distressed or form relationships with other entities, some of which may be our competitors.

These factors may materially impede the willingness or ability of third parties to complete quality nonclinical and clinical studies and may subject us to unexpected cost increases that are beyond our control. Nevertheless, we are responsible for ensuring that each of our nonclinical and clinical studies is conducted in accordance with any applicable protocol, legal, regulatory and scientific requirements and standards, and our reliance on CROs and other third parties does not relieve us of our regulatory responsibilities. We, our CROs and other third parties are required to comply with regulations and guidelines, such as good laboratory practices (GLPs), good clinical practices (GCPs), and current Good Manufacturing Practices. These regulations are enforced by the FDA and comparable foreign regulatory authorities for any products in clinical development. The FDA enforces compliance to regulations through periodic inspections of clinical study sponsors, principal investigators, and third parties. If the FDA determines there was a failure to comply with the regulations the clinical data generated in our clinical studies may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical studies before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our nonclinical studies, clinical studies or product manufacturing complies with these regulations. Our failure or the failure of our CROs to comply with these regulations may require us to repeat clinical studies, which would delay the regulatory approval process and could also subject us to enforcement action up to and including civil and criminal penalties.

Although we design or approve the designs of our product candidate clinical studies, CROs conduct all of the clinical studies. As a result, many important aspects of the execution of our drug development programs are outside of our direct control. In addition, the CROs may not perform all of their obligations under arrangements with us or in compliance with regulatory requirements, but we remain responsible and are subject to enforcement action that may include civil penalties and criminal prosecution for any violations of FDA laws and regulations during the conduct of our clinical studies. If the CROs do not perform clinical studies in a satisfactory manner, breach their

28


 

obligations to us or fail to comply with regulatory requirements, the development and commercialization of our product candidates may be delayed or our development program materially and irreversibly harmed. We may fail to control the amount and timing of resources these CROs devote to our program or our clinical products. If we are unable to rely on clinical data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of our clinical studies and this could significantly delay commercialization and require significantly greater expenditures.

If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any clinical studies such CROs are associated with may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, we believe that our financial results and the commercial prospects for our product candidates in the approved indication would be harmed, our costs could increase and our ability to generate revenue could be delayed.

We rely completely on third-party suppliers to manufacture our nonclinical and clinical drug supplies for our product candidates, and we intend to rely on third parties to produce commercial supplies of any product candidates that are approved.

We do not currently have, nor do we plan to acquire, the infrastructure or capability to internally manufacture the drug supply of our product candidates, or any future product candidates, for use in the conduct of our nonclinical and clinical studies. We lack the internal resources and the capability to manufacture any product candidates on any scale. We depend on third-party contract manufacturing organizations, or CMOs, for all our requirements of raw materials, drug substance and drug product for our future and/or ongoing nonclinical studies and clinical trials of CY6463. We do not have long-term supply agreements in place with our CMOs and each batch of our product candidates is individually contracted under a services agreement on a purchase order basis. We expect to continue to rely on CMOs for the supply of CY6463 for later-stage development and commercialization, as well as for the supply of any other discovery compounds or product candidates that we may identify, and we may not be able to enter into long-term supply agreements with such CMOs on favorable terms. As a further result, we are subject to price fluctuations for our clinical drug supplies. If the prices charged by these CMOs increase, our business, prospects, financial condition and results of operations could be materially harmed. We apply industry risk management practices to minimize the impact to nonclinical and clinical timelines associated with delays to our clinical supplies. However, these delays could still lead to clinical trials delays that could adversely impact our business.

In addition, the facilities used by our contract manufacturers to manufacture the active pharmaceutical ingredient and final drug product must complete a pre-approval inspection by the FDA and other comparable foreign regulatory agencies to assess compliance with applicable requirements, including current GMP, after we submit our new drug application, or NDA, or relevant foreign regulatory submission to the applicable regulatory agency. If the FDA or an applicable foreign regulatory agency determines now or in the future that these facilities are noncompliant, we may need to find alternative manufacturing facilities, which would impede our ability to develop, obtain regulatory approval for or market our product candidates.

Our reliance on third parties requires us to share our confidential information, including trade secrets and know-how, which increases the possibility that our confidential information will be misappropriated or disclosed.

Because we rely on third parties to manufacture our product candidates, and because we collaborate with various CROs and other third parties to conduct our nonclinical studies and clinical trials, we must, at times, share our trade secrets or know-how with them. We seek to protect our confidential information, including know-how and trade secrets, in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors and consultants prior to beginning our collaborations or disclosing confidential information to such parties. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets and know-how. Despite these contractual provisions, the need to share our confidential information with third parties increases the risk that confidential information such as trade secrets and know-how becomes

29


 

known by our competitors, is inadvertently incorporated into the technology of others, or is disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our confidential information including know-how and trade secrets, a competitor's discovery of our confidential information or other unauthorized use or disclosure could impair our competitive position and may have a material adverse effect on our business, prospects, financial condition and results of operations.

Risks Related to Our Intellectual Property Rights

If we are unable to adequately protect our proprietary technologies, or obtain and maintain issued patents that are sufficient to protect our product candidates, others could compete against us more directly, which would have a material adverse impact on our business, prospects, financial condition and results of operations.

Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection in the United States and other countries for commercially important technology, inventions and know-how related to our business, defend and enforce our patents, should they issue, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of third parties. We strive to protect and enhance the proprietary technologies that we believe are important to our business, including seeking patents intended to cover our products and compositions, their methods of use and any other inventions that are important to the development of our business.

We have twenty-one issued U.S. patents, thirty pending U.S. patents applications (of which eight are in the provisional stage), three pending Patent Cooperation Treaty, or PCT, application, and numerous foreign patents and pending patent applications.

Our issued US patents covering 6463 expire in 2037, subject to patent term extension. Our issued U.S. and foreign patents covering olinciguat expire between 2031 and 2037 and our issued U.S. and foreign patents covering praliciguat and related compounds expire between 2031 and 2037, in each case subject to patent term extensions. Multiple pending U.S. and foreign patents applications covering different aspects of CY6463, praliciguat, and olinciguat will expire between 2031 and 2041, subject to patent term extensions. See “Business — Intellectual Property.” We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.

The patent positions of biotechnology and pharmaceutical companies, including ours, involve complex legal and factual questions, which in recent years have been the subject of much litigation, and, therefore, the issuance, scope, validity, enforceability and commercial value of any patent claims that we may obtain cannot be predicted with certainty. Our pending patent applications may not be granted as issued patents in any particular jurisdiction and, even if they do, these patents may not include claims with a sufficient scope to protect our product candidates or otherwise provide any competitive advantage.

Even if our patent applications are issued, competitors and other third parties may infringe, misappropriate or otherwise violate our patents and other intellectual property rights. We may not be able to prevent infringement, misappropriation or other violations of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the attention of our management and key personnel from our business operations

Moreover, our patents, if issued, may be challenged, deemed unenforceable, invalidated or circumvented in the United States and abroad. U.S. patents and patent applications may also be subject to interference, derivation, ex-parte reexamination, post-grant review, or inter-partes review proceedings, supplemental examination and challenges in district court. Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our involvement in litigation or interference proceedings may fail and, even if successful, may result in substantial costs, and distract our management and other employees. Furthermore, an adverse decision in an interference or derivation

30


 

proceeding can result in a third party receiving the patent right sought by us, which in turn could affect our ability to develop, market or otherwise commercialize our product candidates.

Patents may also be subjected to opposition, post-grant review or comparable proceedings lodged in various foreign, both national and regional, patent offices or courts. Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our product candidates or competitive products. In addition, such proceedings may be costly. Thus, any patents, should they issue, that we may own or exclusively license may not provide any protection against competitors.

Furthermore, though a patent, if it were to issue, is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability and it may not provide us with adequate protection to exclude competitors from making similar products. Even if a patent issues and is held to be valid and enforceable, competitors may be able to design around or circumvent our patents, such as by using pre-existing or newly developed technology or products in a non-infringing manner. If these developments were to occur, they could have a material adverse effect on our business, prospects, financial condition and results of operations.

Any litigation to enforce or defend our patent rights, even if we were to prevail, would be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.

In addition, proceedings to enforce or defend our patents, if and when issued, put our patents at risk of being invalidated, held unenforceable or not infringed, or interpreted narrowly. Such proceedings could also provoke third parties to assert counterclaims against us, including that some or all of the claims in one or more of our patents are invalid, not infringed or unenforceable. Grounds for a validity challenge include alleged failures to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for unenforceability assertions of a patent include allegations that someone connected with prosecution of the patent application that matured into the patent withheld relevant information from the U.S. Patent and Trademark Office, or the USPTO, or made a misleading statement, during prosecution of the patent application. In an infringement proceeding, a court may disagree with our allegations and refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question, or may decide that a patent of ours is invalid or unenforceable. An adverse result in any litigation, defense or post-grant proceedings could result in one or more of our patents being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it would have a material adverse effect on the price of our common stock.

The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates.

If any of our patents, if and when issued, covering our product candidates are invalidated or found not infringed or unenforceable, our business, prospects, financial condition and results of operations could be materially harmed.

We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates, if approved.

Our success will depend in part on our ability to operate without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. Other parties may allege that our product candidates or the use of our technologies infringes or otherwise violates patent claims or other intellectual property rights held by them or that we are employing their proprietary technology without authorization. There may be

31


 

third-party patents or patent applications with claims to compositions, materials, formulations, methods of manufacture or methods for treatment related to our product candidates. Because patent applications can take many years to issue, third parties may have currently pending patent applications which may later result in issued patents that our product candidates may infringe, or which such third parties claim are infringed by our technologies.

The pharmaceutical industry is characterized by extensive litigation regarding patents and other intellectual property rights. Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain and cannot be adequately quantified in advance. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either does not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operating results. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.

If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court, or redesign our products. In addition, if any such claim were successfully asserted against us and we could not obtain such a license, we may be forced to stop or delay developing, manufacturing, selling or otherwise commercializing our product candidates. Any claim relating to intellectual property infringement that is successfully asserted against us may require us to pay substantial damages, including treble damages and attorney's fees if we are found to be willfully infringing another party's patents, for past use of the asserted intellectual property and royalties and other consideration going forward if we are forced to take a license.

Any of these risks coming to fruition could have a material adverse effect on our business, prospects, financial condition and results of operations.

We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

Our employees, consultants, non-academic outside scientific collaborators and other advisors enter into confidentiality and intellectual property assignment agreements with us or have entered into confidentiality and intellectual property assignment agreements with Ironwood. We seek to have inventions assigned to us by the parties rendering services whenever possible. However, we may not be able to enter into these agreements with all parties (for example with academic collaborators) or these agreements may not be honored and may not effectively assign intellectual property rights to us.

Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property, or we may have to in-license intellectual property owned by another party. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies and our patent protection could be reduced or eliminated for non-compliance with these requirements.

The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions over the lifetime of our owned patents and applications. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors or other third parties might be able to enter the market earlier

32


 

than would otherwise have been the case and this circumstance could have a material adverse effect on our business, prospects, financial condition and results of operations.

We may not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.

The statutory deadlines for pursuing patent protection in individual foreign jurisdictions are based on the priority date of each of our patent applications and we may not timely file foreign patent applications. Thus, for each of the patent families that we believe provide coverage for our product candidates, we will need to decide whether and where to pursue protection outside the United States. Filing and prosecuting patent applications and defending patents on product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and so we are unlikely to pursue and maintain patents in all countries worldwide. As such, competitors may use our technologies in jurisdictions where we do not pursue and obtain patent protection to develop their own products.

The laws of some foreign countries may not protect intellectual property rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States even if we have a patent in that jurisdiction. Further, a competitor may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third parties from so competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to biotechnology or pharmaceuticals. This could make it difficult for us to stop the infringement of our patents, if obtained, or the misappropriation of or marketing of competing products in violation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries.

Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

If we do not obtain additional protection under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, and similar foreign legislation by extending the patent terms and obtaining data exclusivity for our product candidates, our business, prospects, financial condition and results of operations may be materially harmed.

Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of the U.S. patents we own may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent term extension as compensation for patent term lost during the FDA regulatory review process. A maximum of five years can be restored to the eligible patent. In all cases, the total patent life for the product with the patent extension cannot exceed 14 years from the product's approval date, or in other words, 14 years of potential marketing time. However, we may not be granted an extension because of, for example, failing to

33


 

apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain a patent term extension or the term of any such extension is less than we request, the duration of patent protection we obtain for our product candidates may not provide us with any meaningful commercial or competitive advantage, our competitors may obtain approval of competing products earlier than they would otherwise be able to do so, and our ability to generate revenues could be harmed.

Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.

As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation: the Leahy-Smith America Invents Act, or the America Invents Act. The America Invents Act includes a number of significant changes to U.S. patent law. These provisions affect the way patent applications will be prosecuted and may also affect patent litigation. It is not yet clear what, if any, impact the America Invents Act will have on the operation of our business. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any patents that may issue from our patent applications, all of which could have a material adverse effect on our business, prospects, financial condition and results of operations.

In addition to increasing uncertainty with regard to our ability to obtain future patents, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on these and other decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce any patents that may issue in the future.

We may be subject to damages resulting from claims that we or our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers.

Our employees may have been previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We also engage advisors and consultants who are concurrently employed at universities or who perform services for other entities.

We may be subject to claims that we or our employees, advisors or consultants have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third party. We may be subject to claims that an employee, advisor or consultant performed work for us that conflicts with that person's obligations to a third party, such as an employer, and thus, that the third party has an ownership interest in the intellectual property arising out of work performed for us. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our product candidates, which would materially harm our commercial development efforts.

Risks Related to the Future Commercialization of Our Product Candidates

The incidence and prevalence for target patient populations of our product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate, or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability may be harmed.

The incidence and prevalence for all the conditions we aim to address with our programs vary considerably. Our projections of both the number of people who have these diseases, as well as the subset of people with these

34


 

diseases who have the potential to benefit from treatment with our product candidates, are based on beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases. The total addressable market across all of our product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of our product candidates, if approved for sale for these indications, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products or new patients may become increasingly difficult to identify or gain access to, all of which would harm our results of operations and our business. Further, even if we obtain significant market share for our product candidates, because the potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.

If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates, if approved, we may not be successful in commercializing those product candidates if and when they are approved.

We do not currently have an infrastructure for the sale, marketing, market access, patient service and distribution of pharmaceutical products. In order to market our product candidates, if approved by the FDA or any other regulatory authority outside the United States, we must build our sales, marketing, managerial and other non-technical capabilities, or arrange with third parties to perform these services. There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time-consuming and could delay any product candidate launch. If commercialization is delayed or does not occur, we would have prematurely or unnecessarily incurred such expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel.

If we enter into arrangements with third parties to perform sales, marketing, commercial support and distribution services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may fail to enter into arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, or if we are unable to do so on commercially reasonable terms, we will not be successful in commercializing our product candidates if approved and our business, prospects, financial condition and results of operations will be materially harmed.

Even if we obtain regulatory approval for our product candidates, our product candidates may not achieve broad market acceptance by patients, physicians, healthcare payors or others in the medical community, which would limit the revenue that we generate from their sales.

The future commercial success of our product candidates, if approved by the FDA or other applicable regulatory authorities outside the United States, will depend upon the awareness and acceptance of our product candidates among the medical community, including patients, physicians and healthcare payors. If any of our product candidates are approved but do not achieve an adequate level of acceptance by patients, physicians, healthcare payors and others in the medical community, we may not generate sufficient revenue to become, or remain, profitable. Market acceptance of our product candidates, if approved, will depend on a number of factors, including, among others:

the efficacy and safety of our approved product candidates as demonstrated in clinical trials;
the clinical indications and labeling claims for our product candidates that are approved;
limitations or warnings contained in the labeling approved for our product candidates by the FDA or other applicable regulatory authorities;

35


 

any restrictions on the use of our products together with other medications or restrictions on the use of our products in certain types of patients;
the prevalence and severity of any adverse effects associated with our product candidates;
the size of the target patient population, and the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
the safety, efficacy, cost and other potential advantages of our approved product candidates compared to other available therapies;
our ability to generate cost effectiveness data that supports a profitable price;
our ability to obtain sufficient reimbursement and pricing by third-party payors and government authorities;
the willingness of patients to pay out-of-pocket in the absence of sufficient payor coverage;
the effectiveness of our sales and marketing strategies; or
publicity concerning our products or competing products and treatments.

If our product candidates are approved but do not achieve an adequate level of acceptance by patients, physicians and payors, we may not generate sufficient revenue from our product candidates to become or remain profitable. Before granting reimbursement approval, healthcare payors may require us to demonstrate that our product candidates, in addition to treating these target indications, also provide incremental health benefits to patients. Our efforts to educate the medical community and third-party payors about the benefits of our product candidates may require significant resources and may never be successful.

Reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our products profitably. Price controls may be imposed in certain markets, which may harm our future profitability.

Market acceptance and sales of any approved product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors and government authorities and may be affected by existing and future health care reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor's determination that use of a product is: a covered benefit under its health plan; safe, effective and medically necessary; appropriate for the specific patient; cost-effective; and neither experimental nor investigational.

Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. We or our partners may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our products. If reimbursement is not available or is available only to limited levels, we may not be able to commercialize certain of our products. In addition, in the United States, third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement of new drugs. As a result, significant uncertainty exists as to whether and how much third-party payors will reimburse patients for their use of newly approved drugs, which in turn will put pressure on the pricing of drugs.

In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European

36


 

Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or our partners may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed.

If we fail to comply with healthcare and other regulations, we could face substantial penalties and our business, prospects, financial condition and results of operations could be harmed.

The product candidates that we are evaluating in clinical studies are subject to certain federal and state healthcare laws and regulations that may affect our business. These laws and regulations include:

federal healthcare program anti-kickback laws, which prohibit, among other things, persons from offering, soliciting, receiving or providing remuneration, directly or indirectly, as an inducement or reward for their past, current or potential future prescribing, purchase, use, recommending for use, referral, formulary placement, or dispensing of our products;
the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and which also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;
the Federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug product and medical device research, development, and marketing, prohibits manufacturers from marketing or promoting such products prior to approval; and
state law equivalents of the above federal laws, such as anti-kickback laws, state transparency laws, state laws limiting interactions between pharmaceutical manufacturers and members of the healthcare industry and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts.

In addition, we may be subject to privacy and security laws in the various jurisdictions in which we operate, obtain or store personally identifiable information. For example, if we conduct clinical studies in any of the member states of the European Union, the processing of personal data in the European Economic Area, or the EEA, is subject to the 1995 Data Protection Directive, imposing strict obligations and restrictions on the ability to collect, analyze and transfer personal data. In May 2018, the General Data Protection Regulation, or the GDPR, took effect, increasing our obligations with respect to clinical studies conducted in the EEA and increasing the scrutiny applied by clinical study sites located in the EEA to transfers of personal data from such sites to countries that are considered by the European Commission to lack an adequate level of data protection, such as the United States. The compliance obligations imposed by the GDPR may increase our cost of doing business. In addition, the GDPR imposes substantial fines for breaches of data protection requirements, and it confers a private right of action on data subjects for breaches of data protection requirements.

If our operations are found to be in violation of any of the laws described above or any other laws, rules or regulations that apply to us, we will be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could impede our ability to operate our business and our financial results. We cannot be certain that compliance programs will address all areas of potential exposure and the risks in this area cannot be entirely eliminated, particularly because the requirements and government interpretations of the requirements in this space are constantly evolving. Any action against us for violation of these laws, rules or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business, as well as damage our business or reputation. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security, fraud and reporting laws may prove costly.

37


 

We face significant competition in an environment of rapid technological and scientific change, and our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may harm our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.

Our future success depends on our ability to demonstrate and maintain a competitive advantage with respect to the design, development and commercialization of our product candidates. Our objective is to design, develop and commercialize new products with superior efficacy, safety, tolerability and convenience. In many cases, our product candidates that we commercialize will compete with existing, market-leading products. The development and commercialization of new drug products is highly competitive. We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.

Bayer AG and Merck & Co., Inc. (“Bayer/Merck”), have an active collaboration on sGC stimulators including ADEMPAS® (riociguat), which has been approved for the treatment of Pulmonary Arterial Hypertension, (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Verquvo® (vericiguat), which is approved for the treatment of heart failure with reduced ejection fraction. Such sGC products may compete directly with our own product candidates in our non-CNS target indications. Because Bayer/Merck already have experience conducting successful clinical trials and obtaining regulatory approvals for an sGC product, they may be able to conduct clinical trials and obtain regulatory approvals for additional product candidates and target indications more quickly or efficiently than we can.

Furthermore, we are aware of a number of other approved products and late-stage product candidates for the treatment of our target indications.

MELAS. There are currently no approved treatments for MELAS or Mitochondrial Disease in the United States. We believe the following companies are engaged in clinical development of products for the treatment of MELAS or Mitochondrial Disease, which include patients with MELAS:

PTC Therapeutics has a registrational Phase 2/3 study ongoing of vatiquinone, an antioxidant/NQO1 modulator, assessing the treatment of Mitochondrial Disease in participants with refractory epilepsy. Khondrion B.V has a Phase 2b study ongoing with sonlicromanol, a redox modulator, assessing the attention domain of cognitive function in MELAS-spectrum disorders. Abliva AB has a Phase 1a/b study ongoing of KL1333, an NAD+ modulator, in Primary Mitochondrial Disease. Abliva AB has announced plans to initiate a pivotal clinical Phase II/III study of KL1333 in MELAS-Maternally inherited diabetes and deafness (MIDD) and Kearns-Sayre syndrome (KSS)-Chronic progressive external ophthalmoplegia (CPEO) spectrum disorders during 2021. Reneo Pharma LTD ran a Phase 1 study of REN001, a PPARδ agonist, in patients with Primary Mitochondrial Myopathy and has a planned Phase 2/3 study of REN001 in Primary Mitochondrial Myopathy. Astellas Pharma Inc has a planned Phase2/3 study of ASP0367, a PPARδ modulator, in patients with Primary Mitochondrial Myopathy.

ADv. There are currently no approved products in the United States to treat ADv. There are six products approved in the United States to treat AD symptoms.

Aricept® (donepezil) is a cholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer’s type, including in patients with mild, moderate and severe AD. Razadyne® (galantamine) and Exelon® (rivastigmine) are cholinesterase inhibitors indicated for treatment of mild to moderate dementia of the Alzheimer’s type. Namenda® (memantine) is an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Namzaric® is a combination of donepezil and memantine indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. Biogen received FDA approval for aducanumab, an anti-amyloid beta (Aβ) mAb, for the treatment of AD.

38


 

We are not aware of any companies engaged in clinical development of products for the treatment of ADv. There are many companies developing treatments for AD, which could be our competitors. These include the following companies engaged in the late-stage clinical development of products for the treatment of AD:

There are multiple Aβ targeting agents in Phase 3 studies for the treatment of AD, including Eli Lilly’s solanezumab (anti-Aβ mAb), Eisai/Biogen’s BAN2401 (anti-Aβ mAb), Roche’s gantenerumab (anti-Aβ mAb), Alzheon’s ALZ-801 (Aβ aggregation inhibitor) and AZTherapies’ALZT-OP1 (Aβ aggregation inhibitor). Compounds in Phase 3 studies with other mechanisms of action include TauRx’s TRx0237/LMTX (Tau aggregation inhibitor), Shanghai Greenvalley Pharmaceutical Co., Ltd.’s GV-971 (oligomannate), and AB Science’s masitinib (c-Kit, Lyn, Fyn and CSF1R kinase inhibitor). Compounds in Phase 2/3 studies include AgeneBio’s AGB-101 (SV2A inhibitor), Grifols IVIG (Immunoglobulin), Cortexyme’s atuzaginstat (bacterial protease inhibitor), Anavex’s ANAVEX 2-73 (Sigma-1, M2/M3 RA), and vTv Therapeutics’ azeliragon/TTP-488 (RAGE antagonist). There are many other companies engaged in earlier stage clinical development for products targeting AD.

CIAS. There are currently no approved products in the United States to treat CIAS. There many companies developing treatments for CIAS. These include the following companies engaged in the late-stage clinical development of products for the treatment of CIAS:

Boehringer Ingelheim has three ongoing registrational Phase 3 studies of the glycine transporter type-1 inhibitor, BI 425809, assessing safety and efficacy for the treatment of CIAS. Biogen has an ongoing Phase 2 study of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor positive allosteric modulator, BIIB104, assessing safety and efficacy in participants with CIAS. Neurocrine Biosciences has an ongoing Phase 2 study of the d-amino acid oxidase inhibitor, luvadaxistat, in participants with CIAS. atai Life Sciences has announced plans for a Phase 2 study of the cholinergic, glutamatergic and gamma-aminobutyric acid- B receptor modulator, RL-007, for the treatment of CIAS.

If our product candidates do not obtain regulatory approvals in our target indications prior to these or any other competing product candidates, or if our product candidates do not demonstrate superior efficacy, safety or tolerability compared to these and any other approved therapeutics for our target indications, we may not be able to compete effectively.

Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, nonclinical testing, conducting clinical studies, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market.

In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors' products and our competitors may allege that our products infringe, misappropriate or otherwise violate their intellectual property. The availability of our competitors' products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. See “—Risks Related to Our Intellectual Property Rights.”

The impact of healthcare reform and other governmental and private payor initiatives may harm our business.

Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to health care availability, the method of delivery or payment for health care products and services could harm our business, operations and financial condition. There is

39


 

significant interest in promoting health care reform, as evidenced by the enactment in the United States of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act in 2010. It is likely that federal and state legislatures within the United States and foreign governments will continue to consider changes to existing health care legislation. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect: the demand for any drug products for which we may obtain regulatory approval; our ability to set a price that we believe is fair for our products; our ability to obtain coverage and reimbursement approval for a product; our ability to generate revenues and achieve or maintain profitability; and the level of taxes that we are required to pay.

Our future growth may depend, in part, on our ability to commercialize our product candidates outside the United States, where we would be subject to additional regulatory burdens and other risks and uncertainties.

Our future profitability may depend, in part, on our ability to commercialize our product candidates outside the United States for which we may rely on partnerships with third parties. If we commercialize our product candidates outside the United States, we would be subject to additional risks and uncertainties, including:

our customers' ability to obtain reimbursement for our product candidates outside the United States;
our ability to gain reimbursement in foreign markets at a price that is profitable;
our inability to directly control commercial activities because we are relying on third parties;
the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;
different medical practices and customs in foreign countries affecting acceptance in the marketplace;
import or export licensing requirements;
longer accounts receivable collection times;
longer lead times for shipping;
language barriers for technical training;
reduced protection of intellectual property rights in some foreign countries;
the existence of additional potentially relevant third-party intellectual property rights;
foreign currency exchange rate fluctuations; and
the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.

Foreign sales of our product candidates could also be harmed by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs.

Our ability to generate meaningful revenues in jurisdictions outside of the United States may be limited due to the strict price controls and reimbursement limitations imposed by governments outside of the United States.

In some countries, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies, or to meet other criteria for pricing approval. If reimbursement of a product candidate, if approved, is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, prospects, financial condition and results of operations could be harmed.

40


 

If any of our product candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales of affected products.

Under the Hatch-Waxman Act, a pharmaceutical manufacturer may file an abbreviated new drug application, or an ANDA, seeking approval of a generic copy of an approved, small-molecule innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA that references the FDA's prior approval of the small-molecule innovator product. The Hatch-Waxman Act also provides for certain periods of regulatory exclusivity. These include, subject to certain exceptions, the period during which an FDA-approved drug is subject to orphan drug exclusivity. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, "Approved Drug Products with Therapeutic Equivalence Evaluations," known as the "Orange Book." If there are patents listed in the Orange Book, a generic or NDA applicant that seeks to market its product before expiration of the patents must include in the ANDA a "Paragraph IV certification," challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents.

Accordingly, if any of our product candidates are approved, competitors could file ANDAs for generic versions of our small-molecule drug products or NDAs that reference our small-molecule drug products, respectively. If there are patents listed for our small-molecule drug products in the Orange Book, those ANDAs and NDAs would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit.

We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any of our patents that are listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially.

Risks Related to Our Business Operations

Our prospects for success depend on our ability to retain our management team and to attract, retain and motivate qualified personnel.

We are highly dependent on our management, scientific and medical personnel, including our Chief Executive Officer, Peter M. Hecht, Ph.D., our Chief Financial Officer, Anjeza Gjino, our Chief Scientific Officer, Andreas Busch, Ph.D., and our Chief Operating Officer, Cheryl Gault. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. The loss of the services of any of our executive officers, other key employees and other scientific and medical advisors and an inability to find suitable replacements could result in delays in product development and harm our business. In particular, we continue our search for a new Chief Medical Officer, the absence of which for a continued period may have an adverse effect on our clinical and pre-clinical operations. Pursuant to their employment arrangements, each of our executive officers, and other employees may voluntarily terminate their employment at any time, with or without notice. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.

We may not be able to attract or retain qualified management and scientific personnel in the future due to the competition for a limited number of qualified personnel among biopharmaceutical, biotechnology, pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high quality candidates than what we may be able to offer. We also experience competition for the hiring of scientific personnel from universities and research institutions. The failure to succeed in nonclinical or clinical studies may make it more challenging to recruit and retain qualified personnel. In addition, in order to induce employees to continue their employment with us, we have provided equity awards that vest over time and the value to our employees of such equity awards may be significantly affected by

41


 

movements in our stock price that are beyond our control and may be at any time insufficient to counteract more lucrative offers from other companies. If we are unable to continue to attract and retain high quality personnel, the rate and success at which we can develop and commercialize product candidates will be limited.

We may need to expand our organization and we may experience difficulties in managing growth of our employee base, which could disrupt our operations.

As of December 31, 2021, we had 32 full-time employees and we will continue to align our workforce with our business priorities throughout 2022. To the extent our operations grow, we may need to expand our full-time employee base and hire more consultants and contractors. Our management may then need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing this growth. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate revenues could be adversely affected and we may not be able to implement our business strategy.

We face potential product liability exposure, and, if claims are brought against us, we may incur substantial liability.

The use of our product candidates in clinical studies and the sale of our products, if approved, exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers or others selling or otherwise coming into contact with our product candidates. For example, we may be sued if any product candidate we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, including as a result of interactions with alcohol or other drugs, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we become subject to product liability claims and cannot successfully defend ourselves against them, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in, among other things: withdrawal of subjects from our clinical studies; substantial monetary awards to patients or other claimants; decreased demand for our product candidates or any future product candidates following marketing approval, if obtained; damage to our reputation and exposure to adverse publicity; increased FDA warnings on product labels; litigation costs; distraction of management's attention from our primary business; loss of potential revenue; and the inability to successfully commercialize our product candidates or any future product candidates, if approved.

We maintain product liability insurance coverage for our clinical studies through both domestic and international insurance policies, subject to an annual coverage limit. Nevertheless, our insurance coverage may be insufficient to reimburse us for any expenses or losses we may suffer if a judgment or settlement exceeds available insurance proceeds. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses, including if insurance coverage becomes increasingly expensive. If and when we obtain marketing approval for our product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may not be able to obtain this product liability insurance on commercially reasonable terms. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if resolved in our favor, could be substantial, particularly in light of the size of our business and financial resources. A product liability claim or series of claims brought against us could cause our stock price to decline and, if we are unsuccessful in defending such a claim or claims and the resulting judgments exceed our insurance coverage, our business, prospects, financial condition and results of operations could be materially harmed.

During the course of treatment, patients may suffer adverse events, including death, for reasons that may or may not be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our product candidates, if approved, or require us to suspend or abandon our commercialization efforts of any approved product candidates. Even in a circumstance in which we do not believe

42


 

that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, prospects, financial condition and results of operations.

If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could result in sanctions or other penalties that would harm our business.

We are subject to the reporting requirements of the Securities Exchange Act of 1934, or The Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and the rules and regulations of the Nasdaq Global Select Market, or Nasdaq. We are an “emerging growth company” and a “smaller reporting company.” For so long as we remain either an emerging growth company or a smaller reporting company, we will be exempt from Section 404(b) of the Sarbanes-Oxley Act, which requires auditor attestation to the effectiveness of internal control over financial reporting. We will cease to be an emerging growth company on the date that is the earliest of (i) the last day of the fiscal year in which we have total gross annual revenues of $1.07 billion or more; (ii) December 31, 2024, the last day of our fiscal year following the fifth anniversary of the date of the Separation; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Even after we no longer qualify as an emerging growth company, we may still qualify as a smaller reporting company, which would allow us to take advantage of many of the same exemptions from disclosure requirements, including exemption from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on the exemptions available to us as an emerging growth company and/or smaller reporting company. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

We are, however, subject to Section 404(a) of the Sarbanes-Oxley Act. Beginning with our annual report on Form 10-K for the fiscal year ended December 31, 2021, we must include a management assessment of the effectiveness of our internal control over financial reporting. As of the expiration of our emerging growth company status and smaller reporting company status, we will be broadly subject to enhanced reporting and other requirements under the Exchange Act and Sarbanes-Oxley Act. We have engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. There can be no assurances that in future periods we will be able to timely conclude that our internal control over financial reporting is effective as required by Section 404(a).

We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.

If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our business, prospects, financial condition and results of operations could be harmed, our investors could lose confidence in our reported financial information, the market price of our stock could decline, and we could be subject to sanctions or investigations by the SEC or other regulatory authorities.

43


 

Unfavorable global economic conditions could harm our business, prospects, financial condition and results of operations.

Our results of operations could be harmed by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business, prospects, financial condition and results of operations.

Our internal computer systems, or those of our third-party CROs, CMOs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product candidates' development programs.

Despite the implementation of security measures, our internal computer systems and those of our third-party CROs, CMOs, business development partners and other contractors and consultants may be vulnerable to damage from computer viruses, unauthorized access, ransomware, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical study data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the further development of our product candidates could be delayed. Insurance may not be adequate to fully cover costs to restore data and resume normal working operations, which could harm our business, prospects, financial condition and results of operation.

Our employees may engage in misconduct or other improper activities, including violating applicable regulatory standards and requirements or engaging in insider trading, which could significantly harm our business.

We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with the regulations of the FDA and applicable foreign regulators, provide accurate information to the FDA and applicable foreign regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately and/or disclose unauthorized activities to us. In particular, research and development, commercialization and business arrangements in the healthcare industry are subject to considerable laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict, regulate or prohibit a wide range of activities pertaining to clinical trials including the informed consent process, data integrity and conducting the study in accordance with the investigational plan, and for approved products, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of, including trading on, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may be ineffective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions, possible exclusions from participation in Medicare, Medicaid and other U.S. federal healthcare programs, contractual damages and reputational harm.

If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We and any contract manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated

44


 

materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.

We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act, or the FCPA, and other worldwide anti-bribery laws.

We are subject to the FCPA, which prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations. In some countries in which we operate, the pharmaceutical and life sciences industries are exposed to a high risk of corruption associated with the conduct of clinical trials and other interactions with healthcare professionals and institutions. Any such activities could expose us to potential liability under the FCPA, which may result in us incurring significant criminal and civil penalties and to potential liability under the anti-corruption laws and regulations of other jurisdictions in which we operate. In addition, the costs we may incur in defending against an FCPA investigation could be significant.

Risks Related to the Separation

Our rights under the intellectual property license agreement with Ironwood could be challenged.

In connection with the Separation, we entered into an intellectual property license agreement with Ironwood, in connection with which Ironwood granted to us a license to use certain Ironwood know-how in connection with our research and development of sGC stimulator products. If we were to use such licensed know-how and if our rights under the intellectual property license agreement were challenged by a third party or we were otherwise prevented from exercising our rights as contemplated under the intellectual property license agreement, our research and development activities could be delayed until we were able to either resume exercising such rights or develop or acquire adequate alternative know-how.

Our agreements with Ironwood may not reflect terms that would have resulted from negotiations with unaffiliated third parties.

The agreements related to the Separation, including, among others, the separation agreement (which we refer to as the "Separation Agreement"), the employment matters agreement, the tax matters agreement, the intellectual property license agreement, and the development agreement (which we refer to as the "Development Agreement"), were negotiated in the context of the Separation while we were still controlled by Ironwood. Until the distribution occurred, Ironwood effectively had the sole and absolute discretion to determine and change the terms of the Separation, including the terms of any agreements between Ironwood and us and the establishment of the record date and distribution date. As a result, the provisions thereof may be unfavorable to us and may not reflect terms that would have resulted from negotiations between unaffiliated third parties.

Risks Related to Ownership of Our Common Stock

The market price of our common stock may fluctuate widely and you could lose all or part of your investment in our common stock as a result.

Our common stock has a limited trading history and the market price has fluctuated widely, and may in the future fluctuate widely, depending upon many factors, some of which are beyond our control, including the following:

a relatively low-volume trading market for our shares of common stock may result, which could cause trades of small blocks of shares to have a significant impact on the price of our shares of common stock;

45


 

results and timing of nonclinical studies and clinical studies of our product candidates;
the commercial performance of our products, if approved, as well as the costs associated with such activities;
results of clinical studies of our competitors' products;
failure to adequately protect our trade secrets;
our inability to raise additional capital and the terms on which we raise it;
commencement or termination of any strategic partnership or licensing arrangement;
regulatory developments with respect to our products or our competitors' products, including any developments, litigation or public concern about the safety of such products;
announcements concerning product development results, including clinical trial results, the introduction of new products or intellectual property rights of us or others;
actual or anticipated fluctuations in our financial condition and our quarterly and annual operating results;
deviations in our operating results from any guidance we may provide or the estimates of securities analysts;
additions and departures of key personnel;
the passage of legislation or other regulatory developments affecting us or our industry;
fluctuations in the valuation of companies perceived by investors to be comparable to us;
sales of our common stock by us, our insiders or our other shareholders;
strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;
announcement or expectation of additional financing efforts;
publication of research reports by securities analysts about us or our competitors or our industry and speculation regarding our company or our stock price in the financial or scientific press or in online investor communities;
changes in market conditions in the pharmaceutical and biotechnology sector;
Nasdaq's rules, which impose certain continued listing requirements, including a minimum $1 bid price, such that a failure to meet these requirements would lead Nasdaq to take steps to delist our common stock; and
changes in general market and economic conditions.

In addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, results of operations, financial condition and prospects. If any of the foregoing occurs, it could cause our stock price to fall and may expose us to lawsuits that, even if unsuccessful, could be costly to defend and a distraction to management.

The market price for our common stock is particularly volatile.

The market for our common stock is characterized by significant price volatility when compared to seasoned issuers, and we expect that our stock price will continue to be more volatile than those of a seasoned issuer. Several factors cause the volatility in our share price. We are a speculative or “risky” investment due to our short operating history, lack of revenues and the uncertain success (including of regulatory approval) of any of our product candidates. As a consequence of this risk, more risk-averse investors may, under the fear of losing all or most of their investment in the event of negative news or lack of progress, be more inclined to sell their shares of our

46


 

common stock more quickly and at greater discounts than would be the case with the stock of a seasoned issuer. Plaintiffs have, in the past, initiated securities class action litigation against a company following periods of volatility in the market price of its securities. We may in the future be the target of such litigation. Securities litigation could result in substantial costs and liabilities and could divert management’s attention and resources.

If securities or industry analysts fail to initiate or maintain coverage of our stock, publish a negative report or change their recommendations regarding our stock adversely, our stock price and trading volume could decline.

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us, our business, our market or our competitors. If securities or industry analysts fail to initiate coverage of our stock, the lack of exposure to the market could cause our stock price or trading volume to decline. If any of the analysts who cover us or may cover us in the future publish a negative report or change their recommendation regarding our stock adversely, or provide more favorable relative recommendations about our competitors, our stock price would likely decline. If any analyst who covers us or may cover us in the future were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

We do not expect to pay any cash dividends for the foreseeable future.

We do not anticipate that we will pay any cash dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our operations. In addition, any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our common stock.

We have anti-takeover provisions in our articles of organization and bylaws and are subject to provisions of Massachusetts law that may frustrate any attempt to remove or replace our current board of directors or to effect a change of control or other business combination involving our company.

Our restated articles of organization and bylaws and certain provisions of Massachusetts law may discourage certain types of transactions involving an actual or potential change of control of our company that might be beneficial to us or our security holders. For example, our bylaws grant our directors the right to adjourn any meetings of shareholders. Our board of directors also may issue shares of any class or series of preferred stock in the future without shareholder approval and upon such terms as our board of directors may determine. The rights of the holders of our common stock will be subject to, and may be harmed by, the rights of the holders of any class or series of preferred stock that may be issued in the future. Massachusetts state law also prohibits us from engaging in specified business combinations unless the combination is approved or consummated in a prescribed manner. These provisions, alone or together, could delay hostile takeovers and changes in control of our company or changes in our management.

Our articles of organization designate the state and federal courts located within the Commonwealth of Massachusetts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our shareholders, which could discourage lawsuits against us and our directors and officers.

Our restated articles of organization designate the state and federal courts located within the Commonwealth of Massachusetts as the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to us or our shareholders, creditors or other constituents, any action asserting a claim arising pursuant to any provision of the Massachusetts Business Corporation Act, or the MBCA, or any action asserting a claim governed by the internal affairs doctrine, in all cases subject to the court's having personal jurisdiction over the indispensable parties named as defendants. In additional, our articles of organization provide that unless our board of directors consents in writing to the selection of an alternative forum, the U.S. federal district courts shall be the exclusive forum for the resolutions of any complaint asserting a cause of action arising under the U.S. federal securities laws. This exclusive forum provision may limit the ability of our shareholders to bring a claim in a judicial forum that such shareholders find favorable for disputes with us or our directors or officers, which may discourage such lawsuits against the

47


 

company and our directors and officers. Alternatively, if a court outside of Massachusetts were to find this exclusive forum provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings described above, we may incur additional costs associated with resolving such matters in other jurisdictions, which could harm our business, prospects, financial condition and results of operations.

Item 1B. Unresolved Staff Comments.

None.

Item 2. Properties

In April 2021 we completed our exit from our prior laboratory and office facilities in Cambridge Massachusetts and moved to an operating model under which we outsource our research and development laboratory work and we are currently leasing office space on an “as-needed” basis.

We are not a party to any material legal proceedings at this time. From time to time, we may be subject to various legal proceedings and claims, which may have a material adverse effect on our financial position or results of operations.

Item 4. Mine Safety Disclosures.

Not applicable.

48


 

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information for Common Stock

Our common stock is listed on the Nasdaq Global Select Market under the symbol “CYCN.”

Holders of Record

As of February 18, 2022, we had 93 holders of record of our common stock, which excludes stockholders whose shares were held in nominee or street name by brokers. The actual number of common stockholders is greater than the number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

Dividend Policy

We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects and any other factors deemed relevant by our board of directors.

Unregistered Sales of Equity Securities

The following sets forth information as to all securities we sold in 2021 which were not registered under the Securities Act:

On June 3, 2021, the Company entered into a Common Stock Purchase Agreement (the “June 2021 Equity Private Placement”) for a private placement of 5,735,988 shares of the Company’s common stock for total gross proceeds of approximately $18 million. The closing of the June 2021 Equity Private Placement occurred on June 7, 2021. The June 2021 Equity Private Placement was exempt from registration under the Securities Act pursuant to Regulation D thereunder. The Company did not use a placement agent or broker in connection with the June 2021 Equity Private Placement and incurred no commissions and no material direct transaction fees. In connection with the June 2021 Equity Private Placement transaction, on June 16, 2021, the Company filed a registration statement on Form S-3, with the U.S. Securities and Exchange Commission, registering for resale the shares of common stock and shares of common stock sold in the June 2021 Equity Private Placement, which registration statement was declared effective by the SEC on June 23, 2021.

Purchase of Equity Securities by the Issuer and Affiliated Parties

None.

Item 6. Selected Financial Data.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

49


 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in this Annual Report on Form 10-K.

Forward-Looking Information

The following discussion of our financial condition and results of operations should be read in conjunction with the audited consolidated financial statements and the corresponding notes included in this Annual Report on Form 10‑K. This discussion contains forward‑looking statements that involve significant risks and uncertainties. As a result of many factors, such as those referenced or set forth under “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” in Item 1A of this Annual Report on Form 10‑K, our actual results may differ materially from those anticipated in these forward‑looking statements.

Overview

We are a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative medicines for people with serious diseases of the CNS, including cognitive and neurodegenerative disorders. Our current lead asset, CY6463, is a pioneering, CNS-penetrant sGC stimulator in clinical development for ADv, CIAS, and MELAS. sGC stimulators are small molecules that act synergistically with NO on sGC to boost production of cyclic guanosine monophosphate, or cGMP. cGMP is a key second messenger that, when produced by sGC, regulates diverse and critical biological functions in the CNS including blood flow and vascular dynamics, inflammatory and fibrotic processes, bioenergetics, metabolism and neuronal function.

We operate in one reportable business segment—human therapeutics.

Financial Overview

Research and Development Expense. Research and development expenses are incurred in connection with the discovery and development of our product candidates. These expenses consist primarily of the following costs: compensation, benefits and other employee-related expenses, research and development related facilities, third-party contracts relating to nonclinical study and clinical trial activities. All research and development expenses are charged to operations as incurred.

CNS assets. The core of our portfolio is CY6463, an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and potentially disease-modifying therapy for CNS diseases associated with cognitive impairment. NO-sGC-cGMP is a fundamental CNS signaling network, but it has not yet been leveraged for its full therapeutic potential. CY6463 enhances the brain’s natural ability to produce cGMP, an important second messenger in the CNS, by stimulating sGC, a key node in the NO-sGC-cGMP pathway. This pathway is critical to basic CNS functions, and deficient NO-sGC-cGMP signaling is believed to play an important role in the pathogenesis of many CNS diseases. Agents that stimulate sGC to produce cGMP may compensate for deficient NO signaling.

In January 2020, we announced positive Phase 1 study results that provided the foundation for continued development of CY6463. The Phase 1 healthy participant study results indicate that CY6463 was well tolerated. Pharmacokinetic (PK) data, obtained from both blood and cerebral spinal fluid (CSF), support once-daily dosing with or without food and demonstrated CY6463 penetration of the blood-brain-barrier with CSF concentrations expected to be pharmacologically active.

In October 2020, we announced positive topline results from our CY6463 Phase 1 translational pharmacology study in healthy elderly participants. Treatment with CY6463 for 15 days in this 24-subject study confirmed and extended results seen in the earlier first-in-human Phase 1 study: once-daily oral treatment demonstrated blood-brain-barrier penetration with expected CNS exposure and target engagement. Results also showed significant improvements in neurophysiological and objective performance measures as well as in inflammatory biomarkers associated with aging and neurodegenerative diseases. CY6463 was safe and generally

50


 

well tolerated in this study. Significant effects on cerebral blood flow and markers of bioenergetics were not observed in this study of healthy elderly participants. We believe that these results, together with nonclinical data, support continued development of CY6463 as a potential new medicine for serious CNS diseases.

We have initiated exploratory clinical trials with CY6463 ADv, CIAS, and MELAS. The ADv study will be supported in part by a grant from the Alzheimer's Association’s Part the Cloud-Gates Partnership Grant Program, which provides Cyclerion with $2 million of funding over two years.

Our next-generation CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with greater CSF-to-plasma exposure relative to CY6463 based on nonclinical studies, CY3018 is intended to expand the potential of sGC stimulation for the treatment of disorders of the CNS.

Non-CNS assets. We have other assets that are outside of our current strategic focus. These non-core assets are not being internally developed at this time. Praliciguat is an orally administered, once-daily systemic sGC stimulator. On June 3, 2021, we entered into a License Agreement with Akebia relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the pharmaceutical compound praliciguat and other related products and forms, thereof enumerated in such agreement. Olinciguat is an orally administered, once-daily, vascular sGC stimulator that was evaluated in a Phase 2 study of participants with sickle cell disease. We released topline results from this study in October 2020. Olinciguat is available for licensing to a third party partner.

The following table summarizes our research and development expenses, employee and facility related costs allocated to research and development expense, and discovery and pre-clinical phase programs, for the years ended December 31, 2021 and 2020. The product pipeline expenses relate primarily to external costs associated with nonclinical studies and clinical trial costs, which are presented by development candidate.

 

 

 

Year Ended
December 31,

 

 

 

2021

 

 

2020

 

 

 

(in thousands)

 

Product pipeline external costs:

 

 

 

 

 

 

CY6463

 

$

12,396

 

 

$

5,561

 

CY3018

 

 

3,310

 

 

 

 

Olinciguat

 

 

252

 

 

 

6,868

 

Praliciguat

 

 

(401

)

 

 

311

 

Discovery research

 

 

700

 

 

 

1,218

 

Total product pipeline external costs

 

 

16,257

 

 

 

13,958

 

Personnel and related internal costs

 

 

11,374

 

 

 

27,503

 

Facilities and other

 

 

10,005

 

 

 

14,953

 

Total research and development expenses

 

$

37,636

 

 

$

56,414

 

 

Securing regulatory approvals for new drugs is a lengthy and costly process. Any failure by us to obtain, or any delay in obtaining, regulatory approvals would materially adversely affect our product development efforts and our business overall.

Given the inherent uncertainties of pharmaceutical product development, we cannot estimate with any degree of certainty how our programs will evolve, and therefore the amount of time or money that would be required to obtain regulatory approval to market them. As a result of these uncertainties surrounding the timing and outcome of any approvals, we are currently unable to estimate precisely when, if ever, our discovery and development candidates will be approved. We invest carefully in our pipeline, and the commitment of funding for each subsequent stage of our development programs is dependent upon the receipt of clear, supportive data.

The successful development of our product candidates is highly uncertain and subject to a number of risks including, but not limited to:

The full impact of COVID-19 pandemic continues to develop and could continue to adversely affect our programs and operations, including our clinical trials, corporate development, and other activities.

51


 

Cyclerion works closely with its clinical trial sites and investigators to deliver trials in a manner consistent with the safety of study participants and healthcare professionals.
The duration of clinical trials may vary substantially according to the type and complexity of the product candidate and may take longer than expected.
The United States FDA and comparable agencies outside the United States impose substantial and varying requirements on the introduction of therapeutic pharmaceutical products, which typically require lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures.
Data obtained from nonclinical and clinical activities at any step in the testing process may be adverse and lead to discontinuation or redirection of development activity. Data obtained from these activities also are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.
The duration and cost of discovery, nonclinical studies and clinical trials may vary significantly over the life of a product candidate and are difficult to predict.
The costs, timing and outcome of regulatory review of a product candidate may not be favorable, and, even if approved, a product may face post-approval development and regulatory requirements.
The emergence of competing technologies and products and other adverse market developments may reduce or eliminate the potential value of our pipeline.

As a result of the factors listed above, including the factors discussed under the “Risk Factors” section in Item 1A of this Annual Report on Form 10-K, we are unable to determine the duration and costs to complete current or future nonclinical and clinical stages of our product candidates or when, or to what extent, we will generate revenues from the commercialization and sale of our product candidates. Development timelines, probability of success and development costs vary widely. We anticipate that we will make determinations as to which additional programs to pursue and how much funding to direct to each program on an ongoing basis in response to the data from the studies of each product candidate, the competitive landscape and ongoing assessments of such product candidate’s commercial potential.

General and Administrative Expense. General and administrative expense consists primarily of compensation, benefits and other employee-related expenses for personnel in our administrative, finance, legal, information technology, business development, and human resource functions. Other costs include the legal costs of pursuing patent protection of our intellectual property, general and administrative related facility costs, insurance costs and professional fees for accounting and legal services. We record all general and administrative expenses as incurred.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make certain estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. We base our estimates on our historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from our estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.

We believe that our application of accounting policies requires significant judgments and estimates on the part of management and is the most critical to aid in fully understanding and evaluating our reported financial results. Our significant accounting policies are more fully described in Note 2, Summary of Significant Accounting Policies, of the consolidated financial statements elsewhere in this Annual Report on Form 10-K.

52


 

All research and development expenses are expensed as incurred. We defer and capitalize nonrefundable advance payments we make for research and development activities until the related goods are received or the related services are performed. See Note 2, Summary of Significant Accounting Policies, of the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.

Results of Operations

The revenue and expenses reflected in the consolidated financial statements may not be indicative of revenue and expenses that will be incurred by us in the future. The following discussion summarizes the key factors we believe are necessary for an understanding of our consolidated financial statements.

 

Expenses

 

 

 

Year Ended
December 31,

 

 

Change

 

 

 

2021

 

 

2020

 

 

$

 

 

%

 

 

 

(dollars in thousands)

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Revenue from license agreement

 

$

3,000

 

 

$

 

 

$

3,000

 

 

 

100

%

Revenue from development agreement

 

 

320

 

 

 

 

 

 

320

 

 

 

100

%

Revenue from grants

 

 

622

 

 

 

 

 

 

622

 

 

 

100

%

Revenue from related party

 

 

 

 

 

2,296

 

 

 

(2,296

)

 

 

(100

)%

Total revenues

 

 

3,942

 

 

 

2,296

 

 

 

1,646

 

 

 

72

%

Cost and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

37,636

 

 

 

56,414

 

 

 

(18,778

)

 

 

(33

)%

General and administrative

 

 

20,620

 

 

 

28,816

 

 

 

(8,196

)

 

 

(28

)%

Loss/ (Gain) on lease modification and termination

 

 

881

 

 

 

(1,669

)

 

 

2,550

 

 

 

(153

)%

Total cost and expenses

 

 

59,137

 

 

 

83,561

 

 

 

(24,424

)

 

 

(29

)%

Loss from operations

 

 

(55,195

)

 

 

(81,265

)

 

 

26,070

 

 

 

(32

)%

Sublease termination income, net

 

 

 

 

 

2,875

 

 

 

(2,875

)

 

 

(100

)%

Gain on Extinguishment of Debt

 

 

3,564

 

 

 

 

 

 

3,564

 

 

 

100

%

Interest and other (expenses) income, net

 

 

(16

)

 

 

588

 

 

 

(604

)

 

 

(103

)%

Net loss

 

$

(51,647

)

 

$

(77,802

)

 

$

26,155

 

 

 

(34

)%

 

Revenues. As of January 2021, revenues earned from the services performed under the Development Agreement for Ironwood, are not considered to be related party revenues (see Note 3). The increase in revenue of approximately $1.6 million for the year ended December 31, 2021, compared to the year ended December 31, 2020, can be attributed to $3.0 million in revenue from the License Agreement (see Note 14), approximately $0.6 million in revenue associated with the PTC Grant (see Note 15) and approximately $0.3 million in revenue from the Akebia Supply Agreement (see Note 14), offset by a decrease in revenue generated from services performed under the Development Agreement, which ended on March 31, 2021.

Research and development expenses. The decrease in research and development expenses of approximately $18.8 million for the year ended December 31, 2021 compared to the year ended December 31, 2020 was primarily driven by a decrease of approximately $16.1 million in salaries, and other employee-related expenses, including $4.5 million in stock-based compensation, primarily due to lower average headcount, a decrease of approximately $9.2 million in facilities and other operating costs allocated to research and development primarily due to the reduction in the Company's total leased premises, partially offset of approximately $2.3 million in external research costs, and approximately $4.2 million related to a non-cash write-off of leasehold improvements related to the Termination Agreement in 2021. The increase in external research costs was primarily due to an increase of approximately $6.8 million in clinical trial costs for CY6463 in MELAS, CIAS and ADv, an increase of approximately $3.3 million associated with CY3018, offset by approximately $6.6 million related to olinciguat and approximately $0.7 million related to praliciguat studies, due to the completion of both studies, and a decrease of approximately $0.5 million in discovery costs.

General and administrative expenses. The decrease in general and administrative expenses of approximately $8.2 million for the year ended December 31, 2021 compared to the year ended December 31, 2020 was primarily driven by a decrease of approximately $5.4 million in salaries and other employee-related costs, including $2.5 million in stock-based compensation, primarily due to lower average headcount, a decrease of approximately $2.0 million in facilities and operating costs, primarily due to the reduction in Company's total leased

53


 

premises, a decrease of approximately $2.3 million in outside professional and corporate expenses, including a decrease of approximately $1.7 million in professional expenses related to the Company's 2020 financing activities, and a decrease of approximately $0.6 million of administrative costs, partially offset by an increase of approximately $2.1 million related to a non-cash write-off of leasehold improvements related to the Termination Agreement in 2021.

Loss (Gain) on lease modification and termination. The loss on lease modification and termination of approximately $0.9 million recorded for the year ended December 31, 2021 is related to the lease termination of the Head Lease at 301 Binney Street in Cambridge, Massachusetts that was executed on April 30, 2021, compared to a gain on lease modification and termination of approximately $1.7 million in the year ended December 31, 2020 related to the Lease Amendment of the Head Lease at 301 Binney Street in Cambridge, Massachusetts that was executed in February 28, 2020 (see Note 8 to the Consolidated Financial Statements).

Sublease termination income, net. The sublease termination income, net of $2.9 million recorded in the year ended December 31, 2020 represents the difference between the consideration received and the consideration given up related to the Sublease Termination Agreement that was executed on September 15, 2020.

Gain on Extinguishment of Debt. The gain on extinguishment of debt of $3.5 million recorded in the year ended December 31, 2021 represents the write off of the Paycheck Protection Program ("PPP") loan, which was forgiven by the Small Business Association ("SBA") in November 2021.

Interest and other (expenses) income, net. Interest and other (expenses) income, net decreased by approximately $0.6 million for the year ended December 31, 2021, compared to the year ended December 31, 2020 due to a decrease of approximately $0.3 million in interest income driven by lower interest rates in the current year as compared to the prior year, and a decrease of approximately $0.3 million due to net sublease income recorded in 2020.

Liquidity and Capital Resources

Prior to the Separation, the primary source of liquidity for our business was cash flow allocated to Cyclerion from Ironwood. Post Separation, transfers of cash to and from Ironwood related to the Development Agreement and provisions of the Separation Agreement, have been reflected in the consolidated statement of cash flows.

After the Separation on April 1, 2019, we raised approximately $165 million net of direct financing expenses with the closing of the 2019 Equity Private Placement on April 2, 2019.

On July 29, 2020, we closed on a private placement of 6,062,500 shares of our common stock, pursuant to a Common Stock Purchase Agreement, for total gross proceeds of approximately $24.3 million. There were no material fees or commissions related to the transaction. The Company intends to use the proceeds to fund working capital and other general corporate purposes.

On September 3, 2020, the Company entered into a sales agreement (which we refer to as the "Sales Agreement") with Jefferies with respect to the ATM Offering under the Registration Statement on Form S-3 (the "Shelf"). Under the ATM Offering, the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million through Jefferies as its sales agent. The Company will pay to Jefferies cash commissions of 3.0 percent of the gross proceeds of sales of common stock under the Sales Agreement. During the year ended December 31, 2021, the Company sold 3,353,059 shares of common stock for net proceeds of $12.5 million under the ATM Offering.

On June 7, 2021, the Company closed on a private placement of 5,735,988 shares of common stock, pursuant to a Common Stock Purchase Agreement, for total gross proceeds of approximately $18 million. There were no material fees or commissions related to the transactions. The Company intends to use the proceeds to fund working capital and other general corporate purposes.

Our ability to continue to fund our operations and meet capital needs will depend on our ability to generate cash from operations and access to capital markets and other sources of capital, as further described below. We

54


 

anticipate that our principal uses of cash in the future will be primarily to fund our operations, working capital needs, capital expenditures and other general corporate purposes.

On December 31, 2021, we had approximately $54.0 million of unrestricted cash and cash equivalents. Our cash equivalents include amounts held in U.S. government money market funds. We invest cash in excess of immediate requirements in accordance with our investment policy, which requires all investments held by us to be at least “AAA” rated or equivalent, with a remaining final maturity when purchased of less than twelve months, so as to primarily achieve liquidity and capital preservation.

Going Concern

Based on the timing expectations of our research and development plans, including our clinical trials, we expect that our existing cash and cash equivalents as of December 31, 2021, will be sufficient to fund our planned operating expenses and capital expenditure requirements through the next 12 months following the date of this Annual Report on Form 10-K. We have based this estimate on assumptions that may prove to be wrong, particularly as the process of testing drug candidates in clinical trials is costly and the timing of progress in these trials is uncertain.

Cash Flows

The following is a summary of cash flows for the years ended December 31, 2021 and 2020:

 

 

 

Year Ended
December 31,

 

 

Change

 

 

 

2021

 

 

2020

 

 

$

 

 

%

 

 

 

(dollars in thousands)

 

Net cash used in operating activities

 

$

(36,517

)

 

$

(72,490

)

 

$

35,973

 

 

 

(50

)%

Net cash provided by investing activities

 

$

1,457

 

 

$

18

 

 

$

1,439

 

 

 

7992

%

Net cash provided by financing activities

 

$

30,785

 

 

$

28,090

 

 

$

2,695

 

 

 

10

%

Cash Flows from Operating Activities

Net cash used in operating activities was $36.5 million for the year ended December 31, 2021 compared to $72.5 million for the year ended December 31, 2020. The decrease in net cash used in operations of $36.0 million primarily relates to a decrease in our net loss of $26.2 million, non-cash leasehold improvement write off of $6.3 million in the current year, the recording of non-cash loss on lease termination of $0.9 million in the current year and non-cash gain on lease modification of $1.7 million in prior year, non-cash gain on lease termination of sublease for $2.9 million in prior year, and a decrease in working capital accounts of $8.8 million, partially offset by the recording of a non-cash gain on extinguishment of debt of $3.6 million due to the PPP Loan forgiveness in the current year and a decrease of stock-based compensation and other non-cash items of $7.2 million.

Cash Flows from Investing Activities

Net cash provided by investing activities was $1.5 million for the year ended December 31, 2021 compared to net cash provided by investing activities of a de minimis amount for the year ended December 31, 2020. The increase in net cash provided by investing activities of $1.4 million was primarily from an increase in cash received from sale of lab equipment in 2021.

Cash Flows from Financing Activities

Net cash provided by financing activities was $30.8 million for the year ended December 31, 2021 compared to $28.1 million for the year ended December 31, 2020. The increase of $2.7 million was the result of cash received from the June 2021 Equity Private Placement of $18 million, net proceeds from the ATM Offering of $12.5 million, partially offset by the cash received from the 2020 Equity Private Placement of $24.3 million, and the cash received from the short-term note payable of $3.5 million in 2020.

55


 

Debt – Paycheck Protection Program

On April 21, 2020, we received loan proceeds in the amount of approximately $3.5 million pursuant to a promissory note agreement (the “Promissory Note”) with a bank under the Paycheck Protection Program of which certain key terms were adjusted by the Paycheck Protection Program Flexibility Act (“PPPFA”). The Promissory Note had an initial loan maturity of April 20, 2022, a stated interest rate of 1.0% per annum, and had payments of principal and interest that were due monthly after an initial deferral period where interest accrued, but no payments were due. Under the PPPFA, the initial deferral may be extended from six up to ten months and the loan maturity may be extended from two to five years. The Promissory Note provided for customary events of default, including, among others, those relating to failure to make payment when due and breaches of representations. The loan is subject to all the terms and conditions applicable under the PPPFA and is subject to review by the SBA for compliance with program requirements.

In August 2021, the Company applied with the SBA for forgiveness of the PPP loan and was notified on November 4, 2021, that the SBA has approved our application to forgive the entire amount of the loan and accrued interest. In November 2021, the Company recorded a gain on extinguishment of debt of $3.6 million representing the principal and accrued interest for the PPP Loan.

Funding Requirements

We expect our expenses to fluctuate as we advance the preclinical activities and clinical trials of our product candidates.

We believe that our existing cash and cash equivalents as of December 31, 2021 will enable us to fund our planned operating expenses and capital expenditure requirements at least through the next 12 months following the date of this Annual Report on Form 10-K, excluding net cash flows from potential business development activities. We based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.

Because of the many risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our working capital requirements. Our expenses will fluctuate, and our future funding requirements will depend on, and could increase or decrease significantly as a result of, many factors, including the:

scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical studies and clinical trials;
costs, timing and outcome of regulatory review of our product candidates;
costs of future activities, including medical affairs, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;
cost and timing of necessary actions to support our strategic objectives;
costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and
timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or future product candidates, if any.

A change in any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing of the development of that product candidate. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity

56


 

or convertible debt securities, outstanding equity ownership may be materially diluted, and the terms of securities sold in such transactions could include liquidation or other preferences that adversely affect the rights of holders of common stock. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, debt financing would result in increased fixed payment obligations.

If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us.

If we are unable to raise additional funds when needed, we may be required to delay, reduce or eliminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Contractual Commitments and Obligations

Tax-related Obligations

We exclude assets, liabilities or obligations pertaining to uncertain tax positions from our summary of contractual commitments and obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of December 31, 2021, we had no uncertain tax positions.

Other Funding Commitments

As of December 31, 2021, we had, and continue to have, several ongoing studies in various clinical trial stages. Our most significant clinical trial spending is with clinical research organizations, or CROs. The contracts with CROs generally are cancellable, with notice, at our option and do not have any significant cancellation penalties.

Off-Balance Sheet Arrangements

We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, that would have been established for the purpose of facilitating off-balance sheet arrangements (as that term is defined in Item 303(a)(4)(ii) of Regulation S-K) or other contractually narrow or limited purposes. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in those types of relationships. We enter into guarantees in the ordinary course of business related to the guarantee of our own performance.

New Accounting Pronouncements

For a discussion of new accounting pronouncements see Note 2, Summary of Significant Accounting Policies, of the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 8. Financial Statements and Supplementary Data.

The information required by this Item 8 is set forth in our financial statements included in Part IV, Item 15 of this Annual Report on Form 10-K.

57


 

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and our principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.

With respect to the year ended December 31, 2021, under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of December 31, 2021 to provide reasonable assurance that the information required to be disclosed by us in this Annual Report was (a) reported within the time periods specified by SEC rules and regulations and (b) communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding any required disclosure.

Management's Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S. generally accepted accounting principles (“GAAP”). Internal control over financial reporting is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

Pertain to the maintenance of records that accurately and fairly reflect in reasonable detail the transactions and dispositions of the assets of our company;
Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
Provide reasonable assurances regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material adverse effect on our financial statements.

Management assessed our internal control over financial reporting as of December 31, 2021, the end of our fiscal year. Management based its assessment on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Management’s assessment included evaluation of elements such as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies, and our overall control environment.

Based on this assessment, management has concluded that our internal controls over financial reporting were effective as of December 31, 2021 and provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with GAAP. We reviewed the results of management’s assessment with the Audit Committee of our Board of Directors.

58


 

Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

Attestation Report of the Registered Public Accounting Firm

This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Our report was not subject to attestation by our independent registered public accounting firm pursuant to the rules of the Securities and Exchange Commission for “emerging growth companies” that permit us to provide only management’s report in this report.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal year ended December 31, 2021 which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Internal Controls

In designing and evaluating the disclosure controls and procedures, management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud.

Item 9B. Other Information.

Not applicable.

Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.

Not applicable.

59


 

PART III

We will file a definitive Proxy Statement for our 2021 Annual Meeting of Stockholders, or the Proxy Statement, with the SEC, pursuant to Regulation 14A, not later than 120 days after the end of our fiscal year. Accordingly, certain information required by Part III has been omitted under General Instruction G(3) to Form 10-K. Only those sections of the 2021 Proxy Statement that specifically address the items set forth herein are incorporated by reference.

Item 10. Directors, Executive Officers and Corporate Governance.

The information required by this Item 10 will be included in our Proxy Statement under the captions “Information Regarding the Board of Directors and Corporate Governance,” “Election of Directors,” “Executive Officers” and “Section 16(a) Beneficial Ownership Reporting Compliance” and is incorporated herein by reference.

Item 11. Executive Compensation.

The information required by this Item 11 will be included in our Proxy Statement under the captions “Executive Compensation” and “Director Compensation” and is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this Item 12 will be included in our Proxy Statement under the captions “Security Ownership of Certain Beneficial Owners and Management” and “Securities Authorized for Issuance under Equity Compensation Plans” and is incorporated herein by reference.

The information required by this Item 13 will be included in our Proxy Statement under the captions “Transactions with Related Persons” and “Independence of the Board of Directors” and is incorporated herein by reference.

Item 14. Principal Accounting Fees and Services.

The information required by this Item 14 will be included in our Proxy Statement under the caption “Ratification of Selection of Independent Registered Public Accounting Firm” and is incorporated herein by reference.

60


 

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(a)(1) Financial Statements

See the Index to Consolidated Financial Statements in the Financial Statements Section beginning on page F-1 of this Annual Report on Form 10-K.

(a)(2) Financial Statement Schedules

All financial statement schedules have been omitted as they are not required, not applicable, or the required information is included in the financial statements or notes to the financial statements.

(a)(3) Exhibits

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

 

 

  2.1

 

Separation Agreement, dated March 30, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to Current Report on Form 8-K filed on April 2, 2019 (File No. 001-38787))

 

 

 

  3.1

 

Restated Articles of Organization of Cyclerion Therapeutics, Inc. (incorporated by reference to Exhibit 4.1 to Registration Statement on Form S-8 filed on March 29, 2019) (File No. 333-230615))

 

 

 

  3.2

 

Amended and Restated Bylaws of Cyclerion Therapeutics, Inc. (incorporated by reference to Exhibit 4.2 to Registration Statement on Form S-8 filed on March 29, 2019) (File No. 333-230615))

 

 

 

  4.1

 

Description of Securities Registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended

 

 

 

10.1

 

Tax Matters Agreement, dated March 30, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc. (incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed on April 2, 2019 (File No. 001-38787))

 

 

 

10.2

 

Employee Matters Agreement, dated March 30, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc. (incorporated by reference to Exhibit 10.4 to Current Report on Form 8-K filed on April 2, 2019 (File No. 001-38787))

 

 

 

10.3

 

Development Agreement, dated April 1, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc. (incorporated by reference to Exhibit 10.5 to Current Report on Form 8-K filed on April 2, 2019 (File No. 001-38787))

 

 

 

10.4

 

Intellectual Property License Agreement, dated April 1, 2019, by and between Ironwood Pharmaceuticals, Inc. and Cyclerion Therapeutics, Inc. (incorporated by reference to Exhibit 10.6 to Current Report on Form 8-K filed on April 2, 2019 (File No. 001-38787))

 

 

 

10.5+

 

Form of Indemnification Agreement between Cyclerion Therapeutics, Inc. and individual directors and officers (incorporated by reference to Exhibit 10.7 to Form 10 filed on January 28, 2019 (File No. 001-38787))

 

 

 

10.6+

 

Offer Letter, effective April 1, 2019, by and between Cyclerion Therapeutics, Inc. and Peter M. Hecht, Ph.D. (incorporated by reference to Exhibit 10.11 to Current Report on Form 8-K filed on April 2, 2019 (File No. 001-38787))

 

 

 

10.7+

 

Cyclerion Therapeutics, Inc. 2019 Employee Stock Purchase Plan (incorporated by reference to Exhibit 4.3 to Registration Statement on Form S-8 filed on March 29, 2019 (File No. 333-230615))

 

61


 

 

 

 

10.8+

 

Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan and forms of agreements thereunder (incorporated by reference to Exhibit 4.4 to Registration Statement on Form S-8 filed on March 29, 2019 (File No. 333-230615))

 

 

 

10.9+

 

Cyclerion Therapeutics, Inc. Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan and forms of agreement thereunder (incorporated by reference to Exhibit 4.5 to Registration Statement on Form S-8 filed on March 29, 2019 (File No. 333-230615))

 

 

 

10.10+

 

Cyclerion Therapeutics, Inc. Executive Severance Plan (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on September 25, 2019 (File No. 001-38787))

 

 

 

10.11+

 

Non-Employee Director Compensation Plan (effective June 1, 2019) (incorporated by reference to Exhibit 10.7 on Form 10-Q filed on August 12, 2019 (File No. 001-38737))

 

 

 

10.12

 

Open Market Sale AgreementSM, dated September 3, 2020, by and between Cyclerion Therapeutics, Inc. and Jefferies LLC (incorporated by reference to Exhibit 10.1 of the Company’s Form 8-K filed on September 3, 2020).

 

 

 

10.13*

 

License Agreement, dated as of June 3, 2021, by and between Cyclerion Therapeutics, Inc. and Akebia Therapeutics, Inc (incorporated by reference to Exhibit 10.2 of the Company's Form 10-Q filed on July 30, 2021).

 

 

 

10.14

 

Common Stock Purchase Agreement, dated as of June 3, 2021, by and between Cyclerion Therapeutics, Inc. and the Investors named therein (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-3 filed on June 16, 2021 (File No. 333-257145)).

 

 

 

21.1

 

List of Subsidiaries

 

 

 

23.1

 

Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm

 

 

 

31.1

 

Certificate of Chief Executive Officer (Principal Executive Officer) pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

31.2

 

Certificate of Chief Financial Officer (Principal Financial Officer) pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

32.1

 

Certificate of Chief Executive Officer (Principal Executive Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

32.2

 

Certificate of Chief Financial Officer (Principal Executive Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

101.INS

 

Inline XBRL Instance Document

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

 

Cover Page Interactive Data File

 

+ Indicates a management contract or compensatory plan.

* Certain portions of this exhibit (indicated by asterisks) have been omitted because they are not material and are the type that the Registrant treats as private or confidential.

Item 16. Form 10-K Summary.

Not applicable.

62


 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorized, on February 24, 2022.

 

 

CYCLERION THERAPEUTICS, INC.

 

By:

/s/ Peter Hecht

 

 

Peter M. Hecht

 

 

Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on February 24, 2022.

 

Signature

 

Title

 

/s/ Peter Hecht

 

 

Peter M. Hecht

 

Chief Executive Officer (Principal Executive Officer)

 

/s/ Anjeza Gjino

 

 

Anjeza Gjino

 

Chief Financial Officer (Principal Financial Officer and
Principal Accounting Officer)

 

/s/ Errol De Souza

 

 

Errol De Souza

 

Director

 

/s/ George Conrades

 

 

George Conrades

 

Director

 

/s/ Marsha Fanucci

 

 

Marsha Fanucci

 

Director

 

/s/ Ole Isacson

 

 

Ole Isacson

 

Director

 

/s/ Stephanie Lovell

 

 

Stephanie Lovell

 

Director

 

/s/ Terrance McGuire

 

 

Terrance McGuire

 

Director

 

/s/ Michael Mendelsohn

 

 

Michael Mendelsohn

 

Director

 

 

 

 

 

 

 

63


 

Index to Consolidated Financial Statements of Cyclerion Therapeutics, Inc.

 

 

Page

Report of Independent Registered Public Accounting Firm - PCAOB ID:42

F-2

 

 

Consolidated Balance Sheets as of December 31, 2021 and 2020

F-3

 

 

Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2021 and 2020

F-4

 

 

Consolidated Statement of Stockholders’ Equity for the Years Ended December 31, 2021 and 2020

F-5

 

 

Consolidated Statements of Cash Flows for the Years Ended December 31, 2021 and 2020

F-6

 

 

Notes to the Consolidated Financial Statements

F-7

 

 

F-1


 

Report of Independent Registered Public Accounting Firm

 

To the Shareholders and the Board of Directors of Cyclerion Therapeutics, Inc

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Cyclerion Therapeutics, Inc (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, shareholders' equity and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2018.

Boston, Massachusetts

February 24, 2022

F-2


 

Cyclerion Therapeutics, Inc.

Consolidated Balance Sheets

(In thousands except share and per share data)

 

 

 

December 31,
2021

 

 

December 31,
2020

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

53,961

 

 

$

54,395

 

Accounts receivable

 

 

100

 

 

 

 

Related party accounts receivable

 

 

 

 

 

127

 

Prepaid expenses

 

 

928

 

 

 

816

 

Other current assets

 

 

468

 

 

 

3,163

 

Total current assets

 

 

55,457

 

 

 

58,501

 

Restricted cash, net of current portion

 

 

 

 

 

3,837

 

Property and equipment, net

 

 

65

 

 

 

6,865

 

Operating lease right-of-use asset

 

 

1,402

 

 

 

43,402

 

Other assets

 

 

2,407

 

 

 

2,773

 

Total assets

 

$

59,331

 

 

$

115,378

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

1,828

 

 

$

1,149

 

Related party accounts payable

 

 

 

 

 

286

 

Accrued research and development costs

 

 

6,353

 

 

 

1,421

 

Accrued expenses and other current liabilities

 

 

2,904

 

 

 

7,294

 

Short-term note payable

 

 

 

 

 

3,509

 

Current portion of operating lease liabilities

 

 

 

 

 

3,293

 

Total current liabilities

 

 

11,085

 

 

 

16,952

 

Operating lease liabilities, net of current portion

 

 

 

 

 

38,933

 

Commitments and contingencies (Note 7)

 

 

 

 

 

 

Stockholders' equity

 

 

 

 

 

 

Common stock, no par value, 400,000,000 shares authorized and 43,410,185 issued and outstanding at December 31, 2021 and 400,000,000 shares authorized and 34,047,300 issued and outstanding at December 31, 2020

 

 

 

 

 

 

Accumulated deficit

 

 

(215,076

)

 

 

(163,429

)

Paid-in capital

 

 

263,345

 

 

 

222,949

 

Accumulated other comprehensive loss

 

 

(23

)

 

 

(27

)

Total stockholders' equity

 

 

48,246

 

 

 

59,493

 

Total liabilities and stockholders' equity

 

$

59,331

 

 

$

115,378

 

The accompanying notes are an integral part of these consolidated financial statements.

F-3


 

Cyclerion Therapeutics, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(In thousands except per share data)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Revenues:

 

 

 

 

 

 

Revenue from license agreement

 

$

3,000

 

 

$

 

Revenue from development agreement

 

 

320

 

 

 

 

Revenue from grants

 

 

622

 

 

 

 

Revenue from related party

 

 

 

 

 

2,296

 

Total revenues

 

 

3,942

 

 

 

2,296

 

Cost and expenses:

 

 

 

 

 

 

Research and development

 

 

37,636

 

 

 

56,414

 

General and administrative

 

 

20,620

 

 

 

28,816

 

Loss/ (Gain) on lease modification and termination

 

 

881

 

 

 

(1,669

)

Total cost and expenses

 

 

59,137

 

 

 

83,561

 

Loss from operations

 

 

(55,195

)

 

 

(81,265

)

Sublease termination income, net

 

 

 

 

 

2,875

 

Gain on extinguishment of debt

 

 

3,564

 

 

 

 

Interest and other (expenses) income, net

 

 

(16

)

 

 

588

 

Net loss

 

$

(51,647

)

 

$

(77,802

)

Net loss per share:

 

 

 

 

 

 

Basic and diluted net loss per share

 

$

(1.32

)

 

$

(2.56

)

Weighted average shares used in calculating:

 

 

 

 

 

 

Basic and diluted net loss per share

 

 

39,144

 

 

 

30,403

 

 

 

 

 

 

 

 

Other comprehensive loss:

 

 

 

 

 

 

Net loss

 

$

(51,647

)

 

$

(77,802

)

Other comprehensive loss:

 

 

 

 

 

 

Foreign currency translation adjustment (loss) gain

 

 

4

 

 

 

(7

)

Comprehensive loss

 

$

(51,643

)

 

$

(77,809

)

 

The accompanying notes are an integral part of these consolidated financial statements.

F-4


 

Cyclerion Therapeutics, Inc.

Consolidated Statements of Stockholders’ Equity

(In thousands except share data)

 

 

 

Common Stock

 

 

Paid-in

 

 

Accumulated

 

 

Accumulated
other
comprehensive

 

 

Total
Stockholders’

 

 

 

Shares

 

 

Amount

 

 

capital

 

 

deficit

 

 

loss

 

 

equity

 

Balance at December 31, 2019

 

 

27,598,133

 

 

$

 

 

$

183,376

 

 

$

(85,627

)

 

$

(20

)

 

$

97,729

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(77,802

)

 

 

 

 

 

(77,802

)

Issuance of common stock - 2020 private placement

 

 

6,062,500

 

 

 

 

 

 

24,250

 

 

 

 

 

 

 

 

 

24,250

 

Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan

 

 

386,667

 

 

 

 

 

 

331

 

 

 

 

 

 

 

 

 

331

 

Share-based compensation expense related to issuance of stock options and RSUs to employees and employee stock purchase plan

 

 

 

 

 

 

 

 

14,992

 

 

 

 

 

 

 

 

 

14,992

 

Foreign currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(7

)

 

 

(7

)

Balance at December 31, 2020

 

 

34,047,300

 

 

$

 

 

$

222,949

 

 

$

(163,429

)

 

$

(27

)

 

$

59,493

 

Net loss

 

 

 

 

$

 

 

$

 

 

$

(51,647

)

 

$

 

 

 

(51,647

)

Issuance of common stock - 2021 equity private placement

 

 

5,735,988

 

 

 

 

 

 

18,028

 

 

 

 

 

 

 

 

 

18,028

 

Issuance of common stock - ATM

 

 

3,353,059

 

 

 

 

 

 

12,475

 

 

 

 

 

 

 

 

 

12,475

 

Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan

 

 

273,838

 

 

 

 

 

 

282

 

 

 

 

 

 

 

 

 

282

 

Share-based compensation expense related to issuance of stock options and RSUs to employees and employee stock purchase plan

 

 

 

 

 

 

 

 

7,915

 

 

 

 

 

 

 

 

 

7,915

 

Share‑based compensation expense related to issuance of stock options and RSUs to non-employees

 

 

 

 

 

 

 

 

1,696

 

 

 

 

 

 

 

 

 

1,696

 

Foreign currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4

 

 

 

4

 

Balance at December 31, 2021

 

 

43,410,185

 

 

$

 

 

$

263,345

 

 

$

(215,076

)

 

$

(23

)

 

$

48,246

 

 

The accompanying notes are an integral part of these consolidated financial statements.

F-5


 

Cyclerion Therapeutics, Inc.

Consolidated Statements of Cash Flows

(In thousands)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss

 

$

(51,647

)

 

$

(77,802

)

Adjustments to reconcile net loss to net cash (used in) operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

472

 

 

 

2,297

 

Net loss on disposal of property and equipment

 

 

6,322

 

 

 

159

 

(Gain) / loss on lease modification and termination

 

 

881

 

 

 

(1,669

)

Sublease termination income, net

 

 

 

 

 

(2,875

)

Gain on extinguishment of debt

 

 

(3,564

)

 

 

 

Share-based compensation expense

 

 

9,611

 

 

 

14,992

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

(100

)

 

 

 

Related party accounts receivable

 

 

127

 

 

 

1,346

 

Prepaid expenses

 

 

(112

)

 

 

1,150

 

Other current assets

 

 

1,244

 

 

 

(55

)

Operating lease assets

 

 

(59

)

 

 

(2,598

)

Other assets

 

 

366

 

 

 

(888

)

Accounts payable

 

 

679

 

 

 

(1,301

)

Related party accounts payable

 

 

(286

)

 

 

205

 

Accrued research and development costs

 

 

4,932

 

 

 

(776

)

Accrued expenses and other current liabilities

 

 

(4,335

)

 

 

(1,983

)

Operating lease liabilities

 

 

(1,048

)

 

 

(2,692

)

Net cash (used in) operating activities

 

 

(36,517

)

 

 

(72,490

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

Purchases of property and equipment

 

 

(7

)

 

 

(1,524

)

Proceeds from sale of property and equipment

 

 

1,464

 

 

 

1,542

 

Net cash provided by investing activities

 

 

1,457

 

 

 

18

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

Proceeds from equity private placement and ATM

 

 

30,503

 

 

 

24,250

 

Proceeds from exercises of stock options and ESPP

 

 

282

 

 

 

331

 

Proceeds from short-term note payable

 

 

 

 

 

3,509

 

Net cash provided by financing activities

 

 

30,785

 

 

 

28,090

 

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

 

4

 

 

 

(7

)

Net decrease in cash, cash equivalents and restricted cash

 

 

(4,271

)

 

 

(44,389

)

Cash, cash equivalents and restricted cash, beginning of period

 

 

58,232

 

 

 

102,621

 

Cash, cash equivalents and restricted cash, end of period

 

$

53,961

 

 

$

58,232

 

Supplemental cash flow disclosure:

 

 

 

 

 

 

Cash paid for initial direct costs of lease modification

 

$

 

 

$

6,507

 

Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets

 

 

 

 

 

 

Cash and cash equivalents

 

$

53,961

 

 

$

54,395

 

Restricted cash

 

 

 

 

 

3,837

 

Total cash, cash equivalents and restricted cash

 

$

53,961

 

 

$

58,232

 

 

The accompanying notes are an integral part of these consolidated financial statements.

F-6


 

Cyclerion Therapeutics, Inc.

Notes to the Consolidated Financial Statements

1. Nature of Business

Nature of Operations

Cyclerion Therapeutics, Inc. (“Cyclerion”, the “Company” or “we”) is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Our lead asset, CY6463, is a pioneering, central nervous system (CNS) penetrant, soluble guanylate cyclase (sGC) stimulator that is currently in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS). sGC stimulators are small molecules that act synergistically with nitric oxide (NO) as positive allosteric modulators of sGC to boost production of cyclic guanosine monophosphate (cGMP). cGMP is a key second messenger that, when produced by sGC, regulates diverse and critical biological functions in the CNS including neuronal function, neuroinflammation, cellular bioenergetics, and vascular function.

Cyclerion GmbH, a wholly owned subsidiary, was incorporated in Zug, Switzerland on May 3, 2019. Cyclerion GmbH is an operational entity with one employee who is the Company’s Chief Scientific Officer. The functional currency is the Swiss franc.

Cyclerion Securities Corporation, a wholly owned subsidiary, was incorporated in Massachusetts on November 15, 2019 and was granted securities corporation status in Massachusetts for the 2019 tax year. Cyclerion Securities Corporation has no employees.

Company Overview

The Company’s mission is to develop treatments that restore cognitive function. Its priorities are advancing its ongoing CY6463 clinical programs and next generation compound, CY3018.

CNS assets. CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases. NO-sGC-cGMP is a fundamental CNS signaling network, but it has not yet been leveraged for its full therapeutic potential. CY6463 enhances the brain’s natural ability to produce cGMP, an important second messenger in the CNS, by stimulating sGC, a key node in the NO-sGC-cGMP pathway. This pathway is critical to basic CNS functions and deficient NO-sGC-cGMP signaling is believed to play an important role in the pathogenesis of neurodegenerative diseases. Agents that stimulate sGC to produce cGMP may compensate for deficient NO signaling.

On January 13, 2020, we announced positive results from our Phase 1 first-in-human study that provided the foundation for continued development of CY6463. The Phase 1 healthy participant study results indicate that CY6463 was well tolerated. Pharmacokinetic (PK) data, obtained from both blood and cerebral spinal fluid (CSF), support once-daily dosing, with or without food, and demonstrated CY6463 penetration of the blood-brain-barrier with CSF concentrations expected to be pharmacologically active.

On October 14, 2020, we announced positive topline results from our CY6463 Phase 1 translational pharmacology study in healthy elderly participants. Treatment with CY6463 for 15 days in this 24-subject study confirmed and extended results seen in the earlier first-in-human Phase 1 study: once daily oral treatment demonstrated blood-brain-barrier penetration with expected CNS exposure and target engagement. Results also showed significant improvements in neurophysiological and objective performance measures as well as in inflammatory biomarkers associated with aging and neurodegenerative diseases. CY6463 was shown to be safe and generally well tolerated. Significant effects on cerebral blood flow and markers of bioenergetics were not observed in this study of healthy elderly participants. We believe that these results, together with nonclinical data, support continued development of CY6463 as a potential new medicine for serious CNS diseases.

We have initiated exploratory clinical trials with CY6463 ADv, CIAS, and MELAS. The ADv study will be supported in part by a grant from the Alzheimer’s Association’s Part the Cloud-Gates Partnership Grant Program, which provides Cyclerion with $2 million of funding over two years.

F-7


 

Our next generation CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with greater CSF-to-plasma exposure relative to CY6463. CY3018 is intended to expand the potential of sGC stimulation for the treatment of disorders of the CNS.

Non-CNS assets. We have other assets that are outside of our current strategic focus. These non-core assets are not being internally developed at this time. Praliciguat is an orally administered, once-daily systemic sGC stimulator. On June 3, 2021, we entered into a License Agreement with Akebia relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the pharmaceutical compound praliciguat and other related products and forms thereof enumerated in such agreement. Olinciguat is an orally administered, once-daily, vascular sGC stimulator that was evaluated in a Phase 2 study of participants with sickle cell disease. We released topline results from this study in October 2020. Olinciguat is available for licensing to a third party partner.

The Separation

On April 1, 2019, Ironwood completed the separation of its sGC business, and certain other assets and liabilities, into a separate, independent publicly traded company by way of a pro-rata distribution of all of the outstanding shares of common stock of Cyclerion Therapeutics, Inc. through a dividend distribution of one share of the Company’s common stock, with no par value per share, for every 10 shares of Ironwood common stock held by Ironwood stockholders as of the close of business on March 19, 2019, the record date for the Distribution (the entire transaction being the “Separation”). As a result of the Separation, the Company became an independent public company and commenced trading under the symbol “CYCN” on the Nasdaq Global Select Market on April 2, 2019.

2020 Equity Private Placement

On July 29, 2020, the Company entered into a Common Stock Purchase Agreement (the “2020 Equity Private Placement”) for the private placement of 6,062,500 shares of the Company’s common stock, for total gross proceeds of approximately $24.3 million. The closing of the 2020 Equity Private Placement occurred on July 29, 2020. The Company did not utilize the services of a placement agent or broker and accordingly incurred no material related transaction fees, or commissions.

2021 Equity Private Placement

On June 3, 2021, the Company entered into a Common Stock Purchase Agreement (the “June 2021 Equity Private Placement”) for the private placement of 5,735,988 shares of the Company’s common stock, for total gross proceeds of approximately $18 million. The closing of the June 2021 Equity Private Placement occurred on June 7, 2021. The Company did not utilize the services of a placement agent or broker and accordingly incurred no material related transaction fees or commissions.

At-the-Market Offering

On July 24, 2020, the Company filed a Registration Statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) in relation to the registration of common stock, preferred stock, debt securities, warrants and units of any combination thereof for an aggregate initial offering price not to exceed $150.0 million. The Shelf was declared effective as of July 31, 2020. On September 3, 2020, the Company entered into a Sales Agreement (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) with respect to an at-the-market offering (the “ATM Offering”) under the Shelf. Under the ATM Offering, the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million through Jefferies as its sales agent. The Company will pay to Jefferies cash commissions of 3.0 percent of the gross proceeds of sales of common stock under the Sales Agreement. During the year ended December 31, 2021, the Company sold 3,353,059 shares of its common stock for net proceeds of $12.5 million under the ATM Offering, after deducting commissions paid to Jefferies of approximately $0.4 million.

F-8


 

Basis of Presentation

The consolidated financial statements and the related disclosures have been prepared in accordance with U.S. generally accepted accounting principles. In the opinion of management, the consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company’s financial position and the results of its operations for the fiscal years presented.

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion GmbH, and Cyclerion Securities Corporation. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements.

Going Concern

At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company’s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company’s cash needs and comparing those needs to the current cash and cash equivalent balances. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company’s plans or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern.

The Company has experienced negative operating cash flows for all historical periods presented and the Company expects these losses to continue into the foreseeable future as the Company continues the development and clinical testing of its product candidates CY6463, CY3018 and its discovery research programs. Through December 31, 2021, the Company had raised an aggregate of $219.8 million (in net proceeds) from equity private placements and the ATM Offering.

After considering the Company’s current research and development plans and the timing expectations related to the progress of its programs, and after considering its existing cash and cash equivalents of $54.0 million as of December 31, 2021, the Company did not identify conditions or events that would raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these financial statements were issued.

2. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Cyclerion Therapeutics, Inc. and its wholly owned subsidiaries, Cyclerion GmbH and Cyclerion Securities Corporation. All intercompany transactions and balances are eliminated in consolidation.

Segment Information

Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company's chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company currently operates in one reportable business segment - human therapeutics.

Use of Estimates

The preparation of consolidated financial statements in accordance with U.S. GAAP requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, impairment of long-lived assets, valuation procedures for right-of-use

F-9


 

("ROU") assets and operating lease liabilities, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation, and going concern. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.

Cash and Cash Equivalents including Restricted Cash

The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents may consist of money market funds and overnight repurchase agreements. The carrying amount of cash equivalents approximates fair value.

As of December 31, 2021, The Company did not have any restricted cash balances. As of December 31, 2020, the Company was contingently liable under an unused letter of credit with a bank, related to the Company's facility lease, in the amount of approximately $3.8 million. The Company recorded the collateral used to secure the letter of credit as restricted cash. The full amount of restricted cash was recorded as a component of non-current assets at December 31, 2020.

Property and Equipment

Property and equipment, including leasehold improvements, are recorded at cost, and are depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:

 

Asset Description

 

Estimated Useful
Life (In Years)

Laboratory equipment

 

5

Computer and office equipment

 

3

Furniture and fixtures

 

7

Software

 

3

 

Included in property and equipment are certain costs of software obtained for internal use. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred.

Costs for capital assets not yet placed into service have been capitalized as construction in progress and are depreciated in accordance with the above guidelines once placed into service. Maintenance and repair costs are expensed as incurred.

Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. The Company has no capital leases.

Property and equipment that is no longer required for the business is considered disposed of when it ceases to be used. Disposals are either sold or retired and the net book value is removed from the consolidated balance sheet and a corresponding gain or loss on the sale or disposal is recognized as a component of operating expenses in the consolidated statements of operations and comprehensive loss.

Fair Value of Investment Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must

F-10


 

maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

Level 1 — Quoted prices in active markets for identical assets or liabilities.
Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

Foreign Currency Translation Adjustment

The functional currency of the Company’s foreign subsidiary is its local currency, the Swiss franc. The assets and liabilities of the Company’s foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for the Company’s foreign subsidiary is included as a foreign currency translation adjustment in the consolidated statements of stockholders’ equity and as a component of comprehensive loss in the consolidated statements of operations and comprehensive loss.

The Company’s intercompany accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the re-measurement of intercompany balances are recorded in the consolidated statements of operations.

Accounts Receivable

The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding invoices. The Company’s receivables primarily relate to amounts earned under a development agreement with Ironwood, licensing agreement, and supply agreement. The Company believes that credit risks associated with these agreements are not significant. To date, the Company has not had significant write-offs of bad debt and the Company did not have an allowance for doubtful accounts as of December 31, 2021 or 2020.

Impairment of Long-Lived Assets

The Company regularly reviews the carrying amount of its long-lived assets to determine whether indicators of impairment may exist, which warrant adjustments to carrying values or estimated useful lives. If indications of impairment exist, projected future undiscounted cash flows associated with the asset are compared to the carrying amount to determine whether the asset’s value is recoverable. If the carrying value of the asset exceeds such projected undiscounted cash flows, the asset will be written down to its estimated fair value. There were no significant impairments of long-lived assets for the years ended December 31, 2021 or 2020.

Leases

Effective January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) Topic 842, Leases (“ASC 842”) using the optional transition method. The adoption of ASC 842 represents a change in accounting principle that aims to increase transparency and comparability among organizations by requiring the recognition of right-of-use assets and lease liabilities on the balance sheet for both operating and finance leases. In addition, the standard requires enhanced disclosures that meet the objective of enabling financial statement users to assess the amount, timing, and uncertainty of cash flows arising from leases. The reported results for the years ended December 31, 2021 and 2020 reflect the application of ASC 842 guidance.

F-11


 

The recognition of right-of-use assets and lease liabilities related to the Company’s operating leases under ASC 842 has had a material impact on the Company’s consolidated financial statements.

As part of the ASC 842 adoption, the Company has used certain practical expedients outlined in the guidance. These practical expedients include:

Account policy election to use the short-term lease exception by asset class;
Election of the practical expedient package during transition, which includes:
An entity need not reassess whether any expired or existing contracts are or contain leases.
An entity need not reassess the classification for any expired or existing leases. As a result, all leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases under ASC 842, and all leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases under ASC 842.
An entity need not reassess initial direct costs for any existing leases.

The Company had a property lease for its headquarters location at 301 Binney Street, Cambridge, MA (the “Head Lease”). The Company determined if the arrangement was a lease at the inception of the contract. The asset component of the Company’s operating leases was recorded as operating lease right-of-use assets, and the liability component was recorded as current portion of operating lease liabilities and operating lease liabilities, net of current portion, in the Company’s consolidated balance sheets.

ROU assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.

Lease cost was recognized on a straight-line basis over the lease term, and included amounts related to short-term leases. Variable lease costs that do not depend on an index or rate were recognized as incurred.

ROU assets and operating lease liabilities were remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. The difference between the remeasured ROU assets and the operating lease liabilities were recognized as a gain or loss in operating expenses. The Company reviewed any changes to its lease agreements for potential modifications and/or indicators of impairment of the respective ROU asset.

On October 18, 2019, the Company entered into an agreement to sublease 15,700 rentable square feet of its Head Lease to a subtenant (the “Sublease Agreement”). Sublease income was recognized on straight-line basis over the term of the sublease agreement and was recorded net of the related rent expense from the Head Lease within interest and other income, net in the consolidated statements of operations and comprehensive loss. In sublease agreements that contain non-monetary consideration, the Company estimated the fair market value of the non-monetary consideration received using market data and recognized it on a straight-line basis over the sublease term. Variable lease consideration that did not depend on an index or rate was allocated to a non-lease component and was recognized over time in accordance with the pattern of transfer.

No modification or impairment was deemed to have occurred by entering into the sublease agreement because the Company was not released, either fully or in part, from its obligations under the Head Lease. See Note 8, Leases.

On February 28, 2020 the Company entered into an amendment to its Head Lease (the “Lease Amendment”). The Lease Amendment provided for the partial termination of the Company's rights and obligations with respect to a portion of the leased premises of approximately 40,000 rentable square feet. The Company continued to lease approximately 74,000 rentable square feet under terms of the amended lease. The Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease

F-12


 

and not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification and the Company recorded a gain of approximately $2.1 million as a component of operating expenses for the year ended December 31, 2020. No impairment of the ROU asset was deemed to have occurred. See Note 8, Leases.

On September 15, 2020, the Company entered into an amendment to its Head Lease (the “Second Lease Amendment”). The Second Lease Amendment provided for the partial termination of the Company's rights and obligations with respect to a portion of the leased premises of approximately 17,000 rentable square feet (the “Surrender Space”). The Surrender Space included the 15,700 rentable square feet being subleased by the Company to a subtenant. The Company continued to lease approximately 57,000 rentable square feet under terms of the amended lease. The Second Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease and not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification and the Company recorded a loss of approximately $0.4 million as a component of operating expenses for the year ended December 31, 2020. No impairment of the ROU asset was deemed to have occurred. See Note 8, Leases.

On September 15, 2020, concurrent with the execution of the Second Lease Amendment, the Company entered into an agreement with its subtenant to terminate the Sublease Agreement of approximately 15,700 rentable square feet (“the Sublease Termination Agreement”). Under the terms of the Sublease Termination Agreement, the former subtenant is obligated to provide licensed rooms and services to the Company free of charge through the original sublease term. Upon termination of the sublease, the Company recognized sublease termination income of approximately $3.1 million related to the prepaid rooms and services, and wrote off the remaining indirect costs from the sublease of approximately $0.2 million, in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2020. See Note 8, Leases.

On April 30, 2021, the Company entered into a Termination Agreement (the "Termination Agreement") for its Head Lease as initially amended on February 28, 2020, and further amended on September 15, 2020. Pursuant to the Termination Agreement, the Company surrendered the leased space of approximately 57,000 square feet to the building’s landlord. The Company did not pay any termination fees with the Termination Agreement. As a result of the termination of the Head Lease, the related right-of-use asset was written off, the lease liability was derecognized, and the $3.8 million security deposit was returned to the Company and recorded as part of our cash balance. In total, the Company recognized a loss on the termination of the Head Lease of $0.9 million for the year ended December 31, 2021. The loss is included in “General and administrative” expenses on our consolidated statement of operations and comprehensive loss.

Paycheck Protection Program Loan

On April 21, 2020, the Company received loan proceeds in the amount of approximately $3.5 million pursuant to a promissory note agreement with a bank under the Paycheck Protection Program. The Paycheck Protection Program, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The Promissory Note had an original loan maturity of April 20, 2022, a stated interest rate of 1.0% per annum, and had payments of principal and interest that were due monthly after an initial six-month deferral period where interest accrued, but no payments were due. The Promissory Note provided for customary events of default, including, among others, those relating to failure to make payment when due and breaches of representations. The loan was subject to all the terms and conditions applicable under the PPP and was subject to review by the SBA for compliance with program requirements, including the Company’s certification that the economic uncertainty, at the time, made the PPP loan request necessary to support ongoing operations. On October 2, 2020, the SBA issued procedural guidance with respect to PPP loans and changes in ownership and the Company believes that it is compliant with respect to the 2020 Equity Private Placement and the ATM Offering.

In June 2020, the Payroll Protection Program Flexibility Act was signed into law adjusting certain key terms of loans issued under the PPP. In accordance with the PPPFA, the initial deferral period may be extended from six to up to ten months and the loan maturity may be extended from two to five years. The PPPFA also provided for certain other changes, including the extent to which the loan may be forgiven.

The loan’s principal and accrued interest were forgivable to the extent that the proceeds were used for eligible purposes, subject to certain limitations, and that the Company maintained its payroll levels over a twenty-four-week period following the loan date. The loan forgiveness amount may have been reduced if the Company

F-13


 

terminated employees or reduced salaries during the twenty-four-week period. PPP loans are subject to audit and the SBA has indicated that companies that received over $2 million in proceeds should expect an audit. The Company believes that it has used the proceeds for eligible purposes consistent with the provisions of the PPPFA.

As the legal form of the Promissory Note is a debt obligation, the Company accounted for it as debt under Accounting Standards Codification (ASC) 470, Debt and recorded a short-term liability of $3.5 million in the consolidated balance sheets upon receipt of the loan proceeds. The Company accrued interest over the term of the loan and did not record additional interest at a market rate because the guidance on imputing interest in ASC 835-30, Interest excludes transactions where interest rates are prescribed by a government agency. Approximately $0.1 million of interest expense has been recognized within interest and other income, net in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. In August 2021, the Company applied with the SBA for forgiveness of the PPP loan and was notified on November 4, 2021 that the SBA has approved our application to forgive the entire amount of the loan and accrued interest. The Company recorded a gain on extinguishment of debt of $3.6 million representing the principal and accrued interest for the PPP Loan.

Revenue

Upon executing a revenue generating arrangement, the Company assesses whether it is probable the Company will collect consideration in exchange for the good or service it transfers to the customer. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. The Company must develop assumptions that require significant judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The assumptions that are used to determine the stand-alone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company derives revenue from (1) license agreement and (2) supply agreement which are fully described in Note 14, License Agreement.

The Company generated revenue from a Development Agreement with Ironwood, pursuant to which the Company provided certain research and development services with respect to certain of Ironwood’s products and product candidates. Such research and development activities were governed by a joint steering committee composed of representatives of both companies. Services performed were invoiced at a mutually agreed upon rate and the initial term of the agreement was two years from the date of Separation and automatically renewed for one year unless either party notified the other at least six months prior to the expiration. Ironwood and the Company agreed that the Development Agreement would not be renewed beyond its initial term which ended on March 31, 2021.

The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange transactions and are not within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Contribution revenue earned from activities performed pursuant to research and development grants is reported as grant revenue in the Company’s consolidated statements of operations. Revenue from these grants is recognized as the Company incurs qualifying expenses as stipulated by the terms of the respective grant. Cash received from grants in advance of incurring qualifying expenses is recorded as deferred revenue. The Company records revenue and a corresponding receivable when qualifying costs are incurred before receiving payment from the grants.

Research and Development Costs

The Company expenses research and development costs to operations as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. The

F-14


 

Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception.

Research and development expenses are comprised of costs incurred in performing research and development activities, which may include salary, benefits and other employee-related expenses; share-based compensation expense; laboratory supplies and other direct expenses; facilities expenses; overhead expenses; third-party contractual costs relating to nonclinical studies and clinical trial activities and related contract manufacturing expenses, development of manufacturing processes and regulatory registration of third-party manufacturing facilities; and other outside expenses.

General and Administrative Expenses

The Company expenses general and administrative costs to operations as incurred. General and administrative expense consists of compensation, share-based compensation, benefits and other employee-related expenses for personnel in the Company’s administrative, finance, legal, information technology, business development and human resource functions. Other costs include the legal costs of pursuing patent protection of the Company’s intellectual property, general and administrative related facility costs, insurance costs and professional fees for accounting and legal services.

Income taxes

The Company is primarily subject to U.S. federal and Massachusetts state income taxes. For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable.

The tax positions taken or expected to be taken in the course of preparing the Company tax returns are required to be evaluated to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authority. Tax positions not deemed to meet a more-likely-than-not threshold would be recorded as a tax expense in the current year. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. It does not consider the likelihood of whether or not the IRS will review the position. Cyclerion evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect Cyclerion's income tax provision in future periods. There were no uncertain tax positions that require accrual or disclosure in the consolidated financial statements as of December 31, 2021, and 2020. The Company’s policy is to recognize interest and penalties related to income tax, if any, in income tax expense. As of December 31, 2021, and 2020, the Company has no accruals for interest or penalties related to income tax matters.

Patent Costs

Patent fees and patent related costs in connection with filing and prosecuting patent applications are expensed as incurred and are classified as general and administrative expenses in the accompanying consolidated financial statements. The Company incurred and recorded as operating expense legal and other fees related to patents of approximately $1.4 million and $1.7 million for the years ended December 31, 2021 and 2020, respectively.

Interest and Other Income, Net

For the year ended December 31, 2021, interest and other income, net consisted of a de minimis amount of interest income related to interest generated from our cash and cash equivalents balances and a de minimis amount

F-15


 

of interest expense related to the PPP loan. For the year ended December 31, 2020, interest and other income, net consisted of $0.3 million of interest income related to interest generated from our cash and cash equivalents balances and $0.3 million of net sublease income.

Subsequent Events

The Company considers events or transactions that have occurred after the balance sheet date of December 31, 2021, but prior to the filing of the financial statements with the Securities and Exchange Commission, to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of the financial statements accompanying this Annual Report on Form 10-K. See Note 14, Subsequent Events.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the consolidated financial statements, the Company did not adopt any new accounting pronouncements during the years ended December 31, 2021 and 2020, that had a material effect on its consolidated financial statements.

In June 2016 the FASB issued ASU 2016-13, Financial Instruments-Credit Losses. This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. As a smaller reporting company, ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2022, and early adoption is permitted. The Company is currently evaluating the impact that ASU 2016-13 will have on its financial statements and related disclosures.

In May 2021 the FASB issued Accounting Standards Update No. 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the Emerging Issues Task Force (EITF) , which amends the FASB Accounting Standards Codification (ASC or the “Codification”) to provide explicit guidance, and, thus, reduce diversity in practice, on accounting by issuers for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after the modification or exchange. This amendment provides that for an entity that presents earnings per share (EPS) in accordance with Topic 260, the effects of a modification or an exchange of a freestanding equity-classified written call option that is recognized as a dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. The amended guidance becomes mandatorily effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, and should be applied prospectively to modifications or exchanges occurring on or after the effective date. The Company is currently evaluating the impact that ASU 2021-04 will have on its financial statements and related disclosures.

No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company’s consolidated financial statements upon adoption. 

3. Related Party Transactions

Development Agreement with Ironwood

As part of the Separation from Ironwood, the Company entered into a Development Agreement with Ironwood.

Under the Development Agreement, the Company provided certain research and development services to Ironwood at mutually agreed upon rates and the amounts earned are recorded as revenue from related party for the year ended December 31, 2020. Such research and development activities were governed by a joint steering

F-16


 

committee composed of representatives of both Ironwood and the Company. Ironwood and the Company have agreed not to renew the Development Agreement beyond the end of its initial term on March 31, 2021. These transactions under the Development Agreement were considered related party transactions due to Mark Currie’s role as President of the Company through December 31, 2020, and board member of Ironwood. In January 2021, Mark Currie’s role transitioned from President of the Company to a senior advisor on a consulting basis. Therefore, effective January 2021, transactions under the Development Agreement are no longer accounted for as related party transactions. The Company recorded approximately $2.3 million for the year ended December 31, 2020.

Other Related Party Transactions

During the year ended December 31, 2020, the Company recorded approximately $1.5 million of research and development costs to a related party which it engaged to provide research and development transaction support services. The entity became a related party when Mark Currie, the Company’s President through December 31, 2020, joined its board in January 2020. There was approximately $0.3 million due to the related party for the year ended December 31, 2020. In January 2021, Mark Currie’s role transitioned from President of the Company to a senior advisor on a consulting basis. Therefore, effective January 2021, transactions under this agreement are no longer accounted for as related party transactions.

4. Fair Value of Financial Instruments

The Company’s cash equivalents are generally classified within Level 1 of the fair value hierarchy. The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of December 31, 2021 and December 31, 2020 (in thousands):

 

 

 

Fair Value Measurements as of December 31, 2021:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

52,917

 

 

$

 

 

$

 

 

$

52,917

 

Cash equivalents

 

$

52,917

 

 

$

 

 

$

 

 

$

52,917

 

 

 

 

Fair Value Measurements as of December 31, 2020:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

53,240

 

 

$

 

 

$

 

 

$

53,240

 

Cash equivalents

 

$

53,240

 

 

$

 

 

$

 

 

$

53,240

 

During the year ended December 31, 2021 and 2020, there were no transfers between levels. The fair value of the Company's cash equivalents, consisting of money market funds, is based on quoted market prices in active markets with no valuation adjustment.

The Company believes the carrying amounts of its prepaid expenses and other current assets, restricted cash, accounts payable, and accrued expenses approximate their fair value due to the short-term nature of these amounts.

F-17


 

5. Property and Equipment

Property and equipment, net consisted of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Software

 

$

2,214

 

 

$

2,214

 

Computer and office equipment

 

 

51

 

 

 

44

 

Leasehold improvements

 

 

 

 

 

14,894

 

Property and equipment, gross

 

 

2,265

 

 

 

17,152

 

Less: accumulated depreciation and amortization

 

 

(2,200

)

 

 

(10,287

)

Property and equipment, net

 

$

65

 

 

$

6,865

 

As of December 31, 2021, and 2020, the Company’s property and equipment was primarily located in Cambridge, Massachusetts.

Depreciation and amortization expense of the Company’s property and equipment was approximately $0.5 million and $2.3 million for the years ended December 31, 2021 and 2020, respectively.

During the year ended December 31, 2021, the Company recorded a non-cash loss of $6.3 million, on the disposal of leasehold improvements as a result of its Head Lease (as defined below) termination (see Note 8 to the Consolidated Financial Statements). The non-cash loss on the disposal of leasehold improvements was recognized as a component of operating expenses in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021.

6. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Accrued incentive compensation

 

$

1,369

 

 

$

1,720

 

Salaries

 

 

266

 

 

 

514

 

Accrued vacation

 

 

345

 

 

 

555

 

Professional fees

 

 

398

 

 

 

689

 

Accrued severance and benefit costs

 

 

28

 

 

 

3,640

 

Other

 

 

498

 

 

 

176

 

Accrued expenses and other current liabilities

 

$

2,904

 

 

$

7,294

 

 

7. Commitments and Contingencies

Other Funding Commitments

In the normal course of business, the Company enters into contracts with clinical research organizations and other third parties for clinical and preclinical research studies and other services and products for operating purposes. These contracts are generally cancellable, with notice, at the Company’s option and do not have any significant cancellation penalties.

Guarantees

On September 6, 2018, Cyclerion was incorporated in Massachusetts and its officers and directors are indemnified for certain events or occurrences while they are serving in such capacity.

The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business

F-18


 

partners, contractors, clinical sites and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company’s activities. These indemnification provisions generally survive termination of the underlying agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Accordingly, the Company did not have any liabilities recorded for these obligations as of December 31, 2021 or December 31, 2020.

8. Leases

The FASB issued ASU 2016-02, or the leasing standard or ASC 842, in February 2016. ASU 2016-02 requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by all leases with terms of more than 12 months. ASU 2016-02 also requires certain qualitative and quantitative disclosures designed to give financial statement users information on the amount, timing, and uncertainty of cash flows arising from leases.

On April 1, 2019, the Company entered into the Head Lease ("the Head Lease"), a direct operating lease for its former headquarters located at 301 Binney Street, Cambridge, MA consisting of approximately 114,000 rentable square feet of office and laboratory space on the first and second floors. The Head Lease had a term of 123 months with two five-year extension options and certain expansion rights. The Head Lease also included a letter of credit of $7.7 million, posted with the landlord as a security deposit, which was collateralized by a money market account recorded as restricted cash on the Company’s consolidated balance sheets. The Company had also entered into customary non-disturbance arrangements with the building landlord’s mortgagee and with the property ground lessor recognizing Company's leasehold interest in this property.

On February 28, 2020 the Company entered into an amendment to its Head Lease. The Lease Amendment partially terminated the Company’s rights and obligations with respect to an approximately 40,000 rentable square feet. The Company continued to lease the remaining space of approximately 74,000 square feet including the area covered by the subleased premise, discussed below. In connection with this Lease Amendment, the Company reduced its remaining lease payments through June 2029 by approximately $41.9 million and paid a $6.3 million termination fee and $0.2 million related to other initial direct costs, which were deferred and recognized over the remaining lease term. The Company’s security deposit was also reduced by approximately $2.7 million to approximately $5.0 million.

The Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease and not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification of 9.7%, which resulted in a reduction of the ROU asset of $21.4 million and a reduction in the operating lease liabilities of $23.5 million. The Company recorded the resulting gain of approximately $2.1 million as a component of operating expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020.

On September 15, 2020 the Company entered into the Second Lease Amendment to its Head Lease. The Second Lease Amendment provided for the partial termination of the Company’s rights and obligations with respect to a portion of the leased premises of approximately 17,000 rentable square feet. The Surrender Space included 15,700 rentable square feet being subleased by the Company to a subtenant. The Company continued to lease approximately 57,000 square feet of space. The Company reduced its remaining lease payments through June 2029 by approximately $16.9 million. The Company paid no termination or other initial direct costs related to the execution of the Second Lease Amendment. The Company’s security deposit was reduced by approximately $1.2 million to approximately $3.8 million, which is classified as restricted cash on the Company’s consolidated balance sheet as of December 31, 2020.

The Second Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease and not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification of 6.1%, which resulted in a reduction of the ROU asset of $5.9 million and a reduction in the operating lease liabilities of $5.5 million. The

F-19


 

Company recorded the resulting loss of approximately $0.4 million as a component of operating expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020.

On April 30, 2021, the Company entered into a Termination Agreement (the "Termination Agreement") for its Head Lease as initially amended on February 28, 2020, and further amended on September 15, 2020. Pursuant to the Termination Agreement, the Company surrendered the leased space of approximately 57,000 square feet to the building’s landlord. The Company did not pay any termination fees in connection with the Termination Agreement. As a result of the termination of the Head Lease, the related right-of-use asset was written off, the lease liability was derecognized, and the $3.8 million security deposit was returned to the Company and recorded as part of our cash balance. In total, the Company recognized a loss on the termination of the Head Lease of $0.9 million for the year ended December 31, 2021. The loss is included in “General and administrative” expenses on our consolidated statement of operations and comprehensive loss.

The Company had an operating lease ROU asset of approximately $43.4 million related to the amended Head Lease recorded in its consolidated balance sheets as of December 31, 2020. The Company had current and non-current operating lease liabilities of approximately $3.3 million, and $38.9 million, respectively, related to the amended Head Lease recorded in its consolidated balance sheets as of December 31, 2020.

Lease cost was recognized on a straight-line basis over the lease term. For the years ended December 31, 2021 and 2020, the Company recognized a total of approximately $2.4 million and $8.6 million, respectively, of total lease costs. Variable lease costs not subject to an index or rate were recognized as incurred. For the years ended December 31, 2021 and 2020, the Company recognized a total of approximately $0.7 million and $2.2 million, respectively, of variable lease costs related to the Head Lease, as amended.

In May 2021, the Company signed a membership agreement to lease space with WeWork at 501 Boylston Street, Boston, Massachusetts. The lease commenced on August 1, 2021 and was accounted for as a short term lease. The Company recorded $0.1 million in lease expense associated with the membership agreement during the year ended December 31, 2021.

Supplemental cash flow information related to leases for the periods reported is as follows:

 

 

 

December 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Decrease in right-of-use assets related to lease modifications and termination (in thousands)

 

$

42,058

 

 

$

27,333

 

Decrease in operating lease liabilities due to lease modifications and termination (in thousands)

 

$

41,177

 

 

$

29,002

 

Cash paid for amounts included in the measurement of lease liabilities (in thousands)

 

$

1,887

 

 

$

7,411

 

Weighted-average remaining lease term of operating leases (in years)

 

 

 

 

 

8.5

 

Weighted-average discount rate of operating leases

 

 

 

 

 

6.1

%

On October 18, 2019, the Company entered into an agreement with a third party to sublease 15,700 rentable square feet of its lease premises under the Head Lease. The sublease was scheduled to expire on June 30, 2029, unless earlier terminated in accordance with the sublease agreement, and has no extension options. The sublease provides for annual base rent of approximately $1.5 million in the first year, which increases on a yearly basis by 3.0% (subject to an abatement of base rent of approximately $0.7 million for the first six months of the sublease). As part of the consideration for the sublease, the sublessee agreed to provide licensed rooms and services within the sublease premises to the Company over the sublease term free of charge. In addition, the sublessee is responsible for its pro rata share of certain costs, taxes and operating expenses related to the subleased space, the consideration for which is variable and is based on the actual operating costs of the lessor. The Company allocated the total consideration in the sublease agreement between the lease and non-lease components in the contract based on their relative standalone prices. The Company determined that the variable consideration relates exclusively to non-lease components and will be recognized as incurred. The sublease included an initial security deposit of $0.5 million, which was provided by the sublessee in the form of a letter of credit, and an additional security deposit of $0.4 million within nine months of the sublease commencement.

F-20


 

On September 15, 2020, concurrent with execution of the Second Lease Amendment, the Company entered into the Sublease Termination Agreement to terminate its sublease of 15,700 rentable square feet. Under the terms of the Sublease Termination Agreement, the subtenant is relieved of its obligation to provide future cash rental payments to the Company. The agreements requiring the former subtenant to provide licensed rooms and services to the Company free of charge through the original sublease term survived the sublease termination. The Company gained access to the licensed rooms and services beginning in the third quarter of 2021. The letter of credit security deposit related to the sublease was released.

The Company determined that the Sublease Termination Agreement constituted a non-monetary exchange under ASC 845 Nonmonetary Transactions (“ASC 845”) where, in return for the free rooms and the services, the Company agreed to terminate its rights and obligations under the sublease agreement. In accordance with ASC 845, the Company determined that the accounting for the transaction should be based on the fair value of assets or services involved. The Company estimated the fair value of the rooms and services to be approximately $1.5 million and $2.9 million, respectively. Accordingly, prepaid rooms and services of $4.4 million were recorded upon the sublease termination, of which $1.6 million was recorded in other current assets and $2.8 million was recorded in other assets in the consolidated balance sheets as of December 31, 2020. Termination fee income of $3.1 million was recognized related to the rooms and services, after considering the rent receivable balance of $1.3 million outstanding from the subtenant. The remaining unamortized direct costs of $0.2 million were written off. The effects of the Sublease Termination Agreement were recorded within sublease termination income, net in the consolidated statements of operations and comprehensive loss. Total gross sublease income of approximately $1.5 million, and net sublease income of approximately $0.3 million was recorded in interest and other income, net in the consolidated statements of operations and comprehensive loss for year ended December 31, 2020.

The Company determined that the licensed rooms represent a lease under ASC 842. The Company obtained control of the rooms in the third quarter of 2021 and the prepaid rooms balance of approximately $1.4 million was reclassified from other assets to a ROU asset. The related lease expense is recognized on a straight-line basis over the lease term of 8.88 years. The Company recorded $0.1 million of lease expense during the year ended December 31, 2021. The Company determined that the licensed services represent a non-lease component, which is recognized separately from the lease component for this asset class. The expense related to the licensed services is recognized on a straight-line basis over the period the services are received. The Company recorded $0.2 million for the year ended December 31, 2021. Both the lease expense and services expense are recognized as a component of research and development costs in the consolidated statements of operations and comprehensive loss.

9. Share-based Compensation Plans

In 2019, Cyclerion adopted share-based compensation plans. Specifically, Cyclerion adopted the 2019 Employee Stock Purchase Plan (“2019 ESPP”) and the 2019 Equity Incentive Plan (“2019 Equity Plan”). Under the 2019 ESPP, eligible employees may use payroll deductions to purchase shares of stock in offerings under the plan, and thereby acquire an interest in the future of the Company. The 2019 Equity Plan provides for stock options and restricted stock units (“RSUs”).

Cyclerion also mirrored two of Ironwood’s existing plans, the Amended and Restated 2005 Stock Incentive Plan (“2005 Equity Plan”) and the Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan (“2010 Equity Plan). These mirror plans were adopted to facilitate the exchange of Ironwood equity awards for Cyclerion equity awards upon the Separation as part of the equity conversion. As a result of the Separation and in accordance with the EMA, employees of both companies retained their existing Ironwood vested options and received a pro-rata share of Cyclerion options, regardless of which company employed them post-Separation. For employees that were ultimately employed by Cyclerion, unvested Ironwood options and RSUs were converted to unvested Cyclerion options and RSUs.

F-21


 

The following table provides share-based compensation reflected in the Company’s consolidated statements of operations and comprehensive loss for the years ended December 31, 2021 and 2020 (in thousands):

 

 

 

Year Ended
December 31,

 

 

 

2021

 

 

2020

 

Research and development

 

$

3,945

 

 

$

6,799

 

General and administrative

 

 

5,666

 

 

 

8,193

 

 

 

$

9,611

 

 

$

14,992

 

 

Stock Options

Stock options granted under the Company’s equity plans generally have a ten-year term and vest over a period of four years, provided the individual continues to serve at the Company through the vesting dates. Options granted under all equity plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the requisite service period, which is typically the vesting period of each option.

 

A summary of stock option activity for the year ended December 31, 2021 is as follows:

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

Average

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Intrinsic

 

 

 

Number

 

 

Exercise

 

 

Contractual

 

 

Value (in

 

 

 

of Options

 

 

Price

 

 

Term (Years)

 

 

thousands)

 

Outstanding as of December 31, 2020

 

 

7,426,356

 

 

$

11.87

 

 

 

7.0

 

 

$

1,178

 

Granted

 

 

1,176,250

 

 

 

2.98

 

 

 

 

 

 

 

Exercised

 

 

(72,419

)

 

 

2.17

 

 

 

 

 

 

 

Cancelled or forfeited

 

 

(1,449,761

)

 

 

10.69

 

 

 

 

 

 

 

Outstanding as of December 31, 2021

 

 

7,080,426

 

 

$

10.73

 

 

 

6.9

 

 

 

 

Exercisable at December 31, 2021

 

 

4,518,213

 

 

$

13.46

 

 

 

5.9

 

 

$

 

During the years ended December 31, 2021 and 2020, the Company granted stock options to purchase an aggregate of 1,176,250 shares and 1,382,846 shares, respectively, at weighted average grant fair values per option share of $2.17 and $1.97, respectively. The total grant fair value of options granted during the years ended December 31, 2021 and 2020 was $2.6 million and $2.7 million, respectively.

The total intrinsic value of options exercised for the years ended December 31, 2021 and 2020 was $0.1 million and $0.1 million, respectively.

As of December 31, 2021, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested time-based stock options held by the Company’s employees is $8.1 million and the weighted average period over which that expense is expected to be recognized is 3.29 years.

The weighted-average Black-Scholes assumptions used in estimating the fair value of the stock options granted by Cyclerion following the Separation during the years ended December 31, 2021 and 2020 were as follows:

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

Weighted average risk-free interest rate

 

 

1.09

%

 

 

0.43

%

Expected dividend yield

 

 

 

 

 

 

Expected option term (in years)

 

 

5.9

 

 

 

6.3

 

Expected stock price volatility

 

 

85.45

%

 

 

91.73

%

For the years ended December 31, 2021 and 2020, expected volatility was estimated using an average of the historical volatility of the common stock of a group of similar companies that were publicly traded. The

F-22


 

Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

The Company has granted to certain employees performance based options to purchase shares of common stock. These options are subject to performance based milestone vesting. During the year ended December 31, 2021, 50,000 shares vested as a result of performance milestone achievements and no shares vested during the year ended December 31, 2020. The Company recorded a de minimis and no share-based compensation expense related to these performance-based options for the years ended December 31, 2021, and 2020, respectively.

Market-based Stock Options

The Company also has granted to certain employees stock options containing market conditions that vest upon the achievement of specified price targets of the Company’s share price for a period through December 31, 2024. Vesting is measured based upon the average closing price of the Company’s share price for any thirty consecutive trading days, subject to certain service requirements. Stock compensation cost is expensed on a straight-line basis over the derived service period for each stock price target within the award, ranging from approximately 4.0 to 4.6 years. The Company accelerates expense when a stock price target is achieved prior to the derived service period. The Company does not reverse expense recognized if the share price target(s) are ultimately not achieved but expense is reversed when a stock award recipient has a break in service prior to the completion of the derived service period. As of December 31, 2021, there was $0.2 million of unrecognized compensation costs related to stock options containing market conditions, which is expected to be recognized over a weighted-average period of 2.17 years.

A summary of stock awards containing market conditions activity for the years ended December 31, 2021 and 2020 is as follows:

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

Aggregate

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Intrinsic

 

 

 

Number of

 

 

Exercise

 

 

Contractual

 

 

Value (in

 

 

 

Options

 

 

Price

 

 

Term (years)

 

 

thousands)

 

Outstanding as of December 31, 2020

 

 

600,000

 

 

$

2.01

 

 

$

8.9

 

 

$

630

 

Granted

 

 

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

 

 

 

 

 

 

 

 

 

 

Cancelled or forfeited

 

 

(150,000

)

 

$

 

 

$

 

 

$

 

Outstanding as of December 31, 2021

 

 

450,000

 

 

$

2.01

 

 

 

7.9

 

 

$

 

Exercisable at December 31, 2021

 

 

 

 

$

 

 

 

 

 

$

 

The fair value of stock options containing market conditions is estimated using Monte Carlo simulations. No stock options containing market conditions were granted during the years ended December 31, 2021 and 2020.

Restricted Stock Units

The RSUs generally vest 25% per year on the approximate anniversary of the date of grant until fully vested, provided the employee remains continuously employed with the Company through each vesting date. Shares of the Company’s common stock are delivered to the employee upon vesting, subject to payment of applicable withholding taxes. The fair value of all RSUs is based on the market value of the Company’s common stock on the date of grant. Compensation expense, including the effect of estimated forfeitures, is recognized over the applicable service period.

F-23


 

A summary of RSU activity for the years ended December 31, 2021 is as follows:

 

 

 

 

 

 

Weighted Average

 

 

 

Number

 

 

Grant Date

 

 

 

of Shares

 

 

Fair Value

 

Unvested as of December 31, 2020

 

 

294,913

 

 

$

14.52

 

Granted

 

 

39,369

 

 

 

3.17

 

Vested

 

 

(143,774

)

 

 

12.01

 

Forfeited

 

 

(97,704

)

 

 

14.41

 

Unvested as of December 31, 2021

 

 

92,804

 

 

$

13.70

 

As of December 31, 2021, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested restricted stock units by the Company’s employees is $0.7 million and the weighted-average period over which that expense is expected to be recognized is 1.13 years.

10. Loss per share

Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows:

 

 

 

Year Ended
December 31,

 

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

Net loss (in thousands)

 

$

(51,647

)

 

$

(77,802

)

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

Weighted average shares used in calculating net loss per share — basic and diluted (in thousands)

 

 

39,144

 

 

 

30,403

 

Net loss per share — basic and diluted

 

$

(1.32

)

 

$

(2.56

)

 

We exclude shares of common stock related to stock options and RSUs from the calculation of diluted net loss per share since the inclusion of such shares would be anti-dilutive. The following table sets forth potential shares that were considered anti-dilutive for the years ended December 31, 2021 and 2020:

 

 

 

Year Ended
December 31,

 

 

 

2021

 

 

2020

 

Stock Options

 

$

7,530,426

 

 

$

294,913

 

RSUs

 

 

92,804

 

 

 

8,026,356

 

 

 

$

7,623,230

 

 

$

8,321,269

 

 

11. Income Taxes

There was no provision for income taxes for the years ended December 31, 2021, and 2020, due to the Company’s operating losses and a full valuation allowance on deferred tax assets. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows (in thousands):

 

F-24


 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

U.S.

 

$

(51,686

)

 

$

(77,884

)

International

 

 

39

 

 

 

82

 

Loss before benefit from income taxes

 

$

(51,647

)

 

$

(122,406

)

Income tax benefit using U.S. federal statutory rate

 

$

(10,846

)

 

$

(16,338

)

State income taxes, net of federal benefit

 

 

(3,631

)

 

 

(5,619

)

Non-deductible share-based compensation

 

 

(911

)

 

 

16

 

Share-based compensation - shortfalls/(windfalls)

 

 

946

 

 

 

1,047

 

Permanent differences

 

 

(420

)

 

 

(94

)

PPP loan forgiveness

 

 

(748

)

 

 

 

Tax credits

 

 

(805

)

 

 

(2,469

)

Other

 

 

(9

)

 

 

(16

)

Change in valuation allowance

 

 

16,424

 

 

 

23,473

 

 

 

$

 

 

$

 

 

The effective income tax rate is based upon the income for the year, the composition of the income in different countries, and adjustments, if any, for the potential tax consequences, benefits or resolutions of audits or other tax contingencies. Our income tax rate in foreign jurisdictions is lower than our income tax rate in the United States.

Deferred tax assets (liabilities) consist of the following as of December 31, 2021 and 2020 (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

43,700

 

 

$

27,007

 

Tax credit carryforwards

 

 

8,044

 

 

 

7,185

 

Share-based compensation

 

 

7,702

 

 

 

5,890

 

Operating lease - liability

 

 

 

 

 

11,536

 

Property and equipment

 

 

(1

)

 

 

1,362

 

Capitalized research and development

 

 

11,147

 

 

 

12,684

 

Accruals and reserves

 

 

91

 

 

 

518

 

Other

 

 

4

 

 

 

 

Total deferred tax assets

 

$

70,687

 

 

$

66,182

 

 

 

 

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

Operating lease - right of use asset

 

$

(383

)

 

$

(11,857

)

Prepaid sublease termination

 

 

(758

)

 

 

(1,203

)

Total deferred tax liabilities

 

 

(1,141

)

 

 

(13,060

)

Net deferred tax assets

 

 

69,546

 

 

 

53,122

 

 

 

 

 

 

 

 

Valuation allowance

 

 

(69,546

)

 

 

(53,122

)

Net deferred tax assets

 

$

 

 

$

 

 

Management of Cyclerion has evaluated the positive and negative evidence bearing upon the possible realization of its deferred tax assets. Management has considered the Company's history of operating losses, in addition to the expected timing of the reversal of existing temporary differences and concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company will not realize the benefit of its deferred tax assets. Accordingly, the net deferred tax assets have been fully reserved at December 31, 2021 and December 31, 2020. Management reevaluates the positive and negative evidence on a quarterly basis.

F-25


 

The valuation allowance increased by approximately $16.4 million during the year ended December 31, 2021 primarily due to increases in capitalized research and development expenses, net operating losses, tax credit carryforwards and deferred tax assets related to share-based compensation.

Cyclerion did not generate net operating loss carryforwards or tax credit carryforwards available for its use until its inception and operation as a standalone legal entity. At December 31, 2021 and 2020, Cyclerion has federal net operating loss carryforwards of approximately $160 million and $98.8 million, respectively, to offset future federal taxable income that will be carried forward indefinitely until utilized. As of December 31, 2021, and 2020, Cyclerion had state net operating loss carryforwards of approximately $159.6 million and $98.9 million, respectively, to offset future state taxable income, which will begin to expire in 2039 and will continue to expire through 2040. Cyclerion also had tax credit carryforwards of approximately $8.4 million and $7.5 million as of December 31, 2021 and 2020, respectively, to offset future federal and state income taxes. Federal credits begin to expire in 2039 and will continue to expire through 2040. State credits begin to expire in 2022 and continue through 2034.

The Company’s ability to use its operating loss carryforwards and tax credits to offset future taxable income could be subject to restrictions under Section 382 of the U.S. Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”). These potential restrictions may limit the future use of the operating loss carryforwards and tax credits if certain ownership changes described in the Internal Revenue Code occur. Changes in stock ownership may occur that would create these limitations on the Company’s use of the operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist.

The Company has not as yet conducted a study of its research and development credit carry forwards. This study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development credits, and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheets or statements of operations if an adjustment were required.

Upon audit, taxing authorities may challenge all or part of an uncertain income tax position. While Cyclerion has no history of tax audits since its inception on a standalone basis, it may be subject to tax audits by federal and state taxing authorities in the future. Accordingly, Cyclerion regularly assesses the outcome of potential examinations in each of the taxing jurisdictions when determining the adequacy of the amount of unrecognized tax benefit recorded. Cyclerion had no unrecognized tax benefits as of December 31, 2021 and 2020. Cyclerion will recognize interest and penalties, if any, related to uncertain tax positions in income tax expense. As of December 31, 2021 and 2020, no interest or penalties have been accrued. There are no current federal or state income tax audits in progress.

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act is an emergency economic stimulus package in response to the COVID-19 pandemic, which among other things contains numerous income tax provisions, some of which are effective retroactively for fiscal years ended before the date of enactment. The CARES Act includes certain tax relief provisions, including modifications to the NOL rules, including a provision to carryback losses from 2018 – 2021 tax years, temporary changes to business interest expense disallowance rules (IRC §163(j)), qualified improvement property, payroll tax delays/ credits, and several other tax and non-tax benefits. These tax provisions should have no significant income tax ramifications for Cyclerion, but the Company will continue to monitor any changes and guidance in order to consider potential opportunities. The CARES Act also created a program called the Paycheck Protection Program to be administered by the SBA. Cyclerion received $3.5 million of loan proceeds on April 21, 2020 under the PPP, as fully described in Note 2, Summary of Significant Accounting Policies.

12. Defined Contribution Plan

In 2019, Cyclerion adopted a defined contribution 401(k) Savings Plan similar to the plan in place at Ironwood. The plan assets under the Ironwood defined contribution 401(k) Savings Plan were transferred to the Cyclerion plan. Subject to certain IRS limits, eligible employees may elect to contribute from 1% to 100% of their

F-26


 

compensation. Cyclerion contributions to the plan are at the sole discretion of the board of directors. Currently, Cyclerion provides a matching contribution of 75% of the employee’s contributions, up to $6,000 annually.

Included in compensation expense is approximately $0.3 million and $0.5 million related to the defined contribution 401(k) Savings Plan for the years ended December 31, 2021 and 2020, respectively.

13. Workforce Reduction

2020 Workforce Reduction

On November 5, 2020, the Company began a reduction of its current workforce by forty-eight (48) full-time employees to align its resources with its current priorities of focusing on the MELAS study, the planned ADv study and further characterization of CY6463 novel pharmacology.

The Company recorded total costs related to the 2020 Workforce Reduction were approximately $5.0 million including approximately $0.1 million in stock-based compensation from the modification of certain share-based equity awards.

The Company reduced its workforce by thirty-one (31) employees in the fourth quarter of 2020 and recorded approximately $4.1 million of severance and benefits costs in accordance with ASC Topic 420, Exit or Disposal Cost Obligations, or ASC 420, including a de minimis amount of stock-based compensation expense, for the year ended December 31, 2020. The workforce reduction was completed by the end of the first quarter of 2021.

The following table summarizes the accrued liabilities activity recorded in connection with the reduction in workforce for the year ended December 31, 2021 (in thousands):

 

 

 

Amounts
accrued at
December 31,
2020

 

 

Charges

 

 

Amount
paid

 

 

Adjustments

 

 

Amounts
accrued at
December 31,
2021

 

2020 workforce reduction

 

$

(3,640

)

 

$

(878

)

 

$

4,490

 

 

$

 

 

$

(28

)

Total

 

$

(3,640

)

 

$

(878

)

 

$

4,490

 

 

$

 

 

$

(28

)

 

14. License Agreement

Akebia License Agreement

On June 3, 2021, the Company and Akebia entered into a License Agreement (the “License Agreement”) relating to the exclusive worldwide license by the Company to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the pharmaceutical compound known as praliciguat and other related products and forms thereof enumerated in the License Agreement (collectively, the “Products”). Pursuant to the License Agreement, Akebia will be responsible for all future research, development, regulatory, and commercialization activities for the Products.

Akebia paid a $3.0 million up-front payment to the Company upon signing of the License Agreement and the Company is eligible to receive additional milestone cash payments of up to $12.0 million in the next 18 months. Further milestone cash payments by Akebia are scheduled in the License Agreement based on the initiation of phase 3 clinical trials in the U.S. for Products for first and second indication, for FDA approvals, for approvals in certain other major markets, and for certain sales milestones. In addition to these cash milestone payments, Akebia will pay the Company tiered royalty payments on net sales in certain major markets at percentages ranging from the mid-single digits to the high-teens, subject to certain reductions and offsets.

Pursuant to the License Agreement, the Company determined the License Agreement represents a service arrangement under the scope of ASC 606. Given the reversion of the rights under the License Agreement represents a penalty in substance for a termination by Akebia, the contract term would be the stated term of the License Agreement.

F-27


 

The Company determined that the grant of license to our patents and trademarks, know how transfer, the assignment of regulatory submissions and trademarks and additional knowledge transfer assistance obligations represent a single promise and performance obligation to be transferred to Akebia over time due to the nature of the promises in the contract. The provision of development materials on hand was identified as a separate performance obligation. However, it is immaterial in the context of the contract as the development materials are low value and do not have an alternative use to the Company.

The consideration related to sales-based milestone payments, including royalties, will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license. The Company will re-evaluate the probability of achievement of the milestones and any related constraints each reporting period.

Akebia Supply Agreement

On August 3, 2021, the Company and Akebia entered into a Supply Agreement (the “Supply Agreement”) relating to the manufacturing by the Company of the Initial Supply of the Drug Product and placebo ("Initial Supply") for Akebia's use pursuant to the License Agreement. Akebia will pay the Company for the manufacturing costs at mutually agreed upon rates.

The Company determined the Supply Agreement has stand-alone value under the scope of ASC 606 and should not be combined with the License Agreement. Given that the Supply Agreement can be terminated at any time without cause with 30 days notice, the Company deemed the Supply Agreement to be a month-to-month contract. The manufacturing of the Initial Supply by the Company represents a single performance obligation and consideration related to the manufacturing costs will be recognized over time as costs are incurred based on an input method. The Company recorded $0.3 million amount as revenue from the Supply Agreement for the year ended December 31, 2021.

15. Grant Revenue

In August 2021, the Company was approved to receive funding from the PTC Grant for the Phase 2 study of CNS sGC stimulation in AD with vascular features. The granting period is July 1, 2021, to December 31, 2022, and the Company will receive an award of up to $2 million. The Company determined that this transaction is non-reciprocal as there is not considered to be a commensurate value exchanged with the Alzheimer's Association as the funding provider. Where commensurate value is not exchanged for goods and services provided, a recipient assesses whether the grant is conditional or unconditional. The Company considered all conditions and barriers associated with this grant and determined the grant is conditional and revenue will be recognized upon achieving certain milestones and incurring internal costs specifically covered by this grant. Under ASC 958-605, revenues will be recognized as the Company incurs expenses related to the PTC Grant.

The Company incurred approximately $0.6 million of allowable expenses and recognized a corresponding amount of grant revenue for the year ended December 31, 2021.

16. Subsequent Events

The Company has evaluated all events and transactions that occurred after the balance sheet date through the date the consolidated financial statements were issued and determined that there were no such events requiring recognition or disclosure in the consolidated financial statements.

F-28


EX-4.1 2 cycn-ex4_1.htm EX-4.1 EX-4.1

 

Exhibit 4.1

DESCRIPTION OF THE REGISTRANT’S SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF THE

SECURITIES EXCHANGE ACT OF 1934

General

The following description of our capital stock is intended as a summary only and is qualified in its entirety by reference to our articles of organization and bylaws, the Annual Report on Form 10-K to which this description is an exhibit, any and all of which may be amended from time to time, and to the applicable provisions of the Massachusetts Business Corporation Act (“MBCA”).

Our authorized capital stock consists of 400,000,000 shares of our common stock and 100,000,000 shares of our preferred stock, all of which preferred stock is undesignated. As of March 5, 2020, there were 27,754,894 shares of common stock outstanding and no shares of preferred stock outstanding.

Common Stock

Dividend Rights

Subject to preferences that may apply to shares of preferred stock outstanding, holders of outstanding shares of common stock are entitled to receive dividends out of assets legally available at the times and in the amounts as our board of directors may from time to time determine.

Voting Rights

Each outstanding share of common stock is entitled to one vote on all matters submitted to a vote of shareholders. Holders of shares of our common stock have no cumulative voting rights.

Preemptive Rights.

Our common stock is not entitled to preemptive or other similar subscription rights to purchase any of our securities.

Conversion or Redemption Rights

Our common stock is neither convertible nor redeemable.

Liquidation Rights

Upon our liquidation, the holders of our common stock will be entitled to receive pro rata our assets which are legally available for distribution, after payment of all debts and other liabilities and subject to the prior rights of any holders of preferred stock then outstanding.

Listing

Our common stock is listed on the Nasdaq Global Select Market under the trading symbol "CYCN."

Anti-takeover Effects of Our Articles of Organization and Our Bylaws

Our articles of organization and bylaws contain certain provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors but which may have the effect of delaying, deferring or preventing a future takeover or change in control of us unless such takeover or change in control is approved by our board of directors. These provisions include:

 


 

Action by Written Consent and Special Meetings of Shareholders

Our articles of organization provide that shareholder action can be taken only at an annual or special meeting of shareholders or by the unanimous written consent of all shareholders in lieu of such a meeting. Our articles of organization and the bylaws also provide that, except as otherwise required by law, special meetings of the shareholders can only be called pursuant to a resolution adopted by a majority of our board of directors or holders of at least 40% of our then outstanding common stock. Except as described above, shareholders are not permitted to call a special meeting or to require our board of directors to call a special meeting.

Advance Notice Procedures

Our bylaws contain an advance notice procedure for shareholder proposals to be brought before an annual meeting of our shareholders, including proposed nominations of persons for election to the board of directors. Shareholders at an annual meeting will only be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a shareholder who was a shareholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary timely written notice, in proper form, of the shareholder's intention to bring that business before the meeting. Although our bylaws do not give our board of directors the power to approve or disapprove shareholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, the bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us.

Proxy Access

Our bylaws provide that a shareholder or a group of shareholders meeting certain conditions may nominate candidates for election as a director at an annual meeting of our shareholders using "proxy access" provisions. These provisions allow one or more shareholders (up to 20, collectively), owning at least 3% of our outstanding common stock continuously for at least three years, to nominate for election to our board of directors and to be included in our proxy materials up to the greater of two individuals or 20% of our board of directors, subject to the provisions included in our bylaws, including the provision of timely written notice to our Secretary.

Number of Directors and Filling Vacancies and Election of Directors

Our articles of organization provide that the number of directors is established by the board of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office. The ability of our board of directors to increase the number of directors and fill any vacancies may make it more difficult for our shareholders to change the composition of our board of directors. Our bylaws provide that a majority of the votes properly cast for the election of a director shall effect such election unless there are more nominees than directorships, in which case a plurality standard shall apply.

Authorized and Unissued Shares

Our authorized but unissued shares of common stock and preferred stock are available for future issuance without shareholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or otherwise.

Exclusive Forum.

Our articles of organization require, to the fullest extent permitted by law, that derivative actions brought in the name of Cyclerion, actions against our directors, officers and employees for breach of a fiduciary duty and other similar actions may be brought only in specified courts in the Commonwealth of Massachusetts. Although we believe this provision benefits us by providing increased consistency in the application of Massachusetts law in the

 


 

types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers.

Anti-Takeover Provisions under Massachusetts Law

Provisions Regarding Business Combinations

We are subject to the provisions of Chapter 110F of the MBCA. In general, Chapter 110F prohibits a publicly held Massachusetts corporation from engaging in a "business combination" with an "interested stockholder" for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A "business combination" includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An "interested stockholder" is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, five percent or more of the corporation's voting stock.

Under Chapter 110F, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 90% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the business combination was approved by our board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.

A Massachusetts corporation may "opt out" of these provisions with an express provision in its original articles of organization or an express provision in its articles of organization or bylaws resulting from a stockholders' amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented.

Provisions Regarding a Classified Board of Directors

Section 8.06(b) of the MBCA provides that, unless a company opts out of such provision, the terms of directors of a public Massachusetts company shall be staggered by dividing the directors into three groups, as nearly equal in number as possible, with only one group of directors being elected each year. We plan to opt out of this default requirement for a classified board of directors, and expect that all of our directors serve for one-year terms and will be elected annually.

Pursuant to Section 8.06(c)(2) of the MBCA, however, our board of directors may unilaterally opt back into default requirements under Section 8.06(b) of the MBCA and become a classified board of directors without the approval of our stockholders. Sections 8.06(d) and (e) of the MBCA provide that when a board of directors is so classified, (i) stockholders may remove directors only for cause, (ii) the number of directors shall be fixed only by the vote of the board of directors, (iii) vacancies and newly created directorships shall be filled solely by the affirmative vote of a majority of the remaining directors and (iv) a decrease in the number of directors will not shorten the term of any incumbent director. If our board of directors opts into this classified structure in the future, these provisions are likely to increase the time required for stockholders to change the composition of our board of directors. For example, at least two annual meetings would generally be necessary for stockholders to effect a change in a majority of the members of our board of directors. As a result, the ability of our board of directors to adopt a classified structure in the future without the approval of our stockholders could have the effect of discouraging a potential acquirer from making a tender offer for a majority of the outstanding voting interest of our capital stock or otherwise attempting to obtain control of Cyclerion.

 


 

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.

Indemnification of Directors and Officers

Our articles of organization provide that the liability of our directors for damages for any breach of fiduciary duty shall be limited to the fullest extent permitted by law. Our bylaws also provide that we will indemnify, and advance funds to and reimburse expenses of, our directors and officers that have been appointed by our board of directors to the fullest extent permitted by law, and that we may indemnify, and advance funds to and reimburse expenses of, such other officers and employees as determined by our board of directors. The right of indemnification provided under our bylaws is in addition to and not exclusive of any other rights to which any of our directors, officers or any other persons may otherwise be lawfully entitled. We have also entered, or expect to enter, into indemnification agreements with our directors and officers, and we carry insurance policies insuring our directors and officers against certain liabilities that they may incur in their capacity as directors and officers.

Part 8 of the MBCA authorizes the provisions, described above, that is contained in our articles of organization and bylaws. In addition, Sections 8.30 and 8.42 of the MBCA provide that if an officer or director discharges his or her duties in good faith and with the care that a person in a like position would reasonably exercise under similar circumstances and in a manner the officer or director reasonably believes to be in the best interests of the corporation, he or she will not be liable for such action.

 


EX-21.1 3 cycn-ex21_1.htm EX-21.1 EX-21.1

 

Exhibit 21.1

List of Registrant’s Subsidiaries

Cyclerion Securities Corporation, incorporated in Massachusetts, a wholly owned subsidiary.

Cyclerion GmbH, incorporated in Switzerland, a wholly owned subsidiary.

 


EX-23.1 4 cycn-ex23_1.htm EX-23.1 EX-23.1

 

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the following Registration Statements:

 

(1)
Registration Statement (Form S-3 No. 333-257145) of Cyclerion Therapeutics, Inc. and the related Prospectus,

 

(2)
Registration Statement (Form S-3 No. 333-240095) of Cyclerion Therapeutics, Inc. and the related Prospectus,

 

(3)
Registration Statement (Form S-3 No. 333-242334) of Cyclerion Therapeutics, Inc. and the related Prospectus,

 

(4)
Registration Statement (Form S-8 No. 333-248957) pertaining to 2019 Equity Incentive Plan, 2019 Employee Stock Purchase of Cyclerion Therapeutics, Inc.,

 

(5)
Registration Statement (Form S-8 No. 333-258316) pertaining to 2019 Equity Incentive Plan, 2019 Employee Stock Purchase of Cyclerion Therapeutics, Inc.,

 

(6)
Registration Statement (Form S-8 No. 333-230615) pertaining to 2019 Equity Incentive Plan, 2019 Employee Stock Purchase Plan, Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan, and Amended and Restated 2005 Stock Incentive Plan of Cyclerion Therapeutics, Inc.;

 

 

of our report dated February 24, 2022, with respect to the consolidated financial statements of

Cyclerion Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2021.

 

/s/ Ernst & Young LLP

 

Boston, Massachusetts

February 24, 2022

 


EX-31.1 5 cycn-ex31_1.htm EX-31.1 EX-31.1

 

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Peter M. Hecht, certify that:

1. I have reviewed this annual report on Form 10-K of Cyclerion Therapeutics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and (internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 24, 2022

 

By:

/s/ Peter Hecht

 

 

 

Name:

Peter M. Hecht

 

 

 

Title:

Chief Executive Officer (Principal Executive Officer)

 

 


EX-31.2 6 cycn-ex31_2.htm EX-31.2 EX-31.2

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Anjeza Gjino, certify that:

1. I have reviewed this annual report on Form 10-K of Cyclerion Therapeutics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and (internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 24, 2022

 

By:

/s/ Anjeza Gjino

 

 

 

Name:

Anjeza Gjino

 

 

 

Title:

Chief Financial Officer (Principal Financial and Accounting Officer)

 

 


EX-32.1 7 cycn-ex32_1.htm EX-32.1 EX-32.1

 

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Peter M. Hecht, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Annual Report on Form 10-K of Cyclerion Therapeutics, Inc. for the period ended December 31, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Cyclerion Therapeutics, Inc.

 

Date: February 24, 2022

 

By:

/s/ Peter Hecht

 

 

 

Name:

Peter M. Hecht

 

 

 

Title:

Chief Executive Officer (Principal Executive Officer)

 

 


EX-32.2 8 cycn-ex32_2.htm EX-32.2 EX-32.2

 

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Anjeza Gjino, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Annual Report on Form 10-K of Cyclerion Therapeutics, Inc. for the period ended December 31, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Cyclerion Therapeutics, Inc.

 

Date: February 24, 2022

 

By:

/s/ Anjeza Gjino

 

 

 

Name:

Anjeza Gjino

 

 

 

Title:

Chief Financial Officer (Principal Financial and Accounting Officer)

 

 


GRAPHIC 9 img149660584_0.jpg GRAPHIC begin 644 img149660584_0.jpg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end EX-101.LAB 10 cycn-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Segment Reporting, Policy [Policy Text Block] Segment Information Operating Loss Carryforwards Net operating loss carryforwards Operating Loss Carryforwards, Total Forecast [Member] It represents the rentable square feet of short term sublease agreement. Rentable Square Feet Of Short Term Sublease Agreement Rentable square feet Proceeds from Notes Payable Proceeds from short-term note payable Proceeds from Notes Payable, Total Restructuring Type [Axis] Restructuring Type Auditor Location Deferred Revenue Deferred Revenue, Total Cash Cash Cash, Beginning Balance Cash, Ending Balance Operating Expenses [Abstract] Cost and expenses: Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class This member represents the common stock purchase agreement. Common Stock Purchase Agreement [Member] Common Stock Purchase Agreement Represents the information pertaining to separation agreement. Separation Agreement [Member] Separation agreement Operating Income (Loss) Loss from operations Number of shares of Parent Company common stock donated to donor advised fund. Shares Donated Parent Company Number of shares of Ironwood common stock donated to American Endowment Foundation A donor advised fund which received contributions from the chief executive officer. Donor Advised Fund Of Chief Executive Officer [Member] American Endowment Foundation Amount of accrued expenses and other liabilities current. Accrued Expenses And Other Liabilities Current Accrued expenses and other current liabilities Accrued expenses and other current liabilities Entity Emerging Growth Company Entity Emerging Growth Company Credit Derivatives Contract Type [Domain] Credit Derivatives Contract Type Share based compensation expense Share Based Compensation Expense Share based compensation expense Income Tax Disclosure [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination. Deferred Tax Assets Capitalized Research And Development Costs Capitalized research and development Number of Reportable Segments Number of reportable business segment The percentage of increase in annual base rent under the operating sublease. Sublease Annual Base Rent Increase Percent Sublease, Increase in base rent over the term of the lease (as a percent) Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Common stock, no par value, 400,000,000 shares authorized and 43,410,185 issued and outstanding at December 31, 2021 and 400,000,000 shares authorized and 34,047,300 issued and outstanding at December 31, 2020 Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Entity Address, State or Province Entity Address, State or Province Sublease termination agreement estimated fair value of services. Sublease Termination Agreement Estimated Fair Value Of Services Sublease termination agreement estimated fair value of services Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Weighted average risk-free interest rate Accounts Receivable, Related Parties, Current Related party accounts receivable Sublease Income Net sublease income Decrease in operating lease liabilities due to lease modification and termination The amount of decrease in lease liabilities related to the modification of an existing lease. Decrease In Operating Lease Liabilities Related To Lease Modification Represents the information pertaining to the agreement under which the Company provides services to Ironwood and vice versa and those are recorded as operating expenses. Transition Services Agreements [Member] Transition services agreements Represents the amount of annual base rent under operating lease. Lessee Operating Lease Annual Base Rent Annual base rent The amount of leased space terminated from the lease agreement. Rentable Square Feet Terminated From Lease Agreement Rentable space terminated from lease agreement (in square feet) Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted net loss per share (in shares) Weighted average shares used in calculating net loss per share — basic and diluted (in thousands) The entire disclosure of information about leases. Lease Disclosure [Text Block] Leases Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Options Deferred tax liability prepaid sublease termination. Deferred Tax Liability Prepaid Sublease Termination Prepaid sublease termination Legal Entity [Axis] Legal Entity Not Found During Migration Deprecated Concept Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract] WeWork WeWork [Member] Wework. Revenue from related party Revenue from Related Parties The actual duration of the sublease. Subleased Term Subleased term General and Administrative Expense [Member] General and administrative The amount of leased space the Company has agreed to sublease to a third party. Rentable Square Feet Sublease To Third Party Space subleased to third party (in square feet) Accrued Employee Benefits, Current Accrued severance and benefit costs The amount of decrease in remaining operating lease payments related to a lease modification. Lease Modification Decrease In Remaining Operating Lease Payments Decrease in remaining operating lease payments Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Exercisable (in years) Weighted average remaining contractual term, exercisable at the end of period (in years) Market-based Stock Options Market Based Stock Option [Member] Market based stock option. AOCI Including Portion Attributable to Noncontrolling Interest [Member] Accumulated other comprehensive loss Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Accounts Receivable, after Allowance for Credit Loss, Current, Total Short-term Debt Short-term liability Short-term Debt, Total Restructuring Charges Charges Restructuring Charges, Total Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Schedule of Related Party Transactions, by Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] City Area Code City Area Code Provision for income taxes. Provision For Income Taxes Provision for income tax Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted-average assumptions used in estimating the fair value of the stock options Deferred Tax Assets, Gross Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Net deferred tax assets Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted-Average Grant Date Fair Value Schedule Of Earnings Per Share Diluted By Common Class Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block] Revenues [Abstract] Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Cancelled or forfeited (in dollars per share) Revenue Recognition and Deferred Revenue [Abstract] Lessor, Lease, Description [Line Items] Lessor Lease Description [Line Items] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated and combined balance sheets Commitments and Contingencies Commitments and contingencies Issuance of common stock - 2020 private placement (in shares) Stock Issued During Period, Shares, New Issues Scenario [Axis] Consolidated Entities [Domain] Consolidated Entities Salaries Accrued Salaries, Current Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Tenant Improvements Tenant improvement allowance Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Weighted average shares used in calculating: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, beginning of period Total cash, cash equivalents and restricted cash Related Party [Domain] Related Party Represents information pertaining to vested stock options. Vested Stock Options [Member] Vested stock options Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] The amount of deferred tax assets, net of deferred tax liabilities, before valuation allowance. Net Deferred Assets Liabilities Before Valuation Allowance Net deferred tax assets Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Capital Expenditures Incurred but Not yet Paid Fixed asset purchases in accounts payable and accrued expenses The weighted average fair value due to the impact of conversion related to spin-off to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Impact Of Conversion Related To Spin Off Weighted Average Grant Date Fair Value Aggregate impact of conversion related to spin-off (in dollars per share) General and Administrative Expense General and administrative General and Administrative Expense, Total Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited (in shares) Restructuring and Related Cost, Number of Positions Eliminated Reduction in workforce, number of employees Deferred Tax Liabilities, Gross Total deferred tax liabilities Deferred Tax Liabilities, Gross, Total Operating Lease, Right-of-Use Asset Operating lease right-of-use asset Security Exchange Name Security Exchange Name Statistical Measurement [Domain] Statistical Measurement Number of shares issued during the period as a result of an employee stock purchase plan and exercise of stock options and Restricted Stock Units. Stock Issued During Period Shares Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan (in shares) Furniture and Fixtures [Member] Furniture and fixtures Tabular disclosure of the significant assumptions used during the year to estimate the fair value of performance shares, including, but not limited to: (a) expected term of performance shares, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Schedule Of Share Based Payment Award Performance Shares Valuation Assumptions Table [Text Block] Schedule of weighted-average assumptions used in estimating the fair value of the stock awards containing market conditions Cash and Cash Equivalents, Fair Value Disclosure Total cash equivalents Document Period End Date Document Period End Date Income Statement Location [Axis] Income Statement Location Related Party Transaction, Expenses from Transactions with Related Party Related party expense Related Party Transaction [Axis] Related Party Transaction Share based compensation expense related to issuance of stock options and RSUs to non employees Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees Share‑based compensation expense related to issuance of stock options to non-employees. Type of Restructuring [Domain] Type of Restructuring Geographic Distribution [Axis] Geographic Distribution Common Stock, Shares Authorized Common stock, shares authorized Use of Estimates, Policy [Policy Text Block] Use of Estimates Issuance of common stock - ATM (in Values) Stock Issued During Period Values in Share Based Compensation Stock Issued During Period Values in Share Based Compensation Operating Lease, Liability, Current Current portion of operating lease liabilities Less: current portion of operating lease liabilities Related Party [Axis] Related Party Supplemental Cash Flow Information [Abstract] Supplemental cash flow disclosure: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash (used in) operating activities: Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities excluded from the calculation of diluted loss per share Amount of operating lease expense related to subleases. Operating Lease Sublease Expense Rent expense related to sublease Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Share-based compensation Deferred Tax Liabilities, Net [Abstract] Deferred tax liabilities: Jefferies LLC. Jefferies L L C [Member] Jefferies LLC Entity Address, Address Line Two Entity Address, Address Line Two Current Fiscal Year End Date Current Fiscal Year End Date Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net (decrease) increase in cash, cash equivalents and restricted cash Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Rentable square feet sublease to third party terminated from lease agreement. Rentable Square Feet Terminated Sublease To Third Party From Lease Agreement Rentable space terminated from lease agreement (in square feet) Restricted Cash and Cash Equivalents [Abstract] Restricted Cash The amount of cash outflow for a lease termination fee. Payments For Lease Modification Termination Fee Cash paid for lease termination fees Restructuring Costs Restructuring costs Restructuring Costs, Total Property, Plant and Equipment [Member] Property, plant and equipment Disaggregation of Revenue [Table] Notes Payable, Current Short-term note payable Notes Payable, Current, Total Assets [Abstract] ASSETS Termination Agreement Termination agreement. Termination Agreement [Member] PTC Grant Award PTC Grant Award Business Description and Basis of Presentation [Text Block] Nature of Business Share-based Payment Arrangement, Plan Modification, Incremental Cost Incremental compensation expense due to modification Credit Derivatives Contract Type [Axis] Credit Derivatives Contract Type 2021 (remaining nine months) Lessee, Operating Lease, Liability, to be Paid, Year One Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Debt Instrument, Name [Domain] Debt Instrument, Name Private Placement Private Placement [Member] Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Revenue from Contract with Customer [Policy Text Block] Revenue Defined Contribution Plan [Table] Defined Contribution Plan [Table] State and Local Jurisdiction [Member] State Share-based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block] Summary of stock awards containing market conditions activity Additional Paid in Capital, Common Stock Paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Income (Loss) from Continuing Operations before Income Taxes, Foreign International The period of abatement of base rent under the terms of the sublease agreement. Lessor Sublease Abatement Period Sublease, Abatement period Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Software and Software Development Costs [Member] Software Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before benefit from income taxes Document Type Document Type Accounts Receivable Disclosure of accounting policy for related party accounts receivable. Related Party Accounts Receivable Policy Policy [Text Block] Cash commission percentage of gross proceeds of sales of common stock. Cash Commission Percentage Of Gross Proceeds Of Sales Of Common Stock Cash commission of gross proceeds of sales of common stock, percentage Prepaid Rooms Balance Related To Other Assets Prepaid rooms balance reclassified from other assets Prepaid rooms balance related to other assets. Amount of increase (decrease) in operating lease liabilities. Increase Decrease In Operating Lease Liabilities Operating lease liabilities Amount of adjustments made upon separation primarily related to differences between assets and liabilities transferred to Cyclerion as a result of the Separation and assets and liabilities reported in the Company's combined balance sheet. Adjustments Upon Separation Separation-related adjustment Amount of deferred tax liability attributable to taxable temporary differences from operating lease, right of use assets. Deferred Tax Liabilities Operating Lease Right Of Use Assets Operating lease - right of use asset The amount of cash outflow for termination fees and other initial direct costs of lease modification. Payments For Lease Modification Termination Fee And Other Initial Direct Costs Cash paid for initial direct costs of lease modification Domestic Tax Authority [Member] Federal Decrease in right-of-use assets related to lease modification and termination The amount of decrease in right-of-use assets related to the modification of an existing lease. Decrease In Right Of Use Assets Related To Lease Modification Amount of research and development transaction support services. Related Party Transaction Research And Development Transaction Support Services Payments to provide research and development transaction support services Operating Lease, Liability, Noncurrent Operating lease liabilities, net of current portion Noncurrent lease liability Represents information pertaining to current workforce reductions of the Company. Current Workforce Reductions [Member] Current workforce reductions Due from Related Parties Amounts due from related party Due from Related Parties, Total Assets, Current Total current assets Accounts Payable and Accrued Liabilities [Member] Accounts Payable And Accrued Liabilities Number of share options due to conversion related to spin-off. Share Based Compensation Arrangement By Share Based Payment Award Options Impact Of Conversion Related To Spin Off Aggregate impact of conversion related to spin-off (in shares) Selling, General and Administrative Expenses, Policy [Policy Text Block] General and Administrative Expenses Disaggregation of Revenue [Line Items] Employee Stock Option Member Share-based Payment Arrangement, Option [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Outstanding (in years) Weighted average remaining contractual term, outstanding at the end of period (in years) Income Tax Expense (Benefit), Total Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Other Assets, Current Other current assets The gross amount of sublease income, net of the related rent expense from the Master Lease. Gross Sublease Income Net Of Rent Expense Gross sublease income, net of rent expense Earnings Per Share, Basic and Diluted Basic and diluted net loss per share (in dollars per share) Net loss per share — basic and diluted Earnings Per Share, Basic and Diluted, Total Area of Land Rented space (in square feet) Leases [Abstract] Antidilutive Securities [Axis] Antidilutive Securities Consolidation, Policy [Policy Text Block] Principles of Consolidation Security Deposit Liability Contingent liability under an unused letter of credit, posted as a security deposit Letter of credit posted with the landlord as a security deposit Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Unvested the end of the period (in shares) Unvested at the beginning of the period (in shares) PPP loan forgiveness Debt Instrument, Decrease, Forgiveness Represents information pertaining to laboratory equipment. Laboratory Equipment [Member] Laboratory equipment Deferred Tax Assets, Operating Loss Carryforwards Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Total Threshold period of consecutive trading days over which the average closing price of the Company's share price is considered for measurement of vesting of stock awards. Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Measurement Threshold Number Of Consecutive Trading Days Considered Threshold consecutive trading days, used as a base for measurement of vesting of stock awards Common Stock, Shares, Outstanding Ending balance (in shares) Beginning balance (in shares) Common stock, shares outstanding Finite-Lived Intangible Assets [Line Items] Finite Lived Intangible Assets [Line Items] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Amended Headquarters Lease [Member] Represents information pertaining to an amended direct operating lease effective February 28, 2020 for premises located at 301 Binney Street, Cambridge, MA. Lease Amendment Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Cancelled or forfeited (in shares) Collaborative Arrangement and Arrangement Other than Collaborative [Table] Represents services provided to the reporting entity for information systems, accounting, other financial services (such as treasury, audit and purchasing), human resources, legal and facilities. Corporate Costs [Member] Corporate costs Cash and Cash Equivalents [Domain] Cash and Cash Equivalents Effective Income Tax Rate Reconciliation, Disposition of Business, Amount Separation-related adjustments Represents information pertaining to Paycheck Protection Program Loan. Paycheck Protection Program Loan [Member] PPP Loan Represents the information pertaining to the agreement under which Company provides services to Ironwood and the amounts earned are recorded as revenue. Development Agreement [Member] Development agreement Operating Expenses Total cost and expenses Represent information pertaining to initial term of agreement. Initial Term Of Agreement Development Agreement, initial term n/a Patent Costs [Abstract] Patent Costs IPO [Member] IPO Lease, Cost Total lease costs Lease, Cost, Total Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at end of the year (in dollars per share) Outstanding at beginning of the year (in dollars per share) Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Represents the accounting policy on paycheck protection program loan, CARES act. Paycheck Protection Program Loan Cares Act Policy [Text Block] Paycheck Protection Program Loan Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Earnings Per Share [Abstract] Net loss per share: Increase (Decrease) in Other Current Assets Other current assets Lessee, Operating Lease, Liability, to be Paid, Year Two 2022 Net loss Net Income (Loss) Attributable to Parent Net loss Net loss Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Summary of reconciliation of income taxes computed using the U.S. federal statutory rate Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses and Other Current Liabilities Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets. Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate of operating leases Research and Development Expense [Member] Research and development Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities. Deferred Tax Assets Operating Lease Liabilities Operating lease - liability Lessor, Lease, Description [Table] Lessor Lease Description [Table] Document Fiscal Period Focus Document Fiscal Period Focus Decrease in operating lease liabilities due to lease modifications and termination Decrease In Operating Lease Liabilities Related To Lease Modifications And Termination Decrease In Operating Lease Liabilities Related To Lease Modifications And Termination Accounting Policies [Abstract] Increase (Decrease) in Accounts Payable, Related Parties Related party accounts payable Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Entity Address, Address Line One Entity Address, Address Line One Total intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at end of the year (in shares) Outstanding at beginning of the year (in shares) Liabilities, Current Total current liabilities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Entity Address, Postal Zip Code Entity Address, Postal Zip Code Effective Income Tax Rate Reconciliation, Amount [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding Aggregate intrinsic value, outstanding at the end of period Total future minimum lease payments (receipts) Lessee, Operating Lease, Liability, to be Paid Total future minimum lease payments (receipts) Product and Service [Domain] Total revenues Revenues Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount State income taxes, net of federal benefit Net cash (used in) operating activities Net Cash Provided by (Used in) Operating Activities Noncash Investing Items Abstract. Noncash Investing Items [Abstract] Non-cash investing activities Represents the information pertaining to unvested stock options. Unvested Stock Options [Member] Unvested stock options Represents the number of extension options under operating lease. Lessee Operating Lease Number Of Extension Option Number of extension option Equity Components [Axis] Equity Components Assets, Current [Abstract] Current assets: Variable Lease, Cost Variable lease costs Entity Registrant Name Entity Registrant Name Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options due to conversion related to spin off. Share Based Compensation Arrangements By Share Based Payment Award Options Impact Of Conversion Related To Spin Off Weighted Average Exercise Price Aggregate impact of conversion related to spin-off (in dollars per shares) Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Schedule Of Property Plant And Equipment Useful Life Table [Text Block] Schedule of Estimated Useful Lives of Property and Equipment Gain Loss On Sale Of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment Loss on Disposition of Property Plant Equipment Net loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment, Total Lessee, Operating Sublease, Existence of Option to Extend [true false] Operating sublease, option to extend Expected option term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Entity Interactive Data Current Entity Interactive Data Current Entity Address, City or Town Entity Address, City or Town Sublease termination agreement estimated fair value of rooms. Sublease Termination Agreement Estimated Fair Value Of Rooms Sublease termination agreement estimated fair value of rooms Deferred Rent Receivables, Net Rent receivables outstanding from subtenant he amount of capital contributed by the parent through transfers. Contributed Capital Net transfers from Ironwood Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected option term (in years) Trading Symbol Trading Symbol Ironwood Pharmaceuticals, Inc., the parent of the reporting entity. The reporting entity was spun off from Ironwood. Ironwood Pharmaceuticals Inc [Member] Ironwood Related Party Transactions Disclosure [Text Block] Related Party Transactions Sublease termination agreement prepaid rooms and services. Sublease Termination Agreement Prepaid Rooms And Services Sublease termination agreement prepaid rooms and services Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: present value adjustment Local Phone Number Local Phone Number Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement, shortfall or windfall. Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Payment Arrangement Shortfalls Windfalls Amount Share-based compensation - shortfalls/(windfalls) Number of common stock sold Number of common stock sold Stockholders' Equity Attributable to Parent Ending balance Beginning balance Total stockholders' equity Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Weighted-Average Exercise Price Unrecognized Tax Benefits Unrecognized tax benefits Unrecognized Tax Benefits, Beginning Balance Unrecognized Tax Benefits, Ending Balance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Change in valuation allowance Deferred tax assets, valuation allowance Operating Lease, Payments Cash paid for amounts included in the measurement of lease liabilities (in thousands) Gain (loss) on lease modification Gain (Loss) on Termination of Lease Gain (Loss) on Termination of Lease Amount of gain (loss) on modification of lease. Gain Loss On Modification Of Lease Statistical Measurement [Axis] Statistical Measurement Amount received from related party for issuance of shares of common stock. Stock Issued During Period Value Related Party Investment in common stock by related party Entity Small Business Entity Small Business Stock-based compensation from the modification of share based equity awards. Stock Based Compensation From The Modification Of Share Based Equity Awards Stock-based compensation from the modification of share based equity awards Deferred Tax Assets, Tax Credit Carryforwards Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards, Total Organization, Consolidation and Presentation of Financial Statements [Abstract] Lessee, Leases [Policy Text Block] Leases Share Price Purchase price Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV APIC, Share-based Payment Arrangement, Increase for Cost Recognition Share-based compensation expense related to issuance of stock options and RSUs to employees and employee stock purchase plan APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Summary of deferred tax assets (liabilities) Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets Restructuring Plan [Axis] Restructuring Plan Property, Plant and Equipment, Useful Life Estimated Useful Life (In Years) Entity [Domain] Entity Balance Sheet Location [Axis] Balance Sheet Location Defined Contribution Plan, Employer Matching Contribution, Percent of Match Matching contribution (as a percent of employee's contributions) The amount of abatement on annual base rent under the operating sublease. Sublease Annual Base Rent Abatement Sublease, Abatement of base rent Represents the amount of rent abatement. Lessee Operating Lease Rent Abatement Abatement of base rent (Gain) / loss on lease modification and termination Gain Loss On Lease Modification And Termination Gain loss on lease modification and termination. Accrued Bonuses, Current Accrued incentive compensation Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of liabilities. Accrued Research And Development Current Accrued research and development costs Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Sale of Stock [Domain] Sale of Stock Accrued Vacation, Current Accrued vacation Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Other Proceeds from Sale of Property, Plant, and Equipment Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment, Total Related Party Transaction [Line Items] Related Party Transaction [Line Items] Lessee, Operating Lease, Liability, to be Paid, after Year Five 2026 and thereafter Lessee, Lease, Description [Table] Lessee Lease Description [Table] Value of shares issued during the period as a result of an employee stock purchase plan and exercise of stock options and Restricted Stock Units. Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan Class of Stock [Line Items] Nature of Business Income Tax Authority [Axis] Income Tax Authority Professional Fees Legal and other fees Defined Contribution Plan, Cost Compensation expense related to the defined contribution 401(k) Savings Plan Lessee, Operating Lease, Term of Contract Term of lease Prepaid Expense, Current Prepaid expenses Prepaid Expense, Current, Total Issuance of common stock - 2020 private placement Stock Issued During Period, Value, New Issues The amount of annual base rent under the operating sublease. Sublease Annual Base Rent Sublease, Annual base rent The amount of additional security deposit to be provided by the sublessee as defined by the sublease agreement. Lessor Sublease Additional Security Deposit To Be Received Sublease, Additional security deposit to be received Interest Expense Interest Expense, Total Sublease termination income loss net. Sublease Termination Income Loss Net Sublease termination income, net Sublease termination income, net Operating Expense [Member] Operating expenses Property, Plant and Equipment, Disposals Property, Plant and Equipment, Disposals Cash and cash equivalents Cash Equivalents, at Carrying Value Cash Equivalents, at Carrying Value, Total Share-based Payment Arrangement, Noncash Expense Share-based compensation expense Share-based Payment Arrangement, Noncash Expense, Total Effective Income Tax Rate Reconciliation, Tax Credit, Amount Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Summary of RSU activity License And Service Member License and Service [Member] Share-based Payment Arrangement, Option, Activity [Table Text Block] Schedule of stock option activity Lease, Practical Expedients, Package [true false] Election of practical expedients package Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Related Party Transactions [Abstract] Issuance of common stock - ATM (in Shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total Amount of share based compensation upon separation from parent company. Share Based Compensation Upon Separation Ironwood allocation - share-based compensation Workforce reduction plan 2020. Workforce Reduction Plan2020 [Member] 2020 Workforce Reduction Interest and Other Income Interest income generated form cash and cash equivalents balances Interest and Other Income, Total Cyclerion Securities Corporation. Cyclerion Securities Corporation [Member] Cyclerion Securities Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable (in shares) Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Commitments and Contingencies Disclosure [Abstract] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for new operating lease upon lease commencement (in thousands) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Assets Total assets Fair Value, Inputs, Level 2 [Member] Level 2 Property, Plant and Equipment, Other Types [Member] Property, Plant and Equipment, Other Types Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Accrued interest or penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total Statement [Line Items] Statement [Line Items] Liabilities and Equity Total liabilities and stockholders' equity Increase (Decrease) in Accounts Payable, Trade Accounts payable Balance Sheet Location [Domain] Balance Sheet Location Property, Plant and Equipment [Abstract] Statement of Cash Flows [Abstract] Payments for Tenant Improvements Payments for Tenant Improvements Additional Paid-in Capital [Member] Paid in capital Income Tax Examination, Penalties and Interest Accrued Income tax, penalties and interest accrued Income Tax Examination, Penalties and Interest Accrued, Total Title of 12(b) Security Title of 12(b) Security Health care trust fund, Description Health Care Trust Amount Description Health Care Trust Amount Description Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Effect of exchange rate changes on cash, cash equivalents and restricted cash Akbeia Supply Agreement [Member] Akbeia supply agreement member. Fair Value, Inputs, Level 3 [Member] Level 3 Increase (Decrease) in Prepaid Expense Prepaid expenses Cash and Cash Equivalents, at Carrying Value [Abstract] Cash and Cash Equivalents Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Operating Loss Carryforwards [Line Items] Income Taxes Award Type [Domain] Award Type Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Akebia Research License Agreement [Member] Akebia Research License Agreement [Member] Akebia Research License Agreement Member. Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Term (in years) Property, Plant and Equipment [Table Text Block] Schedule of property and equipment, net Fair Value, Inputs, Level 1 [Member] Level 1 Lessee, Operating Lease, Liability, to be Paid, Year Four 2024 Restricted Stock [Member] Restricted Stock Interest and other income, net Nonoperating Income (Expense) Nonoperating Income (Expense), Total Additional milestone cash payment Payment Of Cash Milestone Payment of cash milestone. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Entity Current Reporting Status Entity Current Reporting Status Grant Revenue Revenue from Contract with Customer [Text Block] Entity Voluntary Filers Entity Voluntary Filers Scenario [Domain] License Agreement [Abstract] License agreement abstract. Money Market Funds [Member] Money market funds Maximum amount of Aggregate initial offering price. Maximum Amount Of Aggregate Initial Offering Price Maximum amount of Aggregate initial offering price Restructuring and Related Activities Disclosure [Text Block] Workforce Reduction Documents Incorporated by Reference [Text Block] Documents Incorporated by Reference Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) Performance Shares [Member] Performance stock options Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of share-based compensation expense Retirement Benefits [Abstract] Accrued Liabilities and Other Liabilities [Abstract] Revenue from license agreement Revenue From License Revenue from license. Represents the percentage of increase in annual base rent under operating lease. Lessee Operating Lease Annual Base Rent Increase Percent Increase in base rent on a yearly basis (as a percent) Auditor Firm ID Revenue from grants Revenue from grant. Revenue From Grant Income Statement Location [Domain] Income Statement Location The number of extensions available to the sublessee under the terms of the sublease agreement. Lessor Sublease Number Of Extension Options Sublease, Number of extension options Auditor Name Office Equipment [Member] Computer and office equipment Amount of increase to additional paid-in capital (APIC) from reclassification of net parent company investment. Adjustments To Additional Paid In Capital Reclassification Of Net Parent Company Investment Reclassification of net parent company investment Share-based Payment Arrangement, Plan Modification, Number of Grantees Affected Number of employees impacted Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable (in dollars per share) Revenue, Performance Obligation [Abstract] Revenue The number of shares made during the period on other than stock (or unit) option plans due to the impact of conversion related to spin-off. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Impact Of Conversion Related To Spin Off Aggregate impact of conversion related to spin-off (in Shares) Restructuring and Related Costs [Table Text Block] Schedule of accrued liabilities activity allocated to Cyclerion in connection with the reduction in workforce Minimum [Member] Minimum [Member] Minimum Cash and Cash Equivalents [Abstract] Cash equivalents: Measurement Frequency [Domain] Measurement Frequency The term of automatic renewal for the development agreement. Development Agreement Renewal Period Development Agreement, renewal period Security Deposit Returned Security Deposit Returned Security deposit returned to the company. License Agreements License Agreements [Text Block] The entire disclosure for license agreements. Grant [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost And Reserve [Line Items] Other Sundry Liabilities, Current Other Number of shares of common stock distributed on prorata basis by parent company upon separation. Distribution Of Common Stock Shares By Parent Company Upon Separation Distribution of common stock by Ironwood upon separation (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Granted (in shares) Other comprehensive loss: Other comprehensive loss: Statement of Other Comprehensive Income [Abstract] The period after the commencement date within which the additional security deposit is due under the operating sublease. Sublease Additional Security Deposit Period Sublease, additional security deposit period Lessee, Operating Lease, Liability, Payment, Due [Abstract] Future minimum lease payments under non-cancelable operating leases under ASC 842 Document Annual Report Document Annual Report Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Assumptions used to estimate fair value of stock options Assumptions used to estimate fair value of performance-based stock options Deferred Tax Assets, Valuation Allowance Valuation allowance Deferred Tax Assets, Valuation Allowance, Total Comprehensive loss Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest The amount of decrease in security deposit related to a lease modification. Lease Modification Decrease In Security Deposit Decrease in security deposit Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Proceeds from exercises of stock options and ESPP Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised, Total Proceeds from equity private placement and ATM Net Cash Provided by (Used in) Financing Activities [Abstract] Unrecognized share-based compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Income (Loss) from Continuing Operations before Income Taxes, Domestic U.S. Debt Instrument [Axis] Debt Instrument Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Translation Adjustment Entity Filer Category Entity Filer Category Income Tax, Policy [Policy Text Block] Income taxes Severance Costs Severance and benefits costs Represents the information pertaining to Cyclerion GmbH. Cyclerion Gmbh [Member] Cyclerion GmbH Document Fiscal Year Focus Document Fiscal Year Focus Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Construction in Progress [Member] Construction in progress Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value per option share Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Interest and Other Income [Abstract] Interest and other income, net Income Tax Disclosure [Text Block] Income Taxes Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction, Total Entity Ex Transition Period Entity Ex Transition Period Accounts Payable, Related Parties, Current Related party accounts payable The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement, net of related issuance costs. Proceeds From Issuance Of Private Placement Net Of Issuance Costs Net proceeds from issuance of shares to accredited investors Fair Value Disclosures [Abstract] Other Assets Other assets Other Assets, Total Property, Plant and Equipment Disclosure [Text Block] Property and Equipment The amount of cash outflow for initial direct costs of lease modification. Payments For Lease Modification Initial Direct Costs Cash paid for initial direct costs of lease modification Maximum [Member] Maximum Entity Central Index Key Entity Central Index Key The workforce reduction plan which initiated on October 30, 2019. October2019 Workforce Reduction Plan [Member] October 2019 Workforce Reduction Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Write off lease unamortized direct cost. Write Off Lease Unamortized Direct Cost Write off lease unamortized direct cost Number of shares vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares lease expense Operating Lease, Expense Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Income tax benefit using U.S. federal statutory rate Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Entity Tax Identification Number Entity Tax Identification Number Equity Component [Domain] Equity Component The workforce reduction plan which initiated on November 5, 2020. November2020 Workforce Reduction Plan [Member] November 2020 Workforce Reduction Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected stock price volatility Gain on extinguishment of debt Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt, Total Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Numerator: Proceeds from equity private placement and ATM Proceeds from 2020 Equity private placement and ATM Proceeds from Issuance of Private Placement Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Income Tax Authority [Domain] Income Tax Authority Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Expected period to recognize the expense Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Accruals and reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total Chief Executive Officer [Member] Peter Hecht Allowable Expenses on Grant Revenue Allowable Expenses on Grant Revenue Restructuring Plan [Domain] Restructuring Plan Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Consolidated Entities [Axis] Consolidated Entities Accounts receivable Increase (Decrease) in Accounts Receivable Subsequent Events [Abstract] Restructuring Reserve, Accrual Adjustment Adjustments Leasehold Improvements [Member] Leasehold improvements Statement [Table] Statement [Table] Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term of operating leases (in years) Entity File Number Entity File Number Geographic Distribution [Domain] Geographic Distribution Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Plans Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Lessee, Lease, Description [Line Items] Leases Increase (Decrease) in Other Noncurrent Assets Other assets Retained Earnings [Member] Accumulated Deflicit Revenue from Contract with Customer, Excluding Assessed Tax Revenue from related party Revenue from Contract with Customer, Excluding Assessed Tax, Total Lessee, Operating Lease, Discount Rate Incremental borrowing rate (as a percent) Liabilities, Current [Abstract] Current liabilities: Subsequent Events, Policy [Policy Text Block] Subsequent Events Share-based Payment Arrangement [Text Block] Share-based Compensation Plans Deferred Tax Assets, Net of Valuation Allowance [Abstract] Deferred tax assets: Earnings Per Share, Basic and Diluted [Abstract] Denominator: Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Number of investors. Number Of Investors Number of investors for private placement The term advance notice either party must give to cancel the Development Agreement. Development Agreement Period For Notification Of Cancellation Development Agreement, period for notification of cancellation Operating lease liabilities t June 30, 2021 Operating Lease, Liability Lease liability Payments for Restructuring Amount paid Restricted Cash and Cash Equivalents, Noncurrent Restricted cash, net of current portion Restricted cash in non-current assets Restricted Cash and Cash Equivalents, Noncurrent, Total Amount of increase (decrease) in operating lease assets. Increase Decrease In Operating Lease Assets Operating lease assets Common Stock [Member] Common Stock Property and equipment. gross Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Accrued Professional Fees, Current Professional fees Entity Public Float Entity Public Float Restricted Cash and Cash Equivalents Restricted cash Restricted Cash and Cash Equivalents, Total Cover [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Unvested restricted common stock at the end of the period (in dollars per share) Unvested at the beginning of the period (in dollars per share) Related Party Transaction [Domain] Related Party Transaction Commission Paid From Gross Proceeds Of Sales Of Common Stock Commission Paid From Gross Proceeds Of Sales Of Common Stock Commission Paid From Gross Proceeds Of Sales Of Common Stock. Revenue from development agreement Revenue From Development Agreement Revenue from development agreement Statement of Stockholders' Equity [Abstract] Property, Plant and Equipment [Table] Schedule Of Property Plant And Equipment [Table] Represents the other related party transactions. Other Related Party Transactions [Member] Other Related Party Transactions The increase (decrease) during the reporting period in accrued research and development expense. Increase Decrease In Accrued Research And Development Accrued research and development costs Share-based Payment Arrangement [Abstract] Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Accrued expenses and other current liabilities Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount Non-deductible share-based compensation Other Information Pertaining to Income Taxes Income tax credit expiration description Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Investment Instruments Common stock dividend ratio applied to the distribution of shares for the spin-off of the reporting entity from its Parent, as of the separation date. Dividends Common Stock Stock Ratio Common stock dividend issued (shares of Cyclerion per ten shares of Ironwood) Restricted Stock Units (RSUs) [Member] Restricted Stock Units Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Document Transition Report Document Transition Report Represents the information pertaining to net parent company investment. Net Parent Company Investment [Member] Net parent investment Deferred Tax Assets, Property, Plant and Equipment Property and equipment Disclosure of accounting policy for interest and other income. Interest And Other Income Policy Policy [Text Block] Interest and Other Income, Net Lessee, Operating Lease, Renewal Term Renewal term Surrendered Lease Space Surrendered Lease Space Surrendered Lease Space. Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Percent of compensation eligible employees may elect to contribute The amount of initial security deposit provided by the sublessee in the form of a letter of credit. Lessor Sublease Initial Security Deposit Received Sublease, Initial security deposit received Research and Development Expense Research and development Research and Development Expense, Total The amount of cash inflow from tenant improvements received during the period under an operating lease arrangement. Operating Lease Tenant Improvements Received Cash received for tenant improvements included in the measurement of lease liabilities (in thousands) Sublease termination agreement. Sublease Termination Agreement [Member] Sublease Termination Agreement Second amended headquarters lease. Second Amended Headquarters Lease [Member] Second Lease Amendment Share-based Payment Arrangement, Expense Share-based compensation Schedule of Restructuring and Related Costs [Table] Schedule Of Restructuring And Related Costs [Table] Statement of Financial Position [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (in shares) Up Front Payment Received Up Front Payment Received Up Front Payment Received. other Deferred Tax Assets, Tax Deferred Expense, Other Entity Number of Employees Number of employees Due to Related Parties Amounts due to related party Due to Related Parties, Total Represents information pertaining to transactions recorded in interest and other income. Interest And Other Income [Member] Interest and other income, net Decrease in right-of-use assets related to lease modification and termination Decrease In Right Of Use Assets Related To Lease Modifications And Termination The amount of decrease in right-of-use assets related to the modifications and termination of an existing lease. Lessee, Operating Lease, Liability, to be Paid, Year Five 2025 Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity Increase (Decrease) in Accounts Receivable, Related Parties Related party accounts receivable Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Remaining Contractual Term (years) n/a Segment Information [Abstract] Segment Information Cash and Cash Equivalents [Axis] Cash and Cash Equivalents Gain (Loss) on Termination of Lease Gain (Loss) on Termination of Lease Gain (Loss) on Termination of Lease Defined Contribution Plan, Type [Extensible Enumeration] 401 (k) Savings Plan Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of basic and diluted earnings per share Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Restructuring Reserve, Current End of period Beginning of period Patents [Member] Patents Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: The initial term of the sublease. Sublease Initial Term Of Contract Sublease initial term Lessee, Operating Lease, Liability, to be Paid, Year Three 2023 Tabular disclosure of undiscounted cash outflows (inflows) for operating lease payments to be made as lessee and the related payments to be received as lessor from the sublease of a portion of the leased space. Leases Maturity Of Operating Lease Payments As Lessee And Maturity Of Operating Lease Payments To Be Received As Lessor Table [Text Block] Future minimum lease payments under non-cancelable operating leases under ASC 842 Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Other Current Liabilities [Table Text Block] Schedule of accrued expenses and other current liabilities Workforce reduction plan 2019. Workforce Reduction Plan2019 [Member] October 2019 Workforce Reduction The maximum amount per employee of the employer's matching contributions. Defined Contribution Plan Employer Matching Contribution Maximum Maximum amount of employer matching contribution Measurement Frequency [Axis] Measurement Frequency Award Type [Axis] Award Type The tabular disclosure of supplemental cash flow information related to leases. Lessee Operating Lease Supplemental Cash Flow Information Table [Text Block] Schedule of supplemental cash flow information related to leases Entity Shell Company Entity Shell Company Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive loss: Restructuring and Related Activities [Abstract] Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS’ EQUITY Defined Contribution Plan Retirement Benefits [Text Block] ICFR Auditor Attestation Flag Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Stock Issued During Period, Value, Restricted Stock Award, Gross Additional restricted stock awards President [Member] Mark Currie Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Permanent differences Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount, Total Earnings Per Share [Text Block] Loss per share Operating Lease, Impairment Loss ROU asset, impairment loss Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Number of Shares Amendment Flag Amendment Flag Schedule of Stock by Class [Table] Schedule Of Stock By Class [Table] Product and Service [Axis] Schedule of Finite-Lived Intangible Assets [Table] Schedule Of Finite Lived Intangible Assets [Table] Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Total grant date fair value of options granted Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements At The Market Offering. At The Market Offering [Member] ATM Offering Tax Credit Carryforward, Amount Tax credit carryforwards Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized share-based compensation expense Disclosure of accounting policy for patent costs. Patent Costs Policy [Text Block] Patent Costs Fair Value, Recurring [Member] Recurring Subsequent Events Subsequent Events [Text Block] Paycheck Protection Program Member. Paycheck Protection Program [Member] PPP Loan Dilutive Securities, Effect on Basic Earnings Per Share, Options and Restrictive Stock Units Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Property, Plant and Equipment [Line Items] Property and Equipment Other Assets, Noncurrent Other assets Other Assets, Noncurrent, Total Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Exercisable Aggregate intrinsic value, exercisable at the end of period Sale of Stock [Axis] Sale of Stock Represents information pertaining to a direct operating lease for existing premises located at 301 Binney Street, Cambridge, MA. Headquarters Lease [Member] Head Lease Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount unrecognized share-based compensation expense Net Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock EX-101.PRE 11 cycn-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 12 cycn-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.CAL 13 cycn-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.SCH 14 cycn-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Consolidated and Combined Statements of Operations and Comprehensive Loss 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Consolidated and Combined Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Consolidated and Combined Statements of Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Consolidated and Combined Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Consolidated and Combined Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100080 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Share-based Compensation Plans link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Loss per share link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Defined Contribution Plan link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Workforce Reduction link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Grant Revenue link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Share-based Compensation Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Loss per share (Tables) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Workforce Reduction (Tables) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Nature of Business (Details) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Summary of Significant Accounting Policies - Segments and Cash (Details) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Summary of Significant Accounting Policies - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Summary of Significant Accounting Policies - Paycheck Protection Program Loan (Details) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Summary of Significant Accounting Policies - Revenue, Patent Costs, and Interest and Other Income (Details) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Leases - Summary (Details) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Leases - Schedule of supplemental cash flow information related to leases (Details) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - Leases - Future minimum lease operating payments (Details) link:presentationLink link:calculationLink link:definitionLink 100480 - Disclosure - Leases - Sublease as Lessee (Details) link:presentationLink link:calculationLink link:definitionLink 100490 - Disclosure - Leases - Sublease as Lessor (Details) link:presentationLink link:calculationLink link:definitionLink 100500 - Disclosure - Share-based Compensation Plans (Details) link:presentationLink link:calculationLink link:definitionLink 100510 - Disclosure - Share-based Compensation Plans - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 100520 - Disclosure - Share-based Compensation Plans - Schedule of Weighted Average Assumptions used in estimating the fair value of the stock options (Details) link:presentationLink link:calculationLink link:definitionLink 100530 - Disclosure - Share-based Compensation Plans - Stock Awards Containing Market Conditions (Details) link:presentationLink link:calculationLink link:definitionLink 100540 - Disclosure - Share-based Compensation Plans - Summary of RSU activity (Details) link:presentationLink link:calculationLink link:definitionLink 100550 - Disclosure - Loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 100560 - Disclosure - Loss Per Share - Schedule Of Earnings Per Share Diluted By Common Class (Details) link:presentationLink link:calculationLink link:definitionLink 100570 - Disclosure - Income Taxes - Additional disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 100580 - Disclosure - Income Taxes - Reconciliation of income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 100590 - Disclosure - Income Taxes - Deferred tax assets (liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 100600 - Disclosure - Defined Contribution Plan (Details) link:presentationLink link:calculationLink link:definitionLink 100610 - Disclosure - Workforce Reduction (Details) link:presentationLink link:calculationLink link:definitionLink 100620 - Disclosure - License Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100630 - Disclosure - Grant Revenue (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink XML 15 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Feb. 22, 2022
Jun. 30, 2021
Cover [Abstract]      
Entity Registrant Name CYCLERION THERAPEUTICS, INC.    
Document Type 10-K    
Document Period End Date Dec. 31, 2021    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 131.5
Entity Common Stock, Shares Outstanding   43,410,185  
Entity Central Index Key 0001755237    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Entity Tax Identification Number 83-1895370    
Entity File Number 001-38787    
Entity Incorporation, State or Country Code MA    
Entity Address, Address Line One 245 First Street    
Entity Address, Address Line Two 18th Floor    
Entity Address, City or Town Cambridge    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02142    
City Area Code 857    
Local Phone Number 327-8778    
Title of 12(b) Security Common Stock, no par value    
Trading Symbol CYCN    
Security Exchange Name NASDAQ    
Documents Incorporated by Reference

Portions of the registrant’s definitive Proxy Statement, to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934, for its 2022 Annual Meeting of Stockholders are incorporated by reference in Part III of this Form 10-K.

   
ICFR Auditor Attestation Flag false    
Auditor Firm ID 42    
Auditor Name Ernst & Young LLP    
Auditor Location Boston, Massachusetts    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 53,961 $ 54,395
Accounts receivable 100 0
Related party accounts receivable 0 127
Prepaid expenses 928 816
Other current assets 468 3,163
Total current assets 55,457 58,501
Restricted cash, net of current portion 0 3,837
Property and equipment, net 65 6,865
Operating lease right-of-use asset 1,402 43,402
Other assets 2,407 2,773
Total assets 59,331 115,378
Current liabilities:    
Accounts payable 1,828 1,149
Related party accounts payable 0 286
Accrued research and development costs 6,353 1,421
Accrued expenses and other current liabilities 2,904 7,294
Short-term note payable 0 3,509
Current portion of operating lease liabilities 0 3,293
Total current liabilities 11,085 16,952
Operating lease liabilities, net of current portion 0 38,933
Commitments and contingencies
Stockholders' equity    
Common stock, no par value, 400,000,000 shares authorized and 43,410,185 issued and outstanding at December 31, 2021 and 400,000,000 shares authorized and 34,047,300 issued and outstanding at December 31, 2020 0 0
Accumulated deficit (215,076) (163,429)
Paid-in capital 263,345 222,949
Accumulated other comprehensive loss (23) (27)
Total stockholders' equity 48,246 59,493
Total liabilities and stockholders' equity $ 59,331 $ 115,378
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated and Combined Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenues [Abstract]    
Revenue from license agreement $ 3,000 $ 0
Revenue From Development Agreement 320 0
Revenue from grants 622 0
Revenue from related party 0 2,296
Total revenues 3,942 2,296
Cost and expenses:    
Research and development 37,636 56,414
General and administrative 20,620 28,816
Gain (loss) on lease modification 881 (1,669)
Total cost and expenses 59,137 83,561
Loss from operations (55,195) (81,265)
Sublease termination income, net 0 2,875
Gain on extinguishment of debt 3,564 0
Interest and other income, net (16) 588
Net loss $ (51,647) $ (77,802)
Net loss per share:    
Basic and diluted net loss per share (in dollars per share) $ (1.32) $ (2.56)
Weighted average shares used in calculating:    
Basic and diluted net loss per share (in shares) 39,144 30,403
Other comprehensive loss:    
Net loss $ (51,647) $ (77,802)
Other comprehensive loss:    
Foreign currency translation adjustment 4 (7)
Comprehensive loss $ (51,643) $ (77,809)
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated and Combined Statements of Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock
Paid in capital
Accumulated Deflicit
Accumulated other comprehensive loss
Beginning balance at Dec. 31, 2019 $ 97,729   $ 183,376 $ (85,627) $ (20)
Beginning balance (in shares) at Dec. 31, 2019   27,598,133      
Net loss (77,802)     (77,802)  
Issuance of common stock - 2020 private placement 24,250   24,250    
Issuance of common stock - 2020 private placement (in shares)   6,062,500      
Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan 331   331    
Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan (in shares)   386,667      
Share-based compensation expense related to issuance of stock options and RSUs to employees and employee stock purchase plan 14,992   14,992    
Foreign currency translation adjustment (7)       (7)
Ending balance at Dec. 31, 2020 59,493   222,949 (163,429) (27)
Ending balance (in shares) at Dec. 31, 2020   34,047,300      
Net loss (51,647)     (51,647)  
Issuance of common stock - 2020 private placement 18,028   18,028    
Issuance of common stock - 2020 private placement (in shares)   5,735,988      
Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan 282   282    
Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan (in shares)   273,838      
Issuance of common stock - ATM (in Shares)   3,353,059      
Issuance of common stock - ATM (in Values) 12,475   12,475    
Share-based compensation expense related to issuance of stock options and RSUs to employees and employee stock purchase plan 7,915   7,915    
Share based compensation expense related to issuance of stock options and RSUs to non employees 1,696   1,696    
Foreign currency translation adjustment 4     4
Ending balance at Dec. 31, 2021 $ 48,246 $ 0 $ 263,345 $ (215,076) $ (23)
Ending balance (in shares) at Dec. 31, 2021   43,410,185      
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated and Combined Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (51,647) $ (77,802)
Adjustments to reconcile net loss to net cash (used in) operating activities:    
Depreciation and amortization 472 2,297
Net loss on disposal of property and equipment (6,322) (159)
(Gain) / loss on lease modification and termination (881) 1,669
Sublease termination income, net 0 (2,875)
Gain on extinguishment of debt 3,564 0
Share-based compensation expense 9,611 14,992
Changes in operating assets and liabilities:    
Accounts receivable 100 0
Related party accounts receivable (127) (1,346)
Prepaid expenses 112 (1,150)
Other current assets (1,244) 55
Operating lease assets 59 2,598
Other assets (366) 888
Accounts payable 679 (1,301)
Related party accounts payable (286) 205
Accrued research and development costs 4,932 (776)
Accrued expenses and other current liabilities (4,335) (1,983)
Operating lease liabilities (1,048) (2,692)
Net cash (used in) operating activities (36,517) (72,490)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (7) (1,524)
Proceeds from sale of property and equipment 1,464 1,542
Net cash provided by (used in) investing activities 1,457 18
Proceeds from equity private placement and ATM    
Proceeds from equity private placement and ATM 30,503 24,250
Proceeds from exercises of stock options and ESPP 282 331
Proceeds from short-term note payable 0 3,509
Net cash provided by financing activities 30,785 28,090
Effect of exchange rate changes on cash, cash equivalents and restricted cash 4 (7)
Net (decrease) increase in cash, cash equivalents and restricted cash (4,271) (44,389)
Cash, cash equivalents and restricted cash, beginning of period 58,232 102,621
Cash, cash equivalents and restricted cash, end of period 53,961 58,232
Supplemental cash flow disclosure:    
Cash paid for initial direct costs of lease modification 0 6,507
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets    
Cash and cash equivalents 53,961 54,395
Restricted cash 0 3,837
Total cash, cash equivalents and restricted cash $ 53,961 $ 58,232
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated and Combined Statements of Cash Flows (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated and combined balance sheets      
Cash and cash equivalents $ 53,961 $ 54,395  
Restricted cash 0 3,837  
Total cash, cash equivalents and restricted cash $ 53,961 $ 58,232 $ 102,621
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Nature of Business
12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business

1. Nature of Business

Nature of Operations

Cyclerion Therapeutics, Inc. (“Cyclerion”, the “Company” or “we”) is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Our lead asset, CY6463, is a pioneering, central nervous system (CNS) penetrant, soluble guanylate cyclase (sGC) stimulator that is currently in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS). sGC stimulators are small molecules that act synergistically with nitric oxide (NO) as positive allosteric modulators of sGC to boost production of cyclic guanosine monophosphate (cGMP). cGMP is a key second messenger that, when produced by sGC, regulates diverse and critical biological functions in the CNS including neuronal function, neuroinflammation, cellular bioenergetics, and vascular function.

Cyclerion GmbH, a wholly owned subsidiary, was incorporated in Zug, Switzerland on May 3, 2019. Cyclerion GmbH is an operational entity with one employee who is the Company’s Chief Scientific Officer. The functional currency is the Swiss franc.

Cyclerion Securities Corporation, a wholly owned subsidiary, was incorporated in Massachusetts on November 15, 2019 and was granted securities corporation status in Massachusetts for the 2019 tax year. Cyclerion Securities Corporation has no employees.

Company Overview

The Company’s mission is to develop treatments that restore cognitive function. Its priorities are advancing its ongoing CY6463 clinical programs and next generation compound, CY3018.

CNS assets. CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases. NO-sGC-cGMP is a fundamental CNS signaling network, but it has not yet been leveraged for its full therapeutic potential. CY6463 enhances the brain’s natural ability to produce cGMP, an important second messenger in the CNS, by stimulating sGC, a key node in the NO-sGC-cGMP pathway. This pathway is critical to basic CNS functions and deficient NO-sGC-cGMP signaling is believed to play an important role in the pathogenesis of neurodegenerative diseases. Agents that stimulate sGC to produce cGMP may compensate for deficient NO signaling.

On January 13, 2020, we announced positive results from our Phase 1 first-in-human study that provided the foundation for continued development of CY6463. The Phase 1 healthy participant study results indicate that CY6463 was well tolerated. Pharmacokinetic (PK) data, obtained from both blood and cerebral spinal fluid (CSF), support once-daily dosing, with or without food, and demonstrated CY6463 penetration of the blood-brain-barrier with CSF concentrations expected to be pharmacologically active.

On October 14, 2020, we announced positive topline results from our CY6463 Phase 1 translational pharmacology study in healthy elderly participants. Treatment with CY6463 for 15 days in this 24-subject study confirmed and extended results seen in the earlier first-in-human Phase 1 study: once daily oral treatment demonstrated blood-brain-barrier penetration with expected CNS exposure and target engagement. Results also showed significant improvements in neurophysiological and objective performance measures as well as in inflammatory biomarkers associated with aging and neurodegenerative diseases. CY6463 was shown to be safe and generally well tolerated. Significant effects on cerebral blood flow and markers of bioenergetics were not observed in this study of healthy elderly participants. We believe that these results, together with nonclinical data, support continued development of CY6463 as a potential new medicine for serious CNS diseases.

We have initiated exploratory clinical trials with CY6463 ADv, CIAS, and MELAS. The ADv study will be supported in part by a grant from the Alzheimer’s Association’s Part the Cloud-Gates Partnership Grant Program, which provides Cyclerion with $2 million of funding over two years.

Our next generation CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with greater CSF-to-plasma exposure relative to CY6463. CY3018 is intended to expand the potential of sGC stimulation for the treatment of disorders of the CNS.

Non-CNS assets. We have other assets that are outside of our current strategic focus. These non-core assets are not being internally developed at this time. Praliciguat is an orally administered, once-daily systemic sGC stimulator. On June 3, 2021, we entered into a License Agreement with Akebia relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the pharmaceutical compound praliciguat and other related products and forms thereof enumerated in such agreement. Olinciguat is an orally administered, once-daily, vascular sGC stimulator that was evaluated in a Phase 2 study of participants with sickle cell disease. We released topline results from this study in October 2020. Olinciguat is available for licensing to a third party partner.

The Separation

On April 1, 2019, Ironwood completed the separation of its sGC business, and certain other assets and liabilities, into a separate, independent publicly traded company by way of a pro-rata distribution of all of the outstanding shares of common stock of Cyclerion Therapeutics, Inc. through a dividend distribution of one share of the Company’s common stock, with no par value per share, for every 10 shares of Ironwood common stock held by Ironwood stockholders as of the close of business on March 19, 2019, the record date for the Distribution (the entire transaction being the “Separation”). As a result of the Separation, the Company became an independent public company and commenced trading under the symbol “CYCN” on the Nasdaq Global Select Market on April 2, 2019.

2020 Equity Private Placement

On July 29, 2020, the Company entered into a Common Stock Purchase Agreement (the “2020 Equity Private Placement”) for the private placement of 6,062,500 shares of the Company’s common stock, for total gross proceeds of approximately $24.3 million. The closing of the 2020 Equity Private Placement occurred on July 29, 2020. The Company did not utilize the services of a placement agent or broker and accordingly incurred no material related transaction fees, or commissions.

2021 Equity Private Placement

On June 3, 2021, the Company entered into a Common Stock Purchase Agreement (the “June 2021 Equity Private Placement”) for the private placement of 5,735,988 shares of the Company’s common stock, for total gross proceeds of approximately $18 million. The closing of the June 2021 Equity Private Placement occurred on June 7, 2021. The Company did not utilize the services of a placement agent or broker and accordingly incurred no material related transaction fees or commissions.

At-the-Market Offering

On July 24, 2020, the Company filed a Registration Statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) in relation to the registration of common stock, preferred stock, debt securities, warrants and units of any combination thereof for an aggregate initial offering price not to exceed $150.0 million. The Shelf was declared effective as of July 31, 2020. On September 3, 2020, the Company entered into a Sales Agreement (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) with respect to an at-the-market offering (the “ATM Offering”) under the Shelf. Under the ATM Offering, the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million through Jefferies as its sales agent. The Company will pay to Jefferies cash commissions of 3.0 percent of the gross proceeds of sales of common stock under the Sales Agreement. During the year ended December 31, 2021, the Company sold 3,353,059 shares of its common stock for net proceeds of $12.5 million under the ATM Offering, after deducting commissions paid to Jefferies of approximately $0.4 million.

Basis of Presentation

The consolidated financial statements and the related disclosures have been prepared in accordance with U.S. generally accepted accounting principles. In the opinion of management, the consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company’s financial position and the results of its operations for the fiscal years presented.

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion GmbH, and Cyclerion Securities Corporation. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements.

Going Concern

At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company’s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company’s cash needs and comparing those needs to the current cash and cash equivalent balances. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company’s plans or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern.

The Company has experienced negative operating cash flows for all historical periods presented and the Company expects these losses to continue into the foreseeable future as the Company continues the development and clinical testing of its product candidates CY6463, CY3018 and its discovery research programs. Through December 31, 2021, the Company had raised an aggregate of $219.8 million (in net proceeds) from equity private placements and the ATM Offering.

After considering the Company’s current research and development plans and the timing expectations related to the progress of its programs, and after considering its existing cash and cash equivalents of $54.0 million as of December 31, 2021, the Company did not identify conditions or events that would raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these financial statements were issued.

XML 22 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Cyclerion Therapeutics, Inc. and its wholly owned subsidiaries, Cyclerion GmbH and Cyclerion Securities Corporation. All intercompany transactions and balances are eliminated in consolidation.

Segment Information

Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company's chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company currently operates in one reportable business segment - human therapeutics.

Use of Estimates

The preparation of consolidated financial statements in accordance with U.S. GAAP requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, impairment of long-lived assets, valuation procedures for right-of-use

("ROU") assets and operating lease liabilities, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation, and going concern. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.

Cash and Cash Equivalents including Restricted Cash

The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents may consist of money market funds and overnight repurchase agreements. The carrying amount of cash equivalents approximates fair value.

As of December 31, 2021, The Company did not have any restricted cash balances. As of December 31, 2020, the Company was contingently liable under an unused letter of credit with a bank, related to the Company's facility lease, in the amount of approximately $3.8 million. The Company recorded the collateral used to secure the letter of credit as restricted cash. The full amount of restricted cash was recorded as a component of non-current assets at December 31, 2020.

Property and Equipment

Property and equipment, including leasehold improvements, are recorded at cost, and are depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:

 

Asset Description

 

Estimated Useful
Life (In Years)

Laboratory equipment

 

5

Computer and office equipment

 

3

Furniture and fixtures

 

7

Software

 

3

 

Included in property and equipment are certain costs of software obtained for internal use. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred.

Costs for capital assets not yet placed into service have been capitalized as construction in progress and are depreciated in accordance with the above guidelines once placed into service. Maintenance and repair costs are expensed as incurred.

Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. The Company has no capital leases.

Property and equipment that is no longer required for the business is considered disposed of when it ceases to be used. Disposals are either sold or retired and the net book value is removed from the consolidated balance sheet and a corresponding gain or loss on the sale or disposal is recognized as a component of operating expenses in the consolidated statements of operations and comprehensive loss.

Fair Value of Investment Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must

maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

Level 1 — Quoted prices in active markets for identical assets or liabilities.
Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

Foreign Currency Translation Adjustment

The functional currency of the Company’s foreign subsidiary is its local currency, the Swiss franc. The assets and liabilities of the Company’s foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for the Company’s foreign subsidiary is included as a foreign currency translation adjustment in the consolidated statements of stockholders’ equity and as a component of comprehensive loss in the consolidated statements of operations and comprehensive loss.

The Company’s intercompany accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the re-measurement of intercompany balances are recorded in the consolidated statements of operations.

Accounts Receivable

The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding invoices. The Company’s receivables primarily relate to amounts earned under a development agreement with Ironwood, licensing agreement, and supply agreement. The Company believes that credit risks associated with these agreements are not significant. To date, the Company has not had significant write-offs of bad debt and the Company did not have an allowance for doubtful accounts as of December 31, 2021 or 2020.

Impairment of Long-Lived Assets

The Company regularly reviews the carrying amount of its long-lived assets to determine whether indicators of impairment may exist, which warrant adjustments to carrying values or estimated useful lives. If indications of impairment exist, projected future undiscounted cash flows associated with the asset are compared to the carrying amount to determine whether the asset’s value is recoverable. If the carrying value of the asset exceeds such projected undiscounted cash flows, the asset will be written down to its estimated fair value. There were no significant impairments of long-lived assets for the years ended December 31, 2021 or 2020.

Leases

Effective January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) Topic 842, Leases (“ASC 842”) using the optional transition method. The adoption of ASC 842 represents a change in accounting principle that aims to increase transparency and comparability among organizations by requiring the recognition of right-of-use assets and lease liabilities on the balance sheet for both operating and finance leases. In addition, the standard requires enhanced disclosures that meet the objective of enabling financial statement users to assess the amount, timing, and uncertainty of cash flows arising from leases. The reported results for the years ended December 31, 2021 and 2020 reflect the application of ASC 842 guidance.

The recognition of right-of-use assets and lease liabilities related to the Company’s operating leases under ASC 842 has had a material impact on the Company’s consolidated financial statements.

As part of the ASC 842 adoption, the Company has used certain practical expedients outlined in the guidance. These practical expedients include:

Account policy election to use the short-term lease exception by asset class;
Election of the practical expedient package during transition, which includes:
An entity need not reassess whether any expired or existing contracts are or contain leases.
An entity need not reassess the classification for any expired or existing leases. As a result, all leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases under ASC 842, and all leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases under ASC 842.
An entity need not reassess initial direct costs for any existing leases.

The Company had a property lease for its headquarters location at 301 Binney Street, Cambridge, MA (the “Head Lease”). The Company determined if the arrangement was a lease at the inception of the contract. The asset component of the Company’s operating leases was recorded as operating lease right-of-use assets, and the liability component was recorded as current portion of operating lease liabilities and operating lease liabilities, net of current portion, in the Company’s consolidated balance sheets.

ROU assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.

Lease cost was recognized on a straight-line basis over the lease term, and included amounts related to short-term leases. Variable lease costs that do not depend on an index or rate were recognized as incurred.

ROU assets and operating lease liabilities were remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. The difference between the remeasured ROU assets and the operating lease liabilities were recognized as a gain or loss in operating expenses. The Company reviewed any changes to its lease agreements for potential modifications and/or indicators of impairment of the respective ROU asset.

On October 18, 2019, the Company entered into an agreement to sublease 15,700 rentable square feet of its Head Lease to a subtenant (the “Sublease Agreement”). Sublease income was recognized on straight-line basis over the term of the sublease agreement and was recorded net of the related rent expense from the Head Lease within interest and other income, net in the consolidated statements of operations and comprehensive loss. In sublease agreements that contain non-monetary consideration, the Company estimated the fair market value of the non-monetary consideration received using market data and recognized it on a straight-line basis over the sublease term. Variable lease consideration that did not depend on an index or rate was allocated to a non-lease component and was recognized over time in accordance with the pattern of transfer.

No modification or impairment was deemed to have occurred by entering into the sublease agreement because the Company was not released, either fully or in part, from its obligations under the Head Lease. See Note 8, Leases.

On February 28, 2020 the Company entered into an amendment to its Head Lease (the “Lease Amendment”). The Lease Amendment provided for the partial termination of the Company's rights and obligations with respect to a portion of the leased premises of approximately 40,000 rentable square feet. The Company continued to lease approximately 74,000 rentable square feet under terms of the amended lease. The Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease

and not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification and the Company recorded a gain of approximately $2.1 million as a component of operating expenses for the year ended December 31, 2020. No impairment of the ROU asset was deemed to have occurred. See Note 8, Leases.

On September 15, 2020, the Company entered into an amendment to its Head Lease (the “Second Lease Amendment”). The Second Lease Amendment provided for the partial termination of the Company's rights and obligations with respect to a portion of the leased premises of approximately 17,000 rentable square feet (the “Surrender Space”). The Surrender Space included the 15,700 rentable square feet being subleased by the Company to a subtenant. The Company continued to lease approximately 57,000 rentable square feet under terms of the amended lease. The Second Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease and not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification and the Company recorded a loss of approximately $0.4 million as a component of operating expenses for the year ended December 31, 2020. No impairment of the ROU asset was deemed to have occurred. See Note 8, Leases.

On September 15, 2020, concurrent with the execution of the Second Lease Amendment, the Company entered into an agreement with its subtenant to terminate the Sublease Agreement of approximately 15,700 rentable square feet (“the Sublease Termination Agreement”). Under the terms of the Sublease Termination Agreement, the former subtenant is obligated to provide licensed rooms and services to the Company free of charge through the original sublease term. Upon termination of the sublease, the Company recognized sublease termination income of approximately $3.1 million related to the prepaid rooms and services, and wrote off the remaining indirect costs from the sublease of approximately $0.2 million, in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2020. See Note 8, Leases.

On April 30, 2021, the Company entered into a Termination Agreement (the "Termination Agreement") for its Head Lease as initially amended on February 28, 2020, and further amended on September 15, 2020. Pursuant to the Termination Agreement, the Company surrendered the leased space of approximately 57,000 square feet to the building’s landlord. The Company did not pay any termination fees with the Termination Agreement. As a result of the termination of the Head Lease, the related right-of-use asset was written off, the lease liability was derecognized, and the $3.8 million security deposit was returned to the Company and recorded as part of our cash balance. In total, the Company recognized a loss on the termination of the Head Lease of $0.9 million for the year ended December 31, 2021. The loss is included in “General and administrative” expenses on our consolidated statement of operations and comprehensive loss.

Paycheck Protection Program Loan

On April 21, 2020, the Company received loan proceeds in the amount of approximately $3.5 million pursuant to a promissory note agreement with a bank under the Paycheck Protection Program. The Paycheck Protection Program, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The Promissory Note had an original loan maturity of April 20, 2022, a stated interest rate of 1.0% per annum, and had payments of principal and interest that were due monthly after an initial six-month deferral period where interest accrued, but no payments were due. The Promissory Note provided for customary events of default, including, among others, those relating to failure to make payment when due and breaches of representations. The loan was subject to all the terms and conditions applicable under the PPP and was subject to review by the SBA for compliance with program requirements, including the Company’s certification that the economic uncertainty, at the time, made the PPP loan request necessary to support ongoing operations. On October 2, 2020, the SBA issued procedural guidance with respect to PPP loans and changes in ownership and the Company believes that it is compliant with respect to the 2020 Equity Private Placement and the ATM Offering.

In June 2020, the Payroll Protection Program Flexibility Act was signed into law adjusting certain key terms of loans issued under the PPP. In accordance with the PPPFA, the initial deferral period may be extended from six to up to ten months and the loan maturity may be extended from two to five years. The PPPFA also provided for certain other changes, including the extent to which the loan may be forgiven.

The loan’s principal and accrued interest were forgivable to the extent that the proceeds were used for eligible purposes, subject to certain limitations, and that the Company maintained its payroll levels over a twenty-four-week period following the loan date. The loan forgiveness amount may have been reduced if the Company

terminated employees or reduced salaries during the twenty-four-week period. PPP loans are subject to audit and the SBA has indicated that companies that received over $2 million in proceeds should expect an audit. The Company believes that it has used the proceeds for eligible purposes consistent with the provisions of the PPPFA.

As the legal form of the Promissory Note is a debt obligation, the Company accounted for it as debt under Accounting Standards Codification (ASC) 470, Debt and recorded a short-term liability of $3.5 million in the consolidated balance sheets upon receipt of the loan proceeds. The Company accrued interest over the term of the loan and did not record additional interest at a market rate because the guidance on imputing interest in ASC 835-30, Interest excludes transactions where interest rates are prescribed by a government agency. Approximately $0.1 million of interest expense has been recognized within interest and other income, net in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. In August 2021, the Company applied with the SBA for forgiveness of the PPP loan and was notified on November 4, 2021 that the SBA has approved our application to forgive the entire amount of the loan and accrued interest. The Company recorded a gain on extinguishment of debt of $3.6 million representing the principal and accrued interest for the PPP Loan.

Revenue

Upon executing a revenue generating arrangement, the Company assesses whether it is probable the Company will collect consideration in exchange for the good or service it transfers to the customer. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. The Company must develop assumptions that require significant judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The assumptions that are used to determine the stand-alone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company derives revenue from (1) license agreement and (2) supply agreement which are fully described in Note 14, License Agreement.

The Company generated revenue from a Development Agreement with Ironwood, pursuant to which the Company provided certain research and development services with respect to certain of Ironwood’s products and product candidates. Such research and development activities were governed by a joint steering committee composed of representatives of both companies. Services performed were invoiced at a mutually agreed upon rate and the initial term of the agreement was two years from the date of Separation and automatically renewed for one year unless either party notified the other at least six months prior to the expiration. Ironwood and the Company agreed that the Development Agreement would not be renewed beyond its initial term which ended on March 31, 2021.

The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange transactions and are not within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Contribution revenue earned from activities performed pursuant to research and development grants is reported as grant revenue in the Company’s consolidated statements of operations. Revenue from these grants is recognized as the Company incurs qualifying expenses as stipulated by the terms of the respective grant. Cash received from grants in advance of incurring qualifying expenses is recorded as deferred revenue. The Company records revenue and a corresponding receivable when qualifying costs are incurred before receiving payment from the grants.

Research and Development Costs

The Company expenses research and development costs to operations as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. The

Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception.

Research and development expenses are comprised of costs incurred in performing research and development activities, which may include salary, benefits and other employee-related expenses; share-based compensation expense; laboratory supplies and other direct expenses; facilities expenses; overhead expenses; third-party contractual costs relating to nonclinical studies and clinical trial activities and related contract manufacturing expenses, development of manufacturing processes and regulatory registration of third-party manufacturing facilities; and other outside expenses.

General and Administrative Expenses

The Company expenses general and administrative costs to operations as incurred. General and administrative expense consists of compensation, share-based compensation, benefits and other employee-related expenses for personnel in the Company’s administrative, finance, legal, information technology, business development and human resource functions. Other costs include the legal costs of pursuing patent protection of the Company’s intellectual property, general and administrative related facility costs, insurance costs and professional fees for accounting and legal services.

Income taxes

The Company is primarily subject to U.S. federal and Massachusetts state income taxes. For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable.

The tax positions taken or expected to be taken in the course of preparing the Company tax returns are required to be evaluated to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authority. Tax positions not deemed to meet a more-likely-than-not threshold would be recorded as a tax expense in the current year. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. It does not consider the likelihood of whether or not the IRS will review the position. Cyclerion evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect Cyclerion's income tax provision in future periods. There were no uncertain tax positions that require accrual or disclosure in the consolidated financial statements as of December 31, 2021, and 2020. The Company’s policy is to recognize interest and penalties related to income tax, if any, in income tax expense. As of December 31, 2021, and 2020, the Company has no accruals for interest or penalties related to income tax matters.

Patent Costs

Patent fees and patent related costs in connection with filing and prosecuting patent applications are expensed as incurred and are classified as general and administrative expenses in the accompanying consolidated financial statements. The Company incurred and recorded as operating expense legal and other fees related to patents of approximately $1.4 million and $1.7 million for the years ended December 31, 2021 and 2020, respectively.

Interest and Other Income, Net

For the year ended December 31, 2021, interest and other income, net consisted of a de minimis amount of interest income related to interest generated from our cash and cash equivalents balances and a de minimis amount

of interest expense related to the PPP loan. For the year ended December 31, 2020, interest and other income, net consisted of $0.3 million of interest income related to interest generated from our cash and cash equivalents balances and $0.3 million of net sublease income.

Subsequent Events

The Company considers events or transactions that have occurred after the balance sheet date of December 31, 2021, but prior to the filing of the financial statements with the Securities and Exchange Commission, to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of the financial statements accompanying this Annual Report on Form 10-K. See Note 14, Subsequent Events.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the consolidated financial statements, the Company did not adopt any new accounting pronouncements during the years ended December 31, 2021 and 2020, that had a material effect on its consolidated financial statements.

In June 2016 the FASB issued ASU 2016-13, Financial Instruments-Credit Losses. This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. As a smaller reporting company, ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2022, and early adoption is permitted. The Company is currently evaluating the impact that ASU 2016-13 will have on its financial statements and related disclosures.

In May 2021 the FASB issued Accounting Standards Update No. 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the Emerging Issues Task Force (EITF) , which amends the FASB Accounting Standards Codification (ASC or the “Codification”) to provide explicit guidance, and, thus, reduce diversity in practice, on accounting by issuers for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after the modification or exchange. This amendment provides that for an entity that presents earnings per share (EPS) in accordance with Topic 260, the effects of a modification or an exchange of a freestanding equity-classified written call option that is recognized as a dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. The amended guidance becomes mandatorily effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, and should be applied prospectively to modifications or exchanges occurring on or after the effective date. The Company is currently evaluating the impact that ASU 2021-04 will have on its financial statements and related disclosures.

No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company’s consolidated financial statements upon adoption. 

XML 23 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Related Party Transactions
12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

3. Related Party Transactions

Development Agreement with Ironwood

As part of the Separation from Ironwood, the Company entered into a Development Agreement with Ironwood.

Under the Development Agreement, the Company provided certain research and development services to Ironwood at mutually agreed upon rates and the amounts earned are recorded as revenue from related party for the year ended December 31, 2020. Such research and development activities were governed by a joint steering

committee composed of representatives of both Ironwood and the Company. Ironwood and the Company have agreed not to renew the Development Agreement beyond the end of its initial term on March 31, 2021. These transactions under the Development Agreement were considered related party transactions due to Mark Currie’s role as President of the Company through December 31, 2020, and board member of Ironwood. In January 2021, Mark Currie’s role transitioned from President of the Company to a senior advisor on a consulting basis. Therefore, effective January 2021, transactions under the Development Agreement are no longer accounted for as related party transactions. The Company recorded approximately $2.3 million for the year ended December 31, 2020.

Other Related Party Transactions

During the year ended December 31, 2020, the Company recorded approximately $1.5 million of research and development costs to a related party which it engaged to provide research and development transaction support services. The entity became a related party when Mark Currie, the Company’s President through December 31, 2020, joined its board in January 2020. There was approximately $0.3 million due to the related party for the year ended December 31, 2020. In January 2021, Mark Currie’s role transitioned from President of the Company to a senior advisor on a consulting basis. Therefore, effective January 2021, transactions under this agreement are no longer accounted for as related party transactions.

XML 24 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value of Financial Instruments
12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments

4. Fair Value of Financial Instruments

The Company’s cash equivalents are generally classified within Level 1 of the fair value hierarchy. The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of December 31, 2021 and December 31, 2020 (in thousands):

 

 

 

Fair Value Measurements as of December 31, 2021:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

52,917

 

 

$

 

 

$

 

 

$

52,917

 

Cash equivalents

 

$

52,917

 

 

$

 

 

$

 

 

$

52,917

 

 

 

 

Fair Value Measurements as of December 31, 2020:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

53,240

 

 

$

 

 

$

 

 

$

53,240

 

Cash equivalents

 

$

53,240

 

 

$

 

 

$

 

 

$

53,240

 

During the year ended December 31, 2021 and 2020, there were no transfers between levels. The fair value of the Company's cash equivalents, consisting of money market funds, is based on quoted market prices in active markets with no valuation adjustment.

The Company believes the carrying amounts of its prepaid expenses and other current assets, restricted cash, accounts payable, and accrued expenses approximate their fair value due to the short-term nature of these amounts.

XML 25 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment
12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment

5. Property and Equipment

Property and equipment, net consisted of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Software

 

$

2,214

 

 

$

2,214

 

Computer and office equipment

 

 

51

 

 

 

44

 

Leasehold improvements

 

 

 

 

 

14,894

 

Property and equipment, gross

 

 

2,265

 

 

 

17,152

 

Less: accumulated depreciation and amortization

 

 

(2,200

)

 

 

(10,287

)

Property and equipment, net

 

$

65

 

 

$

6,865

 

As of December 31, 2021, and 2020, the Company’s property and equipment was primarily located in Cambridge, Massachusetts.

Depreciation and amortization expense of the Company’s property and equipment was approximately $0.5 million and $2.3 million for the years ended December 31, 2021 and 2020, respectively.

During the year ended December 31, 2021, the Company recorded a non-cash loss of $6.3 million, on the disposal of leasehold improvements as a result of its Head Lease (as defined below) termination (see Note 8 to the Consolidated Financial Statements). The non-cash loss on the disposal of leasehold improvements was recognized as a component of operating expenses in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021.

XML 26 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued Expenses and Other Current Liabilities
12 Months Ended
Dec. 31, 2021
Accrued Liabilities and Other Liabilities [Abstract]  
Accrued Expenses and Other Current Liabilities

6. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Accrued incentive compensation

 

$

1,369

 

 

$

1,720

 

Salaries

 

 

266

 

 

 

514

 

Accrued vacation

 

 

345

 

 

 

555

 

Professional fees

 

 

398

 

 

 

689

 

Accrued severance and benefit costs

 

 

28

 

 

 

3,640

 

Other

 

 

498

 

 

 

176

 

Accrued expenses and other current liabilities

 

$

2,904

 

 

$

7,294

 

XML 27 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

7. Commitments and Contingencies

Other Funding Commitments

In the normal course of business, the Company enters into contracts with clinical research organizations and other third parties for clinical and preclinical research studies and other services and products for operating purposes. These contracts are generally cancellable, with notice, at the Company’s option and do not have any significant cancellation penalties.

Guarantees

On September 6, 2018, Cyclerion was incorporated in Massachusetts and its officers and directors are indemnified for certain events or occurrences while they are serving in such capacity.

The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business

partners, contractors, clinical sites and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company’s activities. These indemnification provisions generally survive termination of the underlying agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Accordingly, the Company did not have any liabilities recorded for these obligations as of December 31, 2021 or December 31, 2020.

XML 28 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases
12 Months Ended
Dec. 31, 2021
Leases [Abstract]  
Leases

8. Leases

The FASB issued ASU 2016-02, or the leasing standard or ASC 842, in February 2016. ASU 2016-02 requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by all leases with terms of more than 12 months. ASU 2016-02 also requires certain qualitative and quantitative disclosures designed to give financial statement users information on the amount, timing, and uncertainty of cash flows arising from leases.

On April 1, 2019, the Company entered into the Head Lease ("the Head Lease"), a direct operating lease for its former headquarters located at 301 Binney Street, Cambridge, MA consisting of approximately 114,000 rentable square feet of office and laboratory space on the first and second floors. The Head Lease had a term of 123 months with two five-year extension options and certain expansion rights. The Head Lease also included a letter of credit of $7.7 million, posted with the landlord as a security deposit, which was collateralized by a money market account recorded as restricted cash on the Company’s consolidated balance sheets. The Company had also entered into customary non-disturbance arrangements with the building landlord’s mortgagee and with the property ground lessor recognizing Company's leasehold interest in this property.

On February 28, 2020 the Company entered into an amendment to its Head Lease. The Lease Amendment partially terminated the Company’s rights and obligations with respect to an approximately 40,000 rentable square feet. The Company continued to lease the remaining space of approximately 74,000 square feet including the area covered by the subleased premise, discussed below. In connection with this Lease Amendment, the Company reduced its remaining lease payments through June 2029 by approximately $41.9 million and paid a $6.3 million termination fee and $0.2 million related to other initial direct costs, which were deferred and recognized over the remaining lease term. The Company’s security deposit was also reduced by approximately $2.7 million to approximately $5.0 million.

The Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease and not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification of 9.7%, which resulted in a reduction of the ROU asset of $21.4 million and a reduction in the operating lease liabilities of $23.5 million. The Company recorded the resulting gain of approximately $2.1 million as a component of operating expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020.

On September 15, 2020 the Company entered into the Second Lease Amendment to its Head Lease. The Second Lease Amendment provided for the partial termination of the Company’s rights and obligations with respect to a portion of the leased premises of approximately 17,000 rentable square feet. The Surrender Space included 15,700 rentable square feet being subleased by the Company to a subtenant. The Company continued to lease approximately 57,000 square feet of space. The Company reduced its remaining lease payments through June 2029 by approximately $16.9 million. The Company paid no termination or other initial direct costs related to the execution of the Second Lease Amendment. The Company’s security deposit was reduced by approximately $1.2 million to approximately $3.8 million, which is classified as restricted cash on the Company’s consolidated balance sheet as of December 31, 2020.

The Second Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease and not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification of 6.1%, which resulted in a reduction of the ROU asset of $5.9 million and a reduction in the operating lease liabilities of $5.5 million. The

Company recorded the resulting loss of approximately $0.4 million as a component of operating expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020.

On April 30, 2021, the Company entered into a Termination Agreement (the "Termination Agreement") for its Head Lease as initially amended on February 28, 2020, and further amended on September 15, 2020. Pursuant to the Termination Agreement, the Company surrendered the leased space of approximately 57,000 square feet to the building’s landlord. The Company did not pay any termination fees in connection with the Termination Agreement. As a result of the termination of the Head Lease, the related right-of-use asset was written off, the lease liability was derecognized, and the $3.8 million security deposit was returned to the Company and recorded as part of our cash balance. In total, the Company recognized a loss on the termination of the Head Lease of $0.9 million for the year ended December 31, 2021. The loss is included in “General and administrative” expenses on our consolidated statement of operations and comprehensive loss.

The Company had an operating lease ROU asset of approximately $43.4 million related to the amended Head Lease recorded in its consolidated balance sheets as of December 31, 2020. The Company had current and non-current operating lease liabilities of approximately $3.3 million, and $38.9 million, respectively, related to the amended Head Lease recorded in its consolidated balance sheets as of December 31, 2020.

Lease cost was recognized on a straight-line basis over the lease term. For the years ended December 31, 2021 and 2020, the Company recognized a total of approximately $2.4 million and $8.6 million, respectively, of total lease costs. Variable lease costs not subject to an index or rate were recognized as incurred. For the years ended December 31, 2021 and 2020, the Company recognized a total of approximately $0.7 million and $2.2 million, respectively, of variable lease costs related to the Head Lease, as amended.

In May 2021, the Company signed a membership agreement to lease space with WeWork at 501 Boylston Street, Boston, Massachusetts. The lease commenced on August 1, 2021 and was accounted for as a short term lease. The Company recorded $0.1 million in lease expense associated with the membership agreement during the year ended December 31, 2021.

Supplemental cash flow information related to leases for the periods reported is as follows:

 

 

 

December 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Decrease in right-of-use assets related to lease modifications and termination (in thousands)

 

$

42,058

 

 

$

27,333

 

Decrease in operating lease liabilities due to lease modifications and termination (in thousands)

 

$

41,177

 

 

$

29,002

 

Cash paid for amounts included in the measurement of lease liabilities (in thousands)

 

$

1,887

 

 

$

7,411

 

Weighted-average remaining lease term of operating leases (in years)

 

 

 

 

 

8.5

 

Weighted-average discount rate of operating leases

 

 

 

 

 

6.1

%

On October 18, 2019, the Company entered into an agreement with a third party to sublease 15,700 rentable square feet of its lease premises under the Head Lease. The sublease was scheduled to expire on June 30, 2029, unless earlier terminated in accordance with the sublease agreement, and has no extension options. The sublease provides for annual base rent of approximately $1.5 million in the first year, which increases on a yearly basis by 3.0% (subject to an abatement of base rent of approximately $0.7 million for the first six months of the sublease). As part of the consideration for the sublease, the sublessee agreed to provide licensed rooms and services within the sublease premises to the Company over the sublease term free of charge. In addition, the sublessee is responsible for its pro rata share of certain costs, taxes and operating expenses related to the subleased space, the consideration for which is variable and is based on the actual operating costs of the lessor. The Company allocated the total consideration in the sublease agreement between the lease and non-lease components in the contract based on their relative standalone prices. The Company determined that the variable consideration relates exclusively to non-lease components and will be recognized as incurred. The sublease included an initial security deposit of $0.5 million, which was provided by the sublessee in the form of a letter of credit, and an additional security deposit of $0.4 million within nine months of the sublease commencement.

On September 15, 2020, concurrent with execution of the Second Lease Amendment, the Company entered into the Sublease Termination Agreement to terminate its sublease of 15,700 rentable square feet. Under the terms of the Sublease Termination Agreement, the subtenant is relieved of its obligation to provide future cash rental payments to the Company. The agreements requiring the former subtenant to provide licensed rooms and services to the Company free of charge through the original sublease term survived the sublease termination. The Company gained access to the licensed rooms and services beginning in the third quarter of 2021. The letter of credit security deposit related to the sublease was released.

The Company determined that the Sublease Termination Agreement constituted a non-monetary exchange under ASC 845 Nonmonetary Transactions (“ASC 845”) where, in return for the free rooms and the services, the Company agreed to terminate its rights and obligations under the sublease agreement. In accordance with ASC 845, the Company determined that the accounting for the transaction should be based on the fair value of assets or services involved. The Company estimated the fair value of the rooms and services to be approximately $1.5 million and $2.9 million, respectively. Accordingly, prepaid rooms and services of $4.4 million were recorded upon the sublease termination, of which $1.6 million was recorded in other current assets and $2.8 million was recorded in other assets in the consolidated balance sheets as of December 31, 2020. Termination fee income of $3.1 million was recognized related to the rooms and services, after considering the rent receivable balance of $1.3 million outstanding from the subtenant. The remaining unamortized direct costs of $0.2 million were written off. The effects of the Sublease Termination Agreement were recorded within sublease termination income, net in the consolidated statements of operations and comprehensive loss. Total gross sublease income of approximately $1.5 million, and net sublease income of approximately $0.3 million was recorded in interest and other income, net in the consolidated statements of operations and comprehensive loss for year ended December 31, 2020.

The Company determined that the licensed rooms represent a lease under ASC 842. The Company obtained control of the rooms in the third quarter of 2021 and the prepaid rooms balance of approximately $1.4 million was reclassified from other assets to a ROU asset. The related lease expense is recognized on a straight-line basis over the lease term of 8.88 years. The Company recorded $0.1 million of lease expense during the year ended December 31, 2021. The Company determined that the licensed services represent a non-lease component, which is recognized separately from the lease component for this asset class. The expense related to the licensed services is recognized on a straight-line basis over the period the services are received. The Company recorded $0.2 million for the year ended December 31, 2021. Both the lease expense and services expense are recognized as a component of research and development costs in the consolidated statements of operations and comprehensive loss.

XML 29 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-based Compensation Plans
12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Share-based Compensation Plans

9. Share-based Compensation Plans

In 2019, Cyclerion adopted share-based compensation plans. Specifically, Cyclerion adopted the 2019 Employee Stock Purchase Plan (“2019 ESPP”) and the 2019 Equity Incentive Plan (“2019 Equity Plan”). Under the 2019 ESPP, eligible employees may use payroll deductions to purchase shares of stock in offerings under the plan, and thereby acquire an interest in the future of the Company. The 2019 Equity Plan provides for stock options and restricted stock units (“RSUs”).

Cyclerion also mirrored two of Ironwood’s existing plans, the Amended and Restated 2005 Stock Incentive Plan (“2005 Equity Plan”) and the Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan (“2010 Equity Plan). These mirror plans were adopted to facilitate the exchange of Ironwood equity awards for Cyclerion equity awards upon the Separation as part of the equity conversion. As a result of the Separation and in accordance with the EMA, employees of both companies retained their existing Ironwood vested options and received a pro-rata share of Cyclerion options, regardless of which company employed them post-Separation. For employees that were ultimately employed by Cyclerion, unvested Ironwood options and RSUs were converted to unvested Cyclerion options and RSUs.

The following table provides share-based compensation reflected in the Company’s consolidated statements of operations and comprehensive loss for the years ended December 31, 2021 and 2020 (in thousands):

 

 

 

Year Ended
December 31,

 

 

 

2021

 

 

2020

 

Research and development

 

$

3,945

 

 

$

6,799

 

General and administrative

 

 

5,666

 

 

 

8,193

 

 

 

$

9,611

 

 

$

14,992

 

 

Stock Options

Stock options granted under the Company’s equity plans generally have a ten-year term and vest over a period of four years, provided the individual continues to serve at the Company through the vesting dates. Options granted under all equity plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the requisite service period, which is typically the vesting period of each option.

 

A summary of stock option activity for the year ended December 31, 2021 is as follows:

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

Average

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Intrinsic

 

 

 

Number

 

 

Exercise

 

 

Contractual

 

 

Value (in

 

 

 

of Options

 

 

Price

 

 

Term (Years)

 

 

thousands)

 

Outstanding as of December 31, 2020

 

 

7,426,356

 

 

$

11.87

 

 

 

7.0

 

 

$

1,178

 

Granted

 

 

1,176,250

 

 

 

2.98

 

 

 

 

 

 

 

Exercised

 

 

(72,419

)

 

 

2.17

 

 

 

 

 

 

 

Cancelled or forfeited

 

 

(1,449,761

)

 

 

10.69

 

 

 

 

 

 

 

Outstanding as of December 31, 2021

 

 

7,080,426

 

 

$

10.73

 

 

 

6.9

 

 

 

 

Exercisable at December 31, 2021

 

 

4,518,213

 

 

$

13.46

 

 

 

5.9

 

 

$

 

During the years ended December 31, 2021 and 2020, the Company granted stock options to purchase an aggregate of 1,176,250 shares and 1,382,846 shares, respectively, at weighted average grant fair values per option share of $2.17 and $1.97, respectively. The total grant fair value of options granted during the years ended December 31, 2021 and 2020 was $2.6 million and $2.7 million, respectively.

The total intrinsic value of options exercised for the years ended December 31, 2021 and 2020 was $0.1 million and $0.1 million, respectively.

As of December 31, 2021, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested time-based stock options held by the Company’s employees is $8.1 million and the weighted average period over which that expense is expected to be recognized is 3.29 years.

The weighted-average Black-Scholes assumptions used in estimating the fair value of the stock options granted by Cyclerion following the Separation during the years ended December 31, 2021 and 2020 were as follows:

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

Weighted average risk-free interest rate

 

 

1.09

%

 

 

0.43

%

Expected dividend yield

 

 

 

 

 

 

Expected option term (in years)

 

 

5.9

 

 

 

6.3

 

Expected stock price volatility

 

 

85.45

%

 

 

91.73

%

For the years ended December 31, 2021 and 2020, expected volatility was estimated using an average of the historical volatility of the common stock of a group of similar companies that were publicly traded. The

Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

The Company has granted to certain employees performance based options to purchase shares of common stock. These options are subject to performance based milestone vesting. During the year ended December 31, 2021, 50,000 shares vested as a result of performance milestone achievements and no shares vested during the year ended December 31, 2020. The Company recorded a de minimis and no share-based compensation expense related to these performance-based options for the years ended December 31, 2021, and 2020, respectively.

Market-based Stock Options

The Company also has granted to certain employees stock options containing market conditions that vest upon the achievement of specified price targets of the Company’s share price for a period through December 31, 2024. Vesting is measured based upon the average closing price of the Company’s share price for any thirty consecutive trading days, subject to certain service requirements. Stock compensation cost is expensed on a straight-line basis over the derived service period for each stock price target within the award, ranging from approximately 4.0 to 4.6 years. The Company accelerates expense when a stock price target is achieved prior to the derived service period. The Company does not reverse expense recognized if the share price target(s) are ultimately not achieved but expense is reversed when a stock award recipient has a break in service prior to the completion of the derived service period. As of December 31, 2021, there was $0.2 million of unrecognized compensation costs related to stock options containing market conditions, which is expected to be recognized over a weighted-average period of 2.17 years.

A summary of stock awards containing market conditions activity for the years ended December 31, 2021 and 2020 is as follows:

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

Aggregate

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Intrinsic

 

 

 

Number of

 

 

Exercise

 

 

Contractual

 

 

Value (in

 

 

 

Options

 

 

Price

 

 

Term (years)

 

 

thousands)

 

Outstanding as of December 31, 2020

 

 

600,000

 

 

$

2.01

 

 

$

8.9

 

 

$

630

 

Granted

 

 

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

 

 

 

 

 

 

 

 

 

 

Cancelled or forfeited

 

 

(150,000

)

 

$

 

 

$

 

 

$

 

Outstanding as of December 31, 2021

 

 

450,000

 

 

$

2.01

 

 

 

7.9

 

 

$

 

Exercisable at December 31, 2021

 

 

 

 

$

 

 

 

 

 

$

 

The fair value of stock options containing market conditions is estimated using Monte Carlo simulations. No stock options containing market conditions were granted during the years ended December 31, 2021 and 2020.

Restricted Stock Units

The RSUs generally vest 25% per year on the approximate anniversary of the date of grant until fully vested, provided the employee remains continuously employed with the Company through each vesting date. Shares of the Company’s common stock are delivered to the employee upon vesting, subject to payment of applicable withholding taxes. The fair value of all RSUs is based on the market value of the Company’s common stock on the date of grant. Compensation expense, including the effect of estimated forfeitures, is recognized over the applicable service period.

A summary of RSU activity for the years ended December 31, 2021 is as follows:

 

 

 

 

 

 

Weighted Average

 

 

 

Number

 

 

Grant Date

 

 

 

of Shares

 

 

Fair Value

 

Unvested as of December 31, 2020

 

 

294,913

 

 

$

14.52

 

Granted

 

 

39,369

 

 

 

3.17

 

Vested

 

 

(143,774

)

 

 

12.01

 

Forfeited

 

 

(97,704

)

 

 

14.41

 

Unvested as of December 31, 2021

 

 

92,804

 

 

$

13.70

 

As of December 31, 2021, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested restricted stock units by the Company’s employees is $0.7 million and the weighted-average period over which that expense is expected to be recognized is 1.13 years.

XML 30 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Loss per share
12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Loss per share

10. Loss per share

Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows:

 

 

 

Year Ended
December 31,

 

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

Net loss (in thousands)

 

$

(51,647

)

 

$

(77,802

)

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

Weighted average shares used in calculating net loss per share — basic and diluted (in thousands)

 

 

39,144

 

 

 

30,403

 

Net loss per share — basic and diluted

 

$

(1.32

)

 

$

(2.56

)

 

We exclude shares of common stock related to stock options and RSUs from the calculation of diluted net loss per share since the inclusion of such shares would be anti-dilutive. The following table sets forth potential shares that were considered anti-dilutive for the years ended December 31, 2021 and 2020:

 

 

 

Year Ended
December 31,

 

 

 

2021

 

 

2020

 

Stock Options

 

$

7,530,426

 

 

$

294,913

 

RSUs

 

 

92,804

 

 

 

8,026,356

 

 

 

$

7,623,230

 

 

$

8,321,269

 

XML 31 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

11. Income Taxes

There was no provision for income taxes for the years ended December 31, 2021, and 2020, due to the Company’s operating losses and a full valuation allowance on deferred tax assets. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

U.S.

 

$

(51,686

)

 

$

(77,884

)

International

 

 

39

 

 

 

82

 

Loss before benefit from income taxes

 

$

(51,647

)

 

$

(122,406

)

Income tax benefit using U.S. federal statutory rate

 

$

(10,846

)

 

$

(16,338

)

State income taxes, net of federal benefit

 

 

(3,631

)

 

 

(5,619

)

Non-deductible share-based compensation

 

 

(911

)

 

 

16

 

Share-based compensation - shortfalls/(windfalls)

 

 

946

 

 

 

1,047

 

Permanent differences

 

 

(420

)

 

 

(94

)

PPP loan forgiveness

 

 

(748

)

 

 

 

Tax credits

 

 

(805

)

 

 

(2,469

)

Other

 

 

(9

)

 

 

(16

)

Change in valuation allowance

 

 

16,424

 

 

 

23,473

 

 

 

$

 

 

$

 

 

The effective income tax rate is based upon the income for the year, the composition of the income in different countries, and adjustments, if any, for the potential tax consequences, benefits or resolutions of audits or other tax contingencies. Our income tax rate in foreign jurisdictions is lower than our income tax rate in the United States.

Deferred tax assets (liabilities) consist of the following as of December 31, 2021 and 2020 (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

43,700

 

 

$

27,007

 

Tax credit carryforwards

 

 

8,044

 

 

 

7,185

 

Share-based compensation

 

 

7,702

 

 

 

5,890

 

Operating lease - liability

 

 

 

 

 

11,536

 

Property and equipment

 

 

(1

)

 

 

1,362

 

Capitalized research and development

 

 

11,147

 

 

 

12,684

 

Accruals and reserves

 

 

91

 

 

 

518

 

Other

 

 

4

 

 

 

 

Total deferred tax assets

 

$

70,687

 

 

$

66,182

 

 

 

 

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

Operating lease - right of use asset

 

$

(383

)

 

$

(11,857

)

Prepaid sublease termination

 

 

(758

)

 

 

(1,203

)

Total deferred tax liabilities

 

 

(1,141

)

 

 

(13,060

)

Net deferred tax assets

 

 

69,546

 

 

 

53,122

 

 

 

 

 

 

 

 

Valuation allowance

 

 

(69,546

)

 

 

(53,122

)

Net deferred tax assets

 

$

 

 

$

 

 

Management of Cyclerion has evaluated the positive and negative evidence bearing upon the possible realization of its deferred tax assets. Management has considered the Company's history of operating losses, in addition to the expected timing of the reversal of existing temporary differences and concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company will not realize the benefit of its deferred tax assets. Accordingly, the net deferred tax assets have been fully reserved at December 31, 2021 and December 31, 2020. Management reevaluates the positive and negative evidence on a quarterly basis.

The valuation allowance increased by approximately $16.4 million during the year ended December 31, 2021 primarily due to increases in capitalized research and development expenses, net operating losses, tax credit carryforwards and deferred tax assets related to share-based compensation.

Cyclerion did not generate net operating loss carryforwards or tax credit carryforwards available for its use until its inception and operation as a standalone legal entity. At December 31, 2021 and 2020, Cyclerion has federal net operating loss carryforwards of approximately $160 million and $98.8 million, respectively, to offset future federal taxable income that will be carried forward indefinitely until utilized. As of December 31, 2021, and 2020, Cyclerion had state net operating loss carryforwards of approximately $159.6 million and $98.9 million, respectively, to offset future state taxable income, which will begin to expire in 2039 and will continue to expire through 2040. Cyclerion also had tax credit carryforwards of approximately $8.4 million and $7.5 million as of December 31, 2021 and 2020, respectively, to offset future federal and state income taxes. Federal credits begin to expire in 2039 and will continue to expire through 2040. State credits begin to expire in 2022 and continue through 2034.

The Company’s ability to use its operating loss carryforwards and tax credits to offset future taxable income could be subject to restrictions under Section 382 of the U.S. Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”). These potential restrictions may limit the future use of the operating loss carryforwards and tax credits if certain ownership changes described in the Internal Revenue Code occur. Changes in stock ownership may occur that would create these limitations on the Company’s use of the operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist.

The Company has not as yet conducted a study of its research and development credit carry forwards. This study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development credits, and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheets or statements of operations if an adjustment were required.

Upon audit, taxing authorities may challenge all or part of an uncertain income tax position. While Cyclerion has no history of tax audits since its inception on a standalone basis, it may be subject to tax audits by federal and state taxing authorities in the future. Accordingly, Cyclerion regularly assesses the outcome of potential examinations in each of the taxing jurisdictions when determining the adequacy of the amount of unrecognized tax benefit recorded. Cyclerion had no unrecognized tax benefits as of December 31, 2021 and 2020. Cyclerion will recognize interest and penalties, if any, related to uncertain tax positions in income tax expense. As of December 31, 2021 and 2020, no interest or penalties have been accrued. There are no current federal or state income tax audits in progress.

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act is an emergency economic stimulus package in response to the COVID-19 pandemic, which among other things contains numerous income tax provisions, some of which are effective retroactively for fiscal years ended before the date of enactment. The CARES Act includes certain tax relief provisions, including modifications to the NOL rules, including a provision to carryback losses from 2018 – 2021 tax years, temporary changes to business interest expense disallowance rules (IRC §163(j)), qualified improvement property, payroll tax delays/ credits, and several other tax and non-tax benefits. These tax provisions should have no significant income tax ramifications for Cyclerion, but the Company will continue to monitor any changes and guidance in order to consider potential opportunities. The CARES Act also created a program called the Paycheck Protection Program to be administered by the SBA. Cyclerion received $3.5 million of loan proceeds on April 21, 2020 under the PPP, as fully described in Note 2, Summary of Significant Accounting Policies.

XML 32 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Defined Contribution Plan
12 Months Ended
Dec. 31, 2021
Retirement Benefits [Abstract]  
Defined Contribution Plan

12. Defined Contribution Plan

In 2019, Cyclerion adopted a defined contribution 401(k) Savings Plan similar to the plan in place at Ironwood. The plan assets under the Ironwood defined contribution 401(k) Savings Plan were transferred to the Cyclerion plan. Subject to certain IRS limits, eligible employees may elect to contribute from 1% to 100% of their

compensation. Cyclerion contributions to the plan are at the sole discretion of the board of directors. Currently, Cyclerion provides a matching contribution of 75% of the employee’s contributions, up to $6,000 annually.

Included in compensation expense is approximately $0.3 million and $0.5 million related to the defined contribution 401(k) Savings Plan for the years ended December 31, 2021 and 2020, respectively.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
Workforce Reduction
12 Months Ended
Dec. 31, 2021
Restructuring and Related Activities [Abstract]  
Workforce Reduction

13. Workforce Reduction

2020 Workforce Reduction

On November 5, 2020, the Company began a reduction of its current workforce by forty-eight (48) full-time employees to align its resources with its current priorities of focusing on the MELAS study, the planned ADv study and further characterization of CY6463 novel pharmacology.

The Company recorded total costs related to the 2020 Workforce Reduction were approximately $5.0 million including approximately $0.1 million in stock-based compensation from the modification of certain share-based equity awards.

The Company reduced its workforce by thirty-one (31) employees in the fourth quarter of 2020 and recorded approximately $4.1 million of severance and benefits costs in accordance with ASC Topic 420, Exit or Disposal Cost Obligations, or ASC 420, including a de minimis amount of stock-based compensation expense, for the year ended December 31, 2020. The workforce reduction was completed by the end of the first quarter of 2021.

The following table summarizes the accrued liabilities activity recorded in connection with the reduction in workforce for the year ended December 31, 2021 (in thousands):

 

 

 

Amounts
accrued at
December 31,
2020

 

 

Charges

 

 

Amount
paid

 

 

Adjustments

 

 

Amounts
accrued at
December 31,
2021

 

2020 workforce reduction

 

$

(3,640

)

 

$

(878

)

 

$

4,490

 

 

$

 

 

$

(28

)

Total

 

$

(3,640

)

 

$

(878

)

 

$

4,490

 

 

$

 

 

$

(28

)

XML 34 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
License Agreements
12 Months Ended
Dec. 31, 2021
License Agreement [Abstract]  
License Agreements

14. License Agreement

Akebia License Agreement

On June 3, 2021, the Company and Akebia entered into a License Agreement (the “License Agreement”) relating to the exclusive worldwide license by the Company to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the pharmaceutical compound known as praliciguat and other related products and forms thereof enumerated in the License Agreement (collectively, the “Products”). Pursuant to the License Agreement, Akebia will be responsible for all future research, development, regulatory, and commercialization activities for the Products.

Akebia paid a $3.0 million up-front payment to the Company upon signing of the License Agreement and the Company is eligible to receive additional milestone cash payments of up to $12.0 million in the next 18 months. Further milestone cash payments by Akebia are scheduled in the License Agreement based on the initiation of phase 3 clinical trials in the U.S. for Products for first and second indication, for FDA approvals, for approvals in certain other major markets, and for certain sales milestones. In addition to these cash milestone payments, Akebia will pay the Company tiered royalty payments on net sales in certain major markets at percentages ranging from the mid-single digits to the high-teens, subject to certain reductions and offsets.

Pursuant to the License Agreement, the Company determined the License Agreement represents a service arrangement under the scope of ASC 606. Given the reversion of the rights under the License Agreement represents a penalty in substance for a termination by Akebia, the contract term would be the stated term of the License Agreement.

The Company determined that the grant of license to our patents and trademarks, know how transfer, the assignment of regulatory submissions and trademarks and additional knowledge transfer assistance obligations represent a single promise and performance obligation to be transferred to Akebia over time due to the nature of the promises in the contract. The provision of development materials on hand was identified as a separate performance obligation. However, it is immaterial in the context of the contract as the development materials are low value and do not have an alternative use to the Company.

The consideration related to sales-based milestone payments, including royalties, will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license. The Company will re-evaluate the probability of achievement of the milestones and any related constraints each reporting period.

Akebia Supply Agreement

On August 3, 2021, the Company and Akebia entered into a Supply Agreement (the “Supply Agreement”) relating to the manufacturing by the Company of the Initial Supply of the Drug Product and placebo ("Initial Supply") for Akebia's use pursuant to the License Agreement. Akebia will pay the Company for the manufacturing costs at mutually agreed upon rates.

The Company determined the Supply Agreement has stand-alone value under the scope of ASC 606 and should not be combined with the License Agreement. Given that the Supply Agreement can be terminated at any time without cause with 30 days notice, the Company deemed the Supply Agreement to be a month-to-month contract. The manufacturing of the Initial Supply by the Company represents a single performance obligation and consideration related to the manufacturing costs will be recognized over time as costs are incurred based on an input method. The Company recorded $0.3 million amount as revenue from the Supply Agreement for the year ended December 31, 2021.

XML 35 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Grant Revenue
12 Months Ended
Dec. 31, 2021
Disaggregation of Revenue [Line Items]  
Grant Revenue

15. Grant Revenue

In August 2021, the Company was approved to receive funding from the PTC Grant for the Phase 2 study of CNS sGC stimulation in AD with vascular features. The granting period is July 1, 2021, to December 31, 2022, and the Company will receive an award of up to $2 million. The Company determined that this transaction is non-reciprocal as there is not considered to be a commensurate value exchanged with the Alzheimer's Association as the funding provider. Where commensurate value is not exchanged for goods and services provided, a recipient assesses whether the grant is conditional or unconditional. The Company considered all conditions and barriers associated with this grant and determined the grant is conditional and revenue will be recognized upon achieving certain milestones and incurring internal costs specifically covered by this grant. Under ASC 958-605, revenues will be recognized as the Company incurs expenses related to the PTC Grant.

The Company incurred approximately $0.6 million of allowable expenses and recognized a corresponding amount of grant revenue for the year ended December 31, 2021.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Subsequent Events
12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events

16. Subsequent Events

The Company has evaluated all events and transactions that occurred after the balance sheet date through the date the consolidated financial statements were issued and determined that there were no such events requiring recognition or disclosure in the consolidated financial statements.

XML 37 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The consolidated financial statements and the related disclosures have been prepared in accordance with U.S. generally accepted accounting principles. In the opinion of management, the consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company’s financial position and the results of its operations for the fiscal years presented.

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion GmbH, and Cyclerion Securities Corporation. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements.

Principles of Consolidation

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Cyclerion Therapeutics, Inc. and its wholly owned subsidiaries, Cyclerion GmbH and Cyclerion Securities Corporation. All intercompany transactions and balances are eliminated in consolidation.

Segment Information

Segment Information

Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company's chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company currently operates in one reportable business segment - human therapeutics.
Use of Estimates

Use of Estimates

The preparation of consolidated financial statements in accordance with U.S. GAAP requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, impairment of long-lived assets, valuation procedures for right-of-use

("ROU") assets and operating lease liabilities, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation, and going concern. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.

Cash and Cash Equivalents

Cash and Cash Equivalents including Restricted Cash

The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents may consist of money market funds and overnight repurchase agreements. The carrying amount of cash equivalents approximates fair value.

Restricted Cash he Company did not have any restricted cash balances. As of December 31, 2020, the Company was contingently liable under an unused letter of credit with a bank, related to the Company's facility lease, in the amount of approximately $3.8 million. The Company recorded the collateral used to secure the letter of credit as restricted cash. The full amount of restricted cash was recorded as a component of non-current assets at December 31, 2020.
Property and Equipment

Property and Equipment

Property and equipment, including leasehold improvements, are recorded at cost, and are depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:

 

Asset Description

 

Estimated Useful
Life (In Years)

Laboratory equipment

 

5

Computer and office equipment

 

3

Furniture and fixtures

 

7

Software

 

3

 

Included in property and equipment are certain costs of software obtained for internal use. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred.

Costs for capital assets not yet placed into service have been capitalized as construction in progress and are depreciated in accordance with the above guidelines once placed into service. Maintenance and repair costs are expensed as incurred.

Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. The Company has no capital leases.

Property and equipment that is no longer required for the business is considered disposed of when it ceases to be used. Disposals are either sold or retired and the net book value is removed from the consolidated balance sheet and a corresponding gain or loss on the sale or disposal is recognized as a component of operating expenses in the consolidated statements of operations and comprehensive loss.
Fair Value of Investment Instruments

Fair Value of Investment Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must

maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

Level 1 — Quoted prices in active markets for identical assets or liabilities.
Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
Foreign Currency Translation Adjustment

Foreign Currency Translation Adjustment

The functional currency of the Company’s foreign subsidiary is its local currency, the Swiss franc. The assets and liabilities of the Company’s foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for the Company’s foreign subsidiary is included as a foreign currency translation adjustment in the consolidated statements of stockholders’ equity and as a component of comprehensive loss in the consolidated statements of operations and comprehensive loss.

The Company’s intercompany accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the re-measurement of intercompany balances are recorded in the consolidated statements of operations.

Accounts Receivable

Accounts Receivable

The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding invoices. The Company’s receivables primarily relate to amounts earned under a development agreement with Ironwood, licensing agreement, and supply agreement. The Company believes that credit risks associated with these agreements are not significant. To date, the Company has not had significant write-offs of bad debt and the Company did not have an allowance for doubtful accounts as of December 31, 2021 or 2020.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

The Company regularly reviews the carrying amount of its long-lived assets to determine whether indicators of impairment may exist, which warrant adjustments to carrying values or estimated useful lives. If indications of impairment exist, projected future undiscounted cash flows associated with the asset are compared to the carrying amount to determine whether the asset’s value is recoverable. If the carrying value of the asset exceeds such projected undiscounted cash flows, the asset will be written down to its estimated fair value. There were no significant impairments of long-lived assets for the years ended December 31, 2021 or 2020.

Leases

Leases

Effective January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) Topic 842, Leases (“ASC 842”) using the optional transition method. The adoption of ASC 842 represents a change in accounting principle that aims to increase transparency and comparability among organizations by requiring the recognition of right-of-use assets and lease liabilities on the balance sheet for both operating and finance leases. In addition, the standard requires enhanced disclosures that meet the objective of enabling financial statement users to assess the amount, timing, and uncertainty of cash flows arising from leases. The reported results for the years ended December 31, 2021 and 2020 reflect the application of ASC 842 guidance.

The recognition of right-of-use assets and lease liabilities related to the Company’s operating leases under ASC 842 has had a material impact on the Company’s consolidated financial statements.

As part of the ASC 842 adoption, the Company has used certain practical expedients outlined in the guidance. These practical expedients include:

Account policy election to use the short-term lease exception by asset class;
Election of the practical expedient package during transition, which includes:
An entity need not reassess whether any expired or existing contracts are or contain leases.
An entity need not reassess the classification for any expired or existing leases. As a result, all leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases under ASC 842, and all leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases under ASC 842.
An entity need not reassess initial direct costs for any existing leases.

The Company had a property lease for its headquarters location at 301 Binney Street, Cambridge, MA (the “Head Lease”). The Company determined if the arrangement was a lease at the inception of the contract. The asset component of the Company’s operating leases was recorded as operating lease right-of-use assets, and the liability component was recorded as current portion of operating lease liabilities and operating lease liabilities, net of current portion, in the Company’s consolidated balance sheets.

ROU assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.

Lease cost was recognized on a straight-line basis over the lease term, and included amounts related to short-term leases. Variable lease costs that do not depend on an index or rate were recognized as incurred.

ROU assets and operating lease liabilities were remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. The difference between the remeasured ROU assets and the operating lease liabilities were recognized as a gain or loss in operating expenses. The Company reviewed any changes to its lease agreements for potential modifications and/or indicators of impairment of the respective ROU asset.

On October 18, 2019, the Company entered into an agreement to sublease 15,700 rentable square feet of its Head Lease to a subtenant (the “Sublease Agreement”). Sublease income was recognized on straight-line basis over the term of the sublease agreement and was recorded net of the related rent expense from the Head Lease within interest and other income, net in the consolidated statements of operations and comprehensive loss. In sublease agreements that contain non-monetary consideration, the Company estimated the fair market value of the non-monetary consideration received using market data and recognized it on a straight-line basis over the sublease term. Variable lease consideration that did not depend on an index or rate was allocated to a non-lease component and was recognized over time in accordance with the pattern of transfer.

No modification or impairment was deemed to have occurred by entering into the sublease agreement because the Company was not released, either fully or in part, from its obligations under the Head Lease. See Note 8, Leases.

On February 28, 2020 the Company entered into an amendment to its Head Lease (the “Lease Amendment”). The Lease Amendment provided for the partial termination of the Company's rights and obligations with respect to a portion of the leased premises of approximately 40,000 rentable square feet. The Company continued to lease approximately 74,000 rentable square feet under terms of the amended lease. The Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease

and not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification and the Company recorded a gain of approximately $2.1 million as a component of operating expenses for the year ended December 31, 2020. No impairment of the ROU asset was deemed to have occurred. See Note 8, Leases.

On September 15, 2020, the Company entered into an amendment to its Head Lease (the “Second Lease Amendment”). The Second Lease Amendment provided for the partial termination of the Company's rights and obligations with respect to a portion of the leased premises of approximately 17,000 rentable square feet (the “Surrender Space”). The Surrender Space included the 15,700 rentable square feet being subleased by the Company to a subtenant. The Company continued to lease approximately 57,000 rentable square feet under terms of the amended lease. The Second Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease and not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification and the Company recorded a loss of approximately $0.4 million as a component of operating expenses for the year ended December 31, 2020. No impairment of the ROU asset was deemed to have occurred. See Note 8, Leases.

On September 15, 2020, concurrent with the execution of the Second Lease Amendment, the Company entered into an agreement with its subtenant to terminate the Sublease Agreement of approximately 15,700 rentable square feet (“the Sublease Termination Agreement”). Under the terms of the Sublease Termination Agreement, the former subtenant is obligated to provide licensed rooms and services to the Company free of charge through the original sublease term. Upon termination of the sublease, the Company recognized sublease termination income of approximately $3.1 million related to the prepaid rooms and services, and wrote off the remaining indirect costs from the sublease of approximately $0.2 million, in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2020. See Note 8, Leases.

On April 30, 2021, the Company entered into a Termination Agreement (the "Termination Agreement") for its Head Lease as initially amended on February 28, 2020, and further amended on September 15, 2020. Pursuant to the Termination Agreement, the Company surrendered the leased space of approximately 57,000 square feet to the building’s landlord. The Company did not pay any termination fees with the Termination Agreement. As a result of the termination of the Head Lease, the related right-of-use asset was written off, the lease liability was derecognized, and the $3.8 million security deposit was returned to the Company and recorded as part of our cash balance. In total, the Company recognized a loss on the termination of the Head Lease of $0.9 million for the year ended December 31, 2021. The loss is included in “General and administrative” expenses on our consolidated statement of operations and comprehensive loss.

Paycheck Protection Program Loan

Paycheck Protection Program Loan

On April 21, 2020, the Company received loan proceeds in the amount of approximately $3.5 million pursuant to a promissory note agreement with a bank under the Paycheck Protection Program. The Paycheck Protection Program, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The Promissory Note had an original loan maturity of April 20, 2022, a stated interest rate of 1.0% per annum, and had payments of principal and interest that were due monthly after an initial six-month deferral period where interest accrued, but no payments were due. The Promissory Note provided for customary events of default, including, among others, those relating to failure to make payment when due and breaches of representations. The loan was subject to all the terms and conditions applicable under the PPP and was subject to review by the SBA for compliance with program requirements, including the Company’s certification that the economic uncertainty, at the time, made the PPP loan request necessary to support ongoing operations. On October 2, 2020, the SBA issued procedural guidance with respect to PPP loans and changes in ownership and the Company believes that it is compliant with respect to the 2020 Equity Private Placement and the ATM Offering.

In June 2020, the Payroll Protection Program Flexibility Act was signed into law adjusting certain key terms of loans issued under the PPP. In accordance with the PPPFA, the initial deferral period may be extended from six to up to ten months and the loan maturity may be extended from two to five years. The PPPFA also provided for certain other changes, including the extent to which the loan may be forgiven.

The loan’s principal and accrued interest were forgivable to the extent that the proceeds were used for eligible purposes, subject to certain limitations, and that the Company maintained its payroll levels over a twenty-four-week period following the loan date. The loan forgiveness amount may have been reduced if the Company

terminated employees or reduced salaries during the twenty-four-week period. PPP loans are subject to audit and the SBA has indicated that companies that received over $2 million in proceeds should expect an audit. The Company believes that it has used the proceeds for eligible purposes consistent with the provisions of the PPPFA.

As the legal form of the Promissory Note is a debt obligation, the Company accounted for it as debt under Accounting Standards Codification (ASC) 470, Debt and recorded a short-term liability of $3.5 million in the consolidated balance sheets upon receipt of the loan proceeds. The Company accrued interest over the term of the loan and did not record additional interest at a market rate because the guidance on imputing interest in ASC 835-30, Interest excludes transactions where interest rates are prescribed by a government agency. Approximately $0.1 million of interest expense has been recognized within interest and other income, net in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. In August 2021, the Company applied with the SBA for forgiveness of the PPP loan and was notified on November 4, 2021 that the SBA has approved our application to forgive the entire amount of the loan and accrued interest. The Company recorded a gain on extinguishment of debt of $3.6 million representing the principal and accrued interest for the PPP Loan.

Revenue

Revenue

Upon executing a revenue generating arrangement, the Company assesses whether it is probable the Company will collect consideration in exchange for the good or service it transfers to the customer. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. The Company must develop assumptions that require significant judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The assumptions that are used to determine the stand-alone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company derives revenue from (1) license agreement and (2) supply agreement which are fully described in Note 14, License Agreement.

The Company generated revenue from a Development Agreement with Ironwood, pursuant to which the Company provided certain research and development services with respect to certain of Ironwood’s products and product candidates. Such research and development activities were governed by a joint steering committee composed of representatives of both companies. Services performed were invoiced at a mutually agreed upon rate and the initial term of the agreement was two years from the date of Separation and automatically renewed for one year unless either party notified the other at least six months prior to the expiration. Ironwood and the Company agreed that the Development Agreement would not be renewed beyond its initial term which ended on March 31, 2021.

The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange transactions and are not within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Contribution revenue earned from activities performed pursuant to research and development grants is reported as grant revenue in the Company’s consolidated statements of operations. Revenue from these grants is recognized as the Company incurs qualifying expenses as stipulated by the terms of the respective grant. Cash received from grants in advance of incurring qualifying expenses is recorded as deferred revenue. The Company records revenue and a corresponding receivable when qualifying costs are incurred before receiving payment from the grants.

Research and Development Costs

Research and Development Costs

The Company expenses research and development costs to operations as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. The

Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception.

Research and development expenses are comprised of costs incurred in performing research and development activities, which may include salary, benefits and other employee-related expenses; share-based compensation expense; laboratory supplies and other direct expenses; facilities expenses; overhead expenses; third-party contractual costs relating to nonclinical studies and clinical trial activities and related contract manufacturing expenses, development of manufacturing processes and regulatory registration of third-party manufacturing facilities; and other outside expenses.

General and Administrative Expenses

General and Administrative Expenses

The Company expenses general and administrative costs to operations as incurred. General and administrative expense consists of compensation, share-based compensation, benefits and other employee-related expenses for personnel in the Company’s administrative, finance, legal, information technology, business development and human resource functions. Other costs include the legal costs of pursuing patent protection of the Company’s intellectual property, general and administrative related facility costs, insurance costs and professional fees for accounting and legal services.

Income taxes

Income taxes

The Company is primarily subject to U.S. federal and Massachusetts state income taxes. For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable.

The tax positions taken or expected to be taken in the course of preparing the Company tax returns are required to be evaluated to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authority. Tax positions not deemed to meet a more-likely-than-not threshold would be recorded as a tax expense in the current year. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. It does not consider the likelihood of whether or not the IRS will review the position. Cyclerion evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect Cyclerion's income tax provision in future periods. There were no uncertain tax positions that require accrual or disclosure in the consolidated financial statements as of December 31, 2021, and 2020. The Company’s policy is to recognize interest and penalties related to income tax, if any, in income tax expense. As of December 31, 2021, and 2020, the Company has no accruals for interest or penalties related to income tax matters.

Patent Costs

Patent Costs

Patent fees and patent related costs in connection with filing and prosecuting patent applications are expensed as incurred and are classified as general and administrative expenses in the accompanying consolidated financial statements. The Company incurred and recorded as operating expense legal and other fees related to patents of approximately $1.4 million and $1.7 million for the years ended December 31, 2021 and 2020, respectively.

Interest and Other Income, Net

Interest and Other Income, Net

For the year ended December 31, 2021, interest and other income, net consisted of a de minimis amount of interest income related to interest generated from our cash and cash equivalents balances and a de minimis amount

of interest expense related to the PPP loan. For the year ended December 31, 2020, interest and other income, net consisted of $0.3 million of interest income related to interest generated from our cash and cash equivalents balances and $0.3 million of net sublease income.

Subsequent Events

Subsequent Events

The Company considers events or transactions that have occurred after the balance sheet date of December 31, 2021, but prior to the filing of the financial statements with the Securities and Exchange Commission, to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of the financial statements accompanying this Annual Report on Form 10-K. See Note 14, Subsequent Events.
New Accounting Pronouncements

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the consolidated financial statements, the Company did not adopt any new accounting pronouncements during the years ended December 31, 2021 and 2020, that had a material effect on its consolidated financial statements.

In June 2016 the FASB issued ASU 2016-13, Financial Instruments-Credit Losses. This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. As a smaller reporting company, ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2022, and early adoption is permitted. The Company is currently evaluating the impact that ASU 2016-13 will have on its financial statements and related disclosures.

In May 2021 the FASB issued Accounting Standards Update No. 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the Emerging Issues Task Force (EITF) , which amends the FASB Accounting Standards Codification (ASC or the “Codification”) to provide explicit guidance, and, thus, reduce diversity in practice, on accounting by issuers for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after the modification or exchange. This amendment provides that for an entity that presents earnings per share (EPS) in accordance with Topic 260, the effects of a modification or an exchange of a freestanding equity-classified written call option that is recognized as a dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. The amended guidance becomes mandatorily effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, and should be applied prospectively to modifications or exchanges occurring on or after the effective date. The Company is currently evaluating the impact that ASU 2021-04 will have on its financial statements and related disclosures.

No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company’s consolidated financial statements upon adoption. 

XML 38 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Schedule of Estimated Useful Lives of Property and Equipment

Property and equipment, including leasehold improvements, are recorded at cost, and are depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:

 

Asset Description

 

Estimated Useful
Life (In Years)

Laboratory equipment

 

5

Computer and office equipment

 

3

Furniture and fixtures

 

7

Software

 

3

 

XML 39 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value of Financial Instruments (Tables)
12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy

The Company’s cash equivalents are generally classified within Level 1 of the fair value hierarchy. The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of December 31, 2021 and December 31, 2020 (in thousands):

 

 

 

Fair Value Measurements as of December 31, 2021:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

52,917

 

 

$

 

 

$

 

 

$

52,917

 

Cash equivalents

 

$

52,917

 

 

$

 

 

$

 

 

$

52,917

 

 

 

 

Fair Value Measurements as of December 31, 2020:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

53,240

 

 

$

 

 

$

 

 

$

53,240

 

Cash equivalents

 

$

53,240

 

 

$

 

 

$

 

 

$

53,240

 

XML 40 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment (Tables)
12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment, net

Property and equipment, net consisted of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Software

 

$

2,214

 

 

$

2,214

 

Computer and office equipment

 

 

51

 

 

 

44

 

Leasehold improvements

 

 

 

 

 

14,894

 

Property and equipment, gross

 

 

2,265

 

 

 

17,152

 

Less: accumulated depreciation and amortization

 

 

(2,200

)

 

 

(10,287

)

Property and equipment, net

 

$

65

 

 

$

6,865

 

XML 41 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued Expenses and Other Current Liabilities (Tables)
12 Months Ended
Dec. 31, 2021
Accrued Liabilities and Other Liabilities [Abstract]  
Schedule of accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Accrued incentive compensation

 

$

1,369

 

 

$

1,720

 

Salaries

 

 

266

 

 

 

514

 

Accrued vacation

 

 

345

 

 

 

555

 

Professional fees

 

 

398

 

 

 

689

 

Accrued severance and benefit costs

 

 

28

 

 

 

3,640

 

Other

 

 

498

 

 

 

176

 

Accrued expenses and other current liabilities

 

$

2,904

 

 

$

7,294

 

XML 42 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases (Tables)
12 Months Ended
Dec. 31, 2021
Leases [Abstract]  
Schedule of supplemental cash flow information related to leases

Supplemental cash flow information related to leases for the periods reported is as follows:

 

 

 

December 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Decrease in right-of-use assets related to lease modifications and termination (in thousands)

 

$

42,058

 

 

$

27,333

 

Decrease in operating lease liabilities due to lease modifications and termination (in thousands)

 

$

41,177

 

 

$

29,002

 

Cash paid for amounts included in the measurement of lease liabilities (in thousands)

 

$

1,887

 

 

$

7,411

 

Weighted-average remaining lease term of operating leases (in years)

 

 

 

 

 

8.5

 

Weighted-average discount rate of operating leases

 

 

 

 

 

6.1

%

XML 43 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-based Compensation Plans (Tables)
12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of share-based compensation expense

The following table provides share-based compensation reflected in the Company’s consolidated statements of operations and comprehensive loss for the years ended December 31, 2021 and 2020 (in thousands):

 

 

 

Year Ended
December 31,

 

 

 

2021

 

 

2020

 

Research and development

 

$

3,945

 

 

$

6,799

 

General and administrative

 

 

5,666

 

 

 

8,193

 

 

 

$

9,611

 

 

$

14,992

 

 

Schedule of stock option activity

A summary of stock option activity for the year ended December 31, 2021 is as follows:

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

Average

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Intrinsic

 

 

 

Number

 

 

Exercise

 

 

Contractual

 

 

Value (in

 

 

 

of Options

 

 

Price

 

 

Term (Years)

 

 

thousands)

 

Outstanding as of December 31, 2020

 

 

7,426,356

 

 

$

11.87

 

 

 

7.0

 

 

$

1,178

 

Granted

 

 

1,176,250

 

 

 

2.98

 

 

 

 

 

 

 

Exercised

 

 

(72,419

)

 

 

2.17

 

 

 

 

 

 

 

Cancelled or forfeited

 

 

(1,449,761

)

 

 

10.69

 

 

 

 

 

 

 

Outstanding as of December 31, 2021

 

 

7,080,426

 

 

$

10.73

 

 

 

6.9

 

 

 

 

Exercisable at December 31, 2021

 

 

4,518,213

 

 

$

13.46

 

 

 

5.9

 

 

$

 

Schedule of weighted-average assumptions used in estimating the fair value of the stock options

The weighted-average Black-Scholes assumptions used in estimating the fair value of the stock options granted by Cyclerion following the Separation during the years ended December 31, 2021 and 2020 were as follows:

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

Weighted average risk-free interest rate

 

 

1.09

%

 

 

0.43

%

Expected dividend yield

 

 

 

 

 

 

Expected option term (in years)

 

 

5.9

 

 

 

6.3

 

Expected stock price volatility

 

 

85.45

%

 

 

91.73

%

Summary of stock awards containing market conditions activity

A summary of stock awards containing market conditions activity for the years ended December 31, 2021 and 2020 is as follows:

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

Aggregate

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Intrinsic

 

 

 

Number of

 

 

Exercise

 

 

Contractual

 

 

Value (in

 

 

 

Options

 

 

Price

 

 

Term (years)

 

 

thousands)

 

Outstanding as of December 31, 2020

 

 

600,000

 

 

$

2.01

 

 

$

8.9

 

 

$

630

 

Granted

 

 

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

 

 

 

 

 

 

 

 

 

 

Cancelled or forfeited

 

 

(150,000

)

 

$

 

 

$

 

 

$

 

Outstanding as of December 31, 2021

 

 

450,000

 

 

$

2.01

 

 

 

7.9

 

 

$

 

Exercisable at December 31, 2021

 

 

 

 

$

 

 

 

 

 

$

 

Schedule of weighted-average assumptions used in estimating the fair value of the stock awards containing market conditions

The fair value of stock options containing market conditions is estimated using Monte Carlo simulations. No stock options containing market conditions were granted during the years ended December 31, 2021 and 2020.

Summary of RSU activity

A summary of RSU activity for the years ended December 31, 2021 is as follows:

 

 

 

 

 

 

Weighted Average

 

 

 

Number

 

 

Grant Date

 

 

 

of Shares

 

 

Fair Value

 

Unvested as of December 31, 2020

 

 

294,913

 

 

$

14.52

 

Granted

 

 

39,369

 

 

 

3.17

 

Vested

 

 

(143,774

)

 

 

12.01

 

Forfeited

 

 

(97,704

)

 

 

14.41

 

Unvested as of December 31, 2021

 

 

92,804

 

 

$

13.70

 

XML 44 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Loss per share (Tables)
12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Schedule of basic and diluted earnings per share

Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows:

 

 

 

Year Ended
December 31,

 

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

Net loss (in thousands)

 

$

(51,647

)

 

$

(77,802

)

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

Weighted average shares used in calculating net loss per share — basic and diluted (in thousands)

 

 

39,144

 

 

 

30,403

 

Net loss per share — basic and diluted

 

$

(1.32

)

 

$

(2.56

)

 

Schedule Of Earnings Per Share Diluted By Common Class The following table sets forth potential shares that were considered anti-dilutive for the years ended December 31, 2021 and 2020:

 

 

 

Year Ended
December 31,

 

 

 

2021

 

 

2020

 

Stock Options

 

$

7,530,426

 

 

$

294,913

 

RSUs

 

 

92,804

 

 

 

8,026,356

 

 

 

$

7,623,230

 

 

$

8,321,269

 

XML 45 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Summary of reconciliation of income taxes computed using the U.S. federal statutory rate

A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

U.S.

 

$

(51,686

)

 

$

(77,884

)

International

 

 

39

 

 

 

82

 

Loss before benefit from income taxes

 

$

(51,647

)

 

$

(122,406

)

Income tax benefit using U.S. federal statutory rate

 

$

(10,846

)

 

$

(16,338

)

State income taxes, net of federal benefit

 

 

(3,631

)

 

 

(5,619

)

Non-deductible share-based compensation

 

 

(911

)

 

 

16

 

Share-based compensation - shortfalls/(windfalls)

 

 

946

 

 

 

1,047

 

Permanent differences

 

 

(420

)

 

 

(94

)

PPP loan forgiveness

 

 

(748

)

 

 

 

Tax credits

 

 

(805

)

 

 

(2,469

)

Other

 

 

(9

)

 

 

(16

)

Change in valuation allowance

 

 

16,424

 

 

 

23,473

 

 

 

$

 

 

$

 

Summary of deferred tax assets (liabilities)

Deferred tax assets (liabilities) consist of the following as of December 31, 2021 and 2020 (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

43,700

 

 

$

27,007

 

Tax credit carryforwards

 

 

8,044

 

 

 

7,185

 

Share-based compensation

 

 

7,702

 

 

 

5,890

 

Operating lease - liability

 

 

 

 

 

11,536

 

Property and equipment

 

 

(1

)

 

 

1,362

 

Capitalized research and development

 

 

11,147

 

 

 

12,684

 

Accruals and reserves

 

 

91

 

 

 

518

 

Other

 

 

4

 

 

 

 

Total deferred tax assets

 

$

70,687

 

 

$

66,182

 

 

 

 

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

 

Operating lease - right of use asset

 

$

(383

)

 

$

(11,857

)

Prepaid sublease termination

 

 

(758

)

 

 

(1,203

)

Total deferred tax liabilities

 

 

(1,141

)

 

 

(13,060

)

Net deferred tax assets

 

 

69,546

 

 

 

53,122

 

 

 

 

 

 

 

 

Valuation allowance

 

 

(69,546

)

 

 

(53,122

)

Net deferred tax assets

 

$

 

 

$

 

XML 46 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Workforce Reduction (Tables)
12 Months Ended
Dec. 31, 2021
Restructuring and Related Activities [Abstract]  
Schedule of accrued liabilities activity allocated to Cyclerion in connection with the reduction in workforce

The following table summarizes the accrued liabilities activity recorded in connection with the reduction in workforce for the year ended December 31, 2021 (in thousands):

 

 

 

Amounts
accrued at
December 31,
2020

 

 

Charges

 

 

Amount
paid

 

 

Adjustments

 

 

Amounts
accrued at
December 31,
2021

 

2020 workforce reduction

 

$

(3,640

)

 

$

(878

)

 

$

4,490

 

 

$

 

 

$

(28

)

Total

 

$

(3,640

)

 

$

(878

)

 

$

4,490

 

 

$

 

 

$

(28

)

XML 47 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Nature of Business (Details)
12 Months Ended
Jun. 03, 2021
USD ($)
shares
Sep. 03, 2020
USD ($)
Jul. 29, 2020
USD ($)
shares
Apr. 01, 2019
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
Jul. 24, 2020
USD ($)
Nov. 15, 2019
Employee
May 03, 2019
Employee
Nature of Business                  
Health care trust fund, Description         We have initiated exploratory clinical trials with CY6463 ADv, CIAS, and MELAS. The ADv study will be supported in part by a grant from the Alzheimer’s Association’s Part the Cloud-Gates Partnership Grant Program, which provides Cyclerion with $2 million of funding over two years.        
Common stock dividend issued (shares of Cyclerion per ten shares of Ironwood)       0.1          
Proceeds from equity private placement and ATM         $ 30,503,000 $ 24,250,000      
Proceeds from 2020 Equity private placement and ATM         30,503,000 24,250,000      
Issuance of common stock - 2020 private placement         18,028,000 $ 24,250,000      
Cash and cash equivalents         54,000,000.0        
Private Placement                  
Nature of Business                  
Issuance of common stock - 2020 private placement (in shares) | shares 5,735,988   6,062,500            
Proceeds from equity private placement and ATM $ 18,000,000   $ 24,300,000            
Proceeds from 2020 Equity private placement and ATM $ 18,000,000   $ 24,300,000            
Net proceeds from issuance of shares to accredited investors         219,800        
IPO                  
Nature of Business                  
Maximum amount of Aggregate initial offering price             $ 150,000,000.0    
ATM Offering | Jefferies LLC                  
Nature of Business                  
Cash commission of gross proceeds of sales of common stock, percentage   3.00%              
Net Proceeds from Issuance of Common Stock         12,500,000        
Commission Paid From Gross Proceeds Of Sales Of Common Stock         $ 400,000        
Number of common stock sold | shares         3,353,059        
ATM Offering | Maximum | Jefferies LLC                  
Nature of Business                  
Issuance of common stock - 2020 private placement   $ 50,000,000.0              
Cyclerion GmbH                  
Nature of Business                  
Number of employees | Employee                 1
Cyclerion Securities Corporation                  
Nature of Business                  
Number of employees | Employee               0  
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Segments and Cash (Details)
$ in Millions
12 Months Ended
Dec. 31, 2021
Segment
Dec. 31, 2020
USD ($)
Segment Information    
Number of reportable business segment | Segment 1  
Restricted Cash    
Contingent liability under an unused letter of credit, posted as a security deposit | $   $ 3.8
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Property and Equipment (Details)
12 Months Ended
Dec. 31, 2021
Laboratory equipment  
Property and Equipment  
Estimated Useful Life (In Years) 5 years
Computer and office equipment  
Property and Equipment  
Estimated Useful Life (In Years) 3 years
Furniture and fixtures  
Property and Equipment  
Estimated Useful Life (In Years) 7 years
Software  
Property and Equipment  
Estimated Useful Life (In Years) 3 years
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Leases (Details)
$ in Thousands
12 Months Ended
Sep. 15, 2020
USD ($)
ft²
Feb. 28, 2020
USD ($)
ft²
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Apr. 30, 2021
USD ($)
ft²
Oct. 18, 2019
ft²
Apr. 01, 2019
ft²
Leases              
Election of practical expedients package       true      
Space subleased to third party (in square feet) | ft² 15,700         15,700  
Rentable space terminated from lease agreement (in square feet) | ft² 15,700            
Gain (Loss) on Termination of Lease     $ 881 $ (1,669)      
Gain (loss) on lease modification     881 (1,669)      
Sublease termination agreement prepaid rooms and services       4,400      
Gain (Loss) on Termination of Lease     6,300        
Head Lease              
Leases              
Space subleased to third party (in square feet) | ft²           15,700  
Rented space (in square feet) | ft²             114,000
Gain (Loss) on Termination of Lease     900        
Security Deposit Returned         $ 3,800    
Lease Amendment              
Leases              
Rentable space terminated from lease agreement (in square feet) | ft²   40,000          
Rented space (in square feet) | ft²   74,000          
Gain (Loss) on Termination of Lease       2,100      
ROU asset, impairment loss   $ 0          
Gain (loss) on lease modification       2,100      
Second Lease Amendment              
Leases              
Space subleased to third party (in square feet) | ft² 15,700            
Rentable space terminated from lease agreement (in square feet) | ft² 17,000            
Rented space (in square feet) | ft² 57,000            
Gain (Loss) on Termination of Lease       (400)      
ROU asset, impairment loss $ 0            
Rentable space terminated from lease agreement (in square feet) | ft² 15,700            
Gain (loss) on lease modification       $ (400)      
Sublease Termination Agreement              
Leases              
Rentable space terminated from lease agreement (in square feet) | ft² 15,700       57,000    
Gain (Loss) on Termination of Lease     3,100        
Gain (loss) on lease modification     3,100        
Sublease termination agreement prepaid rooms and services $ 3,100            
Write off lease unamortized direct cost $ 200   200        
Termination Agreement              
Leases              
Gain (Loss) on Termination of Lease     $ 900        
Security Deposit Returned         $ 3,800    
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Paycheck Protection Program Loan (Details) - USD ($)
$ in Thousands
12 Months Ended
Apr. 21, 2020
Dec. 31, 2021
Dec. 31, 2020
Leases      
Proceeds from short-term note payable   $ 0 $ 3,509
Short-term liability   3,500  
Gain (Loss) on Extinguishment of Debt   3,564 $ 0
PPP Loan      
Leases      
Proceeds from short-term note payable $ 3,500    
Interest Expense   $ 100  
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Revenue, Patent Costs, and Interest and Other Income (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenue    
Development Agreement, initial term 2 years  
Development Agreement, renewal period 1 year  
Development Agreement, period for notification of cancellation 6 months  
Interest and other income, net    
Net sublease income   $ 0.3
Interest and other income, net    
Interest and other income, net    
Interest income generated form cash and cash equivalents balances   0.3
Net sublease income   $ 0.3
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Income Taxes (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
Income tax, penalties and interest accrued $ 0 $ 0
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Related Party Transactions (Details)
$ in Millions
12 Months Ended
Dec. 31, 2020
USD ($)
Other Related Party Transactions  
Related Party Transaction [Line Items]  
Amounts due to related party $ 0.3
Payments to provide research and development transaction support services 1.5
Ironwood | Development agreement  
Related Party Transaction [Line Items]  
Revenue from related party $ 2.3
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value of Financial Instruments (Details) - Recurring - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Cash equivalents:    
Total cash equivalents $ 52,917 $ 53,240
Level 1    
Cash equivalents:    
Total cash equivalents 52,917 53,240
Money market funds    
Cash equivalents:    
Total cash equivalents 52,917 53,240
Money market funds | Level 1    
Cash equivalents:    
Total cash equivalents $ 52,917 $ 53,240
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Property and Equipment    
Property and equipment. gross $ 2,265 $ 17,152
Less: accumulated depreciation and amortization (2,200) (10,287)
Property and equipment, net 65 6,865
Depreciation and amortization 472 2,297
Gain (Loss) on Termination of Lease 6,300  
Gain Loss On Sale Of Property Plant Equipment 6,322 159
Software    
Property and Equipment    
Property and equipment. gross 2,214 2,214
Computer and office equipment    
Property and Equipment    
Property and equipment. gross 51 44
Leasehold improvements    
Property and Equipment    
Property and equipment. gross $ 0 $ 14,894
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Accrued Liabilities and Other Liabilities [Abstract]    
Accrued incentive compensation $ 1,369 $ 1,720
Salaries 266 514
Accrued vacation 345 555
Professional fees 398 689
Accrued severance and benefit costs 28 3,640
Other 498 176
Accrued expenses and other current liabilities $ 2,904 $ 7,294
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Summary (Details)
$ in Thousands
12 Months Ended
Sep. 15, 2020
USD ($)
ft²
Feb. 28, 2020
USD ($)
ft²
Apr. 01, 2019
USD ($)
ft²
Item
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2021
Apr. 30, 2021
USD ($)
ft²
Oct. 18, 2019
ft²
Leases                
Term of lease           8 years 10 months 17 days    
Letter of credit posted with the landlord as a security deposit         $ 3,800      
Operating lease right-of-use asset       $ 1,402 43,402      
Rentable space terminated from lease agreement (in square feet) | ft² 15,700              
Space subleased to third party (in square feet) | ft² 15,700             15,700
Gain (loss) on lease modification       881 (1,669)      
Gain (Loss) on Termination of Lease       6,300        
Current portion of operating lease liabilities       0 3,293      
Noncurrent lease liability       0 38,933      
Total lease costs       2,400 8,600      
Head Lease                
Leases                
Rented space (in square feet) | ft²     114,000          
Term of lease     123 months          
Number of extension option | Item     2          
Renewal term     5 years          
Letter of credit posted with the landlord as a security deposit     $ 7,700          
Security Deposit Returned             $ 3,800  
Space subleased to third party (in square feet) | ft²               15,700
Gain (Loss) on Termination of Lease       900        
Lease Amendment                
Leases                
Rented space (in square feet) | ft²   74,000            
Letter of credit posted with the landlord as a security deposit   $ 5,000            
Incremental borrowing rate (as a percent)   9.70%            
Rentable space terminated from lease agreement (in square feet) | ft²   40,000            
Decrease in security deposit   $ 2,700            
Decrease in remaining operating lease payments   41,900            
Cash paid for lease termination fees   6,300            
Cash paid for initial direct costs of lease modification   200            
Decrease in right-of-use assets related to lease modification and termination   21,400            
Decrease in operating lease liabilities due to lease modification and termination   $ 23,500            
Gain (loss) on lease modification         2,100      
Second Lease Amendment                
Leases                
Rented space (in square feet) | ft² 57,000              
Letter of credit posted with the landlord as a security deposit         3,800      
Incremental borrowing rate (as a percent) 6.10%              
Operating lease right-of-use asset         43,400      
Rentable space terminated from lease agreement (in square feet) | ft² 17,000              
Decrease in security deposit       1,200        
Decrease in remaining operating lease payments $ 16,900              
Cash paid for lease termination fees 0              
Cash paid for initial direct costs of lease modification 0              
Decrease in right-of-use assets related to lease modification and termination 5,900              
Decrease in operating lease liabilities due to lease modification and termination $ 5,500              
Space subleased to third party (in square feet) | ft² 15,700              
Gain (loss) on lease modification         (400)      
Current portion of operating lease liabilities         3,300      
Noncurrent lease liability         38,900      
Variable lease costs       700 $ 2,200      
Termination Agreement                
Leases                
Surrendered Lease Space | ft²             57,000  
Security Deposit Returned             $ 3,800  
Gain (Loss) on Termination of Lease       900        
WeWork                
Leases                
Total lease costs       $ 100        
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Schedule of supplemental cash flow information related to leases (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Leases [Abstract]    
Decrease in right-of-use assets related to lease modification and termination $ 42,058 $ 27,333
Decrease in operating lease liabilities due to lease modifications and termination 41,177 29,002
Cash paid for amounts included in the measurement of lease liabilities (in thousands) $ 1,887 $ 7,411
Weighted-average remaining lease term of operating leases (in years)   8 years 6 months
Weighted-average discount rate of operating leases   6.10%
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Future minimum lease operating payments (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Future minimum lease payments under non-cancelable operating leases under ASC 842    
Less: current portion of operating lease liabilities $ 0 $ 3,293
Operating lease liabilities, net of current portion $ 0 $ 38,933
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Sublease as Lessee (Details)
3 Months Ended
Mar. 31, 2019
Leases [Abstract]  
Operating sublease, option to extend true
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Sublease as Lessor (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Sep. 15, 2020
USD ($)
ft²
Oct. 18, 2019
USD ($)
ft²
Item
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Apr. 01, 2019
Lessor Lease Description [Line Items]            
Space subleased to third party (in square feet) | ft² 15,700 15,700        
Sublease termination agreement estimated fair value of rooms       $ 1,500    
Sublease termination agreement estimated fair value of services       2,900    
Sublease termination agreement prepaid rooms and services         $ 4,400  
Other current assets       468 3,163  
Gain (loss) on lease modification       881 (1,669)  
Gross sublease income, net of rent expense         1,500  
Net sublease income         300  
Prepaid rooms balance reclassified from other assets     $ 1,400      
Term of lease     8 years 10 months 17 days      
lease expense       100    
License And Service Member            
Lessor Lease Description [Line Items]            
lease expense       200    
Head Lease            
Lessor Lease Description [Line Items]            
Space subleased to third party (in square feet) | ft²   15,700        
Sublease, Annual base rent   $ 1,500        
Sublease, Increase in base rent over the term of the lease (as a percent)   3.00%        
Sublease, Abatement of base rent   $ 700        
Sublease, Abatement period   6 months        
Sublease, Number of extension options | Item   0        
Sublease, Initial security deposit received   $ 500        
Sublease, Additional security deposit to be received   $ 400        
Sublease, additional security deposit period   9 months        
Term of lease           123 months
Sublease Termination Agreement            
Lessor Lease Description [Line Items]            
Sublease termination agreement prepaid rooms and services $ 3,100          
Other current assets         1,600  
Other assets         $ 2,800  
Gain (loss) on lease modification       3,100    
Rent receivables outstanding from subtenant       1,300    
Write off lease unamortized direct cost $ 200     $ 200    
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-based Compensation Plans (Details)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2021
USD ($)
TradingDay
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Share-based Compensation Plans    
Share-based compensation $ 9,611 $ 14,992
Number of shares vested | shares 50,000 0
Unrecognized share-based compensation expense $ 200  
Expected period to recognize the expense 2 years 2 months 1 day  
Weighted average grant date fair value per option share | $ / shares   $ 1.97
Granted (in shares) | shares 0 0
Research and development    
Share-based Compensation Plans    
Share-based compensation $ 3,945 $ 6,799
General and administrative    
Share-based Compensation Plans    
Share-based compensation $ 5,666 8,193
Restricted Stock Units    
Share-based Compensation Plans    
Expected period to recognize the expense 1 year 1 month 17 days  
Unrecognized share-based compensation expense $ 700  
Performance stock options    
Share-based Compensation Plans    
Threshold consecutive trading days, used as a base for measurement of vesting of stock awards | TradingDay 30  
Performance stock options | Minimum [Member]    
Share-based Compensation Plans    
Expected option term (in years) 4 years  
Performance stock options | Maximum    
Share-based Compensation Plans    
Expected option term (in years) 4 years 7 months 6 days  
Employee Stock Option Member    
Share-based Compensation Plans    
Share based compensation expense $ 0 $ 0
Expected period to recognize the expense 3 years 3 months 14 days  
Weighted average grant date fair value per option share | $ / shares $ 2.17  
Unrecognized share-based compensation expense $ 8,100  
Granted (in shares) | shares 1,176,250 1,382,846
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-based Compensation Plans - Stock Options (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Number of Options    
Granted (in shares) 0 0
Weighted Average Remaining Contractual Term (years)    
Granted (in shares) 0 0
Weighted average grant date fair value per option share   $ 1.97
Total intrinsic value $ 100 $ 100
Unrecognized share-based compensation expense $ 200,000  
Expected period to recognize the expense 2 years 2 months 1 day  
Assumptions used to estimate fair value of stock options    
Weighted average risk-free interest rate 1.09% 0.43%
Expected dividend yield 0.00% 0.00%
Expected option term (in years) 5 years 10 months 24 days 6 years 3 months 18 days
Expected stock price volatility 85.45% 91.73%
Number of shares vested 50,000 0
Employee Stock Option Member    
Number of Options    
Outstanding at beginning of the year (in shares) 7,426,356  
Granted (in shares) 1,176,250 1,382,846
Exercised (in shares) (72,419)  
Cancelled or forfeited (in shares) (1,449,761)  
Outstanding at end of the year (in shares) 7,080,426 7,426,356
Exercisable (in shares) 4,518,213  
Weighted Average Exercise Price    
Outstanding at beginning of the year (in dollars per share) $ 11.87  
Granted (in dollars per share) 2.98  
Exercised (in dollars per share) 2.17  
Cancelled or forfeited (in dollars per share) 10.69  
Outstanding at end of the year (in dollars per share) 10.73 $ 11.87
Exercisable (in dollars per share) $ 13.46  
Weighted Average Remaining Contractual Term (years)    
Weighted Average Remaining Contractual Term, Outstanding (in years) 6 years 10 months 24 days 7 years
Weighted Average Remaining Contractual Term, Exercisable (in years) 5 years 10 months 24 days  
Aggregate Intrinsic Value, Outstanding $ 0 $ 1,178,000
Aggregate Intrinsic Value, Exercisable $ 0  
Granted (in shares) 1,176,250 1,382,846
Weighted average grant date fair value per option share $ 2.17  
Total grant date fair value of options granted $ 2,600,000 $ 2,700
Expected period to recognize the expense 3 years 3 months 14 days  
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-based Compensation Plans - Schedule of Weighted Average Assumptions used in estimating the fair value of the stock options (Details)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]    
Weighted average risk-free interest rate 1.09% 0.43%
Expected dividend yield 0.00% 0.00%
Expected option term (in years) 5 years 10 months 24 days 6 years 3 months 18 days
Expected stock price volatility 85.45% 91.73%
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-based Compensation Plans - Stock Awards Containing Market Conditions (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Number of Options    
Granted (in shares) 0 0
Assumptions used to estimate fair value of performance-based stock options    
Weighted average risk-free interest rate 1.09% 0.43%
Expected dividend yield 0.00% 0.00%
Expected stock price volatility 85.45% 91.73%
Performance stock options | Minimum    
Assumptions used to estimate fair value of performance-based stock options    
Expected option term (in years) 4 years  
Performance stock options | Maximum    
Assumptions used to estimate fair value of performance-based stock options    
Expected option term (in years) 4 years 7 months 6 days  
Employee Stock Option Member    
Number of Options    
Outstanding at beginning of the year (in shares) 7,426,356  
Granted (in shares) 1,176,250 1,382,846
Exercised (in shares) (72,419)  
Cancelled or forfeited (in shares) (1,449,761)  
Outstanding at end of the year (in shares) 7,080,426 7,426,356
Exercisable (in shares) 4,518,213  
Weighted-Average Exercise Price    
Outstanding at beginning of the year (in dollars per share) $ 11.87  
Granted (in dollars per share) 2.98  
Exercised (in dollars per share) 2.17  
Cancelled or forfeited (in dollars per share) 10.69  
Outstanding at end of the year (in dollars per share) 10.73 $ 11.87
Exercisable (in dollars per share) $ 13.46  
Weighted Average Remaining Contractual Term (years)    
Weighted average remaining contractual term, outstanding at the end of period (in years) 6 years 10 months 24 days 7 years
Weighted Average Remaining Contractual Term, Exercisable (in years) 5 years 10 months 24 days  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 6 years 10 months 24 days 7 years
Aggregate intrinsic value, outstanding at the end of period $ 0 $ 1,178
Aggregate intrinsic value, exercisable at the end of period $ 0  
Market-based Stock Options    
Number of Options    
Outstanding at beginning of the year (in shares) 600,000  
Cancelled or forfeited (in shares) (150,000)  
Outstanding at end of the year (in shares) 450,000 600,000
Weighted-Average Exercise Price    
Outstanding at beginning of the year (in dollars per share) $ 2.01  
Outstanding at end of the year (in dollars per share) $ 2.01 $ 2.01
Weighted Average Remaining Contractual Term (years)    
Weighted average remaining contractual term, outstanding at the end of period (in years) 7 years 10 months 24 days  
Weighted Average Remaining Contractual Term, Exercisable (in years)   8 years 10 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 7 years 10 months 24 days  
Aggregate intrinsic value, exercisable at the end of period   $ 630
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-based Compensation Plans - Summary of RSU activity (Details) - $ / shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Weighted-Average Grant Date Fair Value    
Expected period to recognize the expense 2 years 2 months 1 day  
Weighted average grant date fair value per option share   $ 1.97
Restricted Stock Units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 25.00%  
Number of Shares    
Unvested at the beginning of the period (in shares) 294,913  
Granted (in shares) 39,369  
Vested (in shares) (143,774)  
Forfeited (in shares) (97,704)  
Unvested the end of the period (in shares) 92,804 294,913
Weighted-Average Grant Date Fair Value    
Unvested at the beginning of the period (in dollars per share) $ 14.52  
Granted (in dollars per share) 3.17  
Vested (in dollars per share) 12.01  
Forfeited (in dollars per share) 14.41  
Unvested restricted common stock at the end of the period (in dollars per share) $ 13.70 $ 14.52
Expected period to recognize the expense 1 year 1 month 17 days  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value $ 3.17  
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Loss per share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Numerator:    
Net loss $ (51,647) $ (77,802)
Denominator:    
Weighted average shares used in calculating net loss per share — basic and diluted (in thousands) 39,144 30,403
Net loss per share — basic and diluted $ (1.32) $ (2.56)
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Loss Per Share - Schedule Of Earnings Per Share Diluted By Common Class (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]    
Dilutive Securities, Effect on Basic Earnings Per Share, Options and Restrictive Stock Units $ 7,623,230 $ 8,321,269
Employee Stock Option Member    
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]    
Dilutive Securities, Effect on Basic Earnings Per Share, Options and Restrictive Stock Units 7,530,426 294,913
Restricted Stock Units    
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]    
Dilutive Securities, Effect on Basic Earnings Per Share, Options and Restrictive Stock Units $ 92,804 $ 8,026,356
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Additional disclosures (Details) - USD ($)
12 Months Ended
Apr. 21, 2020
Dec. 31, 2021
Dec. 31, 2020
Income Taxes      
Deferred tax assets, valuation allowance   $ 16,424,000 $ 23,473,000
Tax credit carryforwards   8,400 7,500
Provision for income tax   0 0
Unrecognized tax benefits   0 0
Accrued interest or penalties   0 0
Proceeds from short-term note payable   0 3,509,000
PPP Loan      
Income Taxes      
Proceeds from short-term note payable $ 3,500,000    
Federal      
Income Taxes      
Net operating loss carryforwards   $ 160,000,000 98,800,000
Income tax credit expiration description   Federal credits begin to expire in 2039 and will continue to expire through 2040. State credits begin to expire in 2022 and continue through 2034  
State      
Income Taxes      
Net operating loss carryforwards   $ 159,600,000 $ 98,900,000
Income tax credit expiration description   begin to expire in 2039 and will continue to expire through 2040  
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Reconciliation of income taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
U.S. $ (51,686) $ (77,884)
International 39 82
Loss before benefit from income taxes (51,647) (122,406)
Income tax benefit using U.S. federal statutory rate (10,846) (16,338)
State income taxes, net of federal benefit (3,631) (5,619)
Non-deductible share-based compensation (911) 16
Share-based compensation - shortfalls/(windfalls) 946 1,047
Permanent differences (420) (94)
Tax credits (805) (2,469)
Other (9) (16)
Change in valuation allowance 16,424 23,473
Income Tax Expense (Benefit), Total 0 $ 0
Paycheck Protection Program Loan [Member]    
PPP loan forgiveness $ 748  
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Deferred tax assets (liabilities) (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:    
Net operating loss carryforwards $ 43,700 $ 27,007
Tax credit carryforwards 8,044 7,185
Share-based compensation 7,702 5,890
Operating lease - liability 0 11,536
Property and equipment 1 1,362
Capitalized research and development 11,147 12,684
Accruals and reserves 91 518
other 4  
Total deferred tax assets 70,687 66,182
Deferred tax liabilities:    
Operating lease - right of use asset 383 11,857
Prepaid sublease termination 758 (1,203)
Total deferred tax liabilities (1,141) (13,060)
Net deferred tax assets 69,546 53,122
Valuation allowance (69,546) (53,122)
Net deferred tax assets $ 0 $ 0
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
Defined Contribution Plan (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Defined Contribution Plan    
401 (k) Savings Plan us-gaap:QualifiedPlanMember  
Matching contribution (as a percent of employee's contributions) 75.00%  
Maximum amount of employer matching contribution $ 6,000  
Compensation expense related to the defined contribution 401(k) Savings Plan $ 300,000 $ 500,000
Minimum    
Defined Contribution Plan    
Percent of compensation eligible employees may elect to contribute 1.00%  
Maximum    
Defined Contribution Plan    
Percent of compensation eligible employees may elect to contribute 100.00%  
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Workforce Reduction (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Nov. 05, 2020
USD ($)
Employees
Dec. 31, 2020
USD ($)
Employees
Dec. 31, 2021
USD ($)
2020 Workforce Reduction      
Restructuring Cost And Reserve [Line Items]      
Beginning of period     $ 3,640
Charges     (878)
Amount paid     4,490
Adjustments     0
End of period   $ 3,640 $ 28
Current workforce reductions | November 2020 Workforce Reduction      
Restructuring Cost And Reserve [Line Items]      
Reduction in workforce, number of employees | Employees 48 31  
Restructuring costs $ 5,000    
Severance and benefits costs   $ 4,100  
Stock-based compensation from the modification of share based equity awards $ 100    
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
License Agreement - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended 18 Months Ended
Jun. 03, 2021
Dec. 31, 2021
Dec. 31, 2020
Mar. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenues   $ 3,942 $ 2,296  
Akebia Research License Agreement [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Up Front Payment Received $ 3,000      
Akebia Research License Agreement [Member] | Forecast [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Additional milestone cash payment       $ 12,000
Akbeia Supply Agreement [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenues   $ 300    
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
Grant Revenue (Additional Information) (Details) - USD ($)
$ in Millions
12 Months Ended 18 Months Ended
Dec. 31, 2021
Dec. 31, 2022
Revenue Recognition and Deferred Revenue [Abstract]    
PTC Grant Award   $ 2.0
Allowable Expenses on Grant Revenue $ 0.6  
XML 77 cycn-20211231_htm.xml IDEA: XBRL DOCUMENT 0001755237 us-gaap:OfficeEquipmentMember 2020-12-31 0001755237 cycn:SecondAmendedHeadquartersLeaseMember 2021-01-01 2021-12-31 0001755237 2021-07-01 2022-12-31 0001755237 cycn:SecondAmendedHeadquartersLeaseMember 2020-09-14 2020-09-15 0001755237 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-12-31 0001755237 cycn:CurrentWorkforceReductionsMember cycn:November2020WorkforceReductionPlanMember 2020-11-05 2020-11-05 0001755237 us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0001755237 cycn:SubleaseTerminationAgreementMember 2020-09-15 0001755237 us-gaap:RetainedEarningsMember 2021-12-31 0001755237 cycn:AtTheMarketOfferingMember cycn:JefferiesLLCMember 2021-12-31 0001755237 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-12-31 0001755237 2021-06-30 0001755237 cycn:OtherRelatedPartyTransactionsMember 2020-12-31 0001755237 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001755237 cycn:LaboratoryEquipmentMember 2021-01-01 2021-12-31 0001755237 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001755237 2019-10-18 0001755237 cycn:TerminationAgreementMember 2021-01-01 2021-12-31 0001755237 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001755237 cycn:CurrentWorkforceReductionsMember cycn:November2020WorkforceReductionPlanMember 2020-10-01 2020-12-31 0001755237 cycn:CyclerionSecuritiesCorporationMember 2019-11-15 0001755237 cycn:HeadquartersLeaseMember 2019-10-18 0001755237 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001755237 2019-12-31 0001755237 srt:MaximumMember 2021-01-01 2021-12-31 0001755237 us-gaap:DomesticCountryMember 2020-12-31 0001755237 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001755237 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001755237 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001755237 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0001755237 2021-12-31 0001755237 cycn:WorkforceReductionPlan2020Member 2021-12-31 0001755237 cycn:AtTheMarketOfferingMember cycn:JefferiesLLCMember 2020-09-03 2020-09-03 0001755237 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001755237 cycn:SecondAmendedHeadquartersLeaseMember 2020-01-01 2020-12-31 0001755237 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001755237 us-gaap:OfficeEquipmentMember 2021-01-01 2021-12-31 0001755237 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001755237 us-gaap:CommonStockMember 2020-12-31 0001755237 cycn:AtTheMarketOfferingMember cycn:JefferiesLLCMember 2021-01-01 2021-12-31 0001755237 cycn:WeworkMember 2021-01-01 2021-12-31 0001755237 cycn:AkebiaResearchLicenseAgreementMember 2021-06-03 2021-06-03 0001755237 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001755237 us-gaap:DomesticCountryMember 2021-12-31 0001755237 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001755237 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001755237 cycn:AmendedHeadquartersLeaseMember 2020-01-01 2020-12-31 0001755237 2021-09-30 0001755237 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001755237 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001755237 cycn:SubleaseTerminationAgreementMember 2020-12-31 0001755237 srt:MaximumMember us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0001755237 us-gaap:CommonStockMember 2019-12-31 0001755237 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001755237 cycn:HeadquartersLeaseMember 2019-10-17 2019-10-18 0001755237 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001755237 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001755237 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001755237 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001755237 cycn:HeadquartersLeaseMember 2021-04-30 0001755237 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001755237 cycn:AmendedHeadquartersLeaseMember 2020-02-27 2020-02-28 0001755237 srt:MinimumMember 2021-01-01 2021-12-31 0001755237 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001755237 2020-01-01 2020-12-31 0001755237 cycn:HeadquartersLeaseMember 2019-04-01 2019-04-01 0001755237 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-01-01 2021-12-31 0001755237 cycn:MarketBasedStockOptionMember 2020-01-01 2020-12-31 0001755237 cycn:SubleaseTerminationAgreementMember 2021-01-01 2021-12-31 0001755237 2020-12-31 0001755237 cycn:CyclerionGmbhMember 2019-05-03 0001755237 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001755237 cycn:PaycheckProtectionProgramMember 2020-04-21 2020-04-21 0001755237 2019-01-01 2019-03-31 0001755237 us-gaap:CommonStockMember 2021-12-31 0001755237 2022-02-22 0001755237 2019-04-01 2019-04-01 0001755237 cycn:MarketBasedStockOptionMember 2021-01-01 2021-12-31 0001755237 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001755237 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001755237 us-gaap:RetainedEarningsMember 2019-12-31 0001755237 cycn:MarketBasedStockOptionMember 2020-12-31 0001755237 cycn:SecondAmendedHeadquartersLeaseMember 2020-09-15 0001755237 cycn:MarketBasedStockOptionMember 2021-12-31 0001755237 srt:MaximumMember cycn:AtTheMarketOfferingMember cycn:JefferiesLLCMember 2020-09-03 2020-09-03 0001755237 us-gaap:IPOMember 2020-07-24 0001755237 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001755237 2021-01-01 2021-12-31 0001755237 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-12-31 0001755237 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001755237 cycn:SecondAmendedHeadquartersLeaseMember 2020-12-31 0001755237 us-gaap:OfficeEquipmentMember 2021-12-31 0001755237 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0001755237 cycn:AkbeiaSupplyAgreementMember 2021-01-01 2021-12-31 0001755237 cycn:TerminationAgreementMember 2021-04-30 0001755237 us-gaap:PrivatePlacementMember 2021-06-03 2021-06-03 0001755237 us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0001755237 us-gaap:RetainedEarningsMember 2020-12-31 0001755237 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001755237 us-gaap:PrivatePlacementMember 2021-01-01 2021-12-31 0001755237 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001755237 cycn:InterestAndOtherIncomeMember 2020-01-01 2020-12-31 0001755237 us-gaap:EmployeeStockOptionMember 2020-12-31 0001755237 cycn:SubleaseTerminationAgreementMember 2021-12-31 0001755237 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001755237 cycn:PaycheckProtectionProgramLoanMember 2020-04-21 2020-04-21 0001755237 us-gaap:PrivatePlacementMember 2020-07-29 2020-07-29 0001755237 cycn:SubleaseTerminationAgreementMember 2021-04-30 0001755237 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001755237 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001755237 cycn:OtherRelatedPartyTransactionsMember 2020-01-01 2020-12-31 0001755237 cycn:SubleaseTerminationAgreementMember 2020-09-14 2020-09-15 0001755237 srt:ScenarioForecastMember cycn:AkebiaResearchLicenseAgreementMember 2021-10-01 2023-03-31 0001755237 2021-07-01 2021-09-30 0001755237 us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0001755237 cycn:AmendedHeadquartersLeaseMember 2020-02-28 0001755237 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0001755237 us-gaap:EmployeeStockOptionMember 2021-12-31 0001755237 us-gaap:LicenseAndServiceMember 2021-01-01 2021-12-31 0001755237 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001755237 cycn:IronwoodPharmaceuticalsIncMember cycn:DevelopmentAgreementMember 2020-01-01 2020-12-31 0001755237 cycn:WorkforceReductionPlan2020Member 2021-01-01 2021-12-31 0001755237 srt:MinimumMember us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0001755237 cycn:PaycheckProtectionProgramLoanMember 2021-01-01 2021-12-31 0001755237 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001755237 cycn:HeadquartersLeaseMember 2021-01-01 2021-12-31 0001755237 2020-09-15 0001755237 cycn:WorkforceReductionPlan2020Member 2020-12-31 0001755237 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001755237 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001755237 cycn:HeadquartersLeaseMember 2019-04-01 cycn:Employees cycn:Item pure utr:sqft cycn:TradingDay shares iso4217:USD shares cycn:Employee iso4217:USD cycn:Segment http://fasb.org/us-gaap/2021-01-31#QualifiedPlanMember --12-31 FY false true 0001755237 true 10-K true 2021-12-31 2021 false 001-38787 CYCLERION THERAPEUTICS, INC. MA 83-1895370 245 First Street 18th Floor Cambridge MA 02142 857 327-8778 Common Stock, no par value CYCN NASDAQ No No Yes Yes Non-accelerated Filer true true false false false 131500000 43410185 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Portions of the registrant’s definitive Proxy Statement, to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934, for its 2022 Annual Meeting of Stockholders are incorporated by reference in Part III of this Form 10-K.</span></p> 42 Ernst & Young LLP Boston, Massachusetts 53961000 54395000 100000 0 0 127000 928000 816000 468000 3163000 55457000 58501000 0 3837000 65000 6865000 1402000 43402000 2407000 2773000 59331000 115378000 1828000 1149000 0 286000 6353000 1421000 2904000 7294000 0 3509000 0 3293000 11085000 16952000 0 38933000 0 0 -215076000 -163429000 263345000 222949000 -23000 -27000 48246000 59493000 59331000 115378000 3000000 0 320000 0 622000 0 0 2296000 3942000 2296000 37636000 56414000 20620000 28816000 881000 -1669000 59137000 83561000 -55195000 -81265000 0 2875000 3564000 0 -16000 588000 -51647000 -77802000 -1.32 -2.56 39144000 30403000 -51647000 -77802000 4000 -7000 -51643000 -77809000 27598133 183376000 -85627000 -20000 97729000 -77802000 -77802000 6062500 24250000 24250000 386667 331000 331000 14992000 14992000 -7000 -7000 34047300 222949000 -163429000 -27000 59493000 -51647000 -51647000 5735988 18028000 18028000 3353059 12475000 12475000 273838 282000 282000 7915000 7915000 1696000 1696000 4000 4000 43410185 0 263345000 -215076000 -23000 48246000 -51647000 -77802000 472000 2297000 6322000 159000 881000 -1669000 0 2875000 3564000 0 9611000 14992000 -100000 0 127000 1346000 -112000 1150000 1244000 -55000 -59000 -2598000 366000 -888000 679000 -1301000 -286000 205000 4932000 -776000 -4335000 -1983000 -1048000 -2692000 -36517000 -72490000 7000 1524000 1464000 1542000 1457000 18000 30503000 24250000 282000 331000 0 3509000 30785000 28090000 4000 -7000 -4271000 -44389000 58232000 102621000 53961000 58232000 0 6507000 53961000 54395000 0 3837000 53961000 58232000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Nature of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Nature of Operations</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cyclerion Therapeutics, Inc. (“Cyclerion”, the “Company” or “we”) is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Our lead asset, CY6463, is a pioneering, central nervous system (CNS) penetrant, soluble guanylate cyclase (sGC) stimulator that is currently in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS). sGC stimulators are small molecules that act synergistically with nitric oxide (NO) as positive allosteric modulators of sGC to boost production of cyclic guanosine monophosphate (cGMP). cGMP is a key second messenger that, when produced by sGC, regulates diverse and critical biological functions in the CNS including neuronal function, neuroinflammation, cellular bioenergetics, and vascular function.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cyclerion GmbH, a wholly owned subsidiary, was incorporated in Zug, Switzerland on May 3, 2019. Cyclerion GmbH is an operational entity with </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> employee who is the Company’s Chief Scientific Officer. The functional currency is the Swiss franc.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cyclerion Securities Corporation, a wholly owned subsidiary, was incorporated in Massachusetts on November 15, 2019 and was granted securities corporation status in Massachusetts for the 2019 tax year. Cyclerion Securities Corporation has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> employees.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Company Overview</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s mission is to develop treatments that restore cognitive function. Its priorities are advancing its ongoing CY6463 clinical programs and next generation compound, CY3018.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">CNS assets. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CY6463</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases. NO-sGC-cGMP is a fundamental CNS signaling network, but it has not yet been leveraged for its full therapeutic potential. CY6463 enhances the brain’s natural ability to produce cGMP, an important second messenger in the CNS, by stimulating sGC, a key node in the NO-sGC-cGMP pathway. This pathway is critical to basic CNS functions and deficient NO-sGC-cGMP signaling is believed to play an important role in the pathogenesis of neurodegenerative diseases. Agents that stimulate sGC to produce cGMP may compensate for deficient NO signaling.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 13, 2020, we announced positive results from our Phase 1 first-in-human study that provided the foundation for continued development of CY6463. The Phase 1 healthy participant study results indicate that CY6463 was well tolerated. Pharmacokinetic (PK) data, obtained from both blood and cerebral spinal fluid (CSF), support once-daily dosing, with or without food, and demonstrated CY6463 penetration of the blood-brain-barrier with CSF concentrations expected to be pharmacologically active.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 14, 2020, we announced positive topline results from our CY6463 Phase 1 translational pharmacology study in healthy elderly participants. Treatment with CY6463 for 15 days in this 24-subject study confirmed and extended results seen in the earlier first-in-human Phase 1 study: once daily oral treatment demonstrated blood-brain-barrier penetration with expected CNS exposure and target engagement. Results also showed significant improvements in neurophysiological and objective performance measures as well as in inflammatory biomarkers associated with aging and neurodegenerative diseases. CY6463 was shown to be safe and generally well tolerated. Significant effects on cerebral blood flow and markers of bioenergetics were not observed in this study of healthy elderly participants. We believe that these results, together with nonclinical data, support continued development of CY6463 as a potential new medicine for serious CNS diseases.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have initiated exploratory clinical trials with CY6463 ADv, CIAS, and MELAS. The ADv study will be supported in part by a grant from the Alzheimer’s Association’s Part the Cloud-Gates Partnership Grant Program, which provides Cyclerion with $2 million of funding over two years. </span></span><span style="font-size:10.0pt;font-family:Times New Roman;"/></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our next generation CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with greater CSF-to-plasma exposure relative to CY6463. CY3018 is intended to expand the potential of sGC stimulation for the treatment of disorders of the CNS.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-CNS assets.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We have other assets that are outside of our current strategic focus. These non-core assets are not being internally developed at this time.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Praliciguat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is an orally administered, once-daily systemic sGC stimulator. On June 3, 2021, we entered into a License Agreement with Akebia relating to the exclusive worldwide license to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the pharmaceutical compound praliciguat and other related products and forms thereof enumerated in such agreement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Olinciguat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is an orally administered, once-daily, vascular sGC stimulator that was evaluated in a Phase 2 study of participants with sickle cell disease. We released topline results from this study in October 2020. Olinciguat is available for licensing to a third party partner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">The Separation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 1, 2019, Ironwood completed the separation of its sGC business, and certain other assets and liabilities, into a separate, independent publicly traded company by way of a pro-rata distribution of all of the outstanding shares of common stock of Cyclerion Therapeutics, Inc. through a dividend distribution of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> share of the Company’s common stock, with no par value per share, for every 10 shares of Ironwood common stock held by Ironwood stockholders as of the close of business on March 19, 2019, the record date for the Distribution (the entire transaction being the “Separation”). As a result of the Separation, the Company became an independent public company and commenced trading under the symbol “CYCN” on the Nasdaq Global Select Market on April 2, 2019.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020 Equity Private Placement</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 29, 2020, the Company entered into a Common Stock Purchase Agreement (the “2020 Equity Private Placement”) for the private placement of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,062,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company’s common stock, for total gross proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The closing of the 2020 Equity Private Placement occurred on July 29, 2020. The Company did not utilize the services of a placement agent or broker and accordingly incurred no material related transaction fees, or commissions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021 Equity Private Placement</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 3, 2021, the Company entered into a Common Stock Purchase Agreement (the “June 2021 Equity Private Placement”) for the private placement of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,735,988</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company’s common stock, for total gross proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The closing of the June 2021 Equity Private Placement occurred on June 7, 2021. The Company did not utilize the services of a placement agent or broker and accordingly incurred no material related transaction fees or commissions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">At-the-Market Offering</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 24, 2020, the Company filed a Registration Statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) in relation to the registration of common stock, preferred stock, debt securities, warrants and units of any combination thereof for an aggregate initial offering price not to exceed $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Shelf was declared effective as of July 31, 2020. On September 3, 2020, the Company entered into a Sales Agreement (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) with respect to an at-the-market offering (the “ATM Offering”) under the Shelf. Under the ATM Offering, the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million through Jefferies as its sales agent. The Company will pay to Jefferies cash commissions of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> percent of the gross proceeds of sales of common stock under the Sales Agreement. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,353,059</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock for net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the ATM Offering, after deducting commissions paid to Jefferies of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis of Presentation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements and the related disclosures have been prepared in accordance with </span><span style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. generally accepted accounting principles</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In the opinion of management, the consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company’s financial position and the results of its operations for the fiscal years presented.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion GmbH, and Cyclerion Securities Corporation. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Going Concern</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company’s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company’s cash needs and comparing those needs to the current cash and cash equivalent balances. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company’s plans or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has experienced negative operating cash flows for all historical periods presented and the Company expects these losses to continue into the foreseeable future as the Company continues the development and clinical testing of its product candidates CY6463, CY3018 and its discovery research programs. Through December 31, 2021, the Company had raised an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">219.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (in net proceeds) from equity private placements and the ATM Offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After considering the Company’s current research and development plans and the timing expectations related to the progress of its programs, and after considering its existing cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company did not identify conditions or events that would raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these financial statements were issued.</span></p> 1 0 We have initiated exploratory clinical trials with CY6463 ADv, CIAS, and MELAS. The ADv study will be supported in part by a grant from the Alzheimer’s Association’s Part the Cloud-Gates Partnership Grant Program, which provides Cyclerion with $2 million of funding over two years. 0.1 6062500 24300000 5735988 18000000 150000000.0 50000000.0 0.030 3353059 12500000 400000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis of Presentation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements and the related disclosures have been prepared in accordance with </span><span style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. generally accepted accounting principles</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In the opinion of management, the consolidated financial statements reflect all normal recurring adjustments considered necessary for a fair presentation of the Company’s financial position and the results of its operations for the fiscal years presented.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, Cyclerion GmbH, and Cyclerion Securities Corporation. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements.</span></p> 219800 54000000.0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Principles of Consolidation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements include the accounts of Cyclerion Therapeutics, Inc. and its wholly owned subsidiaries, Cyclerion GmbH and Cyclerion Securities Corporation. All intercompany transactions and balances are eliminated in consolidation.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Segment Information</span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company's chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company currently operates in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reportable business segment - human therapeutics.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preparation of consolidated financial statements in accordance with U.S. GAAP requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, impairment of long-lived assets, valuation procedures for right-of-use</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">("ROU") </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">assets and operating lease liabilities, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation, and going concern. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash and Cash Equivalents including Restricted Cash</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents may consist of money market funds and overnight repurchase agreements. The carrying amount of cash equivalents approximates fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, T</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he Company did not have any restricted cash balances. As of December 31, 2020, the Company was contingently liable under an unused letter of credit with a bank, related to the Company's facility lease, in the amount of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company recorded the collateral used to secure the letter of credit as restricted cash. The full amount of restricted cash was recorded as a component of non-current assets at December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Property and Equipment</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, including leasehold improvements, are recorded at cost, and are depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:76.66%;"/> <td style="width:1.673%;"/> <td style="width:21.666%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:Times New Roman;">Asset Description</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated Useful<br/>Life (In Years)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer and office equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Included in property and equipment are certain costs of software obtained for internal use. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs for capital assets not yet placed into service have been capitalized as construction in progress and are depreciated in accordance with the above guidelines once placed into service. Maintenance and repair costs are expensed as incurred.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. The Company has no capital leases.</span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment that is no longer required for the business is considered disposed of when it ceases to be used. Disposals are either sold or retired and the net book value is removed from the consolidated balance sheet and a corresponding gain or loss on the sale or disposal is recognized as a component of operating expenses in the consolidated statements of operations and comprehensive loss.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value of Investment Instruments</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 — Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div></div></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Foreign Currency Translation Adjustment</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The functional currency of the Company’s foreign subsidiary is its local currency, the Swiss franc. The assets and liabilities of the Company’s foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for the Company’s foreign subsidiary is included as a foreign currency translation adjustment in the consolidated statements of stockholders’ equity and as a component of comprehensive loss in the consolidated statements of operations and comprehensive loss.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s intercompany accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the re-measurement of intercompany balances are recorded in the consolidated statements of operations.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Accounts Receivable</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding invoices. The Company’s receivables primarily relate to amounts earned under a development agreement with Ironwood, licensing agreement, and supply agreement. The Company believes that credit risks associated with these agreements are not significant. To date, the Company has not had significant write-offs of bad debt and the Company did not have an allowance for doubtful accounts as of December 31, 2021 or 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Impairment of Long-Lived Assets</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company regularly reviews the carrying amount of its long-lived assets to determine whether indicators of impairment may exist, which warrant adjustments to carrying values or estimated useful lives. If indications of impairment exist, projected future undiscounted cash flows associated with the asset are compared to the carrying amount to determine whether the asset’s value is recoverable. If the carrying value of the asset exceeds such projected undiscounted cash flows, the asset will be written down to its estimated fair value. There were no significant impairments of long-lived assets for the years ended December 31, 2021 or 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Leases</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) Topic 842, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (“ASC 842”) using the optional transition method. The adoption of ASC 842 represents a change in accounting principle that aims to increase transparency and comparability among organizations by requiring the recognition of right-of-use assets and lease liabilities on the balance sheet for both operating and finance leases. In addition, the standard requires enhanced disclosures that meet the objective of enabling financial statement users to assess the amount, timing, and uncertainty of cash flows arising from leases. The reported results for the years ended December 31, 2021 and 2020 reflect the application of ASC 842 guidance.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The recognition of right-of-use assets and lease liabilities related to the Company’s operating leases under ASC 842 has had a material impact on the Company’s consolidated financial statements.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the ASC 842 adoption, the Company has used certain practical expedients outlined in the guidance. These practical expedients include:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Account policy election to use the short-term lease exception by asset class;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Election of the practical expedient package during transition, which includes:</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An entity need not reassess whether any expired or existing contracts are or contain leases.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An entity need not reassess the classification for any expired or existing leases. As a result, all leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases under ASC 842, and all leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases under ASC 842.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An entity need not reassess initial direct costs for any existing leases.</span></div></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company had a property lease for its headquarters location at 301 Binney Street, Cambridge, MA (the “Head Lease”). The Company determined if the arrangement was a lease at the inception of the contract. The asset component of the Company’s operating leases was recorded as operating lease right-of-use assets, and the liability component was recorded as current portion of operating lease liabilities and operating lease liabilities, net of current portion, in the Company’s consolidated balance sheets.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ROU assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease cost was recognized on a straight-line basis over the lease term, and included amounts related to short-term leases. Variable lease costs that do not depend on an index or rate were recognized as incurred.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ROU assets and operating lease liabilities were remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. The difference between the remeasured ROU assets and the operating lease liabilities were recognized as a gain or loss in operating expenses. The Company reviewed any changes to its lease agreements for potential modifications and/or indicators of impairment of the respective ROU asset.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 18, 2019, the Company entered into an agreement to sublease </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet of its Head Lease to a subtenant (the “Sublease Agreement”). Sublease income was recognized on straight-line basis over the term of the sublease agreement and was recorded net of the related rent expense from the Head Lease within interest and other income, net in the consolidated statements of operations and comprehensive loss. In sublease agreements that contain non-monetary consideration, the Company estimated the fair market value of the non-monetary consideration received using market data and recognized it on a straight-line basis over the sublease term. Variable lease consideration that did not depend on an index or rate was allocated to a non-lease component and was recognized over time in accordance with the pattern of transfer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No modification or impairment was deemed to have occurred by entering into the sublease agreement because the Company was not released, either fully or in part, from its obligations under the Head Lease. See Note 8, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February 28, 2020 the Company entered into an amendment to its Head Lease (the “Lease Amendment”). The Lease Amendment provided for the partial termination of the Company's rights and obligations with respect to a portion of the leased premises of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet. The Company continued to lease approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">square feet under terms of the amended lease. The Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification and the Company recorded a gain of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a component of operating expenses for the year ended December 31, 2020. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment of the ROU asset was deemed to have occurred. See Note 8, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 15, 2020, the Company entered into an amendment to its Head Lease (the “Second Lease Amendment”). The Second Lease Amendment provided for the partial termination of the Company's rights and obligations with respect to a portion of the leased premises of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet (the “Surrender Space”). The Surrender Space included the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet being subleased by the Company to a subtenant. The Company continued to lease approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet under terms of the amended lease. The Second Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease and not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification and the Company recorded a loss of approximately </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as a component of operating expenses for the year ended December 31, 2020. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment of the ROU asset was deemed to have occurred. See Note 8, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 15, 2020, concurrent with the execution of the Second Lease Amendment, the Company entered into an agreement with its subtenant to terminate the Sublease Agreement of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet (“the Sublease Termination Agreement”). Under the terms of the Sublease Termination Agreement, the former subtenant is obligated to provide licensed rooms and services to the Company free of charge through the original sublease term. Upon termination of the sublease, the Company recognized sublease termination income of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to the prepaid rooms and services, and wrote off the remaining indirect costs from the sublease of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2020. See Note 8, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 30, 2021, the Company entered into a Termination Agreement (the "Termination Agreement") for its Head Lease as initially amended on February 28, 2020, and further amended on September 15, 2020. Pursuant to the Termination Agreement, the Company surrendered the leased space of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet to the building’s landlord. The Company did not pay any termination fees with the Termination Agreement. As a result of the termination of the Head Lease, the related right-of-use asset was written off, the lease liability was derecognized, and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million security deposit was returned to the Company and recorded as part of our cash balance. In total, the Company recognized a loss on the termination of the Head Lease of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2021. The loss is included in “General and administrative” expenses on our consolidated statement of operations and comprehensive loss.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Paycheck Protection Program Loan</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 21, 2020, the Company received loan proceeds in the amount of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million pursuant to a promissory note agreement with a bank under the Paycheck Protection Program. The Paycheck Protection Program, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The Promissory Note had an original loan maturity of April 20, 2022, a stated interest rate of 1.0% per annum, and had payments of principal and interest that were due monthly after an initial six-month deferral period where interest accrued, but no payments were due. The Promissory Note provided for customary events of default, including, among others, those relating to failure to make payment when due and breaches of representations. The loan was subject to all the terms and conditions applicable under the PPP and was subject to review by the SBA for compliance with program requirements, including the Company’s certification that the economic uncertainty, at the time, made the PPP loan request necessary to support ongoing operations. On October 2, 2020, the SBA issued procedural guidance with respect to PPP loans and changes in ownership and the Company believes that it is compliant with respect to the 2020 Equity Private Placement and the ATM Offering.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, the Payroll Protection Program Flexibility Act was signed into law adjusting certain key terms of loans issued under the PPP. In accordance with the PPPFA, the initial deferral period may be extended from six to up to ten months and the loan maturity may be extended from two to five years. The PPPFA also provided for certain other changes, including the extent to which the loan may be forgiven.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The loan’s principal and accrued interest were forgivable to the extent that the proceeds were used for eligible purposes, subject to certain limitations, and that the Company maintained its payroll levels over a twenty-four-week period following the loan date. The loan forgiveness amount may have been reduced if the Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">terminated employees or reduced salaries during the twenty-four-week period. PPP loans are subject to audit and the SBA has indicated that companies that received over $2 million in proceeds should expect an audit. The Company believes that it has used the proceeds for eligible purposes consistent with the provisions of the PPPFA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the legal form of the Promissory Note is a debt obligation, the Company accounted for it as debt under Accounting Standards Codification (ASC) 470, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and recorded a short-term liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the consolidated balance sheets upon receipt of the loan proceeds. The Company accrued interest over the term of the loan and did not record additional interest at a market rate because the guidance on imputing interest in ASC 835-30, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> excludes transactions where interest rates are prescribed by a government agency. Approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of interest expense has been recognized within interest and other income, net in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2021, the Company applied with the SBA for forgiveness of the PPP loan and was notified on November 4, 2021 that the SBA has approved our application to forgive the entire amount of the loan and accrued interest. The Company recorded a gain on extinguishment of debt of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million representing the principal and accrued interest for the PPP Loan.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Revenue</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon executing a revenue generating arrangement, the Company assesses whether it is probable the Company will collect consideration in exchange for the good or service it transfers to the customer. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (“ASC 606”), it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. The Company must develop assumptions that require significant judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The assumptions that are used to determine the stand-alone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company derives revenue from (1) license agreement and (2) supply agreement which are fully described in Note 14, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company generated revenue from a Development Agreement with Ironwood, pursuant to which the Company provided certain research and development services with respect to certain of Ironwood’s products and product candidates. Such research and development activities were governed by a joint steering committee composed of representatives of both companies. Services performed were invoiced at a mutually agreed upon rate and the initial term of the agreement was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date of Separation and automatically renewed for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> unless either party notified the other at least </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> prior to the expiration. Ironwood and the Company agreed that the Development Agreement would not be renewed beyond its initial term which ended on March 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange transactions and are not within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Contribution revenue earned from activities performed pursuant to research and development grants is reported as grant revenue in the Company’s consolidated statements of operations. Revenue from these grants is recognized as the Company incurs qualifying expenses as stipulated by the terms of the respective grant. Cash received from grants in advance of incurring qualifying expenses is recorded as deferred revenue. The Company records revenue and a corresponding receivable when qualifying costs are incurred before receiving payment from the grants.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Research and Development Costs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company expenses research and development costs to operations as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses are comprised of costs incurred in performing research and development activities, which may include salary, benefits and other employee-related expenses; share-based compensation expense; laboratory supplies and other direct expenses; facilities expenses; overhead expenses; third-party contractual costs relating to nonclinical studies and clinical trial activities and related contract manufacturing expenses, development of manufacturing processes and regulatory registration of third-party manufacturing facilities; and other outside expenses.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General and Administrative Expenses</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company expenses general and administrative costs to operations as incurred. General and administrative expense consists of compensation, share-based compensation, benefits and other employee-related expenses for personnel in the Company’s administrative, finance, legal, information technology, business development and human resource functions. Other costs include the legal costs of pursuing patent protection of the Company’s intellectual property, general and administrative related facility costs, insurance costs and professional fees for accounting and legal services.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Income taxes</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is primarily subject to U.S. federal and Massachusetts state income taxes. For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax positions taken or expected to be taken in the course of preparing the Company tax returns are required to be evaluated to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authority. Tax positions not deemed to meet a more-likely-than-not threshold would be recorded as a tax expense in the current year. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. It does not consider the likelihood of whether or not the IRS will review the position. Cyclerion evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect Cyclerion's income tax provision in future periods. There were no uncertain tax positions that require accrual or disclosure in the consolidated financial statements as of December 31, 2021, and 2020. The Company’s policy is to recognize interest and penalties related to income tax, if any, in income tax expense. As of December 31, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accruals for interest or penalties related to income tax matters.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Patent Costs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patent fees and patent related costs in connection with filing and prosecuting patent applications are expensed as incurred and are classified as general and administrative expenses in the accompanying consolidated financial statements. The Company incurred and recorded as operating expense legal and other fees related to patents of approximately $1.4 million and $1.7 million for the years ended December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Interest and Other Income, Net</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2021, interest and other income, net consisted of a de minimis amount of interest income related to interest generated from our cash and cash equivalents balances and a de minimis amount</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of interest expense related to the PPP loan. For the year ended December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, interest and other income, net consisted of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of interest income related to interest generated from our cash and cash equivalents balances and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of net sublease income.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Subsequent Events</span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers events or transactions that have occurred after the balance sheet date of December 31, 2021, but prior to the filing of the financial statements with the Securities and Exchange Commission, to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of the financial statements accompanying this Annual Report on Form 10-K. See Note 14, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Subsequent Events</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">New Accounting Pronouncements</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the consolidated financial statements, the Company did not adopt any new accounting pronouncements during the years ended December 31, 2021 and 2020, that had a material effect on its consolidated financial statements.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016 the FASB issued ASU 2016-13, Financial Instruments-Credit Losses. This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. As a smaller reporting company, ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2022, and early adoption is permitted. The Company is currently evaluating the impact that ASU 2016-13 will have on its financial statements and related disclosures.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021 the FASB issued Accounting Standards Update No. 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the Emerging Issues Task Force (EITF) , which amends the FASB Accounting Standards Codification (ASC or the “Codification”) to provide explicit guidance, and, thus, reduce diversity in practice, on accounting by issuers for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after the modification or exchange. This amendment provides that for an entity that presents earnings per share (EPS) in accordance with Topic 260, the effects of a modification or an exchange of a freestanding equity-classified written call option that is recognized as a dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. The amended guidance becomes mandatorily effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, and should be applied prospectively to modifications or exchanges occurring on or after the effective date. The Company is currently evaluating the impact that ASU 2021-04 will have on its financial statements and related disclosures.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company’s consolidated financial statements upon adoption.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Principles of Consolidation</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements include the accounts of Cyclerion Therapeutics, Inc. and its wholly owned subsidiaries, Cyclerion GmbH and Cyclerion Securities Corporation. All intercompany transactions and balances are eliminated in consolidation.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Segment Information</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company's chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company currently operates in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reportable business segment - human therapeutics.</span> 1 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preparation of consolidated financial statements in accordance with U.S. GAAP requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, impairment of long-lived assets, valuation procedures for right-of-use</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">("ROU") </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">assets and operating lease liabilities, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation, and going concern. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash and Cash Equivalents including Restricted Cash</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents may consist of money market funds and overnight repurchase agreements. The carrying amount of cash equivalents approximates fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he Company did not have any restricted cash balances. As of December 31, 2020, the Company was contingently liable under an unused letter of credit with a bank, related to the Company's facility lease, in the amount of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company recorded the collateral used to secure the letter of credit as restricted cash. The full amount of restricted cash was recorded as a component of non-current assets at December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span> 3800000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Property and Equipment</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, including leasehold improvements, are recorded at cost, and are depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:76.66%;"/> <td style="width:1.673%;"/> <td style="width:21.666%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:Times New Roman;">Asset Description</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated Useful<br/>Life (In Years)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer and office equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Included in property and equipment are certain costs of software obtained for internal use. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs for capital assets not yet placed into service have been capitalized as construction in progress and are depreciated in accordance with the above guidelines once placed into service. Maintenance and repair costs are expensed as incurred.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term. The Company has no capital leases.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment that is no longer required for the business is considered disposed of when it ceases to be used. Disposals are either sold or retired and the net book value is removed from the consolidated balance sheet and a corresponding gain or loss on the sale or disposal is recognized as a component of operating expenses in the consolidated statements of operations and comprehensive loss.</span> <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, including leasehold improvements, are recorded at cost, and are depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:76.66%;"/> <td style="width:1.673%;"/> <td style="width:21.666%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:Times New Roman;">Asset Description</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated Useful<br/>Life (In Years)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer and office equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"> </span></p> P5Y P3Y P7Y P3Y <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value of Investment Instruments</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 — Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Foreign Currency Translation Adjustment</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The functional currency of the Company’s foreign subsidiary is its local currency, the Swiss franc. The assets and liabilities of the Company’s foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for the Company’s foreign subsidiary is included as a foreign currency translation adjustment in the consolidated statements of stockholders’ equity and as a component of comprehensive loss in the consolidated statements of operations and comprehensive loss.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s intercompany accounts are typically denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the re-measurement of intercompany balances are recorded in the consolidated statements of operations.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Accounts Receivable</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding invoices. The Company’s receivables primarily relate to amounts earned under a development agreement with Ironwood, licensing agreement, and supply agreement. The Company believes that credit risks associated with these agreements are not significant. To date, the Company has not had significant write-offs of bad debt and the Company did not have an allowance for doubtful accounts as of December 31, 2021 or 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Impairment of Long-Lived Assets</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company regularly reviews the carrying amount of its long-lived assets to determine whether indicators of impairment may exist, which warrant adjustments to carrying values or estimated useful lives. If indications of impairment exist, projected future undiscounted cash flows associated with the asset are compared to the carrying amount to determine whether the asset’s value is recoverable. If the carrying value of the asset exceeds such projected undiscounted cash flows, the asset will be written down to its estimated fair value. There were no significant impairments of long-lived assets for the years ended December 31, 2021 or 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Leases</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) Topic 842, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (“ASC 842”) using the optional transition method. The adoption of ASC 842 represents a change in accounting principle that aims to increase transparency and comparability among organizations by requiring the recognition of right-of-use assets and lease liabilities on the balance sheet for both operating and finance leases. In addition, the standard requires enhanced disclosures that meet the objective of enabling financial statement users to assess the amount, timing, and uncertainty of cash flows arising from leases. The reported results for the years ended December 31, 2021 and 2020 reflect the application of ASC 842 guidance.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The recognition of right-of-use assets and lease liabilities related to the Company’s operating leases under ASC 842 has had a material impact on the Company’s consolidated financial statements.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the ASC 842 adoption, the Company has used certain practical expedients outlined in the guidance. These practical expedients include:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Account policy election to use the short-term lease exception by asset class;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Election of the practical expedient package during transition, which includes:</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An entity need not reassess whether any expired or existing contracts are or contain leases.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An entity need not reassess the classification for any expired or existing leases. As a result, all leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases under ASC 842, and all leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases under ASC 842.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An entity need not reassess initial direct costs for any existing leases.</span></div></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company had a property lease for its headquarters location at 301 Binney Street, Cambridge, MA (the “Head Lease”). The Company determined if the arrangement was a lease at the inception of the contract. The asset component of the Company’s operating leases was recorded as operating lease right-of-use assets, and the liability component was recorded as current portion of operating lease liabilities and operating lease liabilities, net of current portion, in the Company’s consolidated balance sheets.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ROU assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease cost was recognized on a straight-line basis over the lease term, and included amounts related to short-term leases. Variable lease costs that do not depend on an index or rate were recognized as incurred.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ROU assets and operating lease liabilities were remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. The difference between the remeasured ROU assets and the operating lease liabilities were recognized as a gain or loss in operating expenses. The Company reviewed any changes to its lease agreements for potential modifications and/or indicators of impairment of the respective ROU asset.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 18, 2019, the Company entered into an agreement to sublease </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet of its Head Lease to a subtenant (the “Sublease Agreement”). Sublease income was recognized on straight-line basis over the term of the sublease agreement and was recorded net of the related rent expense from the Head Lease within interest and other income, net in the consolidated statements of operations and comprehensive loss. In sublease agreements that contain non-monetary consideration, the Company estimated the fair market value of the non-monetary consideration received using market data and recognized it on a straight-line basis over the sublease term. Variable lease consideration that did not depend on an index or rate was allocated to a non-lease component and was recognized over time in accordance with the pattern of transfer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No modification or impairment was deemed to have occurred by entering into the sublease agreement because the Company was not released, either fully or in part, from its obligations under the Head Lease. See Note 8, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February 28, 2020 the Company entered into an amendment to its Head Lease (the “Lease Amendment”). The Lease Amendment provided for the partial termination of the Company's rights and obligations with respect to a portion of the leased premises of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet. The Company continued to lease approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">square feet under terms of the amended lease. The Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification and the Company recorded a gain of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a component of operating expenses for the year ended December 31, 2020. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment of the ROU asset was deemed to have occurred. See Note 8, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 15, 2020, the Company entered into an amendment to its Head Lease (the “Second Lease Amendment”). The Second Lease Amendment provided for the partial termination of the Company's rights and obligations with respect to a portion of the leased premises of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet (the “Surrender Space”). The Surrender Space included the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet being subleased by the Company to a subtenant. The Company continued to lease approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet under terms of the amended lease. The Second Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease and not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification and the Company recorded a loss of approximately </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as a component of operating expenses for the year ended December 31, 2020. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairment of the ROU asset was deemed to have occurred. See Note 8, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 15, 2020, concurrent with the execution of the Second Lease Amendment, the Company entered into an agreement with its subtenant to terminate the Sublease Agreement of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet (“the Sublease Termination Agreement”). Under the terms of the Sublease Termination Agreement, the former subtenant is obligated to provide licensed rooms and services to the Company free of charge through the original sublease term. Upon termination of the sublease, the Company recognized sublease termination income of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to the prepaid rooms and services, and wrote off the remaining indirect costs from the sublease of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2020. See Note 8, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 30, 2021, the Company entered into a Termination Agreement (the "Termination Agreement") for its Head Lease as initially amended on February 28, 2020, and further amended on September 15, 2020. Pursuant to the Termination Agreement, the Company surrendered the leased space of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet to the building’s landlord. The Company did not pay any termination fees with the Termination Agreement. As a result of the termination of the Head Lease, the related right-of-use asset was written off, the lease liability was derecognized, and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million security deposit was returned to the Company and recorded as part of our cash balance. In total, the Company recognized a loss on the termination of the Head Lease of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2021. The loss is included in “General and administrative” expenses on our consolidated statement of operations and comprehensive loss.</span></p> 15700 40000 74000 2100000 0 17000 15700 15700 57000 -400000 0 15700 3100000 200000 57000 3800000 900000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Paycheck Protection Program Loan</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 21, 2020, the Company received loan proceeds in the amount of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million pursuant to a promissory note agreement with a bank under the Paycheck Protection Program. The Paycheck Protection Program, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The Promissory Note had an original loan maturity of April 20, 2022, a stated interest rate of 1.0% per annum, and had payments of principal and interest that were due monthly after an initial six-month deferral period where interest accrued, but no payments were due. The Promissory Note provided for customary events of default, including, among others, those relating to failure to make payment when due and breaches of representations. The loan was subject to all the terms and conditions applicable under the PPP and was subject to review by the SBA for compliance with program requirements, including the Company’s certification that the economic uncertainty, at the time, made the PPP loan request necessary to support ongoing operations. On October 2, 2020, the SBA issued procedural guidance with respect to PPP loans and changes in ownership and the Company believes that it is compliant with respect to the 2020 Equity Private Placement and the ATM Offering.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, the Payroll Protection Program Flexibility Act was signed into law adjusting certain key terms of loans issued under the PPP. In accordance with the PPPFA, the initial deferral period may be extended from six to up to ten months and the loan maturity may be extended from two to five years. The PPPFA also provided for certain other changes, including the extent to which the loan may be forgiven.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The loan’s principal and accrued interest were forgivable to the extent that the proceeds were used for eligible purposes, subject to certain limitations, and that the Company maintained its payroll levels over a twenty-four-week period following the loan date. The loan forgiveness amount may have been reduced if the Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">terminated employees or reduced salaries during the twenty-four-week period. PPP loans are subject to audit and the SBA has indicated that companies that received over $2 million in proceeds should expect an audit. The Company believes that it has used the proceeds for eligible purposes consistent with the provisions of the PPPFA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the legal form of the Promissory Note is a debt obligation, the Company accounted for it as debt under Accounting Standards Codification (ASC) 470, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and recorded a short-term liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the consolidated balance sheets upon receipt of the loan proceeds. The Company accrued interest over the term of the loan and did not record additional interest at a market rate because the guidance on imputing interest in ASC 835-30, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> excludes transactions where interest rates are prescribed by a government agency. Approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of interest expense has been recognized within interest and other income, net in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2021, the Company applied with the SBA for forgiveness of the PPP loan and was notified on November 4, 2021 that the SBA has approved our application to forgive the entire amount of the loan and accrued interest. The Company recorded a gain on extinguishment of debt of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million representing the principal and accrued interest for the PPP Loan.</span></p> 3500000 3500000 100000 3600000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Revenue</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon executing a revenue generating arrangement, the Company assesses whether it is probable the Company will collect consideration in exchange for the good or service it transfers to the customer. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (“ASC 606”), it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. The Company must develop assumptions that require significant judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The assumptions that are used to determine the stand-alone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. The Company derives revenue from (1) license agreement and (2) supply agreement which are fully described in Note 14, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company generated revenue from a Development Agreement with Ironwood, pursuant to which the Company provided certain research and development services with respect to certain of Ironwood’s products and product candidates. Such research and development activities were governed by a joint steering committee composed of representatives of both companies. Services performed were invoiced at a mutually agreed upon rate and the initial term of the agreement was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date of Separation and automatically renewed for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> unless either party notified the other at least </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> prior to the expiration. Ironwood and the Company agreed that the Development Agreement would not be renewed beyond its initial term which ended on March 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company generates revenue from research and development grants under contracts with third parties that do not create customer-vendor relationships. The Company’s research and development grants are non-exchange transactions and are not within the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Contribution revenue earned from activities performed pursuant to research and development grants is reported as grant revenue in the Company’s consolidated statements of operations. Revenue from these grants is recognized as the Company incurs qualifying expenses as stipulated by the terms of the respective grant. Cash received from grants in advance of incurring qualifying expenses is recorded as deferred revenue. The Company records revenue and a corresponding receivable when qualifying costs are incurred before receiving payment from the grants.</span></p> P2Y P1Y P6M <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Research and Development Costs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company expenses research and development costs to operations as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company has not experienced any material differences between accrued or prepaid costs and actual costs since inception.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses are comprised of costs incurred in performing research and development activities, which may include salary, benefits and other employee-related expenses; share-based compensation expense; laboratory supplies and other direct expenses; facilities expenses; overhead expenses; third-party contractual costs relating to nonclinical studies and clinical trial activities and related contract manufacturing expenses, development of manufacturing processes and regulatory registration of third-party manufacturing facilities; and other outside expenses.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General and Administrative Expenses</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company expenses general and administrative costs to operations as incurred. General and administrative expense consists of compensation, share-based compensation, benefits and other employee-related expenses for personnel in the Company’s administrative, finance, legal, information technology, business development and human resource functions. Other costs include the legal costs of pursuing patent protection of the Company’s intellectual property, general and administrative related facility costs, insurance costs and professional fees for accounting and legal services.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Income taxes</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is primarily subject to U.S. federal and Massachusetts state income taxes. For federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in which differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax positions taken or expected to be taken in the course of preparing the Company tax returns are required to be evaluated to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authority. Tax positions not deemed to meet a more-likely-than-not threshold would be recorded as a tax expense in the current year. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. It does not consider the likelihood of whether or not the IRS will review the position. Cyclerion evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Any changes to these estimates, based on the actual results obtained and/or a change in assumptions, could affect Cyclerion's income tax provision in future periods. There were no uncertain tax positions that require accrual or disclosure in the consolidated financial statements as of December 31, 2021, and 2020. The Company’s policy is to recognize interest and penalties related to income tax, if any, in income tax expense. As of December 31, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accruals for interest or penalties related to income tax matters.</span></p> 0 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Patent Costs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patent fees and patent related costs in connection with filing and prosecuting patent applications are expensed as incurred and are classified as general and administrative expenses in the accompanying consolidated financial statements. The Company incurred and recorded as operating expense legal and other fees related to patents of approximately $1.4 million and $1.7 million for the years ended December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Interest and Other Income, Net</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2021, interest and other income, net consisted of a de minimis amount of interest income related to interest generated from our cash and cash equivalents balances and a de minimis amount</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of interest expense related to the PPP loan. For the year ended December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, interest and other income, net consisted of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of interest income related to interest generated from our cash and cash equivalents balances and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of net sublease income.</span></p> 300000 300000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Subsequent Events</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers events or transactions that have occurred after the balance sheet date of December 31, 2021, but prior to the filing of the financial statements with the Securities and Exchange Commission, to provide additional evidence relative to certain estimates or to identify matters that require additional recognition or disclosure. Subsequent events have been evaluated through the filing of the financial statements accompanying this Annual Report on Form 10-K. See Note 14, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Subsequent Events</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">New Accounting Pronouncements</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Except as discussed elsewhere in the notes to the consolidated financial statements, the Company did not adopt any new accounting pronouncements during the years ended December 31, 2021 and 2020, that had a material effect on its consolidated financial statements.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016 the FASB issued ASU 2016-13, Financial Instruments-Credit Losses. This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. As a smaller reporting company, ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2022, and early adoption is permitted. The Company is currently evaluating the impact that ASU 2016-13 will have on its financial statements and related disclosures.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021 the FASB issued Accounting Standards Update No. 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the Emerging Issues Task Force (EITF) , which amends the FASB Accounting Standards Codification (ASC or the “Codification”) to provide explicit guidance, and, thus, reduce diversity in practice, on accounting by issuers for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after the modification or exchange. This amendment provides that for an entity that presents earnings per share (EPS) in accordance with Topic 260, the effects of a modification or an exchange of a freestanding equity-classified written call option that is recognized as a dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. The amended guidance becomes mandatorily effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, and should be applied prospectively to modifications or exchanges occurring on or after the effective date. The Company is currently evaluating the impact that ASU 2021-04 will have on its financial statements and related disclosures.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No other accounting standards known by the Company to be applicable to it that have been issued by the FASB or other standard-setting bodies and that do not require adoption until a future date are expected to have a material impact on the Company’s consolidated financial statements upon adoption.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Development Agreement with Ironwood</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the Separation from Ironwood, the Company entered into a Development Agreement with Ironwood.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Development Agreement, the Company provided certain research and development services to Ironwood at mutually agreed upon rates and the amounts earned are recorded as revenue from related party for the year ended December 31, 2020. Such research and development activities were governed by a joint steering</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">committee composed of representatives of both Ironwood and the Company. Ironwood and the Company have agreed not to renew the Development Agreement beyond the end of its initial term on March 31, 2021. These transactions under the Development Agreement were considered related party transactions due to Mark Currie’s role as President of the Company through December 31, 2020, and board member of Ironwood. In January 2021, Mark Currie’s role transitioned from President of the Company to a senior advisor on a consulting basis. Therefore, effective January 2021, transactions under the Development Agreement are no longer accounted for as related party transactions. The Company recorded approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Related Party Transactions</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, the Company recorded approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of research and development costs to a related party which it engaged to provide research and development transaction support services. The entity became a related party when Mark Currie, the Company’s President through December 31, 2020, joined its board in January 2020. There was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million due to the related party for the year ended December 31, 2020. In January 2021, Mark Currie’s role transitioned from President of the Company to a senior advisor on a consulting basis. Therefore, effective January 2021, transactions under this agreement are no longer accounted for as related party transactions.</span></p> 2300000 1500000 300000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Fair Value of Financial Instruments</span></p><div style="font-size:11.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s cash equivalents are generally classified within Level 1 of the fair value hierarchy. The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and December 31, 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.495%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.332%;"/> <td style="width:0.686%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.236%;"/> <td style="width:0.686%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.236%;"/> <td style="width:0.686%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.332%;"/> <td style="width:0.686%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurements as of December 31, 2021:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,917</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,917</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,917</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,917</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.495%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.332%;"/> <td style="width:0.686%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.236%;"/> <td style="width:0.686%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.236%;"/> <td style="width:0.686%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.332%;"/> <td style="width:0.686%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurements as of December 31, 2020:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,240</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,240</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,240</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,240</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021 and 2020, there were no transfers between levels. The fair value of the Company's cash equivalents, consisting of money market funds, is based on quoted market prices in active markets with no valuation adjustment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company believes the carrying amounts of its prepaid expenses and other current assets, restricted cash, accounts payable, and accrued expenses approximate their fair value due to the short-term nature of these amounts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s cash equivalents are generally classified within Level 1 of the fair value hierarchy. The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and December 31, 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.495%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.332%;"/> <td style="width:0.686%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.236%;"/> <td style="width:0.686%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.236%;"/> <td style="width:0.686%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.332%;"/> <td style="width:0.686%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurements as of December 31, 2021:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,917</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,917</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,917</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,917</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.495%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.332%;"/> <td style="width:0.686%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.236%;"/> <td style="width:0.686%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.236%;"/> <td style="width:0.686%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:11.332%;"/> <td style="width:0.686%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurements as of December 31, 2020:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,240</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,240</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,240</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,240</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 52917000 52917000 52917000 52917000 53240000 53240000 53240000 53240000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Property and Equipment</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.002%;"/> <td style="width:1.478%;"/> <td style="width:1.37%;"/> <td style="width:17.73%;"/> <td style="width:0.921%;"/> <td style="width:1.478%;"/> <td style="width:1.37%;"/> <td style="width:17.73%;"/> <td style="width:0.921%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,214</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,214</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer and office equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,894</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, gross</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,265</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,152</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation and amortization</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,200</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,287</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,865</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, and 2020, the Company’s property and equipment was primarily located in Cambridge, Massachusetts.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense of the Company’s property and equipment was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, the Company recorded a non-cash loss of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, on the disposal of leasehold improvements as a result of its Head Lease (as defined below) termination (see Note 8 to the Consolidated Financial Statements). The non-cash loss on the disposal of leasehold improvements was recognized as a component of operating expenses in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.002%;"/> <td style="width:1.478%;"/> <td style="width:1.37%;"/> <td style="width:17.73%;"/> <td style="width:0.921%;"/> <td style="width:1.478%;"/> <td style="width:1.37%;"/> <td style="width:17.73%;"/> <td style="width:0.921%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,214</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,214</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer and office equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,894</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, gross</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,265</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,152</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation and amortization</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,200</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,287</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,865</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 2214000 2214000 51000 44000 0 14894000 2265000 17152000 2200000 10287000 65000 6865000 500000 2300000 6300000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:59.276%;"/> <td style="width:1.542%;"/> <td style="width:1.381%;"/> <td style="width:16.743%;"/> <td style="width:0.696%;"/> <td style="width:1.542%;"/> <td style="width:1.381%;"/> <td style="width:16.743%;"/> <td style="width:0.696%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued incentive compensation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,369</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,720</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Salaries</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">514</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued vacation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">345</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">555</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">398</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">689</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued severance and benefit costs</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,640</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">498</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">176</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,904</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,294</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:59.276%;"/> <td style="width:1.542%;"/> <td style="width:1.381%;"/> <td style="width:16.743%;"/> <td style="width:0.696%;"/> <td style="width:1.542%;"/> <td style="width:1.381%;"/> <td style="width:16.743%;"/> <td style="width:0.696%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued incentive compensation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,369</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,720</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Salaries</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">266</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">514</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued vacation</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">345</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">555</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">398</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">689</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued severance and benefit costs</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,640</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">498</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">176</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,904</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,294</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 1369000 1720000 266000 514000 345000 555000 398000 689000 28000 3640000 498000 176000 2904000 7294000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Funding Commitments</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the normal course of business, the Company enters into contracts with clinical research organizations and other third parties for clinical and preclinical research studies and other services and products for operating purposes. These contracts are generally cancellable, with notice, at the Company’s option and do not have any significant cancellation penalties.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Guarantees</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 6, 2018, Cyclerion was incorporated in Massachusetts and its officers and directors are indemnified for certain events or occurrences while they are serving in such capacity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">partners, contractors, clinical sites and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company’s activities. These indemnification provisions generally survive termination of the underlying agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal. Accordingly, the Company did not have any liabilities recorded for these obligations as of December 31, 2021 or December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Leases</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FASB issued ASU 2016-02, or the leasing standard or ASC 842, in February 2016. ASU 2016-02 requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by all leases with terms of more than 12 months. ASU 2016-02 also requires certain qualitative and quantitative disclosures designed to give financial statement users information on the amount, timing, and uncertainty of cash flows arising from leases.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 1, 2019, the Company entered into the Head Lease ("the Head Lease"), a direct operating lease for its former headquarters located at 301 Binney Street, Cambridge, MA consisting of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet of office and laboratory space on the first and second floors. The Head Lease had a term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">123</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> months with </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> extension options and certain expansion rights. The Head Lease also included a letter of credit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, posted with the landlord as a security deposit, which was collateralized by a money market account recorded as restricted cash on the Company’s consolidated balance sheets. The Company had also entered into customary non-disturbance arrangements with the building landlord’s mortgagee and with the property ground lessor recognizing Company's leasehold interest in this property.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February 28, 2020 the Company entered into an amendment to its Head Lease. The Lease Amendment partially terminated the Company’s rights and obligations with respect to an approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company continued to lease the remaining space of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet including the area covered by the subleased premise, discussed below. In connection with this Lease Amendment, the Company reduced its remaining lease payments through June 2029 by approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and paid a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million termination fee and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to other initial direct costs, which were deferred and recognized over the remaining lease term. The Company’s security deposit was also reduced by approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease and not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, which resulted in a reduction of the ROU asset of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and a reduction in the operating lease liabilities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company recorded the resulting gain of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a component of operating expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 15, 2020 the Company entered into the Second Lease Amendment to its Head Lease. The Second Lease Amendment provided for the partial termination of the Company’s rights and obligations with respect to a portion of the leased premises of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet. The Surrender Space included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet being subleased by the Company to a subtenant. The Company continued to lease approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of space. The Company reduced its remaining lease payments through June 2029 by approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company paid </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> termination or other initial direct costs related to the execution of the Second Lease Amendment. The Company’s security deposit was reduced by approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which is classified as restricted cash on the Company’s consolidated balance sheet as of December 31, 2020.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Second Lease Amendment was determined to be a lease modification that qualified as a change of accounting on the existing lease and not a separate contract. As such, the ROU assets and operating lease liabilities were remeasured using an incremental borrowing rate at the date of modification of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, which resulted in a reduction of the ROU asset of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and a reduction in the operating lease liabilities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recorded the resulting loss of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a component of operating expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 30, 2021, the Company entered into a Termination Agreement (the "Termination Agreement") for its Head Lease as initially amended on February 28, 2020, and further amended on September 15, 2020. Pursuant to the Termination Agreement, the Company surrendered the leased space of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet to the building’s landlord. The Company did not pay any termination fees in connection with the Termination Agreement. As a result of the termination of the Head Lease, the related right-of-use asset was written off, the lease liability was derecognized, and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million security deposit was returned to the Company and recorded as part of our cash balance. In total, the Company recognized a loss on the termination of the Head Lease of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2021. The loss is included in “General and administrative” expenses on our consolidated statement of operations and comprehensive loss.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company had an operating lease ROU asset of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to the amended Head Lease recorded in its consolidated balance sheets as of December 31, 2020. The Company had current and non-current operating lease liabilities of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, related to the amended Head Lease recorded in its consolidated balance sheets as of December 31, 2020.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease cost was recognized on a straight-line basis over the lease term. For the years ended December 31, 2021 and 2020, the Company recognized a total of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of total lease costs. Variable lease costs not subject to an index or rate were recognized as incurred. For the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, the Company recognized a total of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of variable lease costs related to the Head Lease, as amended.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, the Company signed a membership agreement to lease space with WeWork at 501 Boylston Street, Boston, Massachusetts. The lease commenced on August 1, 2021 and was accounted for as a short term lease. The Company recorded $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in lease expense associated with the membership agreement during the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental cash flow information related to leases for the periods reported is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.867%;"/> <td style="width:1.392%;"/> <td style="width:1.371%;"/> <td style="width:12.904%;"/> <td style="width:0.696%;"/> <td style="width:1.392%;"/> <td style="width:1.371%;"/> <td style="width:11.694%;"/> <td style="width:2.313%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Decrease in right-of-use assets related to lease modifications and termination (in thousands)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,058</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,333</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Decrease in operating lease liabilities due to lease modifications and termination (in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,177</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,002</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of lease liabilities (in thousands)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,887</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,411</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remaining lease term of operating leases (in years)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.5</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average discount rate of operating leases</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 18, 2019, the Company entered into an agreement with a third party to sublease </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet of its lease premises under the Head Lease. The sublease was scheduled to expire on June 30, 2029, unless earlier terminated in accordance with the sublease agreement, and has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> extension options. The sublease provides for annual base rent of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the first year, which increases on a yearly basis by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (subject to an abatement of base rent of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the first </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the sublease). As part of the consideration for the sublease, the sublessee agreed to provide licensed rooms and services within the sublease premises to the Company over the sublease term free of charge. In addition, the sublessee is responsible for its pro rata share of certain costs, taxes and operating expenses related to the subleased space, the consideration for which is variable and is based on the actual operating costs of the lessor. The Company allocated the total consideration in the sublease agreement between the lease and non-lease components in the contract based on their relative standalone prices. The Company determined that the variable consideration relates exclusively to non-lease components and will be recognized as incurred. The sublease included an initial security deposit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which was provided by the sublessee in the form of a letter of credit, and an additional security deposit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million within </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">nine months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the sublease commencement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 15, 2020, concurrent with execution of the Second Lease Amendment, the Company entered into the Sublease Termination Agreement to terminate its sublease of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet. Under the terms of the Sublease Termination Agreement, the subtenant is relieved of its obligation to provide future cash rental payments to the Company. The agreements requiring the former subtenant to provide licensed rooms and services to the Company free of charge through the original sublease term survived the sublease termination. The Company gained access to the licensed rooms and services beginning in the third quarter of 2021. The letter of credit security deposit related to the sublease was released.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determined that the Sublease Termination Agreement constituted a non-monetary exchange under ASC 845 Nonmonetary Transactions (“ASC 845”) where, in return for the free rooms and the services, the Company agreed to terminate its rights and obligations under the sublease agreement. In accordance with ASC 845, the Company determined that the accounting for the transaction should be based on the fair value of assets or services involved. The Company estimated the fair value of the rooms and services to be approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. Accordingly, prepaid rooms and services of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were recorded upon the sublease termination, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded in other current assets and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded in other assets in the consolidated balance sheets as of December 31, 2020. Termination fee income of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recognized related to the rooms and services, after considering the rent receivable balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million outstanding from the subtenant. The remaining unamortized direct costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were written off. The effects of the Sublease Termination Agreement were recorded within sublease termination income, net in the consolidated statements of operations and comprehensive loss. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total gross sublease income of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and net sublease income of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded in interest and other income, net in the consolidated statements of operations and comprehensive loss for year ended December 31, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determined that the licensed rooms represent a lease under ASC 842. The Company obtained control of the rooms in the third quarter of 2021 and the prepaid rooms balance of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was reclassified from other assets to a ROU asset. The related lease expense is recognized on a straight-line basis over the lease term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.88</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years. The Company recorded $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of lease expense during the year ended December 31, 2021. The Company determined that the licensed services represent a non-lease component, which is recognized separately from the lease component for this asset class. The expense related to the licensed services is recognized on a straight-line basis over the period the services are received. The Company recorded $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2021. Both the lease expense and services expense are recognized as a component of research and development costs in the consolidated statements of operations and comprehensive loss.</span></p> 114000 P123M 2 P5Y 7700000 40000 74000 41900000 6300000 200000 2700000 5000000.0 0.097 21400000 23500000 2100000 17000 15700 57000 16900000 0 0 1200000 3800000 0.061 5900000 5500000 -400000 57000 3800000 900000 43400000 3300000 38900000 2400000 8600000 700000 2200000 100000 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental cash flow information related to leases for the periods reported is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.867%;"/> <td style="width:1.392%;"/> <td style="width:1.371%;"/> <td style="width:12.904%;"/> <td style="width:0.696%;"/> <td style="width:1.392%;"/> <td style="width:1.371%;"/> <td style="width:11.694%;"/> <td style="width:2.313%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Decrease in right-of-use assets related to lease modifications and termination (in thousands)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,058</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,333</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Decrease in operating lease liabilities due to lease modifications and termination (in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,177</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,002</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of lease liabilities (in thousands)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,887</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,411</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remaining lease term of operating leases (in years)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.5</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average discount rate of operating leases</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table> 42058000 27333000 41177000 29002000 1887000 7411000 P8Y6M 0.061 15700 0 1500000 0.030 700000 P6M 500000 400000 P9M 15700 1500000 2900000 4400000 1600000 2800000 3100000 1300000 200000 1500000 300000 1400000 P8Y10M17D 100000 200000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Share-based Compensation Plans</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2019, Cyclerion adopted share-based compensation plans. Specifically, Cyclerion adopted the 2019 Employee Stock Purchase Plan (“2019 ESPP”) and the 2019 Equity Incentive Plan (“2019 Equity Plan”). Under the 2019 ESPP, eligible employees may use payroll deductions to purchase shares of stock in offerings under the plan, and thereby acquire an interest in the future of the Company. The 2019 Equity Plan provides for stock options and restricted stock units (“RSUs”).</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cyclerion also mirrored two of Ironwood’s existing plans, the Amended and Restated 2005 Stock Incentive Plan (“2005 Equity Plan”) and the Amended and Restated 2010 Employee, Director and Consultant Equity Incentive Plan (“2010 Equity Plan). These mirror plans were adopted to facilitate the exchange of Ironwood equity awards for Cyclerion equity awards upon the Separation as part of the equity conversion. As a result of the Separation and in accordance with the EMA, employees of both companies retained their existing Ironwood vested options and received a pro-rata share of Cyclerion options, regardless of which company employed them post-Separation. For employees that were ultimately employed by Cyclerion, unvested Ironwood options and RSUs were converted to unvested Cyclerion options and RSUs.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides share-based compensation reflected in the Company’s consolidated statements of operations and comprehensive loss for the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.512%;"/> <td style="width:1.44%;"/> <td style="width:1.63%;"/> <td style="width:13.317%;"/> <td style="width:0.762%;"/> <td style="width:1.44%;"/> <td style="width:1.63%;"/> <td style="width:13.507%;"/> <td style="width:0.762%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,945</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,799</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,666</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,193</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,611</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,992</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock Options</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options granted under the Company’s equity plans generally have a ten-year term and vest over a period of four years, provided the individual continues to serve at the Company through the vesting dates. Options granted under all equity plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the requisite service period, which is typically the vesting period of each option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of stock option activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.943%;"/> <td style="width:1.114%;"/> <td style="width:0.685%;"/> <td style="width:11.566%;"/> <td style="width:0.91%;"/> <td style="width:1.114%;"/> <td style="width:1.371%;"/> <td style="width:11.105%;"/> <td style="width:0.685%;"/> <td style="width:1.114%;"/> <td style="width:0.696%;"/> <td style="width:11.705%;"/> <td style="width:0.685%;"/> <td style="width:1.114%;"/> <td style="width:1.371%;"/> <td style="width:11.137%;"/> <td style="width:0.685%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Remaining</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Intrinsic</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contractual</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value (in</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">of Options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Price</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Term (Years)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,426,356</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.87</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.0</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,178</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,176,250</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.98</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72,419</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.17</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled or forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,449,761</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.69</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,080,426</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.73</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.9</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable at December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,518,213</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.46</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, 2021 and 2020, the Company granted stock options to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,176,250</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,382,846</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, respectively, at weighted average grant fair values per option share of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.17</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.97</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. The total grant fair value of options granted during the years ended December 31, 2021 and 2020 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total intrinsic value of options exercised for the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested time-based stock options held by the Company’s employees is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and the weighted average period over which that expense is expected to be recognized is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.29</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average Black-Scholes assumptions used in estimating the fair value of the stock options granted by Cyclerion following the Separation during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.794%;"/> <td style="width:1.938%;"/> <td style="width:0.696%;"/> <td style="width:17.156%;"/> <td style="width:2.313%;"/> <td style="width:1.938%;"/> <td style="width:0.696%;"/> <td style="width:17.156%;"/> <td style="width:2.313%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.09</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.43</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected option term (in years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85.45</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91.73</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021 and 2020, expected volatility was estimated using an average of the historical volatility of the common stock of a group of similar companies that were publicly traded. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has granted to certain employees performance based options to purchase shares of common stock. These options are subject to performance based milestone vesting. During the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares vested as a result of performance milestone achievements and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares vested during the year ended December 31, 2020. The Company recorded a de minimis and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> share-based compensation expense related to these performance-based options for the years ended December 31, 2021, and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Market-based Stock Options</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also has granted to certain employees stock options containing market conditions that vest upon the achievement of specified price targets of the Company’s share price for a period through December 31, 2024. Vesting is measured based upon the average closing price of the Company’s share price for any </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">thirty</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> consecutive trading days, subject to certain service requirements. Stock compensation cost is expensed on a straight-line basis over the derived service period for each stock price target within the award, ranging from approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.0</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years. The Company accelerates expense when a stock price target is achieved prior to the derived service period. The Company does not reverse expense recognized if the share price target(s) are ultimately not achieved but expense is reversed when a stock award recipient has a break in service prior to the completion of the derived service period. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, there was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of unrecognized compensation costs related to stock options containing market conditions, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.17</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of stock awards containing market conditions activity for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:45.326%;"/> <td style="width:1.285%;"/> <td style="width:0.685%;"/> <td style="width:10.708%;"/> <td style="width:0.91%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:10.322%;"/> <td style="width:0.685%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:10.387%;"/> <td style="width:0.685%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:10.354%;"/> <td style="width:0.685%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Remaining</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Intrinsic</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contractual</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value (in</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Price</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Term (years)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">600,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.01</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.9</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">630</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled or forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150,000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">450,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.01</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.9</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable at December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of stock options containing market conditions is estimated using Monte Carlo simulations. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> stock options containing market conditions were granted during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Restricted Stock Units</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The RSUs generally vest </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per year on the approximate anniversary of the date of grant until fully vested, provided the employee remains continuously employed with the Company through each vesting date. Shares of the Company’s common stock are delivered to the employee upon vesting, subject to payment of applicable withholding taxes. The fair value of all RSUs is based on the market value of the Company’s common stock on the date of grant. Compensation expense, including the effect of estimated forfeitures, is recognized over the applicable service period.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of RSU activity for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 is as follows:</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.289%;"/> <td style="width:1.445%;"/> <td style="width:0.696%;"/> <td style="width:13.266%;"/> <td style="width:0.921%;"/> <td style="width:1.445%;"/> <td style="width:1.381%;"/> <td style="width:14.861%;"/> <td style="width:0.696%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Grant Date</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">of Shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">294,913</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.52</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,369</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.17</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">143,774</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.01</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97,704</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.41</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92,804</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.70</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the unrecognized share-based compensation expense, net of estimated forfeitures, related to all unvested restricted stock units by the Company’s employees is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and the weighted-average period over which that expense is expected to be recognized is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.13</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span></p> <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides share-based compensation reflected in the Company’s consolidated statements of operations and comprehensive loss for the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.512%;"/> <td style="width:1.44%;"/> <td style="width:1.63%;"/> <td style="width:13.317%;"/> <td style="width:0.762%;"/> <td style="width:1.44%;"/> <td style="width:1.63%;"/> <td style="width:13.507%;"/> <td style="width:0.762%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,945</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,799</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,666</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,193</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,611</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,992</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 3945000 6799000 5666000 8193000 9611000 14992000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of stock option activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.943%;"/> <td style="width:1.114%;"/> <td style="width:0.685%;"/> <td style="width:11.566%;"/> <td style="width:0.91%;"/> <td style="width:1.114%;"/> <td style="width:1.371%;"/> <td style="width:11.105%;"/> <td style="width:0.685%;"/> <td style="width:1.114%;"/> <td style="width:0.696%;"/> <td style="width:11.705%;"/> <td style="width:0.685%;"/> <td style="width:1.114%;"/> <td style="width:1.371%;"/> <td style="width:11.137%;"/> <td style="width:0.685%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Remaining</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Intrinsic</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contractual</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value (in</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">of Options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Price</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Term (Years)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,426,356</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.87</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.0</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,178</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,176,250</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.98</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72,419</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.17</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled or forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,449,761</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.69</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,080,426</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.73</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.9</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable at December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,518,213</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.46</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 7426356 11.87 P7Y 1178000 1176250 2.98 72419 2.17 1449761 10.69 7080426 10.73 P6Y10M24D 0 4518213 13.46 P5Y10M24D 0 1176250 1382846 2.17 1.97 2600000 2700 100 100 8100000 P3Y3M14D <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average Black-Scholes assumptions used in estimating the fair value of the stock options granted by Cyclerion following the Separation during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.794%;"/> <td style="width:1.938%;"/> <td style="width:0.696%;"/> <td style="width:17.156%;"/> <td style="width:2.313%;"/> <td style="width:1.938%;"/> <td style="width:0.696%;"/> <td style="width:17.156%;"/> <td style="width:2.313%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.09</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.43</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected option term (in years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85.45</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91.73</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table> 0.0109 0.0043 0 0 P5Y10M24D P6Y3M18D 0.8545 0.9173 50000 0 0 0 30 P4Y P4Y7M6D 200000 P2Y2M1D <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of stock awards containing market conditions activity for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:45.326%;"/> <td style="width:1.285%;"/> <td style="width:0.685%;"/> <td style="width:10.708%;"/> <td style="width:0.91%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:10.322%;"/> <td style="width:0.685%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:10.387%;"/> <td style="width:0.685%;"/> <td style="width:1.285%;"/> <td style="width:1.371%;"/> <td style="width:10.354%;"/> <td style="width:0.685%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Average</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Remaining</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Intrinsic</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contractual</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value (in</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Price</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Term (years)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">600,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.01</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.9</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">630</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled or forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150,000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">450,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.01</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.9</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable at December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 600000 2.01 P8Y10M24D 630000 150000 450000 2.01 P7Y10M24D <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of stock options containing market conditions is estimated using Monte Carlo simulations. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> stock options containing market conditions were granted during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 0 0 0.25 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of RSU activity for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 is as follows:</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.289%;"/> <td style="width:1.445%;"/> <td style="width:0.696%;"/> <td style="width:13.266%;"/> <td style="width:0.921%;"/> <td style="width:1.445%;"/> <td style="width:1.381%;"/> <td style="width:14.861%;"/> <td style="width:0.696%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Grant Date</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">of Shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">294,913</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.52</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,369</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.17</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">143,774</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.01</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97,704</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.41</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92,804</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.70</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 294913 14.52 39369 3.17 143774 12.01 97704 14.41 92804 13.70 700000 P1Y1M17D <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Loss per share</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.807%;"/> <td style="width:1.499%;"/> <td style="width:1.37%;"/> <td style="width:13.307%;"/> <td style="width:0.921%;"/> <td style="width:1.499%;"/> <td style="width:1.37%;"/> <td style="width:13.307%;"/> <td style="width:0.921%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss (in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,647</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77,802</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average shares used in calculating net loss per share — basic and diluted (in thousands)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,144</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,403</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share — basic and diluted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.32</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.56</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We exclude shares of common stock related to stock options and RSUs from the calculation of diluted net loss per share since the inclusion of such shares would be anti-dilutive. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth potential shares that were considered anti-dilutive for the years ended December 31, 2021 and 2020: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.467%;"/> <td style="width:1.478%;"/> <td style="width:1.381%;"/> <td style="width:13.212%;"/> <td style="width:0.696%;"/> <td style="width:1.478%;"/> <td style="width:1.381%;"/> <td style="width:13.212%;"/> <td style="width:0.696%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock Options</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,530,426</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">294,913</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">RSUs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92,804</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,026,356</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,623,230</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,321,269</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.807%;"/> <td style="width:1.499%;"/> <td style="width:1.37%;"/> <td style="width:13.307%;"/> <td style="width:0.921%;"/> <td style="width:1.499%;"/> <td style="width:1.37%;"/> <td style="width:13.307%;"/> <td style="width:0.921%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss (in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,647</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77,802</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average shares used in calculating net loss per share — basic and diluted (in thousands)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,144</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,403</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share — basic and diluted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.32</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.56</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> -51647000 -77802000 39144000 30403000 -1.32 -2.56 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth potential shares that were considered anti-dilutive for the years ended December 31, 2021 and 2020: </span><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.467%;"/> <td style="width:1.478%;"/> <td style="width:1.381%;"/> <td style="width:13.212%;"/> <td style="width:0.696%;"/> <td style="width:1.478%;"/> <td style="width:1.381%;"/> <td style="width:13.212%;"/> <td style="width:0.696%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock Options</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,530,426</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">294,913</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">RSUs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92,804</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,026,356</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,623,230</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,321,269</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 7530426000 294913000 92804000 8026356000 7623230000 8321269000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. Income Taxes</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> provision for income taxes for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, and 2020, due to the Company’s operating losses and a full valuation allowance on deferred tax assets. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.508%;"/> <td style="width:0.995%;"/> <td style="width:2.189%;"/> <td style="width:13.717%;"/> <td style="width:1.47%;"/> <td style="width:0.995%;"/> <td style="width:2.189%;"/> <td style="width:14.467%;"/> <td style="width:1.47%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S.</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,686</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77,884</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">International</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before benefit from income taxes</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,647</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122,406</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax benefit using U.S. federal statutory rate</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,846</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,338</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes, net of federal benefit</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,631</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,619</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-deductible share-based compensation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">911</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation - shortfalls/(windfalls)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">946</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,047</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent differences</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">420</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PPP loan forgiveness</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">748</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credits</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">805</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,469</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,424</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,473</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective income tax rate is based upon the income for the year, the composition of the income in different countries, and adjustments, if any, for the potential tax consequences, benefits or resolutions of audits or other tax contingencies. Our income tax rate in foreign jurisdictions is lower than our income tax rate in the United States.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets (liabilities) consist of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.002%;"/> <td style="width:1.24%;"/> <td style="width:2.266%;"/> <td style="width:13.977%;"/> <td style="width:1.516%;"/> <td style="width:1.24%;"/> <td style="width:2.266%;"/> <td style="width:13.977%;"/> <td style="width:1.516%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43,700</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,007</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credit carryforwards</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,044</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,185</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,702</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,890</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease - liability</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,536</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,362</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Capitalized research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,147</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,684</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and reserves</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">518</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70,687</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66,182</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease - right of use asset</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">383</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,857</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid sublease termination</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">758</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,203</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,141</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,060</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,546</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,122</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,546</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,122</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management of Cyclerion has evaluated the positive and negative evidence bearing upon the possible realization of its deferred tax assets. Management has considered the Company's history of operating losses, in addition to the expected timing of the reversal of existing temporary differences and concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company will not realize the benefit of its deferred tax assets. Accordingly, the net deferred tax assets have been fully reserved at December 31, 2021 and December 31, 2020. Management reevaluates the positive and negative evidence on a quarterly basis.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The valuation allowance increased by approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 primarily due to increases in capitalized research and development expenses, net operating losses, tax credit carryforwards and deferred tax assets related to share-based compensation.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cyclerion did not generate net operating loss carryforwards or tax credit carryforwards available for its use until its inception and operation as a standalone legal entity. At December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, Cyclerion has federal net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">160</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, to offset future federal taxable income that will be carried forward indefinitely until utilized. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, Cyclerion had state net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">159.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, to offset future state taxable income, which will </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">begin to expire in 2039 and will continue to expire through 2040</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Cyclerion also had tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, to offset future federal and state income taxes. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal credits begin to expire in 2039 and will continue to expire through 2040. State credits begin to expire in 2022 and continue through 2034</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s ability to use its operating loss carryforwards and tax credits to offset future taxable income could be subject to restrictions under Section 382 of the U.S. Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”). These potential restrictions may limit the future use of the operating loss carryforwards and tax credits if certain ownership changes described in the Internal Revenue Code occur. Changes in stock ownership may occur that would create these limitations on the Company’s use of the operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has not as yet conducted a study of its research and development credit carry forwards. This study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development credits, and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheets or statements of operations if an adjustment were required.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon audit, taxing authorities may challenge all or part of an uncertain income tax position. While Cyclerion has no history of tax audits since its inception on a standalone basis, it may be subject to tax audits by federal and state taxing authorities in the future. Accordingly, Cyclerion regularly assesses the outcome of potential examinations in each of the taxing jurisdictions when determining the adequacy of the amount of unrecognized tax benefit recorded. Cyclerion had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> unrecognized tax benefits as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020. Cyclerion will recognize interest and penalties, if any, related to uncertain tax positions in income tax expense. As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> interest or penalties have been accrued. There are no current federal or state income tax audits in progress.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act is an emergency economic stimulus package in response to the COVID-19 pandemic, which among other things contains numerous income tax provisions, some of which are effective retroactively for fiscal years ended before the date of enactment. The CARES Act includes certain tax relief provisions, including modifications to the NOL rules, including a provision to carryback losses from 2018 – 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> tax years, temporary changes to business interest expense disallowance rules (IRC §163(j)), qualified improvement property, payroll tax delays/ credits, and several other tax and non-tax benefits. These tax provisions should have no significant income tax ramifications for Cyclerion, but the Company will continue to monitor any changes and guidance in order to consider potential opportunities. The CARES Act also created a program called the Paycheck Protection Program to be administered by the SBA. Cyclerion received $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of loan proceeds on April 21, 2020 under the PPP, as fully described in Note 2,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p> 0 0 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.508%;"/> <td style="width:0.995%;"/> <td style="width:2.189%;"/> <td style="width:13.717%;"/> <td style="width:1.47%;"/> <td style="width:0.995%;"/> <td style="width:2.189%;"/> <td style="width:14.467%;"/> <td style="width:1.47%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S.</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,686</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77,884</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">International</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before benefit from income taxes</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,647</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122,406</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax benefit using U.S. federal statutory rate</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,846</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,338</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes, net of federal benefit</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,631</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,619</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-deductible share-based compensation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">911</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation - shortfalls/(windfalls)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">946</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,047</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent differences</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">420</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PPP loan forgiveness</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">748</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credits</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">805</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,469</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,424</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,473</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> -51686000 -77884000 39000 82000 -51647000 -122406000 -10846000 -16338000 -3631000 -5619000 -911000 16000 946000 1047000 -420000 -94000 748000 805000 2469000 -9000 -16000 16424000 23473000 0 0 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets (liabilities) consist of the following as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:62.002%;"/> <td style="width:1.24%;"/> <td style="width:2.266%;"/> <td style="width:13.977%;"/> <td style="width:1.516%;"/> <td style="width:1.24%;"/> <td style="width:2.266%;"/> <td style="width:13.977%;"/> <td style="width:1.516%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43,700</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,007</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credit carryforwards</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,044</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,185</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,702</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,890</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease - liability</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,536</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,362</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Capitalized research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,147</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,684</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and reserves</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">518</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70,687</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66,182</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease - right of use asset</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">383</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,857</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid sublease termination</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">758</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,203</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,141</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,060</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,546</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,122</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,546</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,122</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 43700000 27007000 8044000 7185000 7702000 5890000 0 11536000 1000 1362000 11147000 12684000 91000 518000 4000 70687000 66182000 -383000 -11857000 -758000 1203000 1141000 13060000 69546000 53122000 69546000 53122000 0 0 16400000 160000000 98800000 159600000 98900000 begin to expire in 2039 and will continue to expire through 2040 8400 7500 Federal credits begin to expire in 2039 and will continue to expire through 2040. State credits begin to expire in 2022 and continue through 2034 0 0 0 0 3500000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Defined Contribution Plan</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2019, Cyclerion adopted a defined contribution </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b54969dd-de8d-4127-9b9b-37f4bc1090ae;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">401(k) Savings Plan</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> similar to the plan in place at Ironwood. The plan assets under the Ironwood defined contribution 401(k) Savings Plan were transferred to the Cyclerion plan. Subject to certain IRS limits, eligible employees may elect to contribute from </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of their</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compensation. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cyclerion contributions to the plan are at the sole discretion of the board of directors. Currently, Cyclerion provides a matching contribution of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the employee’s contributions, up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> annually.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Included in compensation expense is approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to the defined contribution 401(k) Savings Plan for the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span> 0.01 1 0.75 6000 300000 500000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. Workforce Reduction</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2020 Workforce Reduction</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 5, 2020, the Company began a reduction of its current workforce by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">forty-eight</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (48) full-time employees to align its resources with its current priorities of focusing on the MELAS study, the planned ADv study and further characterization of CY6463 novel pharmacology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recorded total costs related to the 2020 Workforce Reduction were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million including approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in stock-based compensation from the modification of certain share-based equity awards.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reduced its workforce by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">thirty-one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (31) employees in the fourth quarter of 2020 and recorded approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of severance and benefits costs in accordance with ASC Topic 420, Exit or Disposal Cost Obligations, or ASC 420, including a de minimis amount of stock-based compensation expense, for the year ended December 31, 2020. The workforce reduction was completed by the end of the first quarter of 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the accrued liabilities activity recorded in connection with the reduction in workforce for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:35.697%;"/> <td style="width:1.114%;"/> <td style="width:1.36%;"/> <td style="width:9.511%;"/> <td style="width:0.91%;"/> <td style="width:1.114%;"/> <td style="width:1.36%;"/> <td style="width:9.436%;"/> <td style="width:0.91%;"/> <td style="width:1.114%;"/> <td style="width:1.36%;"/> <td style="width:9.607%;"/> <td style="width:0.675%;"/> <td style="width:1.114%;"/> <td style="width:1.371%;"/> <td style="width:9.778%;"/> <td style="width:0.675%;"/> <td style="width:1.114%;"/> <td style="width:1.36%;"/> <td style="width:9.511%;"/> <td style="width:0.91%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amounts<br/>accrued at<br/>December 31,<br/>2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Charges</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount<br/>paid</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Adjustments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amounts<br/>accrued at<br/>December 31,<br/>2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2020 workforce reduction</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,640</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">878</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,490</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,640</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">878</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,490</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table></div> 48 5000000.0 100000 31 4100000 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the accrued liabilities activity recorded in connection with the reduction in workforce for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:35.697%;"/> <td style="width:1.114%;"/> <td style="width:1.36%;"/> <td style="width:9.511%;"/> <td style="width:0.91%;"/> <td style="width:1.114%;"/> <td style="width:1.36%;"/> <td style="width:9.436%;"/> <td style="width:0.91%;"/> <td style="width:1.114%;"/> <td style="width:1.36%;"/> <td style="width:9.607%;"/> <td style="width:0.675%;"/> <td style="width:1.114%;"/> <td style="width:1.371%;"/> <td style="width:9.778%;"/> <td style="width:0.675%;"/> <td style="width:1.114%;"/> <td style="width:1.36%;"/> <td style="width:9.511%;"/> <td style="width:0.91%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amounts<br/>accrued at<br/>December 31,<br/>2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Charges</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount<br/>paid</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Adjustments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amounts<br/>accrued at<br/>December 31,<br/>2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2020 workforce reduction</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,640</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">878</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,490</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,640</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">878</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,490</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table> 3640000 -878000 4490000 0 28000 3640000 -878000 4490000 0 28000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Akebia License Agreement</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 3, 2021, the Company and Akebia entered into a License Agreement (the “License Agreement”) relating to the exclusive worldwide license by the Company to Akebia of our rights to the development, manufacture, medical affairs and commercialization of pharmaceutical products containing the pharmaceutical compound known as praliciguat and other related products and forms thereof enumerated in the License Agreement (collectively, the “Products”). Pursuant to the License Agreement, Akebia will be responsible for all future research, development, regulatory, and commercialization activities for the Products.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Akebia paid a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million up-front payment to the Company upon signing of the License Agreement and the Company is eligible to receive additional milestone cash payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the next 18 months. Further milestone cash payments by Akebia are scheduled in the License Agreement based on the initiation of phase 3 clinical trials in the U.S. for Products for first and second indication, for FDA approvals, for approvals in certain other major markets, and for certain sales milestones. In addition to these cash milestone payments, Akebia will pay the Company tiered royalty payments on net sales in certain major markets at percentages ranging from the mid-single digits to the high-teens, subject to certain reductions and offsets.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the License Agreement, the Company determined the License Agreement represents a service arrangement under the scope of ASC 606. Given the reversion of the rights under the License Agreement represents a penalty in substance for a termination by Akebia, the contract term would be the stated term of the License Agreement.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determined that the grant of license to our patents and trademarks, know how transfer, the assignment of regulatory submissions and trademarks and additional knowledge transfer assistance obligations represent a single promise and performance obligation to be transferred to Akebia over time due to the nature of the promises in the contract. The provision of development materials on hand was identified as a separate performance obligation. However, it is immaterial in the context of the contract as the development materials are low value and do not have an alternative use to the Company.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The consideration related to sales-based milestone payments, including royalties, will be recognized when the related sales occur as these amounts have been determined to relate predominantly to the license. The Company will re-evaluate the probability of achievement of the milestones and any related constraints each reporting period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Akebia Supply Agreement</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 3, 2021, the Company and Akebia entered into a Supply Agreement (the “Supply Agreement”) relating to the manufacturing by the Company of the Initial Supply of the Drug Product and placebo ("Initial Supply") for Akebia's use pursuant to the License Agreement. Akebia will pay the Company for the manufacturing costs at mutually agreed upon rates.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determined the Supply Agreement has stand-alone value under the scope of ASC 606 and should not be combined with the License Agreement. Given that the Supply Agreement can be terminated at any time without cause with 30 days notice, the Company deemed the Supply Agreement to be a month-to-month contract. The manufacturing of the Initial Supply by the Company represents a single performance obligation and consideration related to the manufacturing costs will be recognized over time as costs are incurred based on an input method. The Company recorded $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> amount as revenue from the Supply Agreement for the year ended December 31, 2021.</span></p> 3000000.0 12000000.0 300000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. Grant Revenue</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2021, the Company was approved to receive funding from the PTC Grant for the Phase 2 study of CNS sGC stimulation in AD with vascular features. The granting period is July 1, 2021, to December 31, 2022, and the Company will receive an award of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company determined that this transaction is non-reciprocal as there is not considered to be a commensurate value exchanged with the Alzheimer's Association as the funding provider. Where commensurate value is not exchanged for goods and services provided, a recipient assesses whether the grant is conditional or unconditional. The Company considered all conditions and barriers associated with this grant and determined the grant is conditional and revenue will be recognized upon achieving certain milestones and incurring internal costs specifically covered by this grant. Under ASC 958-605, revenues will be recognized as the Company incurs expenses related to the PTC Grant.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company incurred approximately</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of allowable expenses and recognized a corresponding amount of grant revenue for the year ended December 31, 2021.</span> 2000000 600000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">16. Subsequent Events</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has evaluated all events and transactions that occurred after the balance sheet date through the date the consolidated financial statements were issued and determined that there were no such events requiring recognition or disclosure in the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> EXCEL 78 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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end

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 80 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 81 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 131 424 1 false 49 0 false 10 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100040 - Statement - Consolidated and Combined Statements of Operations and Comprehensive Loss Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss Consolidated and Combined Statements of Operations and Comprehensive Loss Statements 3 false false R4.htm 100050 - Statement - Consolidated and Combined Statements of Stockholders' Equity (Deficit) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit Consolidated and Combined Statements of Stockholders' Equity (Deficit) Statements 4 false false R5.htm 100060 - Statement - Consolidated and Combined Statements of Cash Flows Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows Consolidated and Combined Statements of Cash Flows Statements 5 false false R6.htm 100070 - Statement - Consolidated and Combined Statements of Cash Flows (Parenthetical) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlowsParenthetical Consolidated and Combined Statements of Cash Flows (Parenthetical) Statements 6 false false R7.htm 100080 - Disclosure - Nature of Business Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusiness Nature of Business Notes 7 false false R8.htm 100090 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 100100 - Disclosure - Related Party Transactions Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions Related Party Transactions Notes 9 false false R10.htm 100110 - Disclosure - Fair Value of Financial Instruments Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 10 false false R11.htm 100120 - Disclosure - Property and Equipment Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 100130 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 12 false false R13.htm 100140 - Disclosure - Commitments and Contingencies Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 100150 - Disclosure - Leases Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeases Leases Notes 14 false false R15.htm 100160 - Disclosure - Share-based Compensation Plans Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlans Share-based Compensation Plans Notes 15 false false R16.htm 100170 - Disclosure - Loss per share Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShare Loss per share Notes 16 false false R17.htm 100180 - Disclosure - Income Taxes Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes Income Taxes Notes 17 false false R18.htm 100190 - Disclosure - Defined Contribution Plan Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan Defined Contribution Plan Notes 18 false false R19.htm 100200 - Disclosure - Workforce Reduction Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReduction Workforce Reduction Notes 19 false false R20.htm 100210 - Disclosure - License Agreements Sheet http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreements License Agreements Notes 20 false false R21.htm 100220 - Disclosure - Grant Revenue Sheet http://www.cyclerion.com/20211231/taxonomy/role/DisclosureGrantRevenue Grant Revenue Notes 21 false false R22.htm 100230 - Disclosure - Subsequent Events Sheet http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 22 false false R23.htm 100240 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 23 false false R24.htm 100250 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 24 false false R25.htm 100260 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments 25 false false R26.htm 100270 - Disclosure - Property and Equipment (Tables) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipment 26 false false R27.htm 100280 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities 27 false false R28.htm 100290 - Disclosure - Leases (Tables) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesTables Leases (Tables) Tables http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeases 28 false false R29.htm 100300 - Disclosure - Share-based Compensation Plans (Tables) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables Share-based Compensation Plans (Tables) Tables http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlans 29 false false R30.htm 100310 - Disclosure - Loss per share (Tables) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables Loss per share (Tables) Tables http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShare 30 false false R31.htm 100320 - Disclosure - Income Taxes (Tables) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes 31 false false R32.htm 100330 - Disclosure - Workforce Reduction (Tables) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionTables Workforce Reduction (Tables) Tables http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReduction 32 false false R33.htm 100340 - Disclosure - Nature of Business (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails Nature of Business (Details) Details http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusiness 33 false false R34.htm 100350 - Disclosure - Summary of Significant Accounting Policies - Segments and Cash (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSegmentsAndCashDetails Summary of Significant Accounting Policies - Segments and Cash (Details) Details 34 false false R35.htm 100360 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails Summary of Significant Accounting Policies - Property and Equipment (Details) Details 35 false false R36.htm 100370 - Disclosure - Summary of Significant Accounting Policies - Leases (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails Summary of Significant Accounting Policies - Leases (Details) Details http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables 36 false false R37.htm 100380 - Disclosure - Summary of Significant Accounting Policies - Paycheck Protection Program Loan (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPaycheckProtectionProgramLoanDetails Summary of Significant Accounting Policies - Paycheck Protection Program Loan (Details) Details 37 false false R38.htm 100390 - Disclosure - Summary of Significant Accounting Policies - Revenue, Patent Costs, and Interest and Other Income (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails Summary of Significant Accounting Policies - Revenue, Patent Costs, and Interest and Other Income (Details) Details 38 false false R39.htm 100400 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails Summary of Significant Accounting Policies - Income Taxes (Details) Details 39 false false R40.htm 100410 - Disclosure - Related Party Transactions (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions 40 false false R41.htm 100420 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables 41 false false R42.htm 100430 - Disclosure - Property and Equipment (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables 42 false false R43.htm 100440 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities (Details) Details http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables 43 false false R44.htm 100450 - Disclosure - Leases - Summary (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails Leases - Summary (Details) Details 44 false false R45.htm 100460 - Disclosure - Leases - Schedule of supplemental cash flow information related to leases (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails Leases - Schedule of supplemental cash flow information related to leases (Details) Details 45 false false R46.htm 100470 - Disclosure - Leases - Future minimum lease operating payments (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeaseOperatingPaymentsDetails Leases - Future minimum lease operating payments (Details) Details 46 false false R47.htm 100480 - Disclosure - Leases - Sublease as Lessee (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLesseeDetails Leases - Sublease as Lessee (Details) Details 47 false false R48.htm 100490 - Disclosure - Leases - Sublease as Lessor (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails Leases - Sublease as Lessor (Details) Details 48 false false R49.htm 100500 - Disclosure - Share-based Compensation Plans (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails Share-based Compensation Plans (Details) Details http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables 49 false false R50.htm 100510 - Disclosure - Share-based Compensation Plans - Stock Options (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails Share-based Compensation Plans - Stock Options (Details) Details 50 false false R51.htm 100520 - Disclosure - Share-based Compensation Plans - Schedule of Weighted Average Assumptions used in estimating the fair value of the stock options (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails Share-based Compensation Plans - Schedule of Weighted Average Assumptions used in estimating the fair value of the stock options (Details) Details 51 false false R52.htm 100530 - Disclosure - Share-based Compensation Plans - Stock Awards Containing Market Conditions (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails Share-based Compensation Plans - Stock Awards Containing Market Conditions (Details) Details 52 false false R53.htm 100540 - Disclosure - Share-based Compensation Plans - Summary of RSU activity (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails Share-based Compensation Plans - Summary of RSU activity (Details) Details 53 false false R54.htm 100550 - Disclosure - Loss per share (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareDetails Loss per share (Details) Details http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables 54 false false R55.htm 100560 - Disclosure - Loss Per Share - Schedule Of Earnings Per Share Diluted By Common Class (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails Loss Per Share - Schedule Of Earnings Per Share Diluted By Common Class (Details) Details 55 false false R56.htm 100570 - Disclosure - Income Taxes - Additional disclosures (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails Income Taxes - Additional disclosures (Details) Details 56 false false R57.htm 100580 - Disclosure - Income Taxes - Reconciliation of income taxes (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails Income Taxes - Reconciliation of income taxes (Details) Details 57 false false R58.htm 100590 - Disclosure - Income Taxes - Deferred tax assets (liabilities) (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails Income Taxes - Deferred tax assets (liabilities) (Details) Details 58 false false R59.htm 100600 - Disclosure - Defined Contribution Plan (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanDetails Defined Contribution Plan (Details) Details http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan 59 false false R60.htm 100610 - Disclosure - Workforce Reduction (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails Workforce Reduction (Details) Details http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionTables 60 false false R61.htm 100620 - Disclosure - License Agreement - Additional Information (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails License Agreement - Additional Information (Details) Details 61 false false R62.htm 100630 - Disclosure - Grant Revenue (Additional Information) (Details) Sheet http://www.cyclerion.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails Grant Revenue (Additional Information) (Details) Details http://www.cyclerion.com/20211231/taxonomy/role/DisclosureGrantRevenue 62 false false All Reports Book All Reports cycn-20211231.htm cycn-20211231.xsd cycn-20211231_cal.xml cycn-20211231_def.xml cycn-20211231_lab.xml cycn-20211231_pre.xml cycn-ex21_1.htm cycn-ex23_1.htm cycn-ex31_1.htm cycn-ex31_2.htm cycn-ex32_1.htm cycn-ex32_2.htm cycn-ex4_1.htm img149660584_0.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 84 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cycn-20211231.htm": { "axisCustom": 0, "axisStandard": 23, "contextCount": 131, "dts": { "calculationLink": { "local": [ "cycn-20211231_cal.xml" ] }, "definitionLink": { "local": [ "cycn-20211231_def.xml" ] }, "inline": { "local": [ "cycn-20211231.htm" ] }, "labelLink": { "local": [ "cycn-20211231_lab.xml" ] }, "presentationLink": { "local": [ "cycn-20211231_pre.xml" ] }, "schema": { "local": [ "cycn-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 604, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 6, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 10 }, "keyCustom": 79, "keyStandard": 345, "memberCustom": 23, "memberStandard": 24, "nsprefix": "cycn", "nsuri": "http://www.cyclerion.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Fair Value of Financial Instruments", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Property and Equipment", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Accrued Expenses and Other Current Liabilities", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Commitments and Contingencies", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "cycn:LeaseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Leases", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "cycn:LeaseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Share-based Compensation Plans", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlans", "shortName": "Share-based Compensation Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Loss per share", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShare", "shortName": "Loss per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Income Taxes", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Defined Contribution Plan", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan", "shortName": "Defined Contribution Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Workforce Reduction", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReduction", "shortName": "Workforce Reduction", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "cycn:LicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - License Agreements", "role": "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreements", "shortName": "License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "cycn:LicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Grant Revenue", "role": "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureGrantRevenue", "shortName": "Grant Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Subsequent Events", "role": "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "cycn:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "cycn:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Property and Equipment (Tables)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "cycn:LeaseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "cycn:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Leases (Tables)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "cycn:LeaseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "cycn:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Share-based Compensation Plans (Tables)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables", "shortName": "Share-based Compensation Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "cycn:RevenueFromLicense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated and Combined Statements of Operations and Comprehensive Loss", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Consolidated and Combined Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "cycn:RevenueFromLicense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Loss per share (Tables)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables", "shortName": "Loss per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Income Taxes (Tables)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Workforce Reduction (Tables)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionTables", "shortName": "Workforce Reduction (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "cycn:HealthCareTrustAmountDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Nature of Business (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails", "shortName": "Nature of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "cycn:HealthCareTrustAmountDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "span", "p", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "U_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Summary of Significant Accounting Policies - Segments and Cash (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSegmentsAndCashDetails", "shortName": "Summary of Significant Accounting Policies - Segments and Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "span", "p", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "U_Segment", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cycn:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_ce43e22d-ebde-45e9-a3da-8af2439e4b80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cycn:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_ce43e22d-ebde-45e9-a3da-8af2439e4b80", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeLeasesPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_3e94f034-991b-4f00-b524-2dac12354b8e", "decimals": "0", "first": true, "lang": null, "name": "cycn:RentableSquareFeetSubleaseToThirdParty", "reportCount": 1, "unitRef": "U_sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails", "shortName": "Summary of Significant Accounting Policies - Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeLeasesPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_83bdc464-7c74-4e8e-96f6-7da2254b6c25", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeaseImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromNotesPayable", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Summary of Significant Accounting Policies - Paycheck Protection Program Loan (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPaycheckProtectionProgramLoanDetails", "shortName": "Summary of Significant Accounting Policies - Paycheck Protection Program Loan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "cycn:PaycheckProtectionProgramLoanCaresActPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-5", "lang": null, "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "cycn:InitialTermOfAgreement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Summary of Significant Accounting Policies - Revenue, Patent Costs, and Interest and Other Income (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails", "shortName": "Summary of Significant Accounting Policies - Revenue, Patent Costs, and Interest and Other Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "cycn:InitialTermOfAgreement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails", "shortName": "Summary of Significant Accounting Policies - Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_7204ac8b-45eb-419a-80d2-1b70e023b1b3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Consolidated and Combined Statements of Stockholders' Equity (Deficit)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit", "shortName": "Consolidated and Combined Statements of Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_7204ac8b-45eb-419a-80d2-1b70e023b1b3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_89d45ef1-2978-4691-95c0-9deb8cfbaf8d", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Related Party Transactions (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_89d45ef1-2978-4691-95c0-9deb8cfbaf8d", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_0f93702c-97c8-442f-b660-620735a9874b", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Fair Value of Financial Instruments (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails", "shortName": "Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_0f93702c-97c8-442f-b660-620735a9874b", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Property and Equipment (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "shortName": "Accrued Expenses and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "cycn:LeaseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_3e6a6d67-b1e4-45f1-b900-e5c596867186", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Leases - Summary (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "shortName": "Leases - Summary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "cycn:LeaseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-5", "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cycn:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "div", "cycn:LeaseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "cycn:DecreaseInRightOfUseAssetsRelatedToLeaseModificationsAndTermination", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Leases - Schedule of supplemental cash flow information related to leases (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails", "shortName": "Leases - Schedule of supplemental cash flow information related to leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "cycn:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "div", "cycn:LeaseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "cycn:DecreaseInRightOfUseAssetsRelatedToLeaseModificationsAndTermination", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Leases - Future minimum lease operating payments (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeaseOperatingPaymentsDetails", "shortName": "Leases - Future minimum lease operating payments (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R47": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Leases - Sublease as Lessee (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLesseeDetails", "shortName": "Leases - Sublease as Lessee (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeLeasesPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_3e94f034-991b-4f00-b524-2dac12354b8e", "decimals": "0", "first": true, "lang": null, "name": "cycn:RentableSquareFeetSubleaseToThirdParty", "reportCount": 1, "unitRef": "U_sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Leases - Sublease as Lessor (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails", "shortName": "Leases - Sublease as Lessor (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "cycn:LeaseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-5", "lang": null, "name": "cycn:SubleaseTerminationAgreementEstimatedFairValueOfRooms", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Share-based Compensation Plans (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "shortName": "Share-based Compensation Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Consolidated and Combined Statements of Cash Flows", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows", "shortName": "Consolidated and Combined Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "cycn:ScheduleOfShareBasedPaymentAwardPerformanceSharesValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Share-based Compensation Plans - Stock Options (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails", "shortName": "Share-based Compensation Plans - Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Share-based Compensation Plans - Schedule of Weighted Average Assumptions used in estimating the fair value of the stock options (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails", "shortName": "Share-based Compensation Plans - Schedule of Weighted Average Assumptions used in estimating the fair value of the stock options (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "cycn:ScheduleOfShareBasedPaymentAwardPerformanceSharesValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Share-based Compensation Plans - Stock Awards Containing Market Conditions (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "shortName": "Share-based Compensation Plans - Stock Awards Containing Market Conditions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_894e21b4-0120-4b94-9c18-ad10c3931c1c", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Share-based Compensation Plans - Summary of RSU activity (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails", "shortName": "Share-based Compensation Plans - Summary of RSU activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_b9e88634-7c93-4bdc-8db4-57fed8991f7d", "decimals": "2", "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Loss per share (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareDetails", "shortName": "Loss per share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Loss Per Share - Schedule Of Earnings Per Share Diluted By Common Class (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails", "shortName": "Loss Per Share - Schedule Of Earnings Per Share Diluted By Common Class (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Income Taxes - Additional disclosures (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails", "shortName": "Income Taxes - Additional disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-2", "lang": null, "name": "us-gaap:TaxCreditCarryforwardAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Income Taxes - Reconciliation of income taxes (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails", "shortName": "Income Taxes - Reconciliation of income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Income Taxes - Deferred tax assets (liabilities) (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails", "shortName": "Income Taxes - Deferred tax assets (liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Defined Contribution Plan (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanDetails", "shortName": "Defined Contribution Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_4a294a37-b518-46f2-8f8e-7c8ee9d3e673", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Consolidated and Combined Statements of Cash Flows (Parenthetical)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlowsParenthetical", "shortName": "Consolidated and Combined Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_90780a1d-0931-48b9-b570-5e6ec373cece", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestructuringReserveCurrent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Workforce Reduction (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails", "shortName": "Workforce Reduction (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6c5a6b9b-eb59-4706-964a-6e60dbc0866e", "decimals": "-3", "lang": null, "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - License Agreement - Additional Information (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "shortName": "License Agreement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "cycn:LicenseAgreementsTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_20398e00-3225-4f1c-9c44-71bf5d1bab40", "decimals": "-5", "lang": null, "name": "cycn:UpFrontPaymentReceived", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_33f57713-f9dc-473a-8bdb-77ff79588596", "decimals": "-6", "first": true, "lang": null, "name": "cycn:PtcGrantAward", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Grant Revenue (Additional Information) (Details)", "role": "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "shortName": "Grant Revenue (Additional Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_33f57713-f9dc-473a-8bdb-77ff79588596", "decimals": "-6", "first": true, "lang": null, "name": "cycn:PtcGrantAward", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Nature of Business", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusiness", "shortName": "Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Related Party Transactions", "role": "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cycn-20211231.htm", "contextRef": "C_6d7160d0-dfeb-4af5-adbe-b39b84006dfb", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 49, "tag": { "cycn_AccruedExpensesAndOtherLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued expenses and other liabilities current.", "label": "Accrued Expenses And Other Liabilities Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherLiabilitiesCurrent", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cycn_AccruedResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of liabilities.", "label": "Accrued Research And Development Current", "terseLabel": "Accrued research and development costs" } } }, "localname": "AccruedResearchAndDevelopmentCurrent", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cycn_AdjustmentsToAdditionalPaidInCapitalReclassificationOfNetParentCompanyInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from reclassification of net parent company investment.", "label": "Adjustments To Additional Paid In Capital Reclassification Of Net Parent Company Investment", "terseLabel": "Reclassification of net parent company investment" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfNetParentCompanyInvestment", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "cycn_AdjustmentsUponSeparation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of adjustments made upon separation primarily related to differences between assets and liabilities transferred to Cyclerion as a result of the Separation and assets and liabilities reported in the Company's combined balance sheet.", "label": "Adjustments Upon Separation", "terseLabel": "Separation-related adjustment" } } }, "localname": "AdjustmentsUponSeparation", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "cycn_AkbeiaSupplyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Akbeia supply agreement member.", "label": "Akbeia Supply Agreement [Member]" } } }, "localname": "AkbeiaSupplyAgreementMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cycn_AkebiaResearchLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Akebia Research License Agreement Member.", "label": "Akebia Research License Agreement [Member]", "terseLabel": "Akebia Research License Agreement [Member]" } } }, "localname": "AkebiaResearchLicenseAgreementMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "cycn_AllowableExpensesOnGrantRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Allowable Expenses on Grant Revenue", "label": "Allowable Expenses on Grant Revenue" } } }, "localname": "AllowableExpensesOnGrantRevenue", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cycn_AmendedHeadquartersLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to an amended direct operating lease effective February 28, 2020 for premises located at 301 Binney Street, Cambridge, MA.", "label": "Amended Headquarters Lease [Member]", "terseLabel": "Lease Amendment" } } }, "localname": "AmendedHeadquartersLeaseMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "domainItemType" }, "cycn_AtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At The Market Offering.", "label": "At The Market Offering [Member]", "terseLabel": "ATM Offering" } } }, "localname": "AtTheMarketOfferingMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "cycn_CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash commission percentage of gross proceeds of sales of common stock.", "label": "Cash Commission Percentage Of Gross Proceeds Of Sales Of Common Stock", "terseLabel": "Cash commission of gross proceeds of sales of common stock, percentage" } } }, "localname": "CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "percentItemType" }, "cycn_CommissionPaidFromGrossProceedsOfSalesOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Commission Paid From Gross Proceeds Of Sales Of Common Stock.", "label": "Commission Paid From Gross Proceeds Of Sales Of Common Stock", "terseLabel": "Commission Paid From Gross Proceeds Of Sales Of Common Stock" } } }, "localname": "CommissionPaidFromGrossProceedsOfSalesOfCommonStock", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "cycn_CommonStockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member represents the common stock purchase agreement.", "label": "Common Stock Purchase Agreement [Member]", "terseLabel": "Common Stock Purchase Agreement" } } }, "localname": "CommonStockPurchaseAgreementMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "cycn_ContributedCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "he amount of capital contributed by the parent through transfers.", "label": "Contributed Capital", "terseLabel": "Net transfers from Ironwood" } } }, "localname": "ContributedCapital", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "cycn_CorporateCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents services provided to the reporting entity for information systems, accounting, other financial services (such as treasury, audit and purchasing), human resources, legal and facilities.", "label": "Corporate Costs [Member]", "terseLabel": "Corporate costs" } } }, "localname": "CorporateCostsMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cycn_CurrentWorkforceReductionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to current workforce reductions of the Company.", "label": "Current Workforce Reductions [Member]", "terseLabel": "Current workforce reductions" } } }, "localname": "CurrentWorkforceReductionsMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "domainItemType" }, "cycn_CyclerionGmbhMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Cyclerion GmbH.", "label": "Cyclerion Gmbh [Member]", "terseLabel": "Cyclerion GmbH" } } }, "localname": "CyclerionGmbhMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "cycn_CyclerionSecuritiesCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cyclerion Securities Corporation.", "label": "Cyclerion Securities Corporation [Member]", "terseLabel": "Cyclerion Securities Corporation" } } }, "localname": "CyclerionSecuritiesCorporationMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "cycn_DecreaseInOperatingLeaseLiabilitiesRelatedToLeaseModification": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of decrease in lease liabilities related to the modification of an existing lease.", "label": "Decrease In Operating Lease Liabilities Related To Lease Modification", "terseLabel": "Decrease in operating lease liabilities due to lease modification and termination" } } }, "localname": "DecreaseInOperatingLeaseLiabilitiesRelatedToLeaseModification", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "monetaryItemType" }, "cycn_DecreaseInOperatingLeaseLiabilitiesRelatedToLeaseModificationsAndTermination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease In Operating Lease Liabilities Related To Lease Modifications And Termination", "label": "Decrease In Operating Lease Liabilities Related To Lease Modifications And Termination", "terseLabel": "Decrease in operating lease liabilities due to lease modifications and termination" } } }, "localname": "DecreaseInOperatingLeaseLiabilitiesRelatedToLeaseModificationsAndTermination", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "cycn_DecreaseInRightOfUseAssetsRelatedToLeaseModification": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of decrease in right-of-use assets related to the modification of an existing lease.", "label": "Decrease In Right Of Use Assets Related To Lease Modification", "terseLabel": "Decrease in right-of-use assets related to lease modification and termination" } } }, "localname": "DecreaseInRightOfUseAssetsRelatedToLeaseModification", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "monetaryItemType" }, "cycn_DecreaseInRightOfUseAssetsRelatedToLeaseModificationsAndTermination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of decrease in right-of-use assets related to the modifications and termination of an existing lease.", "label": "Decrease In Right Of Use Assets Related To Lease Modifications And Termination", "terseLabel": "Decrease in right-of-use assets related to lease modification and termination" } } }, "localname": "DecreaseInRightOfUseAssetsRelatedToLeaseModificationsAndTermination", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "cycn_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Deferred Tax Assets Capitalized Research And Development Costs", "terseLabel": "Capitalized research and development" } } }, "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cycn_DeferredTaxAssetsOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.", "label": "Deferred Tax Assets Operating Lease Liabilities", "terseLabel": "Operating lease - liability" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cycn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating lease, right of use assets.", "label": "Deferred Tax Liabilities Operating Lease Right Of Use Assets", "negatedLabel": "Operating lease - right of use asset" } } }, "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cycn_DeferredTaxLiabilityPrepaidSubleaseTermination": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liability prepaid sublease termination.", "label": "Deferred Tax Liability Prepaid Sublease Termination", "negatedLabel": "Prepaid sublease termination" } } }, "localname": "DeferredTaxLiabilityPrepaidSubleaseTermination", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cycn_DefinedContributionPlanEmployerMatchingContributionMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The maximum amount per employee of the employer's matching contributions.", "label": "Defined Contribution Plan Employer Matching Contribution Maximum", "terseLabel": "Maximum amount of employer matching contribution" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionMaximum", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanDetails" ], "xbrltype": "monetaryItemType" }, "cycn_DevelopmentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the agreement under which Company provides services to Ironwood and the amounts earned are recorded as revenue.", "label": "Development Agreement [Member]", "terseLabel": "Development agreement" } } }, "localname": "DevelopmentAgreementMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cycn_DevelopmentAgreementPeriodForNotificationOfCancellation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The term advance notice either party must give to cancel the Development Agreement.", "label": "Development Agreement Period For Notification Of Cancellation", "terseLabel": "Development Agreement, period for notification of cancellation" } } }, "localname": "DevelopmentAgreementPeriodForNotificationOfCancellation", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "durationItemType" }, "cycn_DevelopmentAgreementRenewalPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The term of automatic renewal for the development agreement.", "label": "Development Agreement Renewal Period", "terseLabel": "Development Agreement, renewal period" } } }, "localname": "DevelopmentAgreementRenewalPeriod", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "durationItemType" }, "cycn_DistributionOfCommonStockSharesByParentCompanyUponSeparation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock distributed on prorata basis by parent company upon separation.", "label": "Distribution Of Common Stock Shares By Parent Company Upon Separation", "terseLabel": "Distribution of common stock by Ironwood upon separation (in shares)" } } }, "localname": "DistributionOfCommonStockSharesByParentCompanyUponSeparation", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "cycn_DividendsCommonStockStockRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock dividend ratio applied to the distribution of shares for the spin-off of the reporting entity from its Parent, as of the separation date.", "label": "Dividends Common Stock Stock Ratio", "terseLabel": "Common stock dividend issued (shares of Cyclerion per ten shares of Ironwood)" } } }, "localname": "DividendsCommonStockStockRatio", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "pureItemType" }, "cycn_DonorAdvisedFundOfChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A donor advised fund which received contributions from the chief executive officer.", "label": "Donor Advised Fund Of Chief Executive Officer [Member]", "terseLabel": "American Endowment Foundation" } } }, "localname": "DonorAdvisedFundOfChiefExecutiveOfficerMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cycn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementShortfallsWindfallsAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement, shortfall or windfall.", "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Payment Arrangement Shortfalls Windfalls Amount", "terseLabel": "Share-based compensation - shortfalls/(windfalls)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementShortfallsWindfallsAmount", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "cycn_GainLossOnLeaseModificationAndTermination": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain loss on lease modification and termination.", "label": "Gain Loss On Lease Modification And Termination", "negatedLabel": "(Gain) / loss on lease modification and termination" } } }, "localname": "GainLossOnLeaseModificationAndTermination", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cycn_GainLossOnModificationOfLease": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on modification of lease.", "label": "Gain Loss On Modification Of Lease", "negatedLabel": "Gain (Loss) on Termination of Lease", "terseLabel": "Gain (loss) on lease modification", "verboseLabel": "Gain (Loss) on Termination of Lease" } } }, "localname": "GainLossOnModificationOfLease", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "cycn_GrossSubleaseIncomeNetOfRentExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross amount of sublease income, net of the related rent expense from the Master Lease.", "label": "Gross Sublease Income Net Of Rent Expense", "terseLabel": "Gross sublease income, net of rent expense" } } }, "localname": "GrossSubleaseIncomeNetOfRentExpense", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "monetaryItemType" }, "cycn_HeadquartersLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a direct operating lease for existing premises located at 301 Binney Street, Cambridge, MA.", "label": "Headquarters Lease [Member]", "terseLabel": "Head Lease" } } }, "localname": "HeadquartersLeaseMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "domainItemType" }, "cycn_HealthCareTrustAmountDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Care Trust Amount Description", "label": "Health Care Trust Amount Description", "terseLabel": "Health care trust fund, Description" } } }, "localname": "HealthCareTrustAmountDescription", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "cycn_IncreaseDecreaseInAccruedResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in accrued research and development expense.", "label": "Increase Decrease In Accrued Research And Development", "terseLabel": "Accrued research and development costs" } } }, "localname": "IncreaseDecreaseInAccruedResearchAndDevelopment", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cycn_IncreaseDecreaseInOperatingLeaseAssets": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating lease assets.", "label": "Increase Decrease In Operating Lease Assets", "negatedLabel": "Operating lease assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseAssets", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cycn_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cycn_InitialTermOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent information pertaining to initial term of agreement.", "label": "Initial Term Of Agreement", "terseLabel": "Development Agreement, initial term" } } }, "localname": "InitialTermOfAgreement", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "durationItemType" }, "cycn_InterestAndOtherIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to transactions recorded in interest and other income.", "label": "Interest And Other Income [Member]", "terseLabel": "Interest and other income, net" } } }, "localname": "InterestAndOtherIncomeMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "domainItemType" }, "cycn_InterestAndOtherIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for interest and other income.", "label": "Interest And Other Income Policy Policy [Text Block]", "terseLabel": "Interest and Other Income, Net" } } }, "localname": "InterestAndOtherIncomePolicyPolicyTextBlock", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cycn_IronwoodPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ironwood Pharmaceuticals, Inc., the parent of the reporting entity. The reporting entity was spun off from Ironwood.", "label": "Ironwood Pharmaceuticals Inc [Member]", "terseLabel": "Ironwood" } } }, "localname": "IronwoodPharmaceuticalsIncMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cycn_JefferiesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jefferies LLC.", "label": "Jefferies L L C [Member]", "terseLabel": "Jefferies LLC" } } }, "localname": "JefferiesLLCMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "cycn_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "cycn_LeaseDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of information about leases.", "label": "Lease Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeaseDisclosureTextBlock", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "cycn_LeaseModificationDecreaseInRemainingOperatingLeasePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of decrease in remaining operating lease payments related to a lease modification.", "label": "Lease Modification Decrease In Remaining Operating Lease Payments", "terseLabel": "Decrease in remaining operating lease payments" } } }, "localname": "LeaseModificationDecreaseInRemainingOperatingLeasePayments", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "monetaryItemType" }, "cycn_LeaseModificationDecreaseInSecurityDeposit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of decrease in security deposit related to a lease modification.", "label": "Lease Modification Decrease In Security Deposit", "terseLabel": "Decrease in security deposit" } } }, "localname": "LeaseModificationDecreaseInSecurityDeposit", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "monetaryItemType" }, "cycn_LeasesMaturityOfOperatingLeasePaymentsAsLesseeAndMaturityOfOperatingLeasePaymentsToBeReceivedAsLessorTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash outflows (inflows) for operating lease payments to be made as lessee and the related payments to be received as lessor from the sublease of a portion of the leased space.", "label": "Leases Maturity Of Operating Lease Payments As Lessee And Maturity Of Operating Lease Payments To Be Received As Lessor Table [Text Block]", "terseLabel": "Future minimum lease payments under non-cancelable operating leases under ASC 842" } } }, "localname": "LeasesMaturityOfOperatingLeasePaymentsAsLesseeAndMaturityOfOperatingLeasePaymentsToBeReceivedAsLessorTableTextBlock", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "cycn_LesseeOperatingLeaseAnnualBaseRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of annual base rent under operating lease.", "label": "Lessee Operating Lease Annual Base Rent", "terseLabel": "Annual base rent" } } }, "localname": "LesseeOperatingLeaseAnnualBaseRent", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "monetaryItemType" }, "cycn_LesseeOperatingLeaseAnnualBaseRentIncreasePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of increase in annual base rent under operating lease.", "label": "Lessee Operating Lease Annual Base Rent Increase Percent", "terseLabel": "Increase in base rent on a yearly basis (as a percent)" } } }, "localname": "LesseeOperatingLeaseAnnualBaseRentIncreasePercent", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "percentItemType" }, "cycn_LesseeOperatingLeaseNumberOfExtensionOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of extension options under operating lease.", "label": "Lessee Operating Lease Number Of Extension Option", "terseLabel": "Number of extension option" } } }, "localname": "LesseeOperatingLeaseNumberOfExtensionOption", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "integerItemType" }, "cycn_LesseeOperatingLeaseRentAbatement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of rent abatement.", "label": "Lessee Operating Lease Rent Abatement", "terseLabel": "Abatement of base rent" } } }, "localname": "LesseeOperatingLeaseRentAbatement", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "monetaryItemType" }, "cycn_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of supplemental cash flow information related to leases.", "label": "Lessee Operating Lease Supplemental Cash Flow Information Table [Text Block]", "terseLabel": "Schedule of supplemental cash flow information related to leases" } } }, "localname": "LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "cycn_LessorSubleaseAbatementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of abatement of base rent under the terms of the sublease agreement.", "label": "Lessor Sublease Abatement Period", "terseLabel": "Sublease, Abatement period" } } }, "localname": "LessorSubleaseAbatementPeriod", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "durationItemType" }, "cycn_LessorSubleaseAdditionalSecurityDepositToBeReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of additional security deposit to be provided by the sublessee as defined by the sublease agreement.", "label": "Lessor Sublease Additional Security Deposit To Be Received", "terseLabel": "Sublease, Additional security deposit to be received" } } }, "localname": "LessorSubleaseAdditionalSecurityDepositToBeReceived", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "monetaryItemType" }, "cycn_LessorSubleaseInitialSecurityDepositReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of initial security deposit provided by the sublessee in the form of a letter of credit.", "label": "Lessor Sublease Initial Security Deposit Received", "terseLabel": "Sublease, Initial security deposit received" } } }, "localname": "LessorSubleaseInitialSecurityDepositReceived", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "monetaryItemType" }, "cycn_LessorSubleaseNumberOfExtensionOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of extensions available to the sublessee under the terms of the sublease agreement.", "label": "Lessor Sublease Number Of Extension Options", "terseLabel": "Sublease, Number of extension options" } } }, "localname": "LessorSubleaseNumberOfExtensionOptions", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "integerItemType" }, "cycn_LicenseAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement abstract.", "label": "License Agreement [Abstract]" } } }, "localname": "LicenseAgreementAbstract", "nsuri": "http://www.cyclerion.com/20211231", "xbrltype": "stringItemType" }, "cycn_LicenseAgreementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for license agreements.", "label": "License Agreements [Text Block]", "terseLabel": "License Agreements" } } }, "localname": "LicenseAgreementsTextBlock", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreements" ], "xbrltype": "textBlockItemType" }, "cycn_MarketBasedStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Market based stock option.", "label": "Market Based Stock Option [Member]", "terseLabel": "Market-based Stock Options" } } }, "localname": "MarketBasedStockOptionMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails" ], "xbrltype": "domainItemType" }, "cycn_MaximumAmountOfAggregateInitialOfferingPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum amount of Aggregate initial offering price.", "label": "Maximum Amount Of Aggregate Initial Offering Price", "terseLabel": "Maximum amount of Aggregate initial offering price" } } }, "localname": "MaximumAmountOfAggregateInitialOfferingPrice", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "cycn_NetDeferredAssetsLiabilitiesBeforeValuationAllowance": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of deferred tax assets, net of deferred tax liabilities, before valuation allowance.", "label": "Net Deferred Assets Liabilities Before Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "NetDeferredAssetsLiabilitiesBeforeValuationAllowance", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cycn_NetParentCompanyInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to net parent company investment.", "label": "Net Parent Company Investment [Member]", "terseLabel": "Net parent investment" } } }, "localname": "NetParentCompanyInvestmentMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "cycn_NoncashInvestingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noncash Investing Items Abstract.", "label": "Noncash Investing Items [Abstract]", "terseLabel": "Non-cash investing activities" } } }, "localname": "NoncashInvestingItemsAbstract", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "cycn_NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Not Found During Migration Deprecated Concept Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]" } } }, "localname": "NotFoundDuringMigrationDeprecatedConceptDefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract", "nsuri": "http://www.cyclerion.com/20211231", "xbrltype": "stringItemType" }, "cycn_November2020WorkforceReductionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The workforce reduction plan which initiated on November 5, 2020.", "label": "November2020 Workforce Reduction Plan [Member]", "terseLabel": "November 2020 Workforce Reduction" } } }, "localname": "November2020WorkforceReductionPlanMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "domainItemType" }, "cycn_NumberOfCommonStockSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common stock sold", "label": "Number of common stock sold" } } }, "localname": "NumberOfCommonStockSold", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "sharesItemType" }, "cycn_NumberOfInvestors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of investors.", "label": "Number Of Investors", "terseLabel": "Number of investors for private placement" } } }, "localname": "NumberOfInvestors", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "integerItemType" }, "cycn_October2019WorkforceReductionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The workforce reduction plan which initiated on October 30, 2019.", "label": "October2019 Workforce Reduction Plan [Member]", "terseLabel": "October 2019 Workforce Reduction" } } }, "localname": "October2019WorkforceReductionPlanMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "domainItemType" }, "cycn_OperatingLeaseSubleaseExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense related to subleases.", "label": "Operating Lease Sublease Expense", "terseLabel": "Rent expense related to sublease" } } }, "localname": "OperatingLeaseSubleaseExpense", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLesseeDetails" ], "xbrltype": "monetaryItemType" }, "cycn_OperatingLeaseTenantImprovementsReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash inflow from tenant improvements received during the period under an operating lease arrangement.", "label": "Operating Lease Tenant Improvements Received", "terseLabel": "Cash received for tenant improvements included in the measurement of lease liabilities (in thousands)" } } }, "localname": "OperatingLeaseTenantImprovementsReceived", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "cycn_OtherRelatedPartyTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the other related party transactions.", "label": "Other Related Party Transactions [Member]", "terseLabel": "Other Related Party Transactions" } } }, "localname": "OtherRelatedPartyTransactionsMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cycn_PatentCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Patent Costs [Abstract]", "terseLabel": "Patent Costs" } } }, "localname": "PatentCostsAbstract", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "cycn_PatentCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for patent costs.", "label": "Patent Costs Policy [Text Block]", "terseLabel": "Patent Costs" } } }, "localname": "PatentCostsPolicyTextBlock", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cycn_PaycheckProtectionProgramLoanCaresActPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the accounting policy on paycheck protection program loan, CARES act.", "label": "Paycheck Protection Program Loan Cares Act Policy [Text Block]", "terseLabel": "Paycheck Protection Program Loan" } } }, "localname": "PaycheckProtectionProgramLoanCaresActPolicyTextBlock", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cycn_PaycheckProtectionProgramLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Paycheck Protection Program Loan.", "label": "Paycheck Protection Program Loan [Member]", "terseLabel": "PPP Loan" } } }, "localname": "PaycheckProtectionProgramLoanMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPaycheckProtectionProgramLoanDetails" ], "xbrltype": "domainItemType" }, "cycn_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paycheck Protection Program Member.", "label": "Paycheck Protection Program [Member]", "terseLabel": "PPP Loan" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "cycn_PaymentOfCashMilestone": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment of cash milestone.", "label": "Payment Of Cash Milestone", "terseLabel": "Additional milestone cash payment" } } }, "localname": "PaymentOfCashMilestone", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cycn_PaymentsForLeaseModificationInitialDirectCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow for initial direct costs of lease modification.", "label": "Payments For Lease Modification Initial Direct Costs", "terseLabel": "Cash paid for initial direct costs of lease modification" } } }, "localname": "PaymentsForLeaseModificationInitialDirectCosts", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "monetaryItemType" }, "cycn_PaymentsForLeaseModificationTerminationFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow for a lease termination fee.", "label": "Payments For Lease Modification Termination Fee", "terseLabel": "Cash paid for lease termination fees" } } }, "localname": "PaymentsForLeaseModificationTerminationFee", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "monetaryItemType" }, "cycn_PaymentsForLeaseModificationTerminationFeeAndOtherInitialDirectCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow for termination fees and other initial direct costs of lease modification.", "label": "Payments For Lease Modification Termination Fee And Other Initial Direct Costs", "terseLabel": "Cash paid for initial direct costs of lease modification" } } }, "localname": "PaymentsForLeaseModificationTerminationFeeAndOtherInitialDirectCosts", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cycn_PrepaidRoomsBalanceRelatedToOtherAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid rooms balance related to other assets.", "label": "Prepaid rooms balance reclassified from other assets", "terseLabel": "Prepaid Rooms Balance Related To Other Assets" } } }, "localname": "PrepaidRoomsBalanceRelatedToOtherAssets", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "monetaryItemType" }, "cycn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement, net of related issuance costs.", "label": "Proceeds From Issuance Of Private Placement Net Of Issuance Costs", "terseLabel": "Net proceeds from issuance of shares to accredited investors" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "cycn_ProvisionForIncomeTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Provision for income taxes.", "label": "Provision For Income Taxes", "terseLabel": "Provision for income tax" } } }, "localname": "ProvisionForIncomeTaxes", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "cycn_PtcGrantAward": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "PTC Grant Award", "label": "PTC Grant Award" } } }, "localname": "PtcGrantAward", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cycn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToTheConsolidatedBalanceSheets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets.", "label": "Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets" } } }, "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashToTheConsolidatedBalanceSheets", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "cycn_RelatedPartyAccountsReceivablePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for related party accounts receivable.", "label": "Related Party Accounts Receivable Policy Policy [Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "RelatedPartyAccountsReceivablePolicyPolicyTextBlock", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cycn_RelatedPartyTransactionResearchAndDevelopmentTransactionSupportServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of research and development transaction support services.", "label": "Related Party Transaction Research And Development Transaction Support Services", "terseLabel": "Payments to provide research and development transaction support services" } } }, "localname": "RelatedPartyTransactionResearchAndDevelopmentTransactionSupportServices", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "cycn_RentableSquareFeetOfShortTermSubleaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents the rentable square feet of short term sublease agreement.", "label": "Rentable Square Feet Of Short Term Sublease Agreement", "terseLabel": "Rentable square feet" } } }, "localname": "RentableSquareFeetOfShortTermSubleaseAgreement", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLesseeDetails" ], "xbrltype": "areaItemType" }, "cycn_RentableSquareFeetSubleaseToThirdParty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of leased space the Company has agreed to sublease to a third party.", "label": "Rentable Square Feet Sublease To Third Party", "terseLabel": "Space subleased to third party (in square feet)" } } }, "localname": "RentableSquareFeetSubleaseToThirdParty", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "areaItemType" }, "cycn_RentableSquareFeetTerminatedFromLeaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of leased space terminated from the lease agreement.", "label": "Rentable Square Feet Terminated From Lease Agreement", "terseLabel": "Rentable space terminated from lease agreement (in square feet)" } } }, "localname": "RentableSquareFeetTerminatedFromLeaseAgreement", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "areaItemType" }, "cycn_RentableSquareFeetTerminatedSubleaseToThirdPartyFromLeaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rentable square feet sublease to third party terminated from lease agreement.", "label": "Rentable Square Feet Terminated Sublease To Third Party From Lease Agreement", "terseLabel": "Rentable space terminated from lease agreement (in square feet)" } } }, "localname": "RentableSquareFeetTerminatedSubleaseToThirdPartyFromLeaseAgreement", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "areaItemType" }, "cycn_RevenueFromDevelopmentAgreement": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from development agreement", "label": "Revenue From Development Agreement", "terseLabel": "Revenue from development agreement" } } }, "localname": "RevenueFromDevelopmentAgreement", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "cycn_RevenueFromGrant": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from grant.", "label": "Revenue From Grant", "terseLabel": "Revenue from grants" } } }, "localname": "RevenueFromGrant", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "cycn_RevenueFromLicense": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from license.", "label": "Revenue From License", "terseLabel": "Revenue from license agreement" } } }, "localname": "RevenueFromLicense", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "cycn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Schedule Of Property Plant And Equipment Useful Life Table [Text Block]", "terseLabel": "Schedule of Estimated Useful Lives of Property and Equipment" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "cycn_ScheduleOfShareBasedPaymentAwardPerformanceSharesValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of performance shares, including, but not limited to: (a) expected term of performance shares, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Performance Shares Valuation Assumptions Table [Text Block]", "terseLabel": "Schedule of weighted-average assumptions used in estimating the fair value of the stock awards containing market conditions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardPerformanceSharesValuationAssumptionsTableTextBlock", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "cycn_SecondAmendedHeadquartersLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second amended headquarters lease.", "label": "Second Amended Headquarters Lease [Member]", "terseLabel": "Second Lease Amendment" } } }, "localname": "SecondAmendedHeadquartersLeaseMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "domainItemType" }, "cycn_SecurityDepositReturned": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Security deposit returned to the company.", "label": "Security Deposit Returned", "terseLabel": "Security Deposit Returned" } } }, "localname": "SecurityDepositReturned", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "cycn_SegmentInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Segment Information [Abstract]", "terseLabel": "Segment Information" } } }, "localname": "SegmentInformationAbstract", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSegmentsAndCashDetails" ], "xbrltype": "stringItemType" }, "cycn_SeparationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to separation agreement.", "label": "Separation Agreement [Member]", "terseLabel": "Separation agreement" } } }, "localname": "SeparationAgreementMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cycn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingMeasurementThresholdNumberOfConsecutiveTradingDaysConsidered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of consecutive trading days over which the average closing price of the Company's share price is considered for measurement of vesting of stock awards.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Measurement Threshold Number Of Consecutive Trading Days Considered", "terseLabel": "Threshold consecutive trading days, used as a base for measurement of vesting of stock awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingMeasurementThresholdNumberOfConsecutiveTradingDaysConsidered", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails" ], "xbrltype": "integerItemType" }, "cycn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsImpactOfConversionRelatedToSpinOff": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares made during the period on other than stock (or unit) option plans due to the impact of conversion related to spin-off.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Impact Of Conversion Related To Spin Off", "terseLabel": "Aggregate impact of conversion related to spin-off (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsImpactOfConversionRelatedToSpinOff", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "sharesItemType" }, "cycn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsImpactOfConversionRelatedToSpinOffWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value due to the impact of conversion related to spin-off to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Impact Of Conversion Related To Spin Off Weighted Average Grant Date Fair Value", "terseLabel": "Aggregate impact of conversion related to spin-off (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsImpactOfConversionRelatedToSpinOffWeightedAverageGrantDateFairValue", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "decimalItemType" }, "cycn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsImpactOfConversionRelatedToSpinOff": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options due to conversion related to spin-off.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Impact Of Conversion Related To Spin Off", "terseLabel": "Aggregate impact of conversion related to spin-off (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsImpactOfConversionRelatedToSpinOff", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "cycn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsImpactOfConversionRelatedToSpinOffWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options due to conversion related to spin off.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Impact Of Conversion Related To Spin Off Weighted Average Exercise Price", "terseLabel": "Aggregate impact of conversion related to spin-off (in dollars per shares)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsImpactOfConversionRelatedToSpinOffWeightedAverageExercisePrice", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "cycn_ShareBasedCompensationExpense": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation expense", "label": "Share Based Compensation Expense", "verboseLabel": "Share based compensation expense" } } }, "localname": "ShareBasedCompensationExpense", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails" ], "xbrltype": "monetaryItemType" }, "cycn_ShareBasedCompensationUponSeparation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of share based compensation upon separation from parent company.", "label": "Share Based Compensation Upon Separation", "terseLabel": "Ironwood allocation - share-based compensation" } } }, "localname": "ShareBasedCompensationUponSeparation", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "cycn_SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share\u2011based compensation expense related to issuance of stock options to non-employees.", "label": "Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees", "terseLabel": "Share based compensation expense related to issuance of stock options and RSUs to non employees" } } }, "localname": "SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "cycn_SharesDonatedParentCompany": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of Parent Company common stock donated to donor advised fund.", "label": "Shares Donated Parent Company", "terseLabel": "Number of shares of Ironwood common stock donated to American Endowment Foundation" } } }, "localname": "SharesDonatedParentCompany", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "cycn_StockBasedCompensationFromTheModificationOfShareBasedEquityAwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock-based compensation from the modification of share based equity awards.", "label": "Stock Based Compensation From The Modification Of Share Based Equity Awards", "terseLabel": "Stock-based compensation from the modification of share based equity awards" } } }, "localname": "StockBasedCompensationFromTheModificationOfShareBasedEquityAwards", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "monetaryItemType" }, "cycn_StockIssuedDuringPeriodSharesExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan and exercise of stock options and Restricted Stock Units.", "label": "Stock Issued During Period Shares Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "cycn_StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period as a result of an employee stock purchase plan and exercise of stock options and Restricted Stock Units.", "label": "Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "cycn_StockIssuedDuringPeriodValueRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount received from related party for issuance of shares of common stock.", "label": "Stock Issued During Period Value Related Party", "terseLabel": "Investment in common stock by related party" } } }, "localname": "StockIssuedDuringPeriodValueRelatedParty", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "cycn_StockIssuedDuringPeriodValuesInShareBasedCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Values in Share Based Compensation", "label": "Stock Issued During Period Values in Share Based Compensation", "terseLabel": "Issuance of common stock - ATM (in Values)" } } }, "localname": "StockIssuedDuringPeriodValuesInShareBasedCompensation", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "cycn_SubleaseAdditionalSecurityDepositPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period after the commencement date within which the additional security deposit is due under the operating sublease.", "label": "Sublease Additional Security Deposit Period", "terseLabel": "Sublease, additional security deposit period" } } }, "localname": "SubleaseAdditionalSecurityDepositPeriod", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "durationItemType" }, "cycn_SubleaseAnnualBaseRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of annual base rent under the operating sublease.", "label": "Sublease Annual Base Rent", "terseLabel": "Sublease, Annual base rent" } } }, "localname": "SubleaseAnnualBaseRent", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "monetaryItemType" }, "cycn_SubleaseAnnualBaseRentAbatement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of abatement on annual base rent under the operating sublease.", "label": "Sublease Annual Base Rent Abatement", "terseLabel": "Sublease, Abatement of base rent" } } }, "localname": "SubleaseAnnualBaseRentAbatement", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "monetaryItemType" }, "cycn_SubleaseAnnualBaseRentIncreasePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of increase in annual base rent under the operating sublease.", "label": "Sublease Annual Base Rent Increase Percent", "terseLabel": "Sublease, Increase in base rent over the term of the lease (as a percent)" } } }, "localname": "SubleaseAnnualBaseRentIncreasePercent", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "percentItemType" }, "cycn_SubleaseInitialTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The initial term of the sublease.", "label": "Sublease Initial Term Of Contract", "terseLabel": "Sublease initial term" } } }, "localname": "SubleaseInitialTermOfContract", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLesseeDetails" ], "xbrltype": "durationItemType" }, "cycn_SubleaseTerminationAgreementEstimatedFairValueOfRooms": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sublease termination agreement estimated fair value of rooms.", "label": "Sublease Termination Agreement Estimated Fair Value Of Rooms", "terseLabel": "Sublease termination agreement estimated fair value of rooms" } } }, "localname": "SubleaseTerminationAgreementEstimatedFairValueOfRooms", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "monetaryItemType" }, "cycn_SubleaseTerminationAgreementEstimatedFairValueOfServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sublease termination agreement estimated fair value of services.", "label": "Sublease Termination Agreement Estimated Fair Value Of Services", "terseLabel": "Sublease termination agreement estimated fair value of services" } } }, "localname": "SubleaseTerminationAgreementEstimatedFairValueOfServices", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "monetaryItemType" }, "cycn_SubleaseTerminationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sublease termination agreement.", "label": "Sublease Termination Agreement [Member]", "terseLabel": "Sublease Termination Agreement" } } }, "localname": "SubleaseTerminationAgreementMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "domainItemType" }, "cycn_SubleaseTerminationAgreementPrepaidRoomsAndServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sublease termination agreement prepaid rooms and services.", "label": "Sublease Termination Agreement Prepaid Rooms And Services", "terseLabel": "Sublease termination agreement prepaid rooms and services" } } }, "localname": "SubleaseTerminationAgreementPrepaidRoomsAndServices", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "cycn_SubleaseTerminationIncomeLossNet": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sublease termination income loss net.", "label": "Sublease Termination Income Loss Net", "negatedLabel": "Sublease termination income, net", "terseLabel": "Sublease termination income, net" } } }, "localname": "SubleaseTerminationIncomeLossNet", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "cycn_SubleasedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The actual duration of the sublease.", "label": "Subleased Term", "terseLabel": "Subleased term" } } }, "localname": "SubleasedTerm", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLesseeDetails" ], "xbrltype": "durationItemType" }, "cycn_SurrenderedLeaseSpace": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Surrendered Lease Space.", "label": "Surrendered Lease Space", "terseLabel": "Surrendered Lease Space" } } }, "localname": "SurrenderedLeaseSpace", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "areaItemType" }, "cycn_TerminationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination agreement.", "label": "Termination Agreement [Member]", "terseLabel": "Termination Agreement" } } }, "localname": "TerminationAgreementMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "domainItemType" }, "cycn_TransitionServicesAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the agreement under which the Company provides services to Ironwood and vice versa and those are recorded as operating expenses.", "label": "Transition Services Agreements [Member]", "terseLabel": "Transition services agreements" } } }, "localname": "TransitionServicesAgreementsMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "cycn_UnvestedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to unvested stock options.", "label": "Unvested Stock Options [Member]", "terseLabel": "Unvested stock options" } } }, "localname": "UnvestedStockOptionsMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "cycn_UpFrontPaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Up Front Payment Received.", "label": "Up Front Payment Received", "terseLabel": "Up Front Payment Received" } } }, "localname": "UpFrontPaymentReceived", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "cycn_VestedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to vested stock options.", "label": "Vested Stock Options [Member]", "terseLabel": "Vested stock options" } } }, "localname": "VestedStockOptionsMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "cycn_WeworkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wework.", "label": "WeWork [Member]", "terseLabel": "WeWork" } } }, "localname": "WeworkMember", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "domainItemType" }, "cycn_WorkforceReductionPlan2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Workforce reduction plan 2019.", "label": "Workforce Reduction Plan2019 [Member]", "terseLabel": "October 2019 Workforce Reduction" } } }, "localname": "WorkforceReductionPlan2019Member", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "domainItemType" }, "cycn_WorkforceReductionPlan2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Workforce reduction plan 2020.", "label": "Workforce Reduction Plan2020 [Member]", "terseLabel": "2020 Workforce Reduction" } } }, "localname": "WorkforceReductionPlan2020Member", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "domainItemType" }, "cycn_WriteOffLeaseUnamortizedDirectCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Write off lease unamortized direct cost.", "label": "Write Off Lease Unamortized Direct Cost", "terseLabel": "Write off lease unamortized direct cost" } } }, "localname": "WriteOffLeaseUnamortizedDirectCost", "nsuri": "http://www.cyclerion.com/20211231", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityNumberOfEmployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of persons employed by the Entity", "label": "Entity Number of Employees", "terseLabel": "Number of employees" } } }, "localname": "EntityNumberOfEmployees", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "decimalItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r585" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Peter Hecht" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r97", "r203", "r208", "r214", "r392", "r393", "r398", "r399", "r464", "r554" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r97", "r203", "r208", "r214", "r392", "r393", "r398", "r399", "r464", "r554" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r219", "r244", "r305", "r307", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r535", "r537", "r555", "r556" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r219", "r244", "r305", "r307", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r535", "r537", "r555", "r556" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]", "verboseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails" ], "xbrltype": "domainItemType" }, "srt_PresidentMember": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "label": "President [Member]", "terseLabel": "Mark Currie" } } }, "localname": "PresidentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r155", "r274", "r276", "r482", "r534", "r536" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureGrantRevenue", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r155", "r274", "r276", "r482", "r534", "r536" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureGrantRevenue", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r219", "r244", "r285", "r305", "r307", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r535", "r537", "r555", "r556" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r219", "r244", "r285", "r305", "r307", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r535", "r537", "r555", "r556" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r107", "r306" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r107", "r111", "r306" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r107", "r111", "r200", "r306", "r469" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable And Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r37", "r467" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r37", "r96", "r460", "r461" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Related Parties, Current", "terseLabel": "Related party accounts payable" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r24", "r159", "r160" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedPartiesCurrent": { "auth_ref": [ "r45", "r96", "r459", "r461" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.", "label": "Accounts Receivable, Related Parties, Current", "terseLabel": "Related party accounts receivable" } } }, "localname": "AccountsReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r10", "r11", "r39" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 0.0, "parentTag": "cycn_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Accrued incentive compensation" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r10", "r11", "r39" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "cycn_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued severance and benefit costs" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Liabilities [Abstract]" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r10", "r11", "r39" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "cycn_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r10", "r11", "r39" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "cycn_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "terseLabel": "Salaries" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedVacationCurrent": { "auth_ref": [ "r10", "r39", "r284" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "cycn_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Vacation, Current", "terseLabel": "Accrued vacation" } } }, "localname": "AccruedVacationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r35", "r175" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation and amortization", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r27", "r50", "r51", "r52", "r521", "r542", "r543" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r25" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r99", "r100", "r101", "r346", "r347", "r348", "r406" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Paid in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r309", "r311", "r352", "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense related to issuance of stock options and RSUs to employees and employee stock purchase plan", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r311", "r340", "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits": { "auth_ref": [ "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of stock options or restrictive stock units (RSUs).", "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Options and Restrictive Stock Units" } } }, "localname": "AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive securities excluded from the calculation of diluted loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r49", "r52", "r58", "r59", "r60", "r397" ], "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of Land", "terseLabel": "Rented space (in square feet)" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r92", "r139", "r148", "r153", "r162", "r203", "r204", "r205", "r207", "r208", "r209", "r210", "r211", "r212", "r214", "r215", "r392", "r398", "r418", "r465", "r467", "r500", "r518" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r47", "r92", "r162", "r203", "r204", "r205", "r207", "r208", "r209", "r210", "r211", "r212", "r214", "r215", "r392", "r398", "r418", "r465", "r467" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r312", "r344" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r98", "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Nature of Business" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r83", "r84", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Fixed asset purchases in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r32", "r467", "r544", "r545" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "Cash, Ending Balance", "periodStartLabel": "Cash, Beginning Balance", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSegmentsAndCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash equivalents:" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r32", "r81" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlowsParenthetical": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlowsParenthetical", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSegmentsAndCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Total cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r12", "r82" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r12", "r82", "r498" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r76", "r81", "r86" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlowsParenthetical": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated and combined balance sheets" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlowsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r76", "r419" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Nature of Business" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r42", "r199", "r507", "r525" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r196", "r197", "r198", "r201", "r550" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r99", "r100", "r406" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r23", "r249" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r23", "r467" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, no par value, 400,000,000 shares authorized and 43,410,185 issued and outstanding at December 31, 2021 and 400,000,000 shares authorized and 34,047,300 issued and outstanding at December 31, 2020", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r54", "r56", "r65", "r391", "r401", "r510", "r531" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive loss", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r88", "r394" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditDerivativesByContractTypeAxis": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Information by major type of contract of credit derivatives.", "label": "Credit Derivatives Contract Type [Axis]", "terseLabel": "Credit Derivatives Contract Type" } } }, "localname": "CreditDerivativesByContractTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditDerivativesContractTypeDomain": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Represents major types of credit derivative contracts.", "label": "Credit Derivatives Contract Type [Domain]", "terseLabel": "Credit Derivatives Contract Type" } } }, "localname": "CreditDerivativesContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r18", "r19", "r91", "r97", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r429", "r501", "r503", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPaycheckProtectionProgramLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Debt Instrument, Decrease, Forgiveness", "terseLabel": "PPP loan forgiveness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r41", "r91", "r97", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r429" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPaycheckProtectionProgramLoanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r20", "r21", "r368", "r502", "r515" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails": { "order": 0.0, "parentTag": "cycn_NetDeferredAssetsLiabilitiesBeforeValuationAllowance", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities", "totalLabel": "Deferred Tax Liabilities, Gross, Total" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentReceivablesNet": { "auth_ref": [ "r46", "r430", "r431", "r432", "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of rental income recognized over rental payment required by lease.", "label": "Deferred Rent Receivables, Net", "terseLabel": "Rent receivables outstanding from subtenant" } } }, "localname": "DeferredRentReceivablesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "totalLabel": "Deferred Revenue, Total" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r369" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails": { "order": 1.0, "parentTag": "cycn_NetDeferredAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r371" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r376", "r377" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Deferred Tax Assets, Property, Plant and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r374", "r376", "r377" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryforwards", "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r376", "r377" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Share-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": { "auth_ref": [ "r376", "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Other", "terseLabel": "other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r376", "r377" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Accruals and reserves", "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r370" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesDeferredTaxAssetsLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r304" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Compensation expense related to the defined contribution 401(k) Savings Plan" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Contribution Plan Disclosure [Line Items]", "terseLabel": "Defined Contribution Plan" } } }, "localname": "DefinedContributionPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Matching contribution (as a percent of employee's contributions)" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Percent of compensation eligible employees may elect to contribute" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanTable": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.", "label": "Defined Contribution Plan [Table]", "terseLabel": "Defined Contribution Plan [Table]" } } }, "localname": "DefinedContributionPlanTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanTypeExtensibleList": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of defined contribution plan. Includes, but is not limited to, pension plan, other postretirement plan and special and contractual termination benefits payable upon retirement.", "label": "Defined Contribution Plan, Type [Extensible Enumeration]", "terseLabel": "401 (k) Savings Plan" } } }, "localname": "DefinedContributionPlanTypeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r79", "r173" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureGrantRevenue" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureGrantRevenue" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-based Compensation Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r96", "r206", "r208", "r209", "r213", "r214", "r215", "r459", "r505", "r529" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from Related Parties", "terseLabel": "Amounts due from related party", "totalLabel": "Due from Related Parties, Total" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r96", "r206", "r208", "r209", "r213", "r214", "r215", "r459", "r506", "r528" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Amounts due to related party", "totalLabel": "Due to Related Parties, Total" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted net loss per share (in dollars per share)", "totalLabel": "Earnings Per Share, Basic and Diluted, Total", "verboseLabel": "Net loss per share \u2014 basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Weighted average shares used in calculating:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDilutedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareDilutedLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r118", "r119", "r120", "r122" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r419" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r343" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized share-based compensation expense", "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Expected period to recognize the expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r343" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "unrecognized share-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r343" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized share-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Employee Stock Option Member" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r58", "r59", "r60", "r99", "r100", "r101", "r103", "r108", "r110", "r123", "r163", "r249", "r256", "r346", "r347", "r348", "r379", "r380", "r406", "r420", "r421", "r422", "r423", "r424", "r425", "r538", "r539", "r540", "r587" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r408", "r409", "r410", "r414" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r225", "r233", "r234", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r301", "r409", "r471", "r472", "r473" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r408", "r409", "r411", "r412", "r415" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r225", "r286", "r288", "r293", "r301", "r409", "r471" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r225", "r233", "r234", "r286", "r288", "r293", "r301", "r409", "r472" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r225", "r233", "r234", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r301", "r409", "r473" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r225", "r233", "r234", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r301", "r471", "r472", "r473" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r413", "r415" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Investment Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r167", "r168", "r170", "r171", "r483", "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r167", "r169" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation Adjustment" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r79" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Net loss on disposal of property and equipment", "terseLabel": "Loss on Disposition of Property Plant Equipment", "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total", "verboseLabel": "Gain Loss On Sale Of Property Plant Equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r436" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "Gain (Loss) on Termination of Lease", "terseLabel": "Gain (Loss) on Termination of Lease", "verboseLabel": "Gain (Loss) on Termination of Lease" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r79", "r237", "r238" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "terseLabel": "Gain on extinguishment of debt", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPaycheckProtectionProgramLoanDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionAxis": { "auth_ref": [ "r164", "r512", "r513", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Axis]", "terseLabel": "Geographic Distribution" } } }, "localname": "GeographicDistributionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicDistributionDomain": { "auth_ref": [ "r512", "r513", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Domain]", "terseLabel": "Geographic Distribution" } } }, "localname": "GeographicDistributionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Grant [Member]" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureGrantRevenue" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r172", "r178" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r93", "r383" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S." } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r63", "r139", "r147", "r149", "r152", "r154", "r497", "r508", "r513", "r532" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before benefit from income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r93", "r383" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "International" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r177", "r184" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r94", "r362", "r366", "r373", "r381", "r384", "r386", "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Income tax, penalties and interest accrued", "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r95", "r109", "r110", "r138", "r360", "r382", "r385", "r533" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income Tax Expense (Benefit), Total", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r57", "r358", "r359", "r366", "r367", "r372", "r378" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance", "verboseLabel": "Deferred tax assets, valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": { "auth_ref": [ "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.", "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Amount", "terseLabel": "Separation-related adjustments" } } }, "localname": "IncomeTaxReconciliationDispositionOfBusiness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Income tax benefit using U.S. federal statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "terseLabel": "Permanent differences", "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount, Total" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount", "terseLabel": "Non-deductible share-based compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r361" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State income taxes, net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "auth_ref": [ "r361" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount", "negatedLabel": "Tax credits", "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total" } } }, "localname": "IncomeTaxReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r78" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Payable, Related Parties", "terseLabel": "Related party accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r78" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r78" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "auth_ref": [ "r78" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Receivable, Related Parties", "negatedLabel": "Related party accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r78" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r78" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r78" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r78" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest and Other Income", "terseLabel": "Interest income generated form cash and cash equivalents balances", "totalLabel": "Interest and Other Income, Total" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndOtherIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest and Other Income [Abstract]", "terseLabel": "Interest and other income, net" } } }, "localname": "InterestAndOtherIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r61", "r137", "r427", "r428", "r511" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "totalLabel": "Interest Expense, Total" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPaycheckProtectionProgramLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r451", "r453" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Total lease costs", "totalLabel": "Lease, Cost, Total" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasePracticalExpedientsPackage": { "auth_ref": [ "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.", "label": "Lease, Practical Expedients, Package [true false]", "terseLabel": "Election of practical expedients package" } } }, "localname": "LeasePracticalExpedientsPackage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPaycheckProtectionProgramLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPaycheckProtectionProgramLoanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Incremental borrowing rate (as a percent)" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Total future minimum lease payments (receipts)", "totalLabel": "Total future minimum lease payments (receipts)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeaseOperatingPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "2026 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeaseOperatingPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2021 (remaining nine months)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeaseOperatingPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeaseOperatingPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeaseOperatingPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeaseOperatingPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeaseOperatingPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: present value adjustment" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeaseOperatingPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of lease" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether sublessee has option to extend operating sublease.", "label": "Lessee, Operating Sublease, Existence of Option to Extend [true false]", "terseLabel": "Operating sublease, option to extend" } } }, "localname": "LesseeOperatingSubleaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLesseeDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LessorLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessor, Lease, Description [Line Items]", "terseLabel": "Lessor Lease Description [Line Items]" } } }, "localname": "LessorLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorLeaseDescriptionTable": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessor's leases.", "label": "Lessor, Lease, Description [Table]", "terseLabel": "Lessor Lease Description [Table]" } } }, "localname": "LessorLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r30", "r92", "r162", "r418", "r467", "r504", "r523" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r40", "r92", "r162", "r203", "r204", "r205", "r208", "r209", "r210", "r211", "r212", "r214", "r215", "r393", "r398", "r399", "r418", "r465", "r466", "r467" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAndServiceMember": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License and Service [Member]", "terseLabel": "License And Service Member" } } }, "localname": "LicenseAndServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r76" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Proceeds from equity private placement and ATM" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r76" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r76", "r77", "r80" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r53", "r55", "r60", "r64", "r80", "r92", "r102", "r104", "r105", "r106", "r107", "r109", "r110", "r114", "r139", "r147", "r149", "r152", "r154", "r162", "r203", "r204", "r205", "r208", "r209", "r210", "r211", "r212", "r214", "r215", "r407", "r418", "r509", "r530" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cyclerion.com/20211231/taxonomy/role/StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss2": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r69" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Interest and other income, net", "totalLabel": "Nonoperating Income (Expense), Total" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Short-term note payable", "totalLabel": "Notes Payable, Current, Total" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable business segment" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSegmentsAndCashDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Computer and office equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenseMember": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.", "label": "Operating Expense [Member]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total cost and expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Cost and expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r139", "r147", "r149", "r152", "r154" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r439" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseImpairmentLoss": { "auth_ref": [ "r435" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "label": "Operating Lease, Impairment Loss", "terseLabel": "ROU asset, impairment loss" } } }, "localname": "OperatingLeaseImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Future minimum lease payments under non-cancelable operating leases under ASC 842" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeaseOperatingPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r438" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lease liability", "totalLabel": "Operating lease liabilities t June 30, 2021" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeaseOperatingPaymentsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r438" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities", "verboseLabel": "Less: current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeaseOperatingPaymentsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r438" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion", "verboseLabel": "Noncurrent lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesFutureMinimumLeaseOperatingPaymentsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r440", "r447" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities (in thousands)" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r437" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r450", "r453" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate of operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r449", "r453" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term of operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "totalLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Income Taxes" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r15", "r499", "r517" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets", "totalLabel": "Other Assets, Total" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r46", "r467" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r48" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss2": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherInformationPertainingToIncomeTaxes": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Description of events or transactions pertaining to income taxes classified as other.", "label": "Other Information Pertaining to Income Taxes", "terseLabel": "Income tax credit expiration description" } } }, "localname": "OtherInformationPertainingToIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherSundryLiabilitiesCurrent": { "auth_ref": [ "r39", "r202" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "cycn_AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.", "label": "Other Sundry Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherSundryLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r74", "r183" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "terseLabel": "Amount paid" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForTenantImprovements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.", "label": "Payments for Tenant Improvements", "terseLabel": "Payments for Tenant Improvements" } } }, "localname": "PaymentsForTenantImprovements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r71" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r285", "r287", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r308" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Defined Contribution Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance stock options" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r5", "r7", "r165", "r166" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses", "totalLabel": "Prepaid Expense, Current, Total" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net Proceeds from Issuance of Common Stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r72" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from equity private placement and ATM", "verboseLabel": "Proceeds from 2020 Equity private placement and ATM" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r72", "r345" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from exercises of stock options and ESPP", "totalLabel": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised, Total" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r73" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Notes Payable", "terseLabel": "Proceeds from short-term note payable", "totalLabel": "Proceeds from Notes Payable, Total" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPaycheckProtectionProgramLoanDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r70" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property and equipment", "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r546", "r548" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional Fees", "terseLabel": "Legal and other fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r53", "r55", "r60", "r75", "r92", "r102", "r109", "r110", "r139", "r147", "r149", "r152", "r154", "r162", "r203", "r204", "r205", "r208", "r209", "r210", "r211", "r212", "r214", "r215", "r391", "r395", "r396", "r400", "r401", "r407", "r418", "r513" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r35", "r176" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r179", "r551", "r552", "r553" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentDisposals": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Disposals", "terseLabel": "Property, Plant and Equipment, Disposals" } } }, "localname": "PropertyPlantAndEquipmentDisposals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r34", "r174" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Property and equipment. gross", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r13", "r14", "r176", "r467", "r514", "r524" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Property, Plant and Equipment, Other Types [Member]", "terseLabel": "Property, Plant and Equipment, Other Types" } } }, "localname": "PropertyPlantAndEquipmentOtherTypesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r33", "r176", "r551", "r552" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r13", "r176" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r13", "r174" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated Useful Life (In Years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r295", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r295", "r458", "r459", "r461" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r458" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Related party expense" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r295", "r458", "r461", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r456", "r457", "r459", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r356", "r481", "r557" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r12", "r81", "r86", "r498", "r520" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlowsParenthetical": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash and Cash Equivalents, Total" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents [Abstract]", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSegmentsAndCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r9", "r15", "r81", "r86", "r549" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash, net of current portion", "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total", "verboseLabel": "Restricted cash in non-current assets" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails", "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r181", "r183", "r186", "r194", "r195" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Workforce Reduction" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReduction" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of positions eliminated during the period as a result of restructuring activities.", "label": "Restructuring and Related Cost, Number of Positions Eliminated", "terseLabel": "Reduction in workforce, number of employees" } } }, "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r79", "r180", "r189", "r191" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Charges", "totalLabel": "Restructuring Charges, Total" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r182", "r183", "r191", "r192" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost And Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "terseLabel": "Restructuring costs", "totalLabel": "Restructuring Costs, Total" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r183", "r192" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Adjustments" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveCurrent": { "auth_ref": [ "r18", "r183", "r192" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Current", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period" } } }, "localname": "RestructuringReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r26", "r256", "r349", "r467", "r522", "r541", "r543" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r99", "r100", "r101", "r103", "r108", "r110", "r163", "r346", "r347", "r348", "r379", "r380", "r406", "r538", "r540" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deflicit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r135", "r136", "r146", "r150", "r151", "r155", "r156", "r157", "r273", "r274", "r482" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue from related party", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r89", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r283" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r275", "r283" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Grant Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureGrantRevenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r67", "r206", "r208", "r209", "r213", "r214", "r215", "r547" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenue from related party" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuePerformanceObligationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue, Performance Obligation [Abstract]", "terseLabel": "Revenue" } } }, "localname": "RevenuePerformanceObligationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r62", "r92", "r135", "r136", "r146", "r150", "r151", "r155", "r156", "r157", "r162", "r203", "r204", "r205", "r208", "r209", "r210", "r211", "r212", "r214", "r215", "r418", "r513" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r448", "r453" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease upon lease commencement (in thousands)" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Summary of deferred tax assets (liabilities)" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted earnings per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": { "auth_ref": [ "r112", "r113", "r115", "r117", "r121" ], "lang": { "en-us": { "role": { "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLossPerShareScheduleOfEarningsPerShareDilutedByCommonClassDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "auth_ref": [ "r113", "r117", "r121" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]", "terseLabel": "Schedule Of Earnings Per Share Diluted By Common Class" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Summary of reconciliation of income taxes computed using the U.S. federal statutory rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r311", "r339", "r351" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of share-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r167", "r169", "r483" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of RSU activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r35", "r176" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r460", "r461" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r182", "r183", "r184", "r185", "r191", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule Of Restructuring And Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r187", "r188", "r190" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Schedule of accrued liabilities activity allocated to Cyclerion in connection with the reduction in workforce" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r312", "r344" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r317", "r328", "r331" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of weighted-average assumptions used in estimating the fair value of the stock options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r43", "r90", "r124", "r125", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecurityDepositLiability": { "auth_ref": [ "r527" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.", "label": "Security Deposit Liability", "terseLabel": "Contingent liability under an unused letter of credit, posted as a security deposit", "verboseLabel": "Letter of credit posted with the landlord as a security deposit" } } }, "localname": "SecurityDepositLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSegmentsAndCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r140", "r141", "r142", "r143", "r144", "r145", "r156" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "General and Administrative Expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance and benefits costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r78" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Expected option term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested the end of the period (in shares)", "periodStartLabel": "Unvested at the beginning of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "verboseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested restricted common stock at the end of the period (in dollars per share)", "periodStartLabel": "Unvested at the beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "verboseLabel": "Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Assumptions used to estimate fair value of stock options", "verboseLabel": "Assumptions used to estimate fair value of performance-based stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Weighted average risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Plans", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Term (years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r330" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Cancelled or forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value per option share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r344" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding", "verboseLabel": "Aggregate intrinsic value, outstanding at the end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r319", "r344" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of the year (in shares)", "periodStartLabel": "Outstanding at beginning of the year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of the year (in dollars per share)", "periodStartLabel": "Outstanding at beginning of the year (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price", "verboseLabel": "Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r342" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost", "terseLabel": "Incremental compensation expense due to modification" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Number of grantees affected by modification of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Plan Modification, Number of Grantees Affected", "terseLabel": "Number of employees impacted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails" ], "xbrltype": "integerItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r310", "r315" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled or forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.", "label": "Share-based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]", "terseLabel": "Summary of stock awards containing market conditions activity" } } }, "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Purchase price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r334", "r350" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected option term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansScheduleOfWeightedAverageAssumptionsUsedInEstimatingTheFairValueOfTheStockOptionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r344" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable", "verboseLabel": "Aggregate intrinsic value, exercisable at the end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable (in years)", "verboseLabel": "Weighted average remaining contractual term, exercisable at the end of period (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding (in years)", "verboseLabel": "Weighted average remaining contractual term, outstanding at the end of period (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Total grant date fair value of options granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Number of shares vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r16", "r467", "r501", "r519" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Short-term liability", "totalLabel": "Short-term Debt, Total" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPaycheckProtectionProgramLoanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r87", "r98" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r44", "r58", "r59", "r60", "r99", "r100", "r101", "r103", "r108", "r110", "r123", "r163", "r249", "r256", "r346", "r347", "r348", "r379", "r380", "r406", "r420", "r421", "r422", "r423", "r424", "r425", "r538", "r539", "r540", "r587" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfOtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Other Comprehensive Income [Abstract]", "terseLabel": "Other comprehensive loss:", "verboseLabel": "Other comprehensive loss:" } } }, "localname": "StatementOfOtherComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r99", "r100", "r101", "r123", "r482" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfIncomeTaxesDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r22", "r23", "r249", "r256" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock - 2020 private placement (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r22", "r23", "r249", "r256" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock - ATM (in Shares)", "totalLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r22", "r23", "r249", "r256", "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockAwardsContainingMarketConditionsDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationPlansStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r22", "r23", "r249", "r256" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock - 2020 private placement" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r22", "r23", "r249", "r256" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Additional restricted stock awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSharebasedCompensationPlansSummaryOfRsuActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r23", "r28", "r29", "r92", "r161", "r162", "r418", "r467" ], "calculation": { "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfStockholdersEquityDeficit", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r446", "r453" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Net sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSubleaseAsLessorDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesRevenuePatentCostsAndInterestAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reporting subsequent events.", "label": "Subsequent Events, Policy [Policy Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r468", "r470" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow disclosure:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TenantImprovements": { "auth_ref": [ "r526" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.", "label": "Tenant Improvements", "terseLabel": "Tenant improvement allowance" } } }, "localname": "TenantImprovements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r182", "r183", "r191", "r192" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureWorkforceReductionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r357", "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance", "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest or penalties", "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r126", "r127", "r128", "r129", "r130", "r131", "r132" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r445", "r453" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic and diluted net loss per share (in shares)", "verboseLabel": "Weighted average shares used in calculating net loss per share \u2014 basic and diluted (in thousands)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.cyclerion.com/20211231/taxonomy/role/Role_DisclosureLossPerShareDetails", "http://www.cyclerion.com/20211231/taxonomy/role/Role_StatementConsolidatedAndCombinedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r283": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r354": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r388": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5708775-113959" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r426": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123394697&loc=d3e40879-112712" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r463": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r558": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r559": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r560": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r561": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r562": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r563": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r564": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r565": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r566": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r567": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r568": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r569": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r570": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(4)" }, "r571": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(5)" }, "r572": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(i)" }, "r573": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(ii)" }, "r574": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r575": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r576": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r577": { "Name": "Regulation S-K (SK)", "Number": "229", "Publisher": "SEC", "Section": "1402", "Subsection": "Instruction 5" }, "r578": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(1)" }, "r579": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(2)" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r580": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(3)" }, "r581": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(4)" }, "r582": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(5)" }, "r583": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1406" }, "r584": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r585": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r586": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" } }, "version": "2.1" } ZIP 85 0000950170-22-001958-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-001958-xbrl.zip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